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During the past century, tremendous progress has been achieved in the field of organic 
synthesis, with considerable contributions to pharmaceuticals, crop-protection agents, 
and functional materials, among others. Nevertheless, the influence of organic 
synthesis on the environment in terms of pollution, chemical waste, toxic reagents, etc. 
is non-negligible. Therefore, the application of novel, green and cost-effective protocols 
in organic chemistry emerged as a major goal for chemists. In 1988, the 12 principles 
of green chemistry were introduced by Anastas and Warner as a guideline to minimize 
the ecological footprint of synthetic transformations.[1] Moreover, the application of 
catalysis in organic chemistry without stoichiometric metals is important to increase 
the economic benefits and reduce waste formation. 
1.1 Transition Metal-Catalyzed C–H Activation  
Since the early contributions of chemists in the 1970s, transition metal-catalyzed cross-
couplings,[2] as exemplified by the Nobel Prize in chemistry in 2010, have become one 
of the most powerful strategies for modern molecular synthesis.[3] Thus far, 
predominantly palladium-catalyzed cross-couplings, represented by Mizoroki–Heck,[4] 
Suzuki–Miyaura,[5] Migita–Stille,[6] Negishi,[7] Sonogashira-Hagihara,[8] and Hiyama–
couplings,[9] have found widespread applications in pharmaceutical and agrochemical 
industries as well as polymer sciences for the construction of C–C bonds. Additionally, 
transition metal-catalyzed cross-couplings, such as Buchwald-Hartwig,[10] Ullmann–
Goldberg,[11] and Chan–Evans–Lam-couplings,[12] were exploited for C–Het bond 
formations.  
Despite indisputable achievements, cross-coupling reactions are associated with 
significant inherent drawbacks, such as the formation of stoichiometric amounts of 
metal waste. Besides the necessary prefunctionalized organic (pseudo)halides, 
organometallic coupling partners, e.g. Grignard reagents, organostannanes, 
organozinc and organolithium compounds are employed, which are typically sensitive 
and require multistep synthetic procedures (Figure 1.1.1a).[13] Moreover, the 
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production of toxic byproducts results in hazardous pollution and waste. Therefore, 
atom-[14] and step-economical processes[15] have been becoming increasingly 
attractive to chemists. 
In contrast, transition metal-catalyzed site-selective C–H functionalizations[16] have 
obvious advantages since they avoid pre-functionalization steps to construct C–C and 
C–Het bonds (Figure 1.1.1b), thereby providing outstanding levels of resource-
economy.[17] Thus, the influence of organic synthesis on the environment were 
considerably decreased. Although cross dehydrogenative couplings (CDC) with 
molecular hydrogen as the sole byproduct in principle constitute the most sustainable 
concept (Figure 1.1.1c),[18] chemical oxidants, such as expensive silver and copper 
salts, are indispensable to realize these transformations, which in fact compromises 
the resource-economy. Despite the utilization of one prefunctionalized organic 
electrophile in the direct C–H functionalization, these conditions refrain from expensive 
and toxic chemical oxidants and the substrates, such as most commonly used organic 
halides and phenol derivatives, are easy to obtain on large scale in industries (Figure 
1.1.1b).[19]  
 
Figure 1.1.1. Comparison of classical cross-coupling reactions with C–H activation and oxidative C–H/C–
H activation. 
The foremost foundation for developing transition metal-catalyzed C–H 
functionalization is the elucidation of the reaction mechanism. Thus, numerous studies 
have focused on the key C–H activation step, resulting in several mechanistically 
distinct pathways being identified depending on the electronic properties and nature of 
the metal catalyst (Figure 1.1.2). Without considering outer-sphere/radical-type 
mechanisms,[20] five reaction modes are proposed in general.[19c] Oxidative addition 
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was mostly observed for electron-rich late transition metals in low oxidation states.[21] 
Electrophilic substitution was proposed for late transition metals in higher oxidation 
states involved an electrophilic attack of transition metal to the carbon. [22] σ-Bond 
metathesis is a common pathway for early transition-metals, as well as lanthanides 
and actinides which are difficult to change oxidation states.[23] In addition, 1,2-addition 
of C–H bonds to unsaturated M = X bonds, such as metal imido complexes, is 
favored.[19c, 24] Closely related to electrophilic substitution, a base-assisted C–H 
activation event[19c, 25] is proposed to go through an electrophilic attack of the metal and 
deprotonation by carboxylate or carbonate ligands. Within this mechanistic manifold , 
the cleavage of C–H bond and the formation of C–M occurs simultaneously. 
 
Figure 1.1.2. Mechanistic pathways for C–H activation. 
In recent years, the base-assisted mechanism was investigated in detail, unveiling the 
important role of an internal base for the C–H cleavage processes. Based on the 
distinct transition states, base-assisted C–H metalation processes could be further 
categorized (Figure 1.1.3). While the term concerted metalation-deprotonation (CMD) 
was coined by Fagnou/Gorelsky,[26] an agostic interaction between transition metal and 
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the C–H bond was proposed by Macgregor/Davies, being named ambiphilic metal-
ligand activation (AMLA).[27] Both mechanisms involving metalation and deprotonation 
steps proceed through a six-membered transition state and are favorable for electron-
deficient substrates with high kinetic C–H acidity. On the contrary, the base-assisted 
internal electrophilic substitution (BIES) was uncovered by Ackermann for electron-rich 
arenes with acetate or carboxylate ligands and proceeds via an electrophilic 
substitution-type pathway.[28]  
 
Figure 1.1.3. Distinct transition state models for base-assisted C–H metalation. 
Due to the omnipresence of C–H bonds and their similar dissociation energies, site-
selectivity control is a major challenge in direct C–H functionalization.[29] Several typical 
strategies have been introduced to overcome the selectivity issue (Figure 1.1.4). 
Distinct C–H bonds in heterocycles possess inherent differences in their acidities and 
bond dissociation energies, which result in a selective activation of specific C–H bonds 
(electronic bias) (Figure 1.1.4a).[19f, 30] Another approach is the installation of a bulky 
substituent, resulting in a steric control by preventing access to the adjacent C–H 
bonds (steric bias) (Figure 1.1.4b). However, both electronic bias and steric bias have 
intrinsically limited applications owing to the requirement for particular substrates. A 
more widely-used strategy is the introduction of Lewis-basic directing groups, which 
coordinate to the metal center and bring it in close proximity to the desired ortho-, meta- 
or para-C–H bond (Figure 1.1.4c).[31] Recently, transient directing groups that can be 
reversibly installed in situ and removed in the catalytic C–H scission possess have the 
potential to decrease the number of laborious synthetic operations (Figure 1.1.4e).[29e] 
The transient directing group, installed in situ through the reaction of the substrates 
with a catalytic amount of external ligand, can coordinate to the metal center, achieve 
the position-selective C–H activation and finally release the transient ligand. For 
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remote meta-selective C–H activation, one key strategy is the ruthenium-catalyzed σ-
activation (Figure 1.1.4d).[29f, 31a] The generated ortho-substituted cycloruthenated 
complex activates the remote para-C–H bond with respect to the ruthenium center by 
strongly influencing the electronic properties of the aromatic ring. An alternative 
method for meta-C–H functionalization is to exploit carboxylic acids as traceless 
directing groups, that can be removed in a traceless fashion after the carboxylic acid-
directed C–H activation (Figure 1.1.4f).[29g, 32] Palladium/norbornene (NBE) 
cooperative Catellani-catalysis has emerged as a useful approach to accomplish 
selective C–H activation (Figure 1.1.4g).[29a] During this transformation, the ortho-C–
H activation takes place in the presence of NBE to provide a palladium-norbornene 
species, which can further activate the adjacent C–H bond to selectively achieve the 
remote selective meta-C–H bond functionalization. 
 
Figure 1.1.4. Different strategies for selective C–H functionalizations. 
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1.2 Ruthenium-Catalyzed Selective C–H Activation 
During the last decades, C–H functionalization has achieved enormous success 
employing noble metal catalysts, especially palladium, rhodium or ruthenium. Due to 
the significantly lower price of ruthenium, which is only 13% of the price of palladium 
and 3% of rhodium (Figure 1.2.1), the application of ruthenium catalysts for the 
molecular construction is highly desirable.[33]  
 
Figure 1.2.1. The price of 4d and 5d precious metals. 
1.2.1 Ruthenium-Catalyzed ortho-C–H Activation 
In 1965, Chatt and Davidson described the ruthenium-mediated C–H activation, in 
which an in situ generated ruthenium(0)-phosphine complex was employed to achieve 
the C–H cleavage of sodium arene 2 for the generation of hydride-ruthenium(II) 
complex 3 (Figure 1.2.2).[34] 
 
Figure 1.2.2. Ruthenium-mediated C–H activation. 
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Approximately 20 years later, the first regioselective catalytic C–H alkylation of phenols 
employing ruthenium complex 7a and KOPh as the cocatalysts was reported by Lewis 
and Smith, in which the ruthenium complex was obtained from a phosphite derived 
from phenol 4a (Figure 1.2.3).[35] 
 
Figure 1.2.3. Ruthenium-catalyzed C–H alkylation. 
A ruthenium-catalyzed highly site-selective C–H alkylation of aromatic ketones 8 with 
a wide range of olefins was discussed by Murai/Chatani in 1993 (Figure 1.2.4).[36] 
Remarkably, the use of chelation assistance to form the cyclometalated ruthenium-
hydride 10 proved crucial for C–H cleavage. Then, insertion of the alkene 5 into the 
Ru–H bond (or Ru–C bond, the author did not clarify this) provides the desired product 
9 through reductive elimination (Figure 1.2.4). 
 
Figure 1.2.4. Ruthenium-catalyzed C–H alkylation of aromatic ketones. 
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In 2001, Milstein and coworkers introduced the ruthenium-catalyzed oxidative coupling 
of olefin 5b with arene 11a to furnish aryl alkene 12a, using molecular oxygen (Figure 
1.2.5).[37] 
 
Figure 1.2.5. Ruthenium-catalyzed oxidative coupling. 
In the same year, the first ortho-selective C–H mono- or di-arylations with a 
ruthenium(II)-phosphine complex as the catalyst were reported by Oi and Inoue 
(Figure 1.2.6).[38a] An increased amount of aryl bromide 14a and base was beneficial 
for the formation of the diarylated product 15a’. However, the protocol was not fully 
reproducible.[38b] 
 
Figure 1.2.6. Ruthenium-catalyzed ortho-selective C–H arylation. 
In 2008, the Ackermann group developed carboxylate assistance for the first 
ruthenium(II)-catalyzed C–H activation, involving the possible generation of a six-
membered ruthenium-carboxylate species (Figure 1.2.7).[39] 
  
Figure 1.2.7. Ruthenium-catalyzed C–H arylation under carboxylate assistance. 
Subsequently, this novel method was widely applied in ruthenium-catalyzed oxidative 
C–H/N–H[40] and C–H/O–H bond[41] annulations of heteroarenes and olefins with 
alkynes in the presence of copper(II) oxidants by Ackermann and others, providing 
access to various heterocyclic molecules (Figure 1.2.8a–h).[42] In addition, ruthenium-
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catalyzed oxidative alkene annulations of aromatic acids to access 5-membered 
lactones was introduced by Ackermann (Figure 1.2.8i).[43] Employing ruthenium 
catalysis by carboxylate assistance, selective oxidative C(sp2)–H olefinations of 
heteroarenes and olefins were accomplished to deliver the desired aryl alkenes 
(Figure 1.2.8j–r). Various directing groups were explored for these transformations, 
for instance, carboxylic acids,[44] oxazoles/triazoles,[45] ketones/aldehydes,[46] esters,[47] 
carbamates,[48] 2-pyridyloxys,[49] sulfonic acids,[28b] N-dimethylcarbamoyls[50] and 
amides.[51] 
 
Figure 1.2.8. Ruthenium-catalyzed oxidative C–H/X–H annulations with alkynes and alkenes. 
To avoid the use of problematic metal oxidants, such as copper(II) salts, an oxidizing 
directing group was employed by Wang and Ackermann for the ruthenium-catalyzed 
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C–H/N–O functionalization with alkynes 16, leading to the formation of bioactive 
isoquinolones 19 and isoquinolinones 20 (Figure 1.2.9a, b).[52] Moreover, this strategy 
proved also efficient for the olefination or alkene annulation of N-methoxybenzamides 
17A by Li and Wang (Figure 1.2.9c).[53]  
 
Figure 1.2.9. Ruthenium-catalyzed C–H/N–O functionalization with alkynes and alkenes with an oxidizing 
directing group. 
Among the pioneering contributions, the Ackermann group introduced ruthenium-
catalyzed ortho-C(sp2)–H alkylation by carboxylate assistance utilizing electrophilic 
primary and secondary alkyl halides 24 (Figure 1.2.10).[54] 
 
Figure 1.2.10. Ruthenium-catalyzed C–H alkylation by carboxylate assistance. 
1.2.2 Ruthenium-Catalyzed Remote C–H Activation 
As mentioned in chapter 1.1, a strategy for achieving remote C–H activation by 
ruthenium catalysis is represented by the σ-activation through cyclometallation. Herein, 
the development of ruthenium-catalyzed remote C–H activation based on this 
mechanism will be discussed. 
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In 1994, Roper reported this strategy of ruthenium-mediated σ-activation, in which the 
para-C–H nitration of a ruthenium-benzene compound 26a was realized, although in 
low yield (Figure 1.2.11a).[55] Afterwards, van Koten reported another stoichiometric 
para-C–H activation of a ruthenium-arene complex 26b, providing the homo-coupling 
complex 27f as well as the chlorinated product 27g (Figure 1.2.11b).[56] These results 
evidenced that the position-selectivity of C–H activation could be controlled by the 
formed C–Ru bond via the electronic influence of the arene ring. 
 
Figure 1.2.11. C–H activation of cyclometalated ruthenium complexes. 
In 1998, Coudret and coworkers reported the electrophilic C–H bromination of 
phenylpyridine-ruthenium complex 26c at the para-position with respect to the Ru–C 
σ–bond with N-bromosuccinimide (NBS) in excellent yield and regioselectivity (Figure 
1.2.12a).[57] One year later, Roper and Wright described the electrophilic para-C–H 
bromination of phenylpyridine-ruthenium complex 26d using PyHBr3 as the 
halogenating reagent (Figure 1.2.12b).[58] These two examples showed that the formal 
cyclometalated ruthenium complex could be identified as a Friedel-Crafts-type 
ortho/para directing group for the para-C–H activation of Ru–C bond.  




Figure 1.2.12. Remote C–H bromination of cycloruthenium complexes. 
This strategy was utilized as a useful tool for the selective C–H activation with a 
catalytic amount of ruthenium in 2011. In a pioneering contribution by the Ackermann 
group, the first ruthenium-catalyzed meta-C–H alkylation was reported, albeit with low 
yield (Figure 1.2.13).[59] 
 
Figure 1.2.13. The first ruthenium-catalyzed meta-C–H alkylation. 
Later, in the same year, the Frost group reported the ruthenium-catalyzed meta-C–H 
sulfonation of unactivated arene derivatives (Figure 1.2.14a).[60] The ortho-
cyclometalated phenylpyridine species was prepared and demonstrated to be a 
catalytically competent intermediate. Using pyridines as the directing group (Figure 
1.2.14c, g–i), a variety of ruthenium-catalyzed meta-C–H activations, such as primary, 
secondary and tertiary alkylations,[61] benzylations,[62] brominations[63] and nitrations 
were described.[64] Remarkably, Ackermann reported the meta-C–H bromination of 
aryl-substituted purines using a heterogeneous ruthenium catalyst, which set the stage 
for direct nucleobase fluorescent labeling (Figure 1.2.14j).[65] In 2013, ruthenium-
catalyzed carboxylate-assisted meta-C–H alkylations with secondary alkyl halides 
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using a removable directing group were disclosed by the Ackermann group (Figure 
1.2.14b).[66] Subsequently, various removable directing groups were developed as a 
tool to activate remote C–H bonds of anilines,[62c] azoarenes,[67] phenols,[68] and 
ketones,[69] providing the desired meta-substituted products (Figure 1.2.14d–f, k). 
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1.3 Nickel-Catalyzed C–H Activation 
Nickel as an earth-abundant 3d metal is less expensive and less toxic than commonly 
used 4d and 5d transition metals, like palladium, and is thus highly desirable for the 
synthetic transformations. Furthermore, the relatively more electropositive property of 
nickel is advantageous in the process of the oxidative addition with less reactive 
coupling partners.[70] Additionally, nickel bearing 10 d-electrons in a neutral nickel(0) 
species displays different oxidation states from the common lower oxidation states 
nickel(0), nickel(I), and nickel(II) to the relative rare higher oxidation states nickel(III) 
and nickel(IV), which allows unusual mechanistic pathways.[71] Although the 
tremendous progress in cross-coupling reactions has been achieved, for instance, 
Suzuki-Miyaura, Negishi, Kumada cross-couplings,[72] nickel-catalyzed C–H 
functionalizations are more attractive in consideration of economic and ecological 
advantages for modern organic synthesis.[73]  
 
In 1963, the successful synthesis of an ortho-cyclometallated nickel species 31a 
employing the azo moiety as directing group was generally recognized as the first 
example of nickel-mediated C–H activation (Figure 1.3.1a).[74] Forty years later, an 
early example of nickel(0)-catalyzed C–H alkylation of imidazolium salts with olefins 
was described by Cavell using a Ni(cod)2/PPh3 cooperative system (Figure 1.3.1b).[75] 
In 2006, a C–H nickelation of unactivated benzene 11a with an air-stable pincer-
nickel(II) complex 30b in the absence of chelation assistance was reported by Liang 
(Figure 1.3.1c).[76] 




Figure 1.3.1. Early contributions of nickel-catalyzed C–H activation. 
Thereafter, tremendous progresses on nickel-catalyzed C–H functionalizations have 
been achieved for synthetic transformations, especially the formation of C–C bonds 
like arylations, alkylations, alkenylations, alkynylations and hydroarylations of alkynes 
and allenes.[73] Herein, I provide details on C–H arylations, alkynylations and 
alkylations.  
1.3.1 Nickel-Catalyzed C–H Activation for C–C Formation 
1.3.1.1 Nickel-Catalyzed C–H Arylation 
In 2009, Itami and Miura independently reported the nickel-catalyzed direct C–H 
arylation of azole derivatives 32 bearing an electronically activated C–H bond with aryl 
halides 14 (Figure 1.3.2).[77] In both approaches, the strong base LiOtBu was 
necessary to give the desired arylated products 33. Subsequently, a modified protocol 
was introduced by Itami in 2011, employing Mg(OtBu)2 as an alternative base to 
achieve this molecular transformation.[78] 




Figure 1.3.2. Nickel-catalyzed C–H arylation with aryl halides 14A, 14B. 
In addition to aryl halides, arylsilanes 14C were firstly employed by Miura for the nickel-
catalyzed C–H arylation in the presence of copper(II) oxidant (Figure 1.3.3a).[79] Other 
arylating reagents, namely, arylboronic acids 14D and Grignard reagents 14E also 
displayed high-efficacy with different oxidants like, O2 or 1,2-dichloroethane, to obtain 
the corresponding biaryl products 33D, 33E (Figure 1.3.3b, c).[80] In 2009, Tobisu and 
Chatani reported the C–H arylation with arylzinc reagents 14F as the arylated reagents 
(Figure 1.3.3d).[81] 
 
Figure 1.3.3. Nickel-catalyzed oxidative C–H arylation with organic nucleophiles 14C–14F. 
Ackermann early uncovered the C–H/C–O coupling of heteroarenes by palladium and 
cobalt catalysis.[82] In 2012, Itami described the first nickel-catalyzed C–H/C–O 
coupling of azoles 32B and phenol derivatives 14G using the Ni(cod)2/dcype catalytic 
system (Figure 1.3.4a).[83] Mechanistic studies including the isolation and elucidation 
of the key intermediate arylnickel-dcype pivalate 34, kinetic studies and the 
determination of the kinetic isotope effect, revealed the C–H activation as the rate-
1. Introduction  
17 
 
limiting step (Figure 1.3.4b).[84] The same group improved the protocol employing air-
stable Ni(OTf)2 as the catalyst for both C–H alkenylations and arylations of imidazoles, 
thiazoles and oxazoles (Figure 1.3.4c).[85] The key to obtain the desired products was 
the use of the tertiary alcohol tAmylOH, while aprotic solvents and secondary alcohol 
likewise iPrOH failed to give the product. Nickel-catalyzed decarboxylative C–H 
arylation of azole derivatives was successfully introduced using aryl esters 14I and 
benzoic acids 14J (Figure 1.3.4d, e).[86] Recently, Kalyani and coworkers described 
the nickel-catalyzed C–H arylation of azoles 32G with benzonitriles 14K, in which the 
Lewis acid BPh3 was found to be beneficial to decrease the catalyst loading (Figure 
1.3.4f).[87]  
 
Figure 1.3.4. Nickel-catalyzed redox-neutral C–H arylation with unconventional coupling partners 14G–
14K. 
Most known methods focused on the use of electronically activated substrates, like 
pyridine and azole derivatives, containing an acidic C–H bond. However, C–H 
functionalizations of unactivated arenes were thus far undeveloped. Among the 
strategies for the cleavage of inert C–H bonds, the installation of monodentate or 
bidentate directing groups to substrates has become as one of the most powerful and 
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useful tools.[88] In 2014, Chatani reported the nickel-catalyzed C–H arylation with aryl 
iodides 14L with AQ (8-aminoquonoline) as the directing group.[89] Subsequently, 
diverse N,N- and N,O-bidentate directing groups (2-pyridinylisopropyl (PIP) and 
pyridine 1-oxide (PyO)) were utilized to accomplish the transformations with different 
arylated coupling partners including aryl boronic acid esters 14M,[90] silanes 14N,[91] 
carboxylates 14O[92] and halides 14P (Figure 1.3.5a–e).[93] In 2016, an oxidative cross-
dehydrogenative-coupling (CDC) between two heteroarenes was demonstrated by 
You group, delivering the target biaryl products 39, in which the expensive silver 
oxidants could be recycled up to three times without decreasing the efficacy (Figure 
1.3.5f).[94] In 2017, Punji reported a solvent-free C–H arylation using a mono-chelation 
assistance and Ni-pincer catalyst 30c (Figure 1.3.5g).[95] 
 
Figure 1.3.5. Nickel-catalyzed C–H arylation with diverse chelation assistances. 
1.3.1.2 Nickel-Catalyzed C–H Alkynylation 
In 2009, Miura reported the C–H alkynylation of azole derivatives 32 with alkynyl 
bromides 40A with a nickel-based catalyst, in which a catalytic amount of CuI was 
crucial for various substrates, like benzimidazoles and benzothiazoles (Figure 
1.3.6).[96] 




Figure 1.3.6. Nickel-catalyzed C–H alkynylation of azoles 32. 
With bidentate chelation assistance, catalytic C–H arylations of unactivated arenes 
were also proven to be highly-efficient by the group of Shi and Balarman, respectively 
(Figure 1.3.7a, b).[97] In 2016, the first nickel-catalyzed C–H functionalization on 
anilines and purine nucleobases using a monodentate directing group was achieved 
by the Ackermann group (Figure 1.3.7c).[98] One year later, the monodentate chelation 
assistance was also employed by Punji to provide access to the alkynylated indoles 
44 (Figure 1.3.7d).[99] 
 
Figure 1.3.7. Nickel-catalyzed C–H alkynylation of unactivated heteroarenes 25–43 via chelation 
assistance. 
Nickel-catalyzed oxidative C–H alkynylation with terminal alkynes 40C, 40D was also 
described independently by Miura and Shi group, providing the aryl alkynes 45, 46 
without requiring pre-functionalization of the substrates (Figure 1.3.8).[100] In 2010, 
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Miura and coworkers reported a nickel-based catalyst for the activation of acidic C–H 
bonds using molecular oxygen as the oxidant (Figure 1.3.8a).[100b] Subsequently, Shi 
developed a base-free protocol for the direct oxidative C–H alkynylation of unactivated 
arenes 36 using O2 as the oxidant and PIP as the bidentate directing group (Figure 
1.3.8b).[100a] 
 
Figure 1.3.8. Nickel-catalyzed oxidative C–H alkynylation. 
1.3.1.3 Nickel-Catalyzed C–H Alkylation 
Generally, C–H functionalization using non-activated alkyl halides is underdeveloped 
because the alkylmetal species, generated from the oxidative addition, is prone to 
undergo β-hydrogen elimination.[31e, 101] In 2010, the Hu group reported the C–H 
alkylation of 1,3-azoles 32H with alkyl halides 24A containing β-hydrogen atom using 
a pincer nickel catalyst 30d and a co-catalytic amount of CuI (Figure 1.3.9a).[102] In the 
same year, Miura and coworkers demonstrated the Ni(DME)Cl2/terpyridine 49 catalyst 
also worked efficiently in suppressing the β-hydrogen elimination, thus accomplishing 
the alkylative transformation (Figure 1.3.9b).[103] In 2011, an efficient nickel-catalyzed 
C–H alkylation of heteroarenes 32B was achieved by Ackermann using a nitrogen 
ligand-free Ni(DME)Cl2/diglyme catalyst (Figure 1.3.9c).[104] Two years later, Miura 
and Hirano described another approach to bypass the β-hydrogen elimination 
employing N-tosylhydrazone 24C as the alkylating reagent (Figure 1.3.9d).[105] Diazo 
compound 51a, derived from 24C, could react with the arylnickel species 51b to deliver 
51c that underwent a faster proto-demetallation or ligand exchange in comparison with 
the conceivable β-hydrogen elimination to afford the C–H alkylated product 50 (Figure 
1.3.9d).[105] 




Figure 1.3.9. Nickel-catalyzed C–H alkylation of azole derivatives 32. 
In 2012, Qu and Guo reported the first oxidative C–H alkylation of purine and imidazole 
derivatives 32E with alkyl Grignard reagents 24D, using DCE as the oxidant at ambient 
temperature (Figure 1.3.10).[106] 
 
Figure 1.3.10. Nickel-catalyzed oxidative C–H alkylation with Grignard reagents 24D. 
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In 2013, with the assistance of AQ, the Chatani group reported the nickel-catalyzed C–
H alkylation of arenes and olefins with primary alkyl halides 24E (Figure 1.3.11a).[107] 
One year later, with the assistance of bidentate directing group, the Ackermann group 
reported the much challenging secondary alkylation and trifluoroethylation by nickel 
catalysis (Figure 1.3.11b).[108] In 2016, Chatani successfully realized the aromatic C–
H methylation using dicumyl peroxide 24G as the methylating reagent (Figure 
1.3.11c).[109] Recently, the strategy of introducing mono-chelation assistances to 
arenes was proven to be highly efficient for alkylative transformation by Punji and 
Ackermann, respectively (Figure 1.3.11d, e). A C-2 alkylation of indoles 43 in the 
presence of a well-defined nickel-pincer catalyst 30c with pyridine or pyrimidine as the 
monodentate directing group was fulfilled by the group of Punji (Figure 1.3.11d).[110] In 
2017, Ackermann reported the nickel-catalyzed C–H alkylation of purine nucleobases 
53, providing access to crucial structural motifs of various bioactive compounds 54 
(Figure 1.3.11e).[111]  
 
Figure 1.3.11. Nickel-catalyzed C–H alkylation of arenes 35, 43, 53 with chelation assistance.  
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Based on previous reports, a general catalytic mechanism of nickel -catalyzed C–H 
alkylation with bidentate chelation assistance is shown in Figure 1.3.12.[107] First, 
nickel species 55c was obtained from the chelation between 55a and substrate 55b 
through N–H activation, which thus undergo the C–H activation with the aid of a base 
to generate nickel(II) intermediate 55d. Oxidative addition of R-Br to 55d delivers the 
nickel complex 55e, followed by a reductive elimination and the protonation to gain the 
corresponding product 55g and regenerate the nickel (II) species 55a. 
 
Figure 1.3.12. General mechanism of nickel-catalyzed C–H activations with bidentate directing group.  
1.3.2 Nickel-Catalyzed C–H Amination 
In stark contrast with tremendous advances on nickel-catalyzed C–H functionalizations 
for C–C formation, the investigations on the construction of C–Het bonds were so far 
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less developed. However, nitrogen-containing molecules are the key structural 
fragments in natural products, biological molecules and pharmaceutical agents.[112] 
Thereby, the construction of C–N bonds has attracted increasing attention. Recently, 
C–H aminations have been well developed by transition metals, including iridium, 
ruthenium, rhodium, palladium, copper and cobalt.[113] Nickel as an Earth-abundant and 
less-toxic 3d metal was relatively less explored in the amination reactions.  
 
In 2012, the nickel-catalyzed C–H amination of benzoxazoles 32J with secondary 
amines 56 was introduced by Li and Duan.[114] The electronically activated C–H bond 
was prone to cleavage by the use of Ni(OAc)2•4H2O as the catalyst and TBHP as the 
oxidant (Figure 1.3.13). 
 
Figure 1.3.13. Nickel-catalyzed C–H amination of benzoxazoles 32J. 
In 2015, Zhang reported the nickel-catalyzed C–H transformation of unactivated 
arenes 35 with secondary amines 56 in the presence of a nickel/silver catalyst and a 
bidentate directing group, furnishing various arylamines 58 (Figure 1.3.14).[115] After 
extensive mechanistic studies, they proposed a catalytic cycle involving nickel(II/III/I) 
(Figure 1.3.14).[115] With the assistance of a base, the irreversible C–H activation took 
place to deliver nickel(II) species 59c from amide-nickel species 59b. Cyclometaled 
nickel complex 59c underwent oxidative addition to generate the amine-nickel 
intermediate 59d (59d’), which was confirmed by MAIDIL-TOF-MS spectrum. C–N 
bonds were formed through reductive elimination, followed by protonation to obtain the 
desired product 58 and nickel(I) species 59f. The catalytically active nickel(II) 59a was 
finally regenerated by silver(I) carbonate and O2.  




Figure 1.3.14. Nickel-catalyzed C–H amination of arenes and its mechanism. 
Nickel-mediated C–H amination of arenes and olefins 35A with sodium azide 60 in the 
presence of an 8-aminoquioline directing group was firstly described by Tan and 
coworkers, providing access to primary anilines 62A (Figure 1.3.15a).[116] One year 
later, the same group realized this transformative amination utilizing ammonia 61 as a 
cost- and atom-economical amino source under similar conditions (Figure 1.3.15b).[117] 




Figure 1.3.15. Nickel-catalyzed C–H amination for the synthesis of primary anilines 62. 
In 2014, Ge described a nickel-catalyzed intramolecular dehydrogenative C(sp3)–H 
amidation by 8-aminoquinoline assistance, gaining access to various β-lactams 64 
(Figure 1.3.16).[117] The reaction showed a preference for activating the C–H bond of 
β-methyl groups, compared to the C–H bond of β-methylene and γ-methyl groups (64a) 
as well as the aromatic C–H bond (64b). Additionally, this protocol could achieve the 
selective activation of benzylic secondary C(sp3)–H bonds, albeit the more reactive β-
methyl C–H bonds (64c, d).  
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1.3.3 Nickel-Catalyzed C–H Alkoxylation 
C–O bond formations play a crucial role for the synthesis of pharmaceutical agents, [118] 
functional materials,[119] and natural products.[120] Classical cross-couplings like 
Buchwald–Hartwig,[10] Ullmann–Goldberg[11] and Chan–Evans–Lam reactions[12] have 
been well developed for the synthesis of various aryl ethers. The inherent drawbacks 
of cross-coupling reactions, e.g., the requirement of prefunctionalized substrates were 
already discussed in chapter 1.1. In the past decades, C–H activation as a step-
economy and atom-economical synthetic strategy has gained tremendous 
achievements for the C–O formation.[121] Numerous studies mainly focused on the C–
H acetoxylations,[122] hydroxygenations[123] and phenoxylations,[124] but the C–H 
alkoxylation was relatively underdeveloped due to the concomitant competition β-
hydride elimination or overoxidation of alcohols. During the transition metal -catalyzed 
C–H alkoxylations, palladium, copper and cobalt were frequently explored as the 
catalysts with the strategy of installing chelating assistances, which were shown in 
Figure 1.3.17–1.3.19. 
 
Diverse monodentate directing groups containing oxygen and nitrogen atoms were 
successfully designed by many groups for the palladium-catalyzed oxidative C–H 
alkoxylation of unactivated arenes with primary or secondary alcohols, providing 
various aryl ethers (Figure 1.3.17a–r).[125] In most cases, alcohols were employed as 
the solvents, and only primary alcohols or several simple secondary alcohols, such as 
iPrOH and HFIP were converted smoothly. In contrast to the considerable 
achievements by palladium catalysis, copper was less investigated for the C–H 
alkoxylation (Figure 1.3.17s, t).[126] 
 




Figure 1.3.17. Palladium, and copper-catalyzed C–H alkoxylation with alcohols 66 using various 
monodentate directing groups. 
Compared to monodentate chelation assistances, bidentate directing groups were 
more useful and powerful for the C(sp2)–H and C(sp3)–H alkoxylations without affecting 
the resulting molecular structures, since they were readily removable (Figure 
1.3.18).[127] In 2012, Chen employed picolinamide 68 as a N,N-bidentate directing 
group to synthesize alkyl ethers 69 via palladium-catalyzed C(sp2)–H and C(sp3)–H 
activation with primary, secondary and even tertiary alcohols (Figure 1.3.18a).[127d] In 
2013, the PIP auxiliary was successfully developed by the Shi group for functionalizing 
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C(sp2)–H and C(sp3)–H bonds of carboxylic acid derivatives, thus furnishing the 
desired products 71A (Figure 1.3.18b).[127c] Later, AQ was exploited by Rao and 
coworkers to achieve palladium-catalyzed C(sp3)–H alkoxylation using cyclic 
hypervalent iodine reagents 72a or 72b as oxidants for the synthesis of symmetric and 
unsymmetric acetals 71B, 71C (Figure 1.3.18c, d).[127a, 127b]  
 
Figure 1.3.18. Palladium-catalyzed C(sp2)–H and C(sp3)–H alkoxylation using removable bidentate 
directing groups. 72a = 1-methoxy-1,2-benziodoxole-3(1H)-one, 72b = 1-acetoxy-1,2-benziodoxole-
3(1H)-one. 
Not limited to precious 4d transition metals, inexpensive and Earth-abundant 3d 
transition metals, for example, copper[124b, 128] and cobalt[129] were also utilized to 
catalyze oxidative C(sp2)–H alkoxylation with the assistance of bidentate auxiliaries 
(Figure 1.3.19a–h). Notably, Song and Niu reported the first cobalt-catalyzed C–H 
alkoxylation of olefins under mild condition (Figure 1.3.19d).[129e] 




Figure 1.3.19. Copper or cobalt-promoted C(sp2)–H alkoxylations using bidentate directing groups. 
In comparison to the progress that palladium, cobalt and copper have achieved, nickel-
catalyzed C–H alkoxylation continued to be scare, and so far only two examples were 
reported (Figure 1.3.20).[130] In 2019, Cai reported the nickel catalyzed C–H 
alkoxylation of arenes with primary alcohols and one secondary alcohol iPrOH in the 
presence of monodentate chelation assistance (Figure 1.3.20a).[130a] Additionally, 
other C–O formations, like acetoxylations and acyloxylations were also realized with 
slightly modified conditions.[130a] Sundararaju described a bidentate-assisted nickel-
catalyzed C–H alkoxylation of unactivated arenes 35 with primary alcohols employing 
the stoichiometric amounts of silver(I) oxidants, providing an alternative approach for 
the synthesis of aryl ether 73E (Figure 1.3.20b).[130b] 
 
Although considerable improvements on C–H alkoxylations have been achieved by 
transitional metals, these C–O transformative synthesis were limited to use primary 
alcohols or simple less-bulky alcohols and required the over-stoichiometric amounts of 
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alcohols, commonly used as solvents, to increase the catalytic efficiency. 
 
Figure 1.3.20. Nickel-catalyzed C–H alkoxylation using chelation assistance. 
1.3.4 Nickel-Catalyzed C–H Phosphorylation 
Arylphosphonate derivatives are widely used in pharmaceutical and agrochemical 
industry,[131] material chemistry,[132] and ligand design.[133] Although significant 
advances have been made from the early contribution by Hirao[134] for the synthesis of 
organophosphorus compounds, C–H phosphorylation avoiding prefunctionalized 
materials was highly desirable due to its consistency with the concept of green 
chemistry. The strong coordination property of organophosphorus molecules that could 
easily poison a transition metal catalyst resulted in the fact that C–H phosphorylation 
remained so far underdeveloped.[135] Therefore, developing new methodologies were 
very significant and attractive. 
 
In 2013, Yu and coworkers described the palladium-catalyzed intermolecular C–H 
phosphorylation of unactivated arenes 13 with H-phosphonates and diaryl phosphine 
oxides 74, which were added slowly by a syringe pump to minimize the deactivation of 
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the catalyst (Figure 1.3.21).[136] In addition, AgOAc and BQ were mandatory for 
accomplishing this C–P transformation. 
 
Figure 1.3.21. Palladium-catalyzed C–H phosphorylation with slow addition of phosphonating reagents 
74. 
At the same time, Murakami introduced a one-pot method to obtain the 
arylphosphonates 76 in the presence of palladium-silver catalytic system by a masked, 
slow-releasing phosphonating reagent hydroxyalkylphosphonate 74A, which could 
avoid palladium catalyst being poisoned (Figure 1.3.22a).[137] In 2016, Hong 
successfully developed this strategy of a masked, slow-releasing phosphonating 
reagents for rhodium-catalyzed C–P transformations with the assistance of silver(I) 
oxidants, providing access to the corresponding arylphosphonates 78 (Figure 
1.3.22b).[138] The substrates bearing distinct nitrogen-coordinating groups, including 
late-stage functionalized substituents were well investigated.  
 
In 2014, Chen and Yu reported a copper-catalyzed C–P formation of arenes 35 through 
the sequential addition of H-phosphonates 74C (Figure 1.3.23).[139] The construction 
of arylphosphonate derivatives 79 was accomplished employing silver salts and N-
methylmorpholine oxide as co-oxidants and the AQ moiety as a directing group.  




Figure 1.3.22. Palladium and rhodium-catalyzed C–H phosphorylation with masked phosphorylation 
reagents 74A, 74B. 
 
 
Figure 1.3.23. Copper-catalyzed C–H phosphorylation by sequential addition of H-phosphonates 74C. 
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1.4 Oxidative C–H Activation by Metalla-Electrocatalysis 
Oxidative C–H/C–H and C–H/Het–H activation reactions have obtained considerable 
advances due to the use of non-prefunctionalized starting materials.[18] However, 
oxidative C–H activations generally required stoichiometric amounts of expensive and 
toxic metal oxidants, such as copper and silver salts for the regeneration of the active 
metal catalyst, which compromised the overall sustainable nature of organic synthesis. 
Since early contributions from Volta,[140] Kolbe,[141] and Faraday,[142] electrosynthesis 
with inexpensive and waste-free electricity as a viable redox equivalent has recently 
experienced a renaissance, holding the huge potential to accomplish excellent levels 
of oxidant and resource economy.[143] Compared with the classical substrate-controlled 
electrosynthesis, metalla-electrocatalysis sets the stage for transition metal-controlled 
position-selective oxidative C–H activations.[144]  
 
At the outset of this thesis, electrocatalytic C–H activation by nickel catalysis was so 
far unknown.[145] The next part will provide an introduction about electrooxidative C–H 
activation by other transition metals. 
 
1.4.1 Pallada-Electrooxidative C–H Activation 
In 2007, Amatore and Jutand made a pioneering contribution on the electrooxidative 
C–H activation by palladium catalysis (Figure 1.4.1).[146] They successfully modified 
the Fujiwara-Moritani-type reaction[147] with electric current as a redox equivalent to 
replace expensive silver(I) and copper(II) oxidants, albeit with a limited scope. 
 
Figure 1.4.1. Pallada-electrochemical C–H olefination. 
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During the last decade, the powerful pallada-electrocatalysis was well developed with 
the assistance of distinct directing groups to achieve C–H activation for carbon–carbon 
formation[148] like arylation, alkylation and olefination, as well as carbon–heteroatom 
formation, represented by halogenation, phosphorylation and acetoxylation (Figure 
1.4.2).[149] The pyridine-assisted electrocatalytic C–H halogenation with HX or I2 was 
described by Kakiuchi and coworkers (Figure 1.4.2a, b),[149h, 149i] and this protocol was 
further developed under bidentate directing groups by the Kakiuchi and Mei with 
distinct halogenating reagents (Figure 1.4.2h, k).[149b, 149d, 149g] The versatility of pyridine 
chelation group was not only explored for C–H halogenation of arenes by pallada-
electrocatalysis, but also for electrocatalytic intermolecular C–H arylation,[149e] 
phosphorylation[149e] and alkylation (Figure 1.4.2c, d, j).[149e] Moreover, pyridine was 
also developed for the intramolecular C–H amination by Lei in 2020 (Figure 1.4.2l).[149e] 
Noteworthily, in 2017, Mei reported the palladium-catalyzed electrochemical C(sp3)–H 
oxygenation under mild conditions in a divided cell, providing various oxygen-
containing molecules (Figure 1.4.2e).[149e] To accomplish the C–O formation, oxime 
was employed as the directing groups, which was subsequently employed for the C–
H acetoxylation[149e] and alkylation by the same group (Figure 1.4.2f, g).[149e] Another 
example of electrooxidative C(sp3)–H oxygenation of 8-methylquinoline with TMAOAc 
was introduced by the Sanford group (Figure 1.4.2i).[149c]  
 
Rather recently, the first asymmetric electrochemical C–H olefination with palladium 
catalysis was described by the Ackermann group via a transient directing group, 
offering an expedient access to enantioenriched BINOLs, dicarboxylic acids and 
helicenes 84a–84c (Figure 1.4.3).[148a]  
 




Figure 1.4.2. Pallada-electrooxidative C–H activation. 
 
Figure 1.4.3. Asymmetric pallada-electrooxidative C–H activation. 
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1.4.2 Rhoda-Electrooxidative C–H Activation 
During last three years, rhoda-electrooxidative C–H activations has been well 
investigated by Ackermann (Figure 1.4.4). The weak coordination was found to be 
efficient for rhoda-electrocatalytic C–H transformations. In 2018, an air-stable 
Cp*Rh(III) was firstly employed as electrocatalyst by Ackermann for the C–H/O–H 
alkene annulation of weakly coordinating benzoic acids 85A with ample scope in a 
dehydrogenative manner (Figure 1.4.4a).[150] The direct cross-dehydrogenative 
couplings between olefins 5 and benzamides 85B bearing both electron-rich and 
electron-poor substituents were also established with rhodaelectro-catalyst by the 
same group in 2020 (Figure 1.4.4b).[151] Not limited to electrocatalytic C–H activation, 
the challenging electrooxidative C–C cleavage for the synthesis of aryl alkenes 86C 
under electricity was achieved with the versatile rhodium catalysis manifold by the 
Ackermann group, producing molecular hydrogen as the sole byproduct (Figure 
1.4.4c).[152]  
 
The very recent rhoda-electrocatalysis by the same group for the synthesis of 
structurally diversified polycyclic aromatic hydrocarbons (PAHs) in the absence of 
directing groups through cascade C–H annulations showed an outstanding level of 
chemo-selectivity (Figure 1.4.4d).[153] This transformation allowed the diverse novel 
nonplanar substituted PAHs being prepared from the easily accessible alkynes 16 and 
boronic acids 85D. In 2020, a modular assembly of nitrogen-doped polycyclic aromatic 
hydrocarbons (aza-PAHs) 85F was introduced by the same group through a 
combination of rhodium-catalyzed electrochemical cascade C–H activation and alkyne 
annulation (Figure 1.4.4f).[154] In 2019, a flow-rhodaelectro-catalyzed C–H 
functionalization of weakly coordinating imidates 85E with alkynes was firstly 
established, which showed the potential for scale up in industries (Figure 1.4.4e).[155] 




Figure 1.4.4. Rhoda-electrooxidative C–H activation. 
 
Rhoda-electrocatalysis was employed not only for the C–C formation, but also for 
construction of C–Het bonds.[156] In 2019, Xu group elegantly reported a rhodium-
catalyzed electrooxidative aryl C–H phosphorylation with different types of 
phosphorylating reagents 74D, providing a convenient access to bioactive 
arylphosphonates 87a–87g (Figure 1.4.5).[156] Various nitrogen-containing directing 
groups, like pyridazine, pyridine, pyrazole, purine and aminopyridine were put into 
practice and in a dehydrogenative fashion. Moreover, hundred gram-scale 
experiments were performed well, with a huge potential for the synthesis in industry, 
albeit with a decreased yield (75c). 




Figure 1.4.5. Rhoda-electrooxidative C–H phosphorylation. 
1.4.3 Ruthena-Electrooxidative C–H Activation 
Pioneering contributions on ruthena-electrooxidative C–H activation were made 
independently from Xu and Ackermann.[157] In 2018, Xu and coworkers employed 
electricity as redox reagent to promote the ruthenium-catalyzed C–H/N–H activation 
for alkyne annulation, leading to the cost-effective preparation of indole derivatives 
89A (Figure 1.4.6a).[157a] Concurrently, Ackermann reported the first weak O-
coordinated ruthenium-catalyzed electrooxidative C–H/O–H activation/alkyne 
annulations of accessible benzoic acids 88B as well as benzamides 88B’, furnishing 
the desired six-membered heterocycles 89B (Figure 1.4.6b).[157b]  
 
This strategy proved to be broadly applicable for ruthenium-enabled electrooxidative 
C–H activation of phenols or aromatic carbamates 88C, benzylic alcohols 88D and 
imidazoles 88E with alkynes 16 (Figure 1.4.6c–e).[158] 
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In 2019, Tang described a ruthena-electrocatalyst enabled dehydrogenative double C–
H/N–H functionalization of benzoylamide 88F with internal alkynes to gain polycyclic 
isoquinolinones 89F (Figure 1.4.6f).[159] This electrocatalytic transformation was 
performed with high regioselectivity through the generation of intermediate 89F’.  
 
Figure 1.4.6. Ruthena-electrooxidative C–H/X–H annulation. (X = N, O). 
In general, these C–H/N–H or C–H/O–H activations for alkyne annulations were 
accessed with outstanding levels of chemo- and site-selectivity, providing an 
alternative procedure for various useful heterocycles in a resource-economical fashion.  
1.4.4 Irida-Electrooxidative C–H Activation 
5d Transition metal iridium also proved to be particularly effective for the 
electrocatalytic C–H activation. In 2018, Ackermann made a pioneering contribution 
on the irida-electrocatalysis for C–H alkenylation of weak coordinating benzoic acids 
85B with alkenes 5, producing a series of 5-membered heterocycles 90A (Figure 
1.4.7a).[160] Remarkably, the chemo-selectivity was improved by the use of 
benzoquinone as a redox mediator. One year later, the Mei group demonstrated the 
iridium-catalyzed electrooxidative vinylic C–H annulation with alkynes 16 by an 
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undivided cell setup, affording various α-pyrones 90B in a cross-dehydrogenative and 
resource-economic manner (Figure 1.4.7b).[161] Very recently, the direct iridium-
catalyzed electrooxidative C–H alkynylation of arenes 23 with terminal alkyne 40D was 
achieved by Xie and Shi, providing diverse aromatic alkynes 90C (Figure 1.4.7c).[162] 
 
Figure 1.4.7. Irida-electrooxidative C–H/O–H annulation. 
1.4.5 Cobalta-Electrooxidative C–H Activation 
In comparison with the precious 4d and 5d transition metals, the development of less 
toxic, Earth-abundant and cost-effective 3d metals in the electrosynthesis is more 
challenging. 
 
The first 3d metalla-electrocatalysis for C–H activation was achieved with cobalt 
catalysis by the group of Ackermann in 2017, which was actually reported before many 
other transition metals except palladium.[163] The cobalta-electrooxidative C–H 
alkoxylation with primary alcohols 66 using a N,O-bidentate auxiliary could be 
performed at ambient temperature, producing molecular hydrogen as the sole waste 
and avoiding stoichiometric amounts of silver(I) or copper(II) salts (Figure 1.4.8).[163] 
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Not limited to aryl C–H oxygenation, alkenes were also identified as highly-effective 
substrates for the construction of alkenyl ethers 73 (Figure 1.4.8). 
 
Figure 1.4.8. Cobalta-electrooxidative aryl and vinylic C–H oxygenation. 
During the last 3 years, considerable advances on cobaltaelectro-catalyzed C–H 
activations for the construction of C–C[164] and C–Het bonds[165] were gained by 
Ackermann and other groups (Figure 1.4.9). Cobalta-electrocatalysis was extremely 
effective for the C–H/N–H annulation of arene and olefin derivatives 91 with 
alkynes,[164d, 164f, 164i] alkenes,[164g] allenes,[164a, 164h] carbon monoxide or isocyanides[164c, 
164e] to obtain biorelevant heterocycles (Figure 1.4.9a–c, f–g, i–k). The robust cobalt 
catalysis also electrochemically enabled the C–H allylation with inert alkenes 92D for 
the C–C bond construction (Figure 1.4.9l).[164b] In 2018, Ackermann and Lei group 
reported the cross-dehydrogenative coupling between arenes 91 and secondary 
amines 56 with different directing groups (N,O- or N,N-coordinating auxiliaries) for the 
C–Het formation (Figure 1.4.9d, e).[165b, 165c] One year later, Ackermann described a 
cobalt-catalyzed the C–O formation for electrochemically promoted C–H acyloxylation 
(Figure 1.4.9h).[165a]  




Figure 1.4.9. Cobalta-electrooxidative C–H activation. 
In general, a bidentate chelation assistance is essential for accomplishing the selective 
C–H transformation by cobalta-electrocatalysis.  
1.4.6 Cupra-Electrooxidative C–H Activation 
The first electricity-mediated C–H activation by copper catalysis was reported by Mei 
and coworkers in 2018.[166] Using a strategy of installing a directing group, the copper-
catalyzed electrooxidative C–H amination of anilines 94 was achieved with a mild 
condition for the synthesis of aromatic amines 95A in an atom- and step-economical 
fashion (Figure 1.4.10a).[166] A redox mediator-free condition was applied by Nicholls 
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for the cupra-electrooxidative C–H amination of benzamides 35 with AQ as a directing 
group, producing the molecular hydrogen as the sole and benign byproduct (Figure 
1.4.10b).[167] 
 
Recently, the group of Ackermann established the first cupra-electrochemical C–H/N–
H alkyne annulation to gain the bioactive five-membered isoindolones 95B in both 
dehydrogenative and decarboxylative manner (Figure 1.4.10c, d).[168] 
 
Figure 1.4.10. Cupra-electrooxidative C–H activation. 
1.4.7 Ferra-Electrooxidative C–H Activation 
Iron is the most naturally abundant transition metal, explored by Ackermann group in 
2019 for the electrochemical C–H transformation.[169] They described a ferraelectro-
catalyzed C–H arylation with Grignard reagent 15E for the synthesis of biaryls 97A, 
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which avoided the use of cost-intensive dichloro-iso-butane (DCIB) as oxidant (Figure 
1.4.11).[169]  
 
Figure 1.4.11. Ferra-electrooxidative C–H activation.  
1.4.8 Mangana-Electrooxidative C–H Activation 
Having established the C–C formation by ferra-electrocatalysis, Ackermann group 
found that the non-toxic MnCl2 was effective for the transformative C–H arylation of 
picolinic acids under a slightly modified conditions (Figure 1.4.12).[169] 
 
Figure 1.4.12. Mangana-electrooxidative C–H activation. 
 




During the last decades, transition metal-catalyzed C–H functionalization[16] has 
emerged as a powerful tool for the construction of C–C and C–Het bonds due to their 
outstanding levels of atom-[14] and step-economy.[15] C–H bonds are omnipresent in 
organic compounds, therefore, site-selective functionalization of C–H bonds is 
challenging and extremely important. Compared with other 4d transition metals, such 
as palladium and rhodium, cost-effective ruthenium catalysis[33] is highly desirable for 
the selective ortho- or meta-C–H activation.  
 
In this context, with ruthenium as the catalyst, the ortho-C–H alkynylation of benzoic 
acids 98 via weakly-O-coordination should be explored (Figure 2.1). Moreover, in the 
presence of strong chelating nitrogen assistances, the highly selective remote meta-
C–H activation for the construction of C–C bonds through the σ-activation of the 
cycloruthenium intermediate is possible to occur and should be investigated with the 
use of the alkylation, mono- and difluoromethylating reagents (Figure 2.1). 
 
Figure 2.1. Ruthenium-catalyzed selective C–H activation with diverse chelating assistances. 
 
Recently, the elegant merger of metalla-electrocatalyzed oxidative C–H 
functionalization without expensive and toxic metal oxidants holds the unique power 
for the resource-economical and environmentally-benign molecular construction.[144] 
Considerable developments have been achieved by precious 4d and 5d transition 
metals as well as the base metal cobalt. However, cost-effective and Earth-abundant 
3d transition metal nickel for electrocatalytic C–H activation remain so far 
underdeveloped. Therefore, another main objective of the thesis was the C–H 
activation by nickelaelectro-catalysis. 
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Nitrogen-containing compounds are important structural fragments in natural products, 
biological molecules and pharmaceutical agents. The established nickel-catalyzed C–
H amination with stoichiometric amounts of expensive silver(I) or copper(II) salts is 
inconsistent with the real nature of atom-economy.[121] Thereafter, we wish to develop 
a green and inexpensive electricity-promoted nickel-catalyzed C–H transformation in 
a dehydrogenative manner without producing stoichiometric metal waste, which could 
provide an accessible synthetic path to a variety of diverse arylamines 58 (Figure 2.2). 
 
Figure 2.2. Nickela-electrocatalyzed C–H amination with amines 56. 
 
Despite considerable achievements on the traditional metal-catalyzed C–H activation 
for constructing C–O bonds, the C–H alkoxylations were relatively scare due to the 
possible β-elimination or overoxidation of alcohols.[121] Moreover, the sterically 
encumbered secondary alcohols are even less investigated in the C–H activation using 
both chemical- and electro-oxidants. Therefore, the nickela-electrooxidative cross-
dehydrogenative couplings of unactivated arenes 106 with the challenging secondary 
alcohols 66 for the synthesis of biorelevant aryl ethers 107 should be further explored 
(Figure 2.3). 
 
Figure 2.3. Nickela-electrocatalyzed C–H alkoxylation with secondary alcohols 66. 
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The synthesis of arylphosphonate derivatives also has a very important role for 
pharmaceutical and agrochemical industry, [131] [130] [130] [130] material science, and 
coordination chemistry. However, the construction of C–P bonds encounters a major 
challenge, because the phosphorus-containing reagents are inherently strongly-
coordinating molecules,[135] resulting in less developed transition-metal-catalyzed C–H 
phosphorylations.[121] Scare reports on C–P formation were so far restricted to the 
electrosynthesis with precious 4d metals or the methodologies of using a masked 
coupling partner or adding phosphonating reagents slowly or sequentially in the 
presence of stoichiometric silver(I) oxidants. Hence, the cost-effective 3d transition 
metal should be explored for the challenging electrooxidative C–H phosphorylation by 
an operationally-friendly setup to gain useful arylphosphonates 110 (Figure 2.4).  
 
Figure 2.4. Nickela-electrocatalyzed challenging C–H phosphorylation. 
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3. Results and Discussion 
3.1 Selective ortho-C–H Activation by Ruthenium Catalysis 
Recently, the versatile ruthenium(II)-carboxylate catalyst has shown its power for 
ortho-C–H functionalizations with diverse electrophiles.[33a-c] Although considerable 
achievements have been made, ruthenium(II)-catalyzed C–H transformations with 
weakly-O-coordinating assistance remain scarce, with only recent investigations on C–
H arylations[33c] and olefinations.[33a] However, the direct C–H alkynylation of benzoic 
acids by ruthenium catalysis has so far proven elusive.  
 
3.1.1 Optimization and Scope  
Optimization studies on the ruthenium(II)-catalyzed C–H allylations were done by Dr. 
Ruhuai Mei[170] and after testing various bases and solvents, catalytic reaction 
conditions comprised of [RuCl2(p-cymene)]2 (5.0 mol %), K2CO3 (2.0 equiv) in 1,4-
dioxane or NMP at 120 °C for 16 h were identified as optimal. With the optimized 
conditions in hand, the scope of the ruthenium-catalyzed C–H alkynylation of benzoic 
acids was investigated (Figure 3.1.1). The aromatic C–H transformations were not 
limited to mono-C–H alkynylations (99a–99d), but also furnished the di-alkynylated 
product 99e, when 2.5 equivalents of alkynylated bromides 40B were used. 




Figure 3.1.1. Scope of ruthenium-catalyzed C–H alkynylation of benzoic acids 98. 
[a] Ru(O2CMes)2(p-cymene) (10 mol%). [b] 40B (2.5 equiv). 
 
3.1.2 Removal of Silyl Group 
The silyl group was easy to be removed in the presence of nBu4NF, providing the 
corresponding terminal alkyne 100d (Figure 3.1.2), which could be employed for 
further transformations, like Sonogashira–Hagihara cross-couplings.[8]  
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3.1.3 Mechanistic Studies 
A series of mechanistic studies was carried out to understand the reaction mode of the 
ruthenium catalysis. A significant H/D exchange was observed by the reisolated 
substrate [Dn]-98f, when using deuterated cosolvent CD3OD for the C–H alkynylation, 
revealing the reversibility of C–H activation (Figure 3.1.3a). Typical radical scavengers, 
such as TEMPO and BHT, failed to prevent the C–H transformation, ruling out a radical 
mechanism (Figure 3.1.3b). In addition, an intermolecular competition experiment 
between electronically distinct arenes 98 demonstrated that the electron-donating 
arene 98b was more reactive, suggesting a facile base-assisted internal electrophilic 
substitution-type (BIES) C–H activation.[28] 
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3.1.4 Proposal Catalytic Cycle of ortho-C–H Alkynylation 
On the basis of these results, a catalytic cycle was proposed as shown in Figure 3.1.4. 
The initial C–H cleavage occurred with the assistance of carboxylate to deliver 
ruthenium(II) complex 101c, followed by a coordination and oxidative addition to 
generate ruthenium(IV) intermediate 101e. The final product 99 was obtained through 
reductive elimination, together with the regeneration of ruthenium complex 101a.  
 
Figure 3.1.4. Proposed catalytic cycle for ortho-C–H alkynylation by ruthenium catalysis. 
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3.2 Selective meta-C–H Activation by Ruthenium Catalysis 
The control of site-selectivity is of key significance for the development of molecular 
transformation.[16] Compared with the tremendous progress of chelation-assisted 
proximity-induced ortho-C–H functionalizations,[19] remote meta-C–H transformation 
was so far less explored.[29c]  
3.2.1 Optimization and Scope of Ruthenium-Catalyzed meta-C–H Mono- 
and Difluoromethylation 
The optimized conditions were established by Dr. Zhixiong Ruan in the Ackermann 
group, as shown in the Table 3.2.1. After diverse nickel cocatalysts were tested, 
Ni(PPh3)2Cl2 was found to be beneficial to the ruthenium-catalyzed meta-C–H 
transformation (entries 1–4). Further studies revealed that the phosphine ligand was 
the crucial additive for the carboxylate-assisted meta-C–H activation (entries 5–19). 
 
Table 3.2.1. Optimization of ruthenium-catalyzed C–H difluoromethylation [a, c] 
 
Entry [Ru] Additive 103a [%] 
1 [Ru(O2CMes)2(p-cymene)] - ˂ 5 
2 [Ru(O2CMes)2(p-cymene)] Ni(PPh3)2Cl2 72 
3 [RuCl2(p-cymene)]2 Ni(PPh3)2Cl2 --- 
4 - Ni(PPh3)2Cl2 --- 
5 [Ru(O2CMes)2(p-cymene)] NiCl2 ˂ 5 
6 [Ru(O2CMes)2(p-cymene)] NiCl2 + PPh3 71 
7 [Ru(O2CMes)2(p-cymene)] PPh3 62 
8 [Ru(O2CMes)2(p-cymene)] PCy3 12 [b] 
9 [Ru(O2CMes)2(p-cymene)] IPr•HCl --- 
10 [Ru(O2CMes)2(p-cymene)] P(Ad)2nBu ˂ 5 
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11 [Ru(O2CMes)2(p-cymene)] P(nBu)3 7 
12 [Ru(O2CMes)2(p-cymene)] P(OEt)3 --- 
13 [Ru(O2CMes)2(p-cymene)] XPhos --- 
14 [Ru(O2CMes)2(p-cymene)] P(4-MeC6H4)3 ˂ 5 
15 [Ru(O2CMes)2(p-cymene)] Ph2P(O)H --- 
16 [Ru(O2CMes)2(p-cymene)] P(4-C6H4CF3)3 71 
17 [Ru(OAc)2(p-cymene)] P(4-C6H4CF3)3 63 
18 [RuCl2(p-cymene)]2 P(4-C6H4CF3)3 --- 
19 [RuCl3•(H2O)n] P(4-C6H4CF3)3 --- 
[a] Reaction conditions: 13a (0.5 mmol), 102a (3.0 equiv), [Ru] (10 mol %), additive ([Ni]: 10 mol % or [P]: 
20 mol %), Na2CO3 (2.0 equiv), 1,4-dioxane (2.0 mL), 60 °C, 18 h, isolated yield. [b] Conversion was 
determined by 19F NMR using C6F6 as the internal standard. [c] Performed by Dr. Zhixiong Ruan. 
Having established the optimized conditions, we explored the robustness of the 
ruthenium catalysis in the meta-C–H activation with various arenes 13 (Figure 3.2.1). 
With the distinct nitrogen-containing directing groups, arenes 13 bearing both electron-
rich and electron-poor substituents were converted to the desired meta-C–H mono- or 
difluoromethylated products 103b–103j with excellent site-selectivity. Various 
functional groups were well tolerated, for instance, ester, halo and ketone substituents. 
Besides the bromodifluoroacetate 102a, the corresponding amides were as well 
efficiently transferred (103e–103g). In select cases, the use of Ni(PPh3)2Cl2 resulted in 
a high turnover towards products 103, which could either be because of a low 
concentration of the free phosphine or a heterobimetallic regime. Notably, the 
outstanding level of high regioselectivity was demonstrated using the bioactive purine 
substrate bearing acidic C–H bonds and the DG-proximity-induced ortho-C–H bond, 
furnishing only the meta-C–H activated product 103h.  
 




Figure 3.2.1. Scope of meta-C–H mono- and difluoromethylation by ruthenium. [a] Ni(PPh3)2Cl2 (10 mol%) 
instead of P(4-C6H4CF3)3. [b] 70 °C. [c] Performed by Dr. Zhixiong Ruan. 
 
Finally, the successful removal of the ester moiety[171] provided a potential alternative 
to difluoromethylated compounds (Figure 3.2.2). 




Figure 3.2.2. Removal of ester 103. 
3.2.2 Optimization and Scope of meta-C–H Alkylation by Arene-Ligand-
Free Ruthenium Catalysis 
Despite the notable progress on remote C–H functionalization by carboxylate-assisted 
ruthenium catalysis,[60-69] transformative syntheses have been largely limited to the use 
of arene-ruthenium complexes. Moreover, C–H alkylation of purine derivatives 
continued to be elusive, considering their significant roles in biochemistry.[172] 
 
After considerable optimizations of ruthenium complexes, bases and solvents by 
Fernando Fumagalli in the Ackermann group, a catalytic system containing arene-
ligand-free Ru(OAc)2(PPh3)2 (10 mol %), K3PO4 (2.0 equiv) in 1,4-dioxane at 100 °C 
for 18 h was identified as the model reaction condition. 
 
With the optimized single-component Ru(OAc)2(PPh3)2 catalysis in hand, we probed 
its versatility of meta-C–H alkylations of decorated arenes 13 with alkyl halides 24B 
(Figure 3.2.3). Different directing groups bearing a nitrogen-coordinating atom, 
including pyrazole, pyridine, pyrimidine, oxazole and purine, facilitated the C–C 
formation with an outstanding level of chemo- and position-selectivity (103k–103x). 
Remote meta-C–H alkylation was achieved with diverse alkyl halides, such as 
bromodifluoroacetate, tertiary and secondary alkyl bromides, providing corresponding 
meta-products 103v–103x.  




Figure 3.2.3. Scope of meta-C–H alkylation by arene-ligand-free ruthenium catalyst. [b] Performed by 
Fernando Fumagalli. 
The mechanism of meta-C–H alkylation was well established,[66] as shown in Figure 
3.2.4. After the coordination of ruthenium(II) biscarboxylate 104a to the substrate 
bearing nitrogen atom, the key reversible C–H activation of substrate 13 took place in 
the presence of a base. Subsequently, an alkyl radical, generated from a single-
electron transfer-type activation of the alkyl halide, underwent an electrophilic attack 
at the para-position of σ-C–Ru bond (104c) to give ruthenium intermediate 104d. 
Finally, rearomatization occurred via SET and deprotonation to form a ruthenium(II) 
complex and the desired product 103 after proto-demetalation.  




Figure 3.2.4. General mechanistic cycle of meta-C–H alkylation by ruthenium. 
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3.3 Nickela-Electrocatalyzed C–H Amination 
Traditional metal-catalyzed C–H functionalization by electrocatalysis bears huge 
potential for constructing molecular complexity, avoiding stoichiometric amounts of 
toxic and expensive metal oxidants.[144] The use of storable, safe and waste-free 
electricity as formal oxidant for C–H activation is likewise attractive. Although this 
strategy considerably increased the resource-economy of C–H activation, advances 
were mainly focused on noble 4d and 5d transition metals, such as palladium,[146, 148c, 
148d, 149e-k] ruthenium,[157, 158c] rhodium[150] and iridium.[160] In stark contrast, the 
inexpensive base metal cobalt has been very recently identified as efficient catalyst for 
electrochemical construction of C–C and C–Het bonds through C–H activation.[163, 164f-
i, 165b, 165c] Despite the indisputable progress, less toxic and Earth-abundant nickel 
catalysis remained so far unexplored for electrocatalytic C–H activation. 
 
3.3.1 Optimization Studies 
We started our studies by probing various reaction conditions for the nickela-
electrocatalytic C–H amination (Table 3.3.1, entries 1–13). To our delight, the 
corresponding C–H amination product 58aa was obtained with a yield of 10% when 
using Ni(OAc)2•4H2O as the electrocatalyst and DMA as the solvent in an undivided 
cell (entry 1). After testing various solvents and additives, DMA and NaOPiv emerged 
as being optimal, respectively (entries 2–8). Subsequent investigations of the reaction 
conditions, in terms of additive stoichiometry and reaction concentration, further 
improved the performance of the nickela-electrocatalysis (entries 9–11). The significant 
role of the electricity (entry 12) and the nickel catalyst (entry 13) were demonstrated 
by control experiments. Notably, an extra redox-mediator was not required to 
accomplish the nickela-electrooxidative C–H amination, which was different from a 
recent electrocatalytic C–H amination by copper catalysis.[166] 
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Table 3.3.1. Optimization of nickela-electrochemical C–H amination [a] 
 
Entry Solvent Additive [Ni] 58aa [%] 
1 DMA --- Ni(OAc)2•4H2O 10 
2 DMA PivOH Ni(OAc)2•4H2O 35 
3 DMA NaOPiv Ni(OAc)2•4H2O 55 
4 DMA Na2CO3 Ni(OAc)2•4H2O 24 
5 GVL NaOPiv Ni(OAc)2•4H2O --- 
6 NMP NaOPiv Ni(OAc)2•4H2O 44 
7 DMF NaOPiv Ni(OAc)2•4H2O 22 
8 DMA NaOPiv Ni(OAc)2•4H2O 20 [b] 
9 DMA NaOPiv Ni(OAc)2•4H2O 61 [c] 
10 DMA NaOPiv Ni(OAc)2•4H2O 72 [c, d] 
11 DMA NaOPiv Ni(DME)Cl2 77 
[c, d, e] 
12 DMA NaOPiv Ni(DME)Cl2 --- [ c, d, e, f] 
13 DMA NaOPiv --- --- [d, e] 
[a] Reaction conditions: 35a (0.25 mmol), 56a (0.50 mmol), [Ni] (10 mol %), Additive (0.50 mmol), 
nBu4NBF4 (0.50 mmol), Solvent (2.5 mL), constant current electrolysis (CCE) = 8.0 mA, 10 h, N2, 120 °C, 
graphite felt (GF) anode and nickel-foam cathode. [b] under air. [c] [Ni] (20 mol%). [d] PivONa (0.25 mmol). 
[e] DMA (3.0 mL).  [f] no current. DMA = N,N-dimethylacetamide, GVL = γ-valerolactone, NMP = N-methyl-
2-pyrrolidinone, DMF = N,N-dimethylformamide. 
With the optimized reaction conditions in hand, we next probed the influence exerted 
by the N-substituent of benzamides 35 (Table 3.3.2). Hence, various N,N-chelation 
groups and an N,O-bidentate chelation failed to enable the desired C–N transformation, 
compared with the cobalt manifold.[163, 164f, 164h, 164i] 
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Table 3.3.2. Optimization of directing groups [a] 
 
[a] Reaction conditions: Undivided cell, 35 (0.25 mmol), 56a (0.50 mmol), NaOPiv (0.25 mmol), Ni(DME)Cl2 
(20 mol %), nBu4NBF4 (0.50 mmol), DMA (3.0 mL), 120 °C, 8.0 mA, 10 h, graphite felt (GF) anode, nickel-
foam cathode.  
3.3.2 Scope of Nickela-Electrocatalyzed C–H Amination 
Having established 8-aminoquinoline-assisted electrochemical C–H nitration by nickel 
catalyst, we tested its versatility with diversely decorated benzamides 35 (Figure 3.3.1). 
Arenes bearing both electron-donating and electron-withdrawing substituents could be 
successfully converted to access the desired aryl amines 58aa–58qa. Various valuable 
functional groups, including halo, cyano, sulfide or ester substituents 35g–35j, were 
well tolerated. Intramolecular competition experiments with meta-substituted 
substrates were fully governed by steric interactions, delivering the products 58ka–
58oa with an excellent level of regioselectivity. Moreover, the heteroarenes 35p, 35q 
were identified as amenable substrates likewise to furnish the C–N transformation. 
 




Figure 3.3.1. Nickela-electrocatalyzed C–H amination of arenes 35. [a] Performed by Dr. Ramesh C. 
Samanta. 
Furthermore, the robustness of the nickelaelectro-catalysis was proven by 
electrochemical C–H aminations with differently substituted secondary amines 56, like 
piperazidine and thiazine derivatives (Figure 3.3.2). Thereby, the substrates with 
valuable functional groups were well tolerated, featuring among others ester 56c and 
cyano substituents 56f. Remarkably, even more challenging acyclic secondary amine 
56i could be efficiently converted to corresponding aromatic amide 58ji. 
 
 




Figure 3.3.2. Nickel-catalyzed electrochemical C–H amination with amines 56. [a] By Dr. Nicolas 
Sauermann; [b] By Dr. Ramesh C. Samanta. 
3.3.3 Mechanistic Studies  
3.3.3.1 Competition Experiments 
Given the versatility of the nickela-electrooxidative C–H amination, we felt intrigued to 
probe its modus operandi. The intermolecular competition experiments were firstly 
carried out between electronically distinct arenes 35n and 35k (Figure 3.3.3). In sharp 
contrast to all previously reported electrochemical C–H activations with palladium,[146, 
148c, 148d, 149e-k] ruthenium,[157, 158c] rhodium[150], iridium[160] and cobalt catalysis,[163, 164f-i, 165b, 
165c] arene decorated with electron-poor substituent reacted preferentially to generate 
product 58na (68%), implying a concerted-metalation-deprotonation (CMD) 
mechanism being involved in the C–H cleavage.[26, 173] 




Figure 3.3.3. Competition experiment between electronically different arenes 35. The ratio was 
determined by 1H NMR conversion using 1,3,5-(OMe)3C6H3 as the internal standard.  
3.3.3.2 Experiments with Isotopically Labelled Solvent 
The optimized reaction was conducted in the presence of the cosolvent D3COD. No 
H/D scrambling was found in the reisolated substrate and the desired product (Figure 
3.3.4). 
 
Figure 3.3.4. Deuteration experiment using CD3OD as the cosolvent. 
3.3.3.3 Reaction Profile 
A kinetic profile was measured by means of in-operando React-IR by Dr. Nicolas 
Sauermann in the Ackermann group, showing the consumption of benzamide 35a as 
well as the formation of C–H amination product 58aa (Figure 3.3.5). These results 
revealed that there was no sign of initiation period during the nickela-electrooxidative 
C–H transformation. 




Figure 3.3.5. Reaction profile monitored by in-operando React-IR. Performed by Dr. Nicolas Sauermann. 
3.3.3.4 KIE Studies 
Two independent experiments between substrates 35a and [D5]-35a were conducted 
under the modified optimization condition (Figure 3.3.6). A kinetic isotope effect (KIE) 
of kH/kD ≈ 1.1 was recorded by Dr. Nicolas Sauermann by in-operando React-IR, which 
showed that the C–H bond cleavage was not the rate-limiting step.  
 
Figure 3.3.6. KIE studies by in-operando React-IR. Performed by Dr. Nicolas Sauermann. 




In order to prove the generation of molecular hydrogen, the atmosphere after the 
electrocatalytic C–H amination was collected and analyzed by Headspace GC-
analysis (Figure 3.3.7). The byproduct H2 was detected eventually. 
 
Figure 3.3.7. Headspace GC-analysis. Performed by Dr. Nicolas Sauermann. 
3.3.3.6 Cyclic Voltammetry 
Finally, we conducted detailed studies by means of cyclic voltammetry (Figure 3.3.8). 
Thereby, the electrode potential for the nickel(II/III) event was found by Dr. Nicolas 
Sauermann to be strongly influenced by the addition of both the substrate  35a and 
NaOPiv, which was thus observed at Ep = +0.26 V vs. Fc+/0 (orange) (Figure 3.3.8a). 
By increasing the reaction temperature, a reversible oxidation wave was significantly 
shifted to Ep = -0.18 V vs. Fc+/0 (dark red), which could be rationalized by the generation 
of cyclometalated nickel(III) catalyst (Figure 3.3.8b). Moreover, an additional 
reversible oxidation wave at Ep = +0.49 V vs. Fc+/0 was observed (Figure 3.3.8b), 
which was furthermore indicative of an oxidation to a nickel(IV) species.[174] 
 
Figure 3.3.8. CV data (DMA, 5 mM nBu4NBF4, 100 mVs-1) for a) Ni(DME)Cl2 with the individual 
components of the catalysis. b) Ni(DME)Cl2, NaOPiv and 35a after preheating at 120 °C for 30 min. 
Performed by Dr. Nicolas Sauermann. 
3. Results and Discussion  
67 
 
3.3.4 Proposed Mechanism 
Based on these results, we propose a plausible reaction pathway, as shown in Figure 
3.3.9. The carboxylate-assisted C–H nickelation was commenced to deliver the 
nickel(II) complex 105b, which was converted to nickel(III) species 105c through an 
anodic oxidation. Amide-nickel(IV) 105d was obtained through an anodic oxidation that 
induced the subsequent reductive elimination to release the desired C–N formation of 
58 induced reductive elimination at nickel(III) 105c. Thereby, the desired product 58 
was formed, along with the regeneration of catalytically relevant competent 105a. As 
the byproduct molecular hydrogen was formed at the cathode.  
 
Figure 3.3.9. Proposed catalytic cycle for nickela-electrooxidative C–H amination. 
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3.4 Nickela-Electrocatalyzed C–H Alkoxylation with Secondary 
Alcohols 
Traditional approaches for the construction of C–O bonds, such as Buchwald–
Hartwig,[10] Ullmann–Goldberg[11] or Chan–Evans–Lam reactions,[12] mainly required to 
prefunctionalized substrates, the preparation and use of which increase the cost of 
organic syntheses. Cross dehydrogenative functionalization of C–H bonds was 
increasingly considered as a sustainable method for the improvement of atom- and 
step-economy of organic syntheses.[18] Despite the indisputable progress, 
dehydrogenative C–H alkoxylations were less investigated than hydroxylations,[123] 
acetoxylations[122, 165a] and phenoxylations,[124] mainly because aliphatic alcohols are 
prone to suffer from β-hydride elimination and overoxidation. Particularly, sterically 
encumbered secondary alcohols were underutilized for the C–O formations, compared 
to the previous reports on the use of primary alcohols.[124b, 125b-q, 126, 128, 129b-e, 130]  
 
Although tremendous advances have been achieved by the cross dehydrogenative 
couplings, stoichiometric amounts of expensive and toxic chemical oxidants, such as 
silver(I) or copper(II) salts, were required, which disobey the principle of atom-
economy.[121] Electrosynthesis has gained increasingly considerable attention through 
the use of waste-free and inexpensive electric current as green oxidant. As mentioned 
in chapter 3.3, studies of electrocatalytic C–H activations have mainly focused on 
precious 4d and 5d transition metals, recently with 3d transition metals, for instance, 
cobalt,[163, 164c-i, 165] copper,[166-168] iron and manganese.[169] Despite the indisputable 
advances, such Earth-abundant and cost-effective nickela-electrocatalysis has proven 
elusive until very recently, when we established electrocatalytic C–H aminations with 
diverse amines.[175] Furthermore, we have now found that robust nickel catalysts were 
highly effective for challenging electrooxidative C–H alkoxylations with sterically 
encumbered secondary alcohols 66. 
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3.4.1 Optimization Studies  
We commenced our investigations by optimizing the reaction conditions for the nickela-
electrocatalytic C–H alkoxylation of benzamide 106a with secondary alcohol 66a in an 
undivided cell (Table 3.4.1). After considerable experimentation, the corresponding 
product 107a was obtained in high yield using Ni(DME)Cl2 as the catalyst, bulky 
carboxylate NaO2CAd as the additive and DMA as the solvent (entries 1–6). The 
performance of the nickel catalysts was improved by verifying the concentration of 
alcohols (entries 2, 5). The essential roles of electricity, the nickel complex and the 
carboxylate for the electrocatalytic C–H alkoxylation were confirmed by control 
experiments (entries 7–9). Other nickel complexes, e.g. Ni(cod)2 and Ni(OAc)2 
successfully realized the formation of aryl ether 107a (entries 10, 11). It is particularly 
noteworthy that the nickel catalysts proved uniquely effective for the challenging 
electrooxidative C–H alkoxylation, while other transition metals, like cobalt, copper, 
manganese and even precious palladium, iridium, ruthenium, or rhodium, failed to 
accomplish the C–H transformation under otherwise identical reaction conditions 
(entries 12–18).  
Table 3.4.1. Optimization of nickela-electrooxidative C–H alkoxylation [a] 
 
Entry [TM] Additive 107a [%] 
1 Ni(DME)Cl2 NaOPiv 45 [b] 
2 Ni(DME)Cl2 NaO2CAd 55 [b] 
3 Ni(DME)Cl2 KOAc 24 [b] 
4 Ni(DME)Cl2 K2HPO4 --- [b] 
5 Ni(DME)Cl2 NaO2CAd 74 
6 Ni(DME)Cl2 NaO2CAd 69 [c] 
7 --- NaO2CAd --- 
8 Ni(DME)Cl2 --- --- 
9 Ni(DME)Cl2 NaO2CAd --- [d] 
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10 Ni(cod)2 NaO2CAd 67 
11 Ni(OAc)2∙4H2O NaO2CAd 49 [b] 
12 Co(OAc)2·4H2O NaO2CAd --- 
13 Mn(OAc)2 NaO2CAd --- 
14 Cu(OAc)2·H2O NaO2CAd --- 
15 Ru(OAc)2(PPh3)2 NaO2CAd --- 
16 [Cp*RhCl2]2 NaO2CAd --- [e] 
17 Pd(OAc)2 NaO2CAd --- 
18 [Cp*IrCl2]2 NaO2CAd --- [e] 
[a] Reaction conditions: 106a (0.25 mmol), 66a (2.5 mmol), 1-AdCO2H (20 mol %), [TM] (10 mol %), 
Additive (1.0 equiv), nBu4NClO4 (0.5 mmol), DMA (3.0 mL), CCE = 8.0 mA, 12 h, N2, GF Anode and 
nickel-foam Cathode, isolated yield. [b] 1.25 mmol of 66a. [c] DMPU as solvent. [d] Without current. [e] [TM] 
(5.0 mol %). DMPU= 1,3-dimethyltetrahydropyrimidin-2(1H)-one. 
The substitution pattern of the quinoline moiety has considerably affected the efficacy 
of nickela-electrochemical C–H oxygenation. Computation details performed by Dr. 
Lianrui Hu at the PEB0/Def2TZVP level of theory[176] uncovered that the elevated 
electron density at the quinolinyl nitrogen and decreased electron density at the amide 
nitrogen, which was beneficial for this C–H alkoxylation (Table 3.4.2). These results 
revealed the importance of increased σ-donation at the sp2-hybridized quinolinyl 
nitrogen in concert with an anionic amide nitrogen.  
Table 3.4.2. The influence of the electronically-distinct quinoline moiety [a] 
 
[a] Calculation of electron density of N,N-coordinate atoms from modified 8-aminoquinoline (PBE0 Method): 
Recovered starting materials are in parentheses. N2 = net atomic charges of the N2 atom. N12 = net 
atomic charges of the N12 atom. Performed by Dr. Lianrui Hu. 
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Other N,N-bidentate assisted systems were also tested for the challenging C–H 
secondary alkoxylation (Table 3.4.3). The unsuccessful transformative C–O 
constructions furthermore illustrated the introduction of proper chelation system was 
important to accomplish highly-efficient electrosynthesis of aryl ether. 
Table 3.4.3. Directing group power for nickela-electrooxidative alkoxylation [a] 
 
[a] Reaction conditions: 106a (0.25 mmol), 66a (2.5 mmol), 1-AdCO2H (20 mol %), [TM] (10 mol %), 
Additive (1.0 equiv), nBu4NClO4 (0.5 mmol), DMA (3.0 mL), CCE = 8.0 mA, 12 h, N2, GF Anode and 
nickel-foam Cathode, isolated yield. 
The clear benefits of electricity for this transformation were not restricted to act as a 
waste-free and inexpensive oxidant. In fact, the electricity-assisted C–H activation by 
nickel catalysis was highlighted by the outstanding levels of performance in 
comparison to the commonly used chemical oxidants, such as AgOAc, Cu(OAc)2, 
molecular oxygen, PhI(OAc)2, or K2S2O8 (Figure 3.4.1). 




Figure 3.4.1. Electrochemical versus chemical oxidants. 
3.4.2 Testing of Secondary Alcohols Following Reported Methods 
Most of the previous reports on transition metal-catalyzed C–H alkoxylation were 
limited to the use of primary alcohols or simply secondary alcohols, such as HFIP or 
iPrOH. To compare the efficiency of C–H alkoxylation between these known optimized 
reaction conditions and this nickela-electrocatalytic conditions, we next explored the 
performance of secondary alcohol 66a with the previously developed methods (Table 
3.4.4). Although palladium, copper, and cobalt catalysts showed high levels of 
performance for primary alcohols, no or minor conversions were observed with the 
sterically encumbered alcohol 66a (entries 1–2, 5–9). In addition, the failure of known 
chemical oxidative C–H alkoxylations with nickel catalysis (entries 3–4) further 
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Pd(OAc)2 107H: n.r. [a] 












Pd(OAc)2 107J: n.r. [a] 
The reactions were carried out according to the optimized reaction conditions of the literature methods, 
only by replacing the reported alcohol with the secondary alcohol 66a. [a] 66a was oxidized to 
acetophenone. 
3.4.3 Scope of Nickela-Electrocatalyzed C–H Alkoxylation 
Having established the optimized reaction conditions, we probed the versatility of the 
nickela-electrocatalytic C–H oxygenation with diverse secondary alcohols 66 (Figure 
3.4.2). Not only benzylic alcohols were converted efficiently (107f, 107g), but also 
alicyclic, cyclic, and heterocyclic alcohols were identified as viable substrates, 
providing the desired products 107i–107t with moderate to excellent yields. It is 
noteworthy that the naturally occurring alcohols, e.g., menthol, cholesterol, and β-
estradiol were selectively transformed to the natural product hybrids 107u–107w. 
Importantly, no racemization at the stereogenic centers occurred during this 
transformative electrosynthesis (107u, 99% ee). 




Figure 3.4.2. Electrooxidative C–H alkoxylation of arenes 106 with diverse secondary alcohols 66. 
Furthermore, we explored the versatilities of the nickela-electrocatalysis for the C–O 
construction with distinctly decorated arenes 106 (Figure 3.4.3). Thereby, the 
reactions with benzamides containing valuable functional groups, including halide, 
sulfide, ester and cyano substituents 106ah–106am were successfully converted. 
Owing to repulsive steric interactions, high regioselectivity during the C–O 
transformation was confirmed by the generation of sole products 107aa–107ab using 
meta-substituted substrates. To our delight, the power of nickela-electrocatalysis for 
activating the substrate was not only limited to arenes, but also applicable for the 
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heteroarene 106an. Remarkably, the competition of strongly coordinating pyridine and 
8-amininoquinuoline chelation group afforded the unique amide-guided C–H activated 
product 107ao. Additionally, the scale-up electrosynthesis was carried out without 
comprising the efficacy (107aa). 
 
Figure 3.4.3. Electrooxidative C–H alkoxylation of arenes 106. [a] Gram-scale testing with 106aa 
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3.4.4 Mechanistic Studies  
3.4.4.1 Competition Experiments Between Distinct Arenes 
In order to gain insights into the reaction mechanism of the robust nickela-
electrocatalytic C–H alkoxylation, a series of mechanistic experiments were 
implemented. The intermolecular competition experiment was first performed between 
electronically-different para-substituted arenes 106aj and 106ae, with the electron-
poor substrate proceeding faster (Figure 3.4.4a). And the same result was found when 
using meta-substrates 106aa and 106a (Figure 3.4.4b). In sharp contrast with the 
previous electrocatalytic C–H activations by palladium,[146, 148c, 148d, 149e-k] ruthenium,[157, 
158c] rhodium[150], iridium[160] or cobalt catalysis,[163, 164f-i, 165b, 165c] these findings 
suggested a concerted metalation deprotonation (CMD) pathway. [26, 173] 
 
Figure 3.4.4. Competition experiments between arenes 106. Conversions were determined by 1H NMR 
analysis with 1,3,5-(MeO)3C6H3 as the internal standard. 
3.4.4.2 Competition Experiments Between Different Nucleophiles 
Competition experiments between secondary amine 56a and alcohol 66p showed that 
the C–O transformation was more challenging in comparison to the established 
nickela-electrocatalytic C–H amination (Figure 3.4.5a). Moreover, C–H alkoxylation 
occurred faster with primary alcohol 66t than with secondary alcohol 66a, further 
highlighting the power of the established nickela-electrosynthesis (Figure 3.4.5b).  




Figure 3.4.5. Competition experiment between different nucleophiles. Conversion determined by 1H NMR 
analysis with 1,3,5-(MeO)3C6H3 as the internal standard. 
3.4.4.3 Experiments with Isotopically Labelled Solvent 
No H/D screaming was observed when using isotopically labelled tBuOD as the 
additive or using the deuterated substrate [D5]-106a, supporting a plausible irreversible 
C–H activation (Figure 3.4.6).  
 
Figure 3.4.6. Deuteration experiments. 
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3.4.4.4 KIE Studies 
A minor kinetic isotope effect (KIE) of kH/kD ≈ 1.4 as measured by independent 
experiments was suggestive of a facile C–H scission (Figure 3.4.7). 
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3.4.4.5 Headspace GC-Analysis 
Head-space gas-chromatographic analysis performed by Julia Struwe in the 
Ackermann group showed molecular hydrogen as the single stoichiometric byproduct 
(Figure 3.4.8). 
 
Figure 3.4.8. Headspace GC-analysis. Performed by Julia Struwe. 
 
3.4.4.6 Radical Trapping Experiments 
This electrocatalytic C–O formations were prevented through the independent addition 
of several typical radical scavengers, for example, TEMPO, BHT, or BQ, indicating a 
single-electron transfer (SET) step involved in the electrosynthesis (Figure 3.4.9). 
 
Figure 3.4.9. Radical trapping experiment with typical radical scavengers. TEMPO = (2,2,6,6-
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3.4.5.7 Switch On-Off experiments 
Additionally, we conducted electricity on-off experiments to investigate a radical-chain 
scenario (Figure 3.4.10). The C–H alkoxylation was inhibited without the electricity, 
however, the transformation continued after switching on the electric current again, 
thus ruling out a radical-chain process.  
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3.4.4.8 Isolation and Characterization of Nickel(III) Intermediate 
To rationalize the elementary process of C–O formation, the well-defined nickel(III) 
compound NiIII-H1 was independently prepared through electrosynthesis, and fully 
characterized by X-ray diffraction analysis (Figure 3.4.11a, b).[177] Cyclic voltammetric 
studies of NiIII-H1 by Julia Struwe showed a facile oxidation at the potential of +0.50 V 
vs. Fc+/0 (red, Figure 3.4.11c), revealing the generation of a formal nickel(IV) complex. 
 
 
Figure 3.4.11. Isolation and characterization of nickel(III) complex. a) Synthesis of NiIII-H1. b) X-ray 
diffraction analysis of NiIII-H1.  c) CV data of NiIII-H1 (DMA, 0.1 M [nBu4NBF4], 100 mV/s). CV was 
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With the well-defined nickel(III) complex NiIII-H1 in hand, we thus probed its 
performance in catalytic (Figure 3.4.12a, b) and stoichiometric settings (Figure 
3.4.12c). These results clearly manifested that NiIII-H1 was the catalytically relevant 
species in the presence of electricity. 
 
 
Figure 3.4.12. Catalytic and stoichiometric reaction using NiIII-H1. Conversion determined by 1H NMR 
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3.4.4.9 DFT Calculations 
In good agreement with these results, DFT calculations that were performed by Dr. 
Lianrui Hu indicated a non-innocent ligand phenomenon in the oxidation process to 
deliver a formal nickel(IV) species (Figure 3.4.13). The oxidation was thus best 
identified as a ligand-centered process.  
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3.4.5 Proposed Mechanism 
Based on these results, we proposed a catalytic C–H alkoxylation by nickela-
electrocatalysis (Figure 3.4.14). The initial fast C–H nickelation occurred with the 
assistance of the carboxylate in a CMD manner to generate 108b, which underwent 
anodic oxidation to form the catalytically competent 108c. Finally, high-valent 
intermediate nickel(IV) complex NiIV-M2 from the oxidized 108c was coordinated by 
the alcohol 66, along with subsequent deprotonation and reductive elimination to 
furnish the desired product 107 and the regenerated nickel(II) 108a (Figure 3.4.14). 
 
Figure 3.4.14. Proposed mechanism of nickela-electrooxidative C–H alkoxylation. 
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3.4.6 Removal of the Directing Group 
As to the synthetic utility of this method, the 6-methylquinuoline was easily removed in 
a traceless manner to provide efficient access to benzamide 109a, benzoic acid 109b, 
or aromatic aldehyde 109c (Figure 3.4.15). 
 
Figure 3.4.15. Removal of the directing group to obtain a) primary amide 109a; b) benzoic acid 109b; c) 
aromatic aldehyde 109c. 
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3.5 Nickela-Electrocatalyzed C–H Phosphorylation 
Molecular synthesis with phosphorus-containing compound is of significance to access 
bioactive compounds and materials.[132-134] In a concept of step- and atom-economy, 
transition metal-catalyzed C–H phosphorylation without prefunctionalization 
represents a more attractive perspective over the classic Hirao cross-coupling 
reactions.[134] Due to the inherent strong coordination of phosphorus to the metal center, 
the few reports on C–P formation were so far restricted to the method of adding 
phosphonating reagents slowly or sequentially, or using masked substrates.[136-139]  
 
As mentioned in chapter 1.4, electrosynthesis has emerged as an increasingly 
powerful and useful tool for transition metal-catalyzed C–C and C–Het bond formation 
due to the replacement of toxic and costly chemical oxidants and reductants by safe 
and environmentally-benign electric current as redox mediator. To the best of our 
knowledge, nickel-catalyzed C–H phosphorylation using chemical oxidants are not 
described. We hence became attracted to the challenging C–P construction by cost-
efficient electric current as the redox equivalent. 
3.5.1 Optimization Studies  
We commenced our investigations by testing reaction conditions for the nickela-
electrooxidative C–H phosphorylation of arene 106a in presence of an unmasked 
phosphonating reagent 74a, added in a non-sequential manner (Table 3.5.1). After 
additive and ligand optimization (entries 1–9), the desired product 110a was isolated 
in high yield when the organic base TMG was employed as additive and (4-CF3C6H4)3P 
or [3,5-(CF3)2C6H3]3P as ligand (entries 1–9). Control experiments confirmed the 
essential role of the base, the nickel catalyst and the current for the C–H 
phosphorylation (entries 10–12). The use of other nickel complex like Ni(cod)2 led to 
the C–P transformation as well, albeit with slightly reduced efficacy (entry 13). It is 
particularly noteworthy that Earth-abundant nickel catalysis proved to be more effective 
for the 8-aminoquinoline-assisted electrocatalytic C–H phosphorylation than other 3d 
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metals, such as cobalt, copper, manganese and iron, and precious metals likewise 
palladium, rhodium and iridium (entries 14–20). 
Table 3.5.1. Optimization of nickela-electrooxidative C–H phosphorylation [a] 
 
Entry Additive Ligand [TM] 110a [%] 
1 NaO2CAd (4-CF3C6H4)3P Ni(DME)Cl2 62 
2 NaOAc (4-CF3C6H4)3P Ni(DME)Cl2 (35) [b] 
3 DBU (4-CF3C6H4)3P Ni(DME)Cl2 (51) [b] 
4 DBN (4-CF3C6H4)3P Ni(DME)Cl2 (60) [b] 
5 TMG (4-CF3C6H4)3P Ni(DME)Cl2 72 (74) [b] 
6 TMG [3,5-(CF3)2C6H3]3P Ni(DME)Cl2 73 (74) [b] 
7 TMG XPhos Ni(DME)Cl2 67 [e] 
8 TMG --- Ni(DME)Cl2 45 (50) [b] 
9 TMG dtbpy Ni(DME)Cl2 --- 
10 --- [3,5-(CF3)2C6H3]3P Ni(DME)Cl2 --- 
11 TMG [3,5-(CF3)2C6H3]3P -- --- 
12 TMG [3,5-(CF3)2C6H3]3P Ni(DME)Cl2 --- [c] 
13 TMG [3,5-(CF3)2C6H3]3P Ni(cod)2 66 
14 TMG [3,5-(CF3)2C6H3]3P Cu(OAc)2·H2O (<5) [b] 
15 TMG [3,5-(CF3)2C6H3]3P Co(OAc)2·4H2O (<5) [b] 
16 TMG [3,5-(CF3)2C6H3]3P Mn(OAc)2 (8) [b] 
17 TMG [3,5-(CF3)2C6H3]3P Fe(acac)3 (<5) [b] 
18 TMG [3,5-(CF3)2C6H3]3P PdCl2 --- 
19 TMG [3,5-(CF3)2C6H3]3P [Cp*RhCl2]2 --- [d] 
20 TMG [3,5-(CF3)2C6H3]3P [Cp*IrCl2]2 --- [d] 
[a] Reaction conditions: 106a (0.25 mmol), 74a (0.50 mmol), [TM] (10 mol %), phosphine (20 mol %), 
Additive (1.0 equiv), TBAI (0.125 mmol), DMA (3.0 mL), CCE = 8.0 mA, 12 h, N2, graphite felt (GF) anode 
and nickel-foam cathode, isolated yield. [b] Yields were determined by 1H NMR analysis with 1,3,5-
(MeO)3C6H3 as the internal standard. [c] Without current. [d] [TM] (5.0 mol %). DBU = 1,8-
diazabicyclo[5.4.0]undec-7-ene; DBN = 1,5-diazabicyclo[4.3.0]non-5-ene; TMG = tetramethylguanidine; 
dtbpy = 4,4’-di-tert-butyl-2,2′-dipyridyl. [e] Performed by Dr. Antonio Del Vecchio. 
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A series of experiments was conducted by Dr. Antonio Del Vecchio with various typical 
chemical oxidants, such as AgOAc, Cu(OAc)2, Mn(OAc)3, K2S2O8, PhI(OAc)2, or 
molecular oxygen in the absence of electricity, furnishing the arylphosphonates with 
very low or even no conversions (Figure 3.5.1). These results clearly highlighted that 
electricity not only acted as a waste-free and cost-efficient oxidant, but also provided 
a unique efficacy for electron transfer during the C–H phosphorylation. 
 
Figure 3.5.1. Electrochemical vs. chemical oxidants. Reaction conditions: 106a (0.15 mmol), 74a 
(0.30 mmol, 2.0 equiv), phosphine (0.030 mmol, 20 mol %), Ni(DME)Cl2 (0.015 mmol, 10 mol %), TMG 
(0.15 mmol, 1.0 equiv), DMA (1.8 mL), chemical oxidants such as AgOAc (1.3 equiv, 0.20 mmol), 
Cu(OAc)2 (1.3 equiv, 0.20 mmol), Mn(OAc)3 (1.3 equiv, 0.20 mmol), K2S2O8 (1.3 equiv, 0.20 mmol), 
PhI(OAc)2 (1.3 equiv, 0.20 mmol), or O2 (1.0 atm). 1H NMR conversion with 1,3,5-(MeO)3C6H3 as the 






3. Results and Discussion  
90 
 
3.5.2 Scope of the Nickela-Electrocatalyzed C–H Phosphorylation 
Having the optimized electrocatalytic conditions in hand, we next investigated the 
effect of monodentate and bidentate directing groups (Figure 3.5.2). These findings 
emphasized the importance of the 8-aminoquinoline coordinating moiety towards the 
substrate for construction the C–P bond. 
 
Figure 3.5.2. Investigation of the effect of the directing groups. The experiments with 110D–110I were 
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Moreover, it was observed that the efficacy of the nickela-catalytic C–H 
phosphorylation was affected by the substitution pattern of the quinoline moiety 
(Figure 3.5.3, 110a–110f). We continued to probe the versatility of the nickela-
electrooxidative C–H phosphorylation with diversely decorated arenes 106. Thereby, 
substrates with different valuable functional groups including halo, ester or amine 
substituent, were transferred efficiently into aromatic phosponates 110l–110n. The 
excellent regioselectivity of nickela-electrocatalysis regime was shown with meta-
substituent benzamides 106n–106o to deliver the sole product 110q–110u. The 
electrocatalytic C–P formation was not restrained to arenes, but also heteroarenes 
furnished the corresponding arylphosphonates 110v–110W even in a shorter reaction 
time. Remarkably, the competition between the aminoquinoline directing group and 
the monodentate pyridine group exclusively produced the amide-guided C–H 
phosphorylated product 110x. Benzamide containing the protected chiral amino acid 
was well tolerated for providing peptide 110y without notable racemization. The 
strategy of versatile nickela-electrochemical C–H transformation was successfully 
applied to alkenes 106v to give desired product 110z. The efficiency of guanidine-
assisted nickela-electrooxidative C–H phosphorylation was also proven by gram-scale 
experiment with a negligible difference in isolated yields (110o, 1.31 g). 




Figure 3.5.3. Nickela-electrooxidative C(sp2)–H phosphorylation of heteroarenes and olefins 106 with 74a. 
[a] Gram-scale reaction with benzamide (1.31 g of 17); [b] 8.0 mA, 5.0 h; [c] Ni(DME)Cl2 (20 mol %), [3,5-
(CF3)2C6H3]3P (40 mol %), 74a (3.0 equiv). [d] Performed by Dr. Antonio Del Vecchio. 
Subsequently, the robustness of nickela-electrocatalytic C–H functionalization was 
highlighted by the synthesis of target products with valuable phosphonates, phosphine 
oxides and other substrates 74 (Figure 3.5.4, 110ab–110al). Product 110af derived 
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from the bulky natural D-menthol was acquired in a high yield. Six- and seven-
membered cyclic phosphonates 74g–74i were effectively converted. To our delight, 
the scope of phosphonating reagents could be extended to include mono- and 
dialkylphosphine oxides, delivering the desired arylphosphonates 110aj and 110ak 
with satisfactory yields. It is noteworthy that the sterically encumbered 
diaminophosphine oxide was efficiently converted into the corresponding product 
110al, establishing an alternative path for the synthesis of potentially exploitable 
compounds as flame-retardants for epoxy resins.[178]  
 
Figure 3.5.4. Nickela-electrooxidative C–H phosphorylation with phosphonating reagents 74. 
[a] Performed by Dr. Antonio Del Vecchio. 
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3.5.3 Mechanistic Studies  
Intrigued by the unique performance of the nickela-electrocatalytic C–H 
phosphorylation, we became attracted to probing its modus operandi. 
3.5.3.1 Competition Experiment Between Phosphite and Amine 
Intermolecular competition experiments between diisopropyl phosphonate (74a) and 
morpholine (56a) clearly showed that the optimized conditions were particular suitable 
for forming C–P bonds (Figure 3.5.5a). In addition, the conditions for the C–H 
phosphorylation also resulted in excellent yields for C–N formation (Figure 3.5.5b).  
 
Figure 3.5.5. Competition experiment between amine 56a and phosphite 74a.  
3.5.3.2 Experiments with Isotopically Labelled Solvent 
H/D exchange was not observed in both the product [Dn]-110a and the reisolated 
benzamide [Dn]-106a, when utilizing isotopically labelled tBuOD as a co-solvent 
(Figure 3.5.6). 
 
Figure 3.5.6. Deuteration experiment using tBuOD as the co-solvent. 
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3.5.3.3 KIE Studies 
A high kinetic isotope effect (KIE) of kH/kD ≈ 3.2 was found by independent experiments, 
which was indicative of the C–H activation to be the rate-limiting step (Figure 3.5.7). 





y = 0.04286x + 0.2381
R2 = 0.96












Figure 3.5.7. KIE studies by two parallel experiments. 
3.5.3.4 Headspace GC-Analysis 
Molecular hydrogen was generated as the sole byproduct, which was observed by 
Headspace GC-analysis (Figure 3.5.8). 
 
Figure 3.5.8. Headspace GC-analysis. 
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3.5.3.5 Switch On-Off Experiments 
The on-off experiments showed the electrocatalytic C–P transformation rate was faster 
when heating for a period of time before getting through current (Figure 3.5.9a). The 
reason could be that the C–H nickelated species affecting the reaction rate 
accumulated, and then slowly enabled the transformation. The C–H phosphorylation 
was halted in the absence of electricity and continued after switching the electric 
current back on, thus ruling out a radical-chain process (Figure 3.5.9b). 
 
Figure 3.5.9. On-off experiments. a) L1 (in black) standard condition and L2 (in red) with a period without 
electricity for 1.5 h. b) L3 (in blue) with incontinuous current. 
3.5.3.6 Radical Trapping Experiment 
The typical radical scavenger TEMPO, even with up to four equivalents, failed to 
prevent the electrocatalytic C–H transformation, excluding the possible generation of 
radicals (Figure 3.5.10). 
 
Figure 3.5.10. Radical trapping experiment. Performed by Dr. Antonio Del Vecchio. 
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3.5.3.7 Monitoring of the Electrocatalytic Reaction  
The nickela-electrooxidative C–H phosphorylation was monitored by 1H NMR 
spectroscopy, where the consumption of benzamide 106a together with the generation 
of phosphonated product 110a was observed with no sign of an induction period 
(Figure 3.5.11). For the details, please see Figure 5.3.64. 
 
Figure 3.5.11. Monitoring electrocatalytic reaction monitoring between 106a and 74a. 
 
The C–P transformation was monitored by in-operando high-resolution electrospray 
ionization-mass spectrometry (HR-ESI-MS), where two catalytically competent nickel 
intermediates were detected (Figure 3.5.12, performed by Dr. Antonis M. Messinis in 
Ackermann group). The peak at 581 (m/z) corresponds to the nickel(II) species NiII-M3 
or NiII-M4, whereas NiIV-M5 or NiII-M6 from the elimination step was observed at 745 
(m/z) (Figure 3.5.12, box B,C). The nickel-amide dimer NiII-M7 (Figure 3.5.12, box D) 
could finally be observed after approximately seven hours. 




Figure 3.5.12. HESI high resolution mass spectrometric monitoring of the reaction. Performed by Dr. 
Antonis M. Messinis. 
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3.5.3.8 DFT Calculations  
In order to understand the reaction mechanism of nickela-electrooxidative C–H 
phosphorylation, DFT studies of the key steps were carried out by Dr. Rositha Kuniyil 
at the PBE0-D3(BJ)/def2-TZVP+SMD(DMA)//PBE0-D3(BJ)/def2-SVP level of 
theory.[176, 179] The calculations indicated that C–H activations at the guanidine-
coordinated nickel species NiII-H2 (Figure 3.5.13a, barrier of 27.6 kcal/mol) as well as 
at the Ni(III) species NiIII-H4 (Figure 3.5.13b, barrier of 27.3 kcal/mol) are favourable.  
 
Figure 3.5.13. Gibbs free energy profile in kcal mol–1 for the C–H activation elementary step. a), C–H 
activation from the guanidine-coordinated nickel(II) intermediate NiII-H2; b), C–H activation from electron-
positive nickel(III) intermediate NiIII-H4 at the PBE0-D3(BJ)/def2-TZVP+SMD(DMA)//PBE0-D3(BJ)/def2-
SVP level of theory. All DFT calculations of C–P formations were performed by Dr. Rositha Kuniyil. For 
details, see our publications.[180] 
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3.5.3.9 Synthesis, Characterization, and Catalytic Performance of Nickel(II) and 
Nickel(III)  
The nickel (II) species NiII-M0 could not be observed when using bulky carboxylate 
NaO2CAd, while nickel(III) intermediate Ni
III-M1 was isolated under electricity (Figure 
3.5.14a). Noteworthily, TMG was found to be a better coordinating reagent, stabilizing 
the initially-formed C–H nickelation complex by formation of a stable intermediate NiII-
H3, which was isolated and fully characterized by X-ray analysis (Figure 3.5.14b, c). 
NiII-H3 could be further transformed into the cyclonickelated complex NiIII-H1 through 
anodic oxidation, assisted by the aminoquinoline substrate 35a (Figure 3.5.14b). 
Furthermore, cyclic voltammetric studies by Zhipeng Lin of nickel complex NiII-H3 
showed two oxidation waves at the potential of -0.20 V vs. Fc+/0 and +0.50 V vs. Fc+/0, 
providing strong evidence for a Ni(II/III) and Ni(III/IV) redox events (Figure 3.5.14d). 
 
Figure 3.5.14. Synthesis, characterization and catalytic performance of nickel(II) and nickel(III) complexes. 
a) Electrosynthesis of NiIII-M1 with NaO2CAd, isolated yield based on Ni(cod)2 (0.5 mmol). b) Synthesis 
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of NiII-H3 with TMG, isolated yield based on 35a (2.0 mmol); Electrosynthesis of NiIII-H1 from NiII-H3 with 
or without benzamide 35a, isolated yields based on Ni II-H3 (0.20 mmol). c) X-ray analysis of NiII-H3 and 
the CCDC number is 2008267. d) Cyclic voltammograms at 100 mV/s. nBu4NPF6 (0.1 M in DMA); 
concentration of substrates 5 mM; at 110 °C. Ni(DME)Cl2 + TMG + 106a (red); NiII-H3 + TMG (blue); NiII-H3 
+ TMG + 106a (green). CV studies were performed by Zhipeng Lin. 
Electricity-mediated oxidation of NiII-H3 with a different benzamide 106o clearly 
resulted in the formation of several dimeric nickel(III) complexes NiIII-H1, NiIII-M8, 
NiIII-M9 and NiIII-M10. These nickel(III) complexes were collected together by column 
and analysed with HR-HESI-MS by IOBC department, being suggestive of a reversible 
C–H activation (Figure 3.5.15 and Figure 3.5.16).  
 
Figure 3.5.15. The reaction of NiII-H2 with benzamide 106n. 
 
Figure 3.5.16. The HR-MS spectrum of the mixture from the reaction of NiII-H3 with benzamide 106n. 
The mixture of products was analyzed by the IOBC department. 
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To highlight the performance of the nickel(III) complex NiIII-M1 in the electrocatalytic 
C–H phosphorylation with 74a, both stoichiometric and catalytic experiments were 
independently conducted with or without electricity in the presence of NiIII-M1, 
confirming the involvement of NiIII-M1 in the electrosynthesis of C–P bond (Figure 
3.5.17). 
 
Figure 3.5.17. a) Stoichiometric reaction with NiIII-M1. b) Catalytic reaction with NiIII-M1. Conversion 
determined by 1H NMR analysis with 1,3,5-(MeO)3C6H3 as the internal standard.  
3.5.4 Proposed Mechanism 
Based on our findings, a plausible catalytic cycle of C–H phosphorylation has been 
depicted in Figure 3.5.18. Initial C–H activation occurs upon coordination of substrate 
106, anodic oxidation and internal hydrogen transfer to produce nickel(III) 111b. 
Subsequent coordination of phosphonate 74 sets the stage for an oxidation-induced 
reductive elimination at nickel(III) 111d. The TMG additive is proposed to facilitate to 
obtain the desired product 110 and the TMG-coordinated nickel(II) complex 111g, 
which undergoes a protodemetallation to regenerate 111a. The thus-formed protons 
deliver molecular hydrogen through cathodic reduction. 
 




Figure 3.5.18. Proposed catalytic cycle of nickela-electrooxidative C–H phosphorylation.  
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4. Summary and Outlook 
The development of highly step- and atom-economical C–H activations by inexpensive 
and Earth-abundant metals streamlines organic synthesis and offers new tools to 
construct C–C and C–Het bonds for inter alia pharmaceutical, agrochemical chemistry, 
and material sciences. The selective functionalization of inert C–H bonds remains a 
big challenge due to the omnipresent C–H bonds in organic compounds. In this thesis, 
several new synthetic methods have been devised to sustainable selective C–H 
activation by cost-effective ruthenium and nickelaelectro-catalysis. 
 
In the first part, cost-effective ruthenium-catalyzed ortho- or meta-C–H activation of 
decorated arenes were achieved using orienting directing groups. Ruthenium-
catalyzed ortho-C–H alkynylation of diverse benzoic acids 98 through weak 
coordination was achieved, providing step-economical access to aromatic alkynes 99 
(Figure 4.1). With the assistance of various nitrogen-containing directing groups, 
meta-C–H activations including mono- or difluoromethylation and alkylation through 
the σ-activation of the cyclometallated intermediate were efficiently developed by 
ruthenium catalysis (Figure 4.1). 
 





4. Summary and Outlook  
105 
 
Compared with the chemical oxidative C–H functionalizations, electrocatalytic C–H 
activations employ safe, waste-free and cost-efficient electricity as the redox reagent 
to replace toxic and expensive chemical oxidants, which are closely related to the trend 
of atom- and step-economy.  
 
In the second project, we developed the first nickela-electrochemical C–H activation in 
a dehydrogenative manner employing green and cheap electricity as the oxidant, 
providing an expedient approach to arylamines 58 (Figure 4.2). Moreover, the 
mechanism involving a Ni(III/IV/II) catalysis was distinct from the commonly suggested 
C–H amination with a Ni(II/III/I) pathway.[115] 
 
Figure 4.2. Nickela-electrocatalyzed C–H amination. 
In the third project, we developed a carboxylate-enabled nickela-electrocatalytic C–H 
alkoxylations of ample arene derivatives 106 with challenging secondary alcohols 66, 
producing H2 as the sole byproduct (Figure 4.3). The C–H alkoxylation was more 
effective with electricity than with any other chemical oxidants, showing a high level of 
both chemo-selectivity and position-selectivity. Detailed mechanistic studies including 
the isolation of catalytically relevant nickel(III) complex, cyclovoltammetry, and 
computation provided strong support for an oxidation-induced reductive elimination at 
nickel(III). 




Figure 4.3. Nickela-electrocatalyzed C–H alkoxylation with secondary alcohols. 
In the fourth project, we continued to work on electrocatalysis for the first C–H 
phosphorylation by cost-effective nickel using an operationally-simple non-sequential 
manifold, generating molecular hydrogen as the only waste (Figure 4.4). The robust 
electrooxidative C–P transformations allowed for a broad reaction manifold, featuring 
a plethora of heteroarenes and olefins 106 with diverse unmasked phosphorous 
reagents 74 to furnish arylphosphonates, phenylphosphine oxides and 
diazaphospholidine oxides 110. Catalytically competent cyclometallic nickel(II) and 
nickel(III) intermediates were isolated and characterized. Experimental studies and 
cyclovoltammetric analysis were among others strongly suggestive of an oxidation-
induced reductive elimination nickel(III/IV) manifold. 
 
Figure 4.4. Nickela-electrocatalyzed C–H phosphorylation. 
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5. Experimental Section 
5.1 General Remarks 
Catalysis reactions under an atmosphere of air were conducted in the sealed tubes or 
Schlenk tubes. Unless otherwise noted, other reactions were performed under N2 
atmosphere using pre-dried glassware and standard Schlenk techniques. 
If not otherwise noted, yields refer to isolated compounds, estimated to be >95% pure 
as determined by 1H NMR.  
Vacuum 
The following pressures were measured on the used vacuum pump and were not 
corrected: membrane pump vacuum (MPV): 0.5 mbar, oil pump vacuum (OPV): 0.1 
mbar. 
Melting Points (M.p.) 
Melting points were measured using a Stuart® Melting Point Apparatus SMP3 from 
BARLOWORLD SCIENTIFIC. The reported values are uncorrected.  
Chromatography 
Analytical thin layer chromatography (TLC) was performed on 0.25 mm silica gel 60F-
plates (MACHEREY-NAGEL) with 254 nm fluorescent indicator from MERCK. Plates 
were visualized under UV-light. Chromatographic purification of products was 
accomplished by flash column chromatography on MERCK silica gel, grade 60 (0.040–
0.063 mm and 0.063–0.200 mm). 
Gas Chromatography (GC)  
The conversions of the reactions were monitored by applying coupled gas 
chromatography/mass spectrometry using G1760C GCDplus with mass detector HP 
5971, 5890 Series II with mass detector HP 5972 from HEWLETT-PACKARD and 
7890A GC-System with mass detector 5975C (Triplex-Axis-Detector) from AGILENT 
TECHNOLOGIES equipped with HP-5MS columns (30 m × 0.25 mm × 0.25 m). 
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Gel Permeation Chromatography (GPC)  
GPC purifications were performed on a JAI system (JAI-LC-9260 II NEXT) equipped 
with two sequential columns (JAIGEL-2HR, gradient rate: 5.000; JAIGEL-2.5HR, 
gradient rate: 20.000; internal diameter = 20 mm; length = 600 mm; Flush rate = 10.0 
mL/min and chloroform (HPLC-quality with 0.6% ethanol as stabilizer) was used as the 
eluent. 
Infrared Spectroscopy  
Infrared spectra were recorded with a BRUKER Alpha-P ATR FT-IR spectrometer. 
Liquid samples were measured as a film, solid samples neat. The analysis of the 
spectra was carried out using the software from BRUKER OPUS 6. The absorption 
was given in wave numbers (cm−1) and the spectra were recorded in the range of 
4000–400 cm‒1. In situ-IR studies were performed on METTLER TOLEDO ReactIR™ 
15 with an iC IR 4.3 software. 
Mass Spectrometry  
Electron-ionization (EI) mass spectra were recorded on a Jeol AccuTOF instrument at 
70 eV. Electrospray-ionization (ESI) mass spectra were obtained on Bruker micrOTOF 
and maXis instruments. All systems were equipped with time-of-flight (TOF) analyzers. 
The ratios of mass to charge (m/z) were reported and the intensity relative to the base 
peak (I = 100) is given in parenthesis.  
Nuclear Magnetic Resonance Spectroscopy (NMR)  
Nuclear magnetic resonance (NMR) spectra were recorded on VARIAN Inova 500, 600, 
VARIAN Mercury 300, VX 300, VARIAN Avance 300, VARIAN VNMRS 300 and 
BRUKER Avance III 300, 400 and HD 500 spectrometers. All chemical shifts were 
given as δ-values in ppm relative to the residual proton peak of the deuterated solvent 
or its carbon atom, respectively. 1H and 13C NMR spectra were referenced using the 
residual proton or solvent carbon peak (see table), respectively. 13C and 19F NMR were 
measured as proton-decoupled spectra. 
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 1H NMR 13C NMR 
CDCl3 7.26 77.16 
[D]6-DMSO 2.50 39.52 
The observed resonance-multiplicities were described by the following abbreviations: 
s (singlet), d (doublet), t (triplet), q (quartet), hept (heptet), m (multiplet) or analogous 
representations. The coupling constants J were reported in Hertz (Hz). Analysis of the 
recorded spectra was carried out with MestReNova 10 software. 
Electrochemistry 
Nickel foam (Ni) electrodes (10 mm × 15 mm × 1.4 mm, RCM-Ni5763; obtained from 
Recemat BV, Germany) and graphite felt (GF) electrodes (10 mm × 15 mm × 6 mm, 
SIGRACELL®GFA 6 EA, obtained from SGL Carbon, Wiesbaden, Germany) were 
connected using stainless steel adapters. Electrolysis was conducted using an 
AXIOMET AX-3003P potentiostat in constant current mode, CV studies were 
performed using a Metrohm Autolab PGSTAT204 workstation and Nova 2.0 software. 
Divided cells separated by a P4-glassfrit were obtained from Glasgerätebau Ochs 
Laborfachhandel e. K. (Bovenden, Germany). 
Solvents 
All solvents for reactions involving moisture-sensitive reagents were dried, distilled and 
stored under inert atmosphere (N2) according to the following standard procedures.  
Purified by solvent purification system (SPS-800, M. Braun): CH2Cl2, toluene, 
tetrahydrofuran, dimethylformamide, diethylether. 1,2-dichloroethane, N-
methyl-2-pyrrolidone (NMP), N,N-dimethylacetamide (DMA), dimethylsulfoxide 
(DMSO) and γ-valerolactone (GVL) was dried over CaH2 for 8 h, degassed and 
distilled under reduced pressure. 1,2-dimethoxyethane (DME) was dried over sodium 
and freshly distilled under N2. 1,1,1,3,3,3-hexafluoropropan-2-ol (HFIP) was distilled 
from 3 Å molecular sieves. 2,2,2-trifluoroethanol (TFE) was stirred over CaSO4 and 
distilled under reduced pressure. Water was degassed by repeated Freeze-Pump-
Thaw degassing procedure. 1,4-dioxane and di-n-butyl-ether (nBu2O) were distilled 
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from sodium benzophenone ketyl. 
Reagents 
Chemicals obtained from commercial sources with purity above 95% were used 
without further purification. The following compounds were known and were 
synthesized according to previously described methods.  
Nitrogen-containing arenes (13a–13t),[181] indole 106H–106I,[182] benzamides 
derivatives (35a–35q, 106a–106v, 106aa–106am, 106A–106J)[129e, 183]. 
 
The following compounds were synthesized and provided by the persons listed below:  
Karsten Rauch: [RuCl2(p-cymene)]2, [Cp*RhCl2]2, [Cp*IrCl2]2, [Ru(O2CMes)2(p-
cymene)], [Ru(OAc)2(p-cymene). 
Fernando Fumagalli: Ru(OAc)2(PPh3)2 
 
Cooperation clarify: 
In the project of nickela-electrocatalytic C–H amination, Dr. Ramesh C. Samanta and 
Dr. Nicolas Sauermann carried out some experiments for the scope. GC-Headspace 
analysis, KIE studies and reaction profile by in-operando React-IR, and CV studies 
were performed by Dr. Nicolas Sauermann. 
In the project of nickela-electrocatalytic C–H alkoxylation, GC-Headspace analysis and 
CV studies were performed by Julia Struwe. DFT calculations were performed by Dr. 
Lianrui Hu. 
In the project of nickela-electrocatalytic C–H phosphorylation, Dr. Antonio Del Vecchio 
carried out some experiments for the optimization and scope, experiments with 
chemical oxidants and radical trapping experiment. Dr. Antonis M. Messinis monitored 
the reaction by HR-HESI-MS. Dr. Rositha Kuniyil carried out all the DFT calculations. 
Zhipeng Lin performed all the CV studies. 
Dr. Christopher Golz analyzed all the X-ray data in thesis thesis. 
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5.2 General Procedures 
General Procedure A: Ruthenium(II)-Catalyzed C–H Alkynylation of Benzoic 
Acids: Access to Free Acids 99 
A suspension of [RuCl2(p-cymene)]2 (15.3 mg, 5.0 mol %), K2CO3 (138 mg, 1.0 mmol), 
benzoic acid 98 (0.50 mmol), and alkynyl bromide 40B (0.65 mmol, 1.3 equiv) in 1,4-
dioxane (1.0 mL) was stirred under N2 for 16 h at 120 ºC. At ambient temperature, 
AcOH (2.0 mL) was added, the mixture was dry-loaded onto silica gel and purified by 
column chromatography (nhexane/EtOAc/AcOH) to give the products 99. 
 
General Procedure B: Ruthenium(ІІ)-Catalyzed meta-C‒H Mono- and 
Difluoromethylation 
To a solution of substrates 13 (0.50 mmol), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 
10 mol %), P(4-C6H4CF3)3 (46.7 mg, 20 mol %) or Ni(PPh3)2Cl2 (32.7 mg, 10 mol %) 
and Na2CO3 (106 mg, 1.0 mmol) in 1,4-dioxane (2.0 mL), bromodifluoroester 102a 
(304 mg, 1.5 mmol) or bromofluoroester 102b (278 mg, 1.5 mmol) was added. The 
mixture was stirred at 60 °C for 18 h. After completion of the reaction, CH2Cl2 (3.0 mL) 
was added at ambient temperature and the volatiles were removed in vacuo. 
Purification by chromatography on silica gel afforded the desired products 103. 
 
General Procedure C: Ruthenium(II)-Catalyzed meta-Alkylation 
Heteroarene 13 (0.50 mmol), [Ru(OAc)2(PPh3)2] (37.2 mg, 50 μmol, 10 mol %), and 
K3PO4 (212 mg, 1.0 mmol) were placed in a pre-dried 25 mL Ace pressure tube. The 
mixture was evacuated and purged with N2 for three times. Alkyl bromide 24B 
(1.5 mmol) and 1,4-dioxane (2.0 mL) were added and the mixture was stirred at 100 °C. 
After 18 h, the resulting mixture was concentrated in vacuo. Purification of the residue 
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General Procedure D: Nickela-Electrocatalytic C–H Amination 
The electrolysis was carried out in an undivided cell, with a graphite felt (GF) anode 
(10 mm × 15 mm × 6 mm) and a nickel-foam cathode (10 mm × 15 mm × 1.4 mm). 
Ni(DME)Cl2 (11 mg, 0.050 mmol, 20 mol %), PivONa (31 mg, 0.25 mmol, 1.0 equiv), 
nBu4NBF4 (0.50 mmol) and benzamide 35 (0.25 mmol, 1.0 equiv) were dissolved in 
DMA (3.0 mL), and then the amine 56 (0.50 mmol, 2.0 equiv) was added. At 120 °C, 
electrolysis was started with a constant current of 8.0 mA which was then maintained 
for 10 h. At ambient temperature, the mixture was transferred into a separating funnel 
and electrodes were rinsed with EtOAc (10 mL). The mixture was washed with H2O 
(10 mL) and the organic layer was separated. The aqueous layer was extracted with 
EtOAc (2 × 5.0 mL). Evaporation of the collected organic layer and subsequent column 
chromatography on silica gel (nhexane/EtOAc) yielded the desired product 58. 
 
General Procedure E: Nickela-Electrocatalytic C–H Amination 
The electrolysis was carried out in an undivided cell, with a graphite felt (GF) anode 
(10 mm × 15 mm × 6 mm) and a nickel-foam cathode (10 mm × 15 mm × 1.4 mm). 
Ni(DME)Cl2 (11 mg, 0.050 mmol, 20 mol %), PivONa (31 mg, 0.25 mmol, 1.0 equiv), 
nBu4NBF4 (0.50 mmol) and benzamide 35 (0.25 mmol, 1.0 equiv) were dissolved in 
DMA (3.0 mL), and then the amine 56 (1.25 mmol, 5.0 equiv) was added. At 130 °C, 
electrolysis was started with a constant current of 8.0 mA which was then maintained 
for 10 h. At ambient temperature, the mixture was transferred into a separating funnel 
and electrodes were rinsed with EtOAc (10 mL). The mixture was washed with H2O 
(10 mL) and the organic layer was separated. The aqueous layer was extracted with 
EtOAc (2 × 5.0 mL). Evaporation of the collected organic layer and subsequent column 
chromatography on silica gel (nhexane/EtOAc) yielded the desired product 58. 
 
General Procedure F: Nickela-Electrocatalytic C–H Alkoxylation 
The electrolysis was carried out in an undivided cell, with a graphite felt (GF) anode 
(10 mm × 15 mm × 6 mm) and a nickel-foam cathode (10 mm × 15 mm × 1.4 mm). 
Ni(DME)Cl2 (5.5 mg, 0.025 mmol, 10 mol %), 1-AdCO2H (9.0 mg, 0.050 mmol), 
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NaO2CAd (51 mg, 0.25 mmol), nBu4NClO4 (0.50 mmol) and benzamide 106 
(0.25 mmol, 1.0 equiv) were dissolved in DMA (3.0 mL), and then the alcohol 66 
(2.5 mmol) was added. At 130 °C, electrolysis was started with a constant current of 
8.0 mA which was then maintained for 12 h under N2. At ambient temperature, the 
mixture was transferred into a separating funnel and electrodes were rinsed with 
EtOAc (10.0 mL). The mixture was washed with H2O (10.0 mL) and the organic layer 
was separated. The aqueous layer was extracted with EtOAc (2 × 5.0 mL). Evaporation 
of the combined organic layer and subsequent column chromatography on silica gel 
(eluent: nhexane/EtOAc, nhexane/acetone or CH2Cl2/acetone) yielded the desired 
product 107. 
 
General Procedure G: Nickela-Electrocatalytic C–H Phosphorylation 
The electrolysis was carried out in an undivided cell, with a graphite felt (GF) anode 
(10 mm × 15 mm × 6 mm) and a nickel-foam cathode (10 mm × 15 mm × 1.4 mm). 
Benzamide 106 (0.25 mmol, 1.0 equiv), Ni(DME)Cl2 (5.5 mg, 0.025 mmol, 10 mol %), 
[3,5-(CF3)2C6H3]3P (33.5 mg, 0.050 mmol, 20 mol %), TMG (28.8 mg, 0.25 mmol, 1.0 
equiv), nBu4NI (0.125 mmol) and phosphonating reagents 74 were dissolved in DMA 
(3.0 mL). Electrolysis was conducted with a constant current of 8.0 mA which was 
maintained at 110 °C for 12 h under N2. At ambient temperature, the mixture was 
transferred into a separating funnel and electrodes were rinsed with EtOAc (10  mL). 
Subsequently, H2O (10 mL) was added to the mixture and the organic layer was 
collected. The aqueous layer was extracted with EtOAc (2 × 5.0 mL). Evaporation of 
the combined organic layers and subsequent column chromatography on silica gel 
(eluent: nhexane/EtOAc) yielded the desired product 110.  
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5.3 Experimental Procedures and Analytical Data 
5.3.1 Ruthenium-Catalyzed ortho-C–H Alkynylation  
5.3.1.1 Characterization Data 
 
3,6-Dimethoxy-2-[(triisopropylsilyl)ethynyl]benzoic acid (99a) 
The general procedure A was followed using benzoic acid 98a (91 mg, 0.50 mmol) 
and (bromoethynyl)triisopropylsilane (40B) (170 mg, 0.65 mmol, 1.30 equiv). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1) yielded 99a 
(174 mg, 96%) as a white solid. M.p.: 183−184 °C. 1H NMR (300 MHz, CDCl3) δ = 6.80 
(s, 1H), 6.80 (s, 1H), 3.76 (s, 3H), 3.74 (s, 3H), 1.11−1.05 (m, 21H). 13C NMR (75 MHz, 
CDCl3) δ = 171.4 (Cq), 155.2 (Cq), 150.1 (Cq), 126.5 (Cq), 114.0 (CH), 112.7 (CH), 112.5 
(Cq), 100.9 (Cq), 99.1 (Cq), 57.0 (CH3), 56.6 (CH3), 18.6 (CH3), 11.3 (CH). IR (neat): 
2939, 2863, 2154, 1703, 1258, 1061, 881, 660, 457 cm-1. MS (ESI) m/z (relative 
intensity) 385 (55) [M+Na]+, 363 (100) [M+H]+. HR-MS (ESI) m/z calcd for C20H31O4Si 
[M+H]+: 363.1986, found: 363.1987. 
 
2-Methoxy-6-[(triisopropylsilyl)ethynyl]benzoic acid (99b) 
The general procedure A was followed using benzoic acid 98b (76 mg, 0.50 mmol) 
and (bromoethynyl)triisopropylsilane (40B) (170 mg, 0.65 mmol, 1.30 equiv). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1) yielded 99b 
(151 mg, 91%) as a white solid. M.p.: 146–147 °C. 1H NMR (300 MHz, CDCl3) δ = 7.24 
(dd, J = 8.4, 7.7 Hz, 1H), 7.08 (dd, J = 7.7, 1.0 Hz, 1H), 6.85 (dd, J = 8.5, 1.0 Hz, 1H), 
3.80 (s, 3H), 1.09−1.04 (m, 21H). 13C NMR (75 MHz, CDCl3) δ = 171.5 (Cq), 156.4 (Cq), 
130.8 (CH), 125.4 (CH), 125.1 (Cq), 122.9 (Cq), 111.5 (CH), 103.3 (Cq), 96.0 (Cq), 56.0 
(CH3), 18.6 (CH3), 11.3 (CH). IR (neat): 2940, 2863, 2148, 1697, 1463, 1278, 1080, 
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881, 665 cm-1. MS (ESI) m/z (relative intensity) 355 (100) [M+Na]+, 333 (70) [M+H]+. 
HR-MS (ESI) m/z calcd for C19H29O3Si [M+H]+: 333.1880, found: 333.1885. 
 
2-Phenoxy-6-[(triisopropylsilyl)ethynyl]benzoic acid (99c) 
The general procedure A was followed using benzoic acid 98c (107 mg, 0.50 mmol) 
and (bromoethynyl)triisopropylsilane (40B) (170 mg, 0.65 mmol, 1.30 equiv). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1) yielded 99c 
(181 mg, 92%) as a white solid. M.p.: 127–128 °C. 1H NMR (300 MHz, CDCl3) δ = 
7.31–7.23 (m, 2H), 7.19 (s, 1H), 7.17 (d, J = 1.9 Hz, 1H), 7.10–7.02 (m, 1H), 6.98 (t, 
J = 1.0 Hz, 1H), 6.96 (dd, J = 2.0, 0.9 Hz, 1H), 6.73 (dd, J = 5.6, 3.8 Hz, 1H), 1.01−0.95 
(m, 21H). 13C NMR (75 MHz, CDCl3) δ = 171.4 (Cq), 156.4 (Cq), 154.7 (Cq), 130.8 (CH), 
129.8 (CH), 127.5 (CH), 127.4 (Cq), 124.2 (CH), 123.1 (Cq), 119.8 (CH), 118.3 (CH), 
102.8 (Cq), 96.6 (Cq), 18.5 (CH3), 11.2 (CH). IR (neat): 2940, 2863, 2158, 1703, 1571, 
1456, 1238, 997, 654 cm-1. MS (ESI) m/z (relative intensity) 417 (100) [M+Na]+, 395 
(80) [M+H]+. HR-MS (ESI) m/z calcd for C24H31O3Si [M+H]+: 395.2037, found: 395.2030.  
 
3,4,6-Trimethoxy-2-[(triisopropylsilyl)ethynyl]benzoic acid (99d) 
The general procedure A was followed using benzoic acid 98d (106 mg, 0.50 mmol) 
and (bromoethynyl)triisopropylsilane (40B) (170 mg, 0.65 mmol, 1.30 equiv). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1) yielded 99d 
(161 mg, 82%) as a white solid. M. p.: 177−178 ºC. 1H NMR (400 MHz, CDCl3) δ = 
6.48 (s, 1H), 3.88 (s, 3H), 3.85 (s, 3H), 3.83 (s, 3H), 1.12−1.11 (m, 21H). 13C NMR 
(101 MHz, CDCl3) δ = 169.6 (Cq), 155.2 (Cq), 153.8 (Cq), 145.5 (Cq), 118.3 (Cq), 116.5 
(Cq), 101.5 (Cq), 98.9 (Cq), 97.9 (CH), 60.9 (CH3), 56.8 (CH3), 56.2 (CH3), 18.6 (CH3), 
11.3 (CH). IR (neat): 2942, 2864, 2163, 1699, 1583, 1209, 1096, 691 cm-1. MS (ESI) 
m/z (relative intensity) 415 (30) [M+Na]+, 393 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
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C21H33O5Si [M+H]+: 393.2092, found: 393.2092. 
 
3,5-Dimethoxy-4-methyl-2,6-bis[(triisopropylsilyl)ethynyl]benzoic acid (99e) 
The general procedure A was followed using benzoic acid 98e (98 mg, 0.50 mmol) 
(bromoethynyl)triisopropylsilane (40B) (326 mg, 1.25 mmol, 2.50 equiv) and K2CO3 
(207 mg, 1.50 mmol, 3.0 equiv). Purification by column chromatography on silica gel 
(nhexane/EtOAc: 4/1) yielded 99e (197 mg, 71%) as a pale yellow solid. M. p.: 
198−199 ºC. 1H NMR (300 MHz, CDCl3) δ = 3.94 (s, 6H), 2.23 (s, 3H), 1.17−1.10 (m, 
42H). 13C NMR (75 MHz, CDCl3) δ = 170.5 (Cq), 161.1 (Cq), 137.6 (Cq), 127.9 (Cq), 
112.1 (Cq), 100.2 (Cq), 99.0 (Cq), 60.7 (CH3), 18.6 (CH3), 11.3 (CH), 9.6 (CH3). IR (neat): 
2942, 2865, 2153, 1703, 1450, 1389, 994, 882, 661 cm-1. MS (EI) m/z (relative intensity) 
557 [M+H]+ (3), 556 (5), 537 (10), 515 (15), 514 (40), 513 (100), 455 (5). HR-MS (EI) 
m/z calcd for C32H52O4Si2 [M]+: 556.3404, found: 556.3420. 
 
Methyl 2-ethynyl-3,4,6-trimethoxybenzoate (100d) 
Colourless solid. M.p.: 90–91 °C. 1H NMR (300 MHz, CDCl3) δ = 6.54 (s, 1H), 3.91 (s, 
3H), 3.90 (s, 3H), 3.87 (s, 3H), 3.84 (s, 3H), 3.39 (s, 1H). 13C NMR (75 MHz, CDCl3) 
δ = 166.7 (Cq), 154.0 (Cq), 153.2 (Cq), 145.0 (Cq), 118.7 (Cq), 115.8 (Cq), 98.7 (CH), 
84.8 (CH), 61.2 (CH3), 56.6 (CH3), 56.2 (CH3), 52.4 (CH3). IR (neat): 3265, 2950, 1721, 
1585, 1269, 1208, 1027, 814, 650 cm-1. MS (ESI) m/z (relative intensity) 273 (60) 
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5.3.1.2 Radical Trapping Experiment 
 
Figure 5.3.1. Radical trapping experiment. 
Substrate 98d (106 mg, 0.5 mmol, 1.0 equiv), (bromoethynyl)triisopropylsilane (40B) 
(170 mg, 1.3 equiv), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), K2CO3 (138 mg, 
1.0 mmol) and 2,6-bis(1,1-dimethylethyl)-4-methylphenol (110 mg, 0.5 mmol, 1.0 equiv) 
were placed into a 25 mL Schlenk tube equipped with a septum under N2 atmosphere. 
1,4-dioxane (2.0 mL) was introduced via cannula. The reaction mixture was stirred at 
120 °C for 16 h. At ambient temperature, MeCN (3.0 mL), K2CO3 (207 mg, 1.50 mmol) 
and MeI (355 mg, 2.5 mmol) were added and the mixture was stirred at 50 ºC for 
another 2.0 h. At ambient temperature, the mixture was dry loaded onto silica gel and 
purified by column chromatography on silica gel (nhexane/EtOAc: 4/1) to yield 99d’ 
(142 mg, 70%) as an off-white solid. 
5.3.1.3 Removal of Silyl Group 
 
Figure 5.3.2. Traceless removal to access terminal aromatic alkynes. 
Compound 99d’ (203 mg, 0.50 mmol) was dissolved in THF (3 mL) and TBAF (1.0 M 
in THF, 1.50 mL) was then added at ambient temperature with constant stirring for 
12 hours, the mixture was concentrated in vacuo. The residue was dissolved in H2O 
(30 mL) was extracted with EtOAc (3 × 5 mL), and the combined organic layers were 
washed with brine (10 mL), dried over Na2SO4, filtered and evaporated in vacuo. The 
obtained crude product was purified by column chromatography to afford the desired 
terminal alkyne 100d (118 mg, 94% yield) as a white solid. 
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5.3.2 Ruthenium-Catalyzed meta-C–H Mono- and Difluoromethylation 
5.3.2.1 Characterization Data 
 
Ethyl 2,2-difluoro-2-[3-(pyridin-2-yl)phenyl]acetate (103a) 
The general procedure B was followed using substrate 13a (78 mg, 0.50 mmol) and 
102a (304 mg, 1.5 mmol). Isolation by column chromatography (nhexane/EtOAc: 9/1) 
yielded 103a (99 mg, 71%) as a colorless oil. A reaction using Ni(PPh3)2Cl2 (10 mol %) 
instead of P(4-C6H4CF3)3 yielded 103a (100 mg, 72%). 
1H NMR (300 MHz, CDCl3) δ = 
8.71 (ddd, J = 4.8, 1.6, 1.1 Hz, 1H), 8.24 (ddt, J = 1.9, 1.3, 0.7 Hz, 1H), 8.16 (dddt, J = 
7.6, 1.9, 1.4, 0.7 Hz, 1H), 7.83–7.73 (m, 2H), 7.66 (ddd, J = 7.8, 1.9, 1.3 Hz, 1H), 7.57 
(dd, J = 7.8, 7.6 Hz, 1H), 7.30–7.25 (m, 1H), 4.31 (q, J = 7.1 Hz, 2H), 1.31 (t, J = 7.1 Hz, 
3H). 13C NMR (125 MHz, CDCl3) δ = 164.0 (t, 2JC–F = 35.2 Hz, Cq), 156.0 (Cq), 149.7 
(CH), 139.8 (Cq), 136.8 (CH), 133.3 (t, 2JC–F = 25.5 Hz, Cq), 129.4 (t, 4JC–F = 1.7 Hz, 
CH), 129.1 (CH), 125.8 (t, 3JC–F = 6.0 Hz, CH), 123.9 (t, 3JC–F = 6.3 Hz, CH), 122.6 (CH), 
120.6 (CH), 113.3 (t, 1JC–F = 252.0 Hz, Cq), 63.2 (CH2), 14.0 (CH3). 
19F NMR (282 MHz, 
CDCl3) δ = -103.7 (s). IR (neat): 2986, 1761, 1585, 1463, 1290, 1100, 777 cm-1. MS 
(ESI) m/z (relative intensity) 278 (100) [M+H]+. HR-MS (ESI) m/z calcd for C15H14F2NO2 
[M+H]+: 278.0987, found: 278.0994. 
 
Methyl 2-(2-ethoxy-1,1-difluoro-2-oxoethyl)-4-(pyridin-2-yl)benzoate (103b) 
The general procedure B was followed using substrate 13c (107 mg, 0.50 mmol) and 
102a (304 mg, 1.5 mmol). Isolation by column chromatography (nhexane/EtOAc: 6/1) 
yielded 103b (137 mg, 82%) as a colorless oil. A reaction using Ni(PPh3)2Cl2 (10 mol %) 
instead of P(4-C6H4CF3)3 yielded 103b (106 mg, 63%). 
1H NMR (600 MHz, CDCl3) δ = 
8.72 (ddd, J = 4.8, 1.8, 1.1 Hz, 1H), 8.47 (d, J = 1.8 Hz, 1H), 8.21 (dd, J = 8.1, 1.8 Hz, 
1H), 8.10 (d, J = 8.1 Hz, 1H), 7.87–7.70 (m, 2H), 7.30 (ddd, J = 7.0, 4.8, 1.6 Hz, 1H), 
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4.32 (q, J = 7.1 Hz, 2H), 3.87 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H). 13C NMR (125 MHz, 
CDCl3) δ = 166.1 (Cq), 163.1 (t, 2JC–F = 33.6 Hz, Cq), 155.0 (Cq), 149.8 (CH), 143.0 (Cq), 
137.0 (CH), 134.1 (t, 2JC–F = 23.7 Hz, Cq), 131.6 (CH), 128.7 (CH), 128.6 (Cq), 125.2 (t, 
3JC–F = 10.5 Hz, CH), 123.2 (CH), 121.0 (CH), 113.1 (t, 1JC–F = 249.6 Hz, Cq), 62.8 
(CH2), 52.4 (CH3), 13.9 (CH3). 
19F NMR (282 MHz, CDCl3) δ = -99.0 (s). IR (neat): 2987, 
1757, 1721, 1566, 1281, 1080, 753 cm-1. MS (ESI) m/z (relative intensity) 358 (50) 
[M+Na]+, 336 (100) [M+H]+. HR-MS (ESI) m/z calcd for C17H15F2NO4 [M+H]+: 336.1042, 
found: 336.1040. 
 
Ethyl 2-[3-(5-acetylpyridin-2-yl)phenyl]-2,2-difluoroacetate (103c) 
The general procedure B was followed using substrate 13d (99 mg, 0.50 mmol) and 
102a (304 mg, 1.5 mmol). Isolation by column chromatography (nhexane/EtOAc: 5/1) 
yielded 103c (123 mg, 77%) as a colorless oil. A reaction using Ni(PPh3)2Cl2 (10 mol %) 
instead of P(4-C6H4CF3)3 yielded 103c (125 mg, 78%). 
1H NMR (600 MHz, CDCl3) δ = 
9.22 (d, J = 2.3 Hz, 1H), 8.30 (s, 1H), 8.29 (dd, J = 8.2, 2.3 Hz, 1H), 8.20 (dd, J = 7.8, 
1.8 Hz, 1H), 7.85 (dd, J = 8.2 Hz, 1H), 7.70 (dd, J = 7.8, 1.9 Hz, 1H), 7.58 (d, J = 7.8, 
7.8 Hz, 1H), 4.30 (q, J = 7.1 Hz, 2H), 2.65 (s, 3H), 1.30 (t, J = 7.1 Hz, 3H). 13C NMR 
(125 MHz, CDCl3) δ = 196.0 (Cq), 163.8 (t, 2JC–F = 35.0 Hz, Cq), 159.2 (Cq), 149.9 (CH), 
138.6 (Cq), 136.4 (CH), 133.5 (t, 2JC–F = 25.6 Hz, Cq), 130.9 (Cq), 129.7 (t, 4JC–F = 1.8 Hz, 
CH), 129.2 (CH), 126.8 (t, 3JC–F = 6.0 Hz, CH), 124.3 (t, 4JC–F = 6.3 Hz, CH), 120.1 (CH), 
113.1 (t, 1JC–F = 252.2 Hz, Cq), 63.2 (CH2), 26.7 (CH3), 13.9 (CH3). 
19F NMR (282 MHz, 
CDCl3) δ = -103.8. IR (neat): 2986, 1761, 1685, 1588, 1276, 1224, 1100, 806 cm-1. MS 
(ESI) m/z (relative intensity) 342 (30) [M+Na]+, 320 (100) [M+H]+. HR-MS (ESI) m/z 
calcd for C17H16F2NO3 [M+H]+: 320.1093, found: 320.1093. 
 




Ethyl 2-(2-acetyl-5-(1H-pyrazol-1-yl)phenyl)-2,2-difluoroacetate (103d) 
The general procedure B was followed using substrate 13e (93 mg, 0.50 mmol) and 
102a (304 mg, 1.5 mmol). Isolation by column chromatography (nhexane/EtOAc: 4/1) 
yielded 103d (43 mg, 28%) as a brown solid. A reaction using Ni(PPh3)2Cl2 (10 mol %) 
instead of P(4-C6H4CF3)3 yielded 103d (83 mg, 53%). M.p.: 106–107 °C. 
1H NMR (600 
MHz, CDCl3) δ = 8.18 (d, J = 1.9 Hz, 1H), 8.04 (d, J = 2.7 Hz, 1H), 7.99–7.93 (m, 2H), 
7.77 (d, J = 1.7 Hz, 1H), 6.52 (dd, J = 2.6, 1.7 Hz, 1H), 4.35 (q, J = 7.1 Hz, 2H), 2.60 
(s, 3H), 1.33 (t, J = 7.1 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ = 197.9 (Cq), 162.7 (t, 
2JC–F = 32.9 Hz, Cq), 142.6 (Cq), 142.4 (CH), 134.6 (t, 2JC–F = 23.7 Hz, Cq), 133.0 (t, 
3JC-F = 2.8 Hz, Cq), 131.9 (CH), 126.9 (CH), 119.8 (CH), 117.3 (t, 3JC–F = 11.4 Hz, CH), 
112.9 (t, 1JC–F = 250.5 Hz, Cq), 109.0 (CH), 62.8 (CH2), 28.0 (CH3), 13.9 (CH3). 
19F NMR 
(282 MHz, CDCl3) δ = -99.8. IR (neat): 3130, 2923, 1762, 1387, 1268, 1120, 1006, 
742 cm-1. MS (ESI) m/z (relative intensity) 331 (85) [M+Na]+, 309 (100) [M+H]+. HR-
MS (ESI) m/z calcd for C15H15F2N2O3 [M+H]+: 309.1045, found: 309.1048. 
 
2,2-Difluoro-1-morpholino-2-[3-(pyridin-2-yl)phenyl]ethan-1-one (103e) 
The general procedure B was followed using substrate 13a (78 mg, 0.50 mmol) and 
102b (366 mg, 1.5 mmol). Isolation by column chromatography (nhexane/EtOAc: 8/1) 
yielded 103e (49 mg, 31%) as a colorless oil. A reaction using Ni(PPh3)2Cl2 (10 mol %) 
instead of P(4-C6H4CF3)3 yielded 103e (132 mg, 83%). 
1H NMR (400 MHz, CDCl3) δ = 
8.69 (ddd, J = 4.8, 1.6, 1.1 Hz, 1H), 8.20 (d, J = 1.6 Hz, 1H), 8.16–8.08 (m, 1H), 7.81–
7.69 (m, 2H), 7.58–7.51 (m, 2H), 7.26 (ddd, J = 6.7, 4.8, 1.7 Hz, 1H), 3.69–3.68 (m, 
4H), 3.50–3.49 (m, 4H). 13C NMR (101 MHz, CDCl3) δ = 162.0 (t, 2JC–F = 30.3 Hz, Cq), 
155.9 (Cq), 149.7 (CH), 140.0 (Cq), 137.1 (CH), 134.0 (t, 2JC–F = 24.9 Hz, Cq), 129.4 (t, 
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4JC–F = 1.7 Hz, CH), 129.3 (CH), 125.6 (t, 3JC–F = 5.6 Hz, CH), 123.7 (t, 3JC–F = 5.8 Hz, 
CH), 122.8 (CH), 120.7 (CH), 115.6 (t, 1JC–F = 251.2 Hz, Cq), 66.7 (CH2), 66.4 (CH2), 
46.7 (t, 4JC–F = 4.1 Hz, CH2), 43.5 (CH2). 
19F NMR (376 MHz, CDCl3) δ = -94.5 (s). IR 
(neat): 2918, 2856, 1666, 1435, 1225, 1114, 995, 729 cm-1. MS (ESI) m/z (relative 
intensity) 341 (15) [M+Na]+, 319 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C17H16F2N2O2 [M+H]+: 319.1253, found: 319.1257. 
 
N,N-Diethyl-2,2-difluoro-2-[3-(pyridin-2-yl)phenyl]acetamide (103f) 
The general procedure B was followed using substrate 13a (78 mg, 0.50 mmol) and 
102c (345 mg, 1.5 mmol). Isolation by column chromatography (nhexane/EtOAc: 8/1) 
yielded 103f (81 mg, 53%) as a colorless oil. A reaction using Ni(PPh3)2Cl2 (10 mol %) 
instead of P(4-C6H4CF3)3 yielded 103f (62 mg, 41%). 
1H NMR (300 MHz, CDCl3) δ = 
8.63 (dd, J = 4.8, 1.5 Hz, 1H), 8.12 (dd, J = 1.7, 0.9 Hz, 1H), 8.10–8.03 (m, 1H), 7.76–
7.65 (m, 2H), 7.55–7.43 (m, 2H), 7.24–7.13 (m, 1H), 3.37 (q, J = 7.1 Hz, 2H), 3.22 (qt, 
J = 7.0, 1.4 Hz, 2H), 1.11 (t, J = 7.1 Hz, 3H), 1.00 (t, J = 7.0 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ = 162.7 (t, 2JC–F = 29.9 Hz, Cq), 156.1 (Cq), 149.7 (CH), 140.0 (Cq), 
137.0 (CH), 134.6 (t, 2JC–F = 25.1 Hz, Cq), 129.2 (CH), 125.7 (t, 3JC–F = 5.6 Hz, CH), 
123.7 (t, 3JC–F = 5.8 Hz, CH), 122.7 (CH), 120.7 (CH), 115.6 (t, 1JC–F = 250.6 Hz, Cq), 
42.2 (t, 4JC–F = 4.2 Hz, CH2), 41.5 (CH2), 13.9 (CH3), 12.3 (CH3). 
19F NMR (282 MHz, 
CDCl3) δ = -94.7. IR (neat): 2977, 1661, 1461, 1431, 1242, 777, 700 cm-1. MS (ESI) 
m/z (relative intensity) 327 (20) [M+Na]+, 305 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C17H19F2N2O [M+H]+: 305.1460, found: 305.1460. 
 
2,2-Difluoro-2-[3-(pyridin-2-yl)phenyl]-1-(pyrrolidin-1-yl)ethan-1-one (103g) 
The general procedure B was followed using substrate 13a (78 mg, 0.50 mmol) and 
102d (342 mg, 1.5 mmol). Isolation by column chromatography (nhexane/EtOAc: 8/1) 
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yielded 103g (65 mg, 43%) as a colorless oil. A reaction using Ni(PPh3)2Cl2 (10 mol %) 
instead of P(4-C6H4CF3)3 yielded 103g (116 mg, 77%). 
1H NMR (300 MHz, CDCl3) δ = 
8.68 (dd, J = 4.9, 1.4 Hz, 1H), 8.19 (s, 1H), 8.12 (d, J = 7.7 Hz, 1H), 7.82–7.69 (m, 2H), 
7.64–7.48 (m, 2H), 7.28–7.21 (m, 1H), 3.67–3.27 (m, 4H), 1.92–1.70 (m, 4H). 13C NMR 
(75 MHz, CDCl3) δ = 162.1 (t, 2JC–F = 31.1 Hz, Cq), 156.2 (Cq), 149.7 (CH), 139.8 (Cq), 
137.0 (CH), 133.9 (t, 2JC–F = 25.8 Hz, Cq), 129.2 (t, 4JC–F = 1.8 Hz, CH), 129.1 (CH), 
125.9 (t, 3JC–F = 5.9 Hz, CH), 123.9 (t, 3JC–F = 6.0 Hz, CH), 122.6 (CH), 120.8 (CH), 
115.4 (t, 1JC–F = 251.2 Hz, Cq), 47.5 (CH2), 46.8 (t, 1JC–F = 5.0 Hz, CH2), 26.4 (CH2), 
23.2 (CH2). 
19F NMR (282 MHz, CDCl3) δ = -98.5 (s). IR (neat): 2976, 2884, 1657, 
1434, 1223, 1064, 776 cm-1. MS (ESI) m/z (relative intensity) 325 (30) [M+Na]+, 303 
(100) [M+H]+. HR-MS (ESI) m/z calcd for C17H17F2N2O [M+H]+: 303.1303, found: 
303.1307. 
 
Ethyl 2-fluoro-2-[3-(pyrimidin-2-yl)phenyl]acetate (103i) 
The general procedure B was followed using substrate 13g (87 mg, 0.50 mmol) and 
102e (278 mg, 1.5 mmol). Isolation by column chromatography (nhexane/EtOAc: 8/1) 
yielded 103i (86 mg, 62%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ = 8.60 (ddd, 
J = 4.9, 1.8, 1.0 Hz, 1H), 8.11–7.94 (m, 2H), 7.77–7.54 (m, 2H), 7.29–7.02 (m, 2H), 
6.02 (d, J = 46.8 Hz, 1H), 4.29–4.11 (m, 2H), 1.19 (t, J = 7.1 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ = 167.9 (dd, 2,4JC–F = 27.7, 1.0 Hz, Cq), 160.9 (dd, 1,3JC–F = 252.8, 
4.4 Hz, Cq), 155.5 (Cq), 149.7 (CH), 137.0 (CH), 136.1 (dd, 4,4JC–F = 3.4, 1.0 Hz, Cq), 
130.2 (dd, 3,3JC–F = 8.6, 2.5 Hz, CH), 127.5 (dd, 3,5JC–F = 5.5, 3.3 Hz, CH), 122.4 (CH), 
122.2 (dd, 2,2JC–F = 21.2, 14.5 Hz, Cq), 120.3 (CH), 116.3 (d, 2,4JC–F = 21.6, 1.2 Hz, CH), 
83.7 (dd, 1,3JC–F = 185.0, 3.3 Hz, CH), 62.1 (CH2), 14.0 (CH3). 
19F NMR (282 MHz, 
CDCl3) δ = -117.4 (s), -181.5 (s). IR (neat): 2986, 1761, 1711, 1467, 1220, 1055, 
782 cm-1. MS (ESI) m/z (relative intensity) 300 (30) [M+Na]+, 278 (100) [M+H]+. HR-MS 
(ESI) m/z calcd for C15H14F2NO2 [M+H]+: 278.0987, found: 278.0993. 




Ethyl 2-fluoro-2-[2-methyl-5-(1H-pyrazol-1-yl)phenyl]acetate (103j) 
The general procedure B was followed using 1-(p-tolyl)-1H-pyrazole (13h) (79 mg, 
0.50 mmol) and 102e (278 mg, 1.5 mmol). Isolation by column chromatography 
(nhexane/EtOAc: 8/1) yielded 103j (79 mg, 60%) as a colorless oil. 1H NMR (300 MHz, 
CDCl3) δ = 7.89 (dd, J = 2.5, 0.6 Hz, 1H), 7.71 (d, J = 2.5 Hz, 1H), 7.68 (dd, J = 1.8, 
0.6 Hz, 1H), 7.63 (dd, J = 8.2, 2.5 Hz, 1H), 7.26 (d, J = 8.2 Hz, 1H), 6.43 (dd, J = 2.5, 
1.8 Hz, 1H), 5.97 (d, J = 46.8 Hz, 1H), 4.42–4.08 (m, 2H), 2.43 (s, 3H), 1.23 (t, J = 
7.1 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ = 168.1 (d, 2JC–F = 27.7 Hz, Cq), 140.9 (CH), 
138.5 (Cq), 134.3 (d, 3JC–F = 3.8 Hz, Cq), 133.8 (d, 2JC–F = 19.3 Hz, Cq), 131.8 (CH), 
126.6 (CH), 120.1 (d, 4JC–F = 2.2 Hz, CH), 117.7 (d, 3JC–F = 7.8 Hz, CH), 107.6 (CH), 
87.0 (d, 1JC–F = 185.0 Hz, CH), 61.9 (CH2), 18.7 (CH3), 14.1 (CH3). 
19F NMR (282 MHz, 
CDCl3) δ = -181.2 (dd, J = 47.2, 1.2 Hz). IR (neat): 2983, 1923, 1756, 1522, 1393, 
1323, 1043, 751 cm-1. MS (ESI) m/z (relative intensity) 285 (80) [M+Na]+, 263 (100) 
[M+H]+. HR-MS (ESI) m/z calcd for C14H16FN2O2 [M+H]+: 263.1190, found: 263.1194. 
5.3.2.2 Hydrolysis of Ethyl Ester 103 
 
Figure 5.3.3. Traceless removal ethyl ester. 
2,2-Difluoro-2-[3-(pyridin-2-yl)phenyl]acetic acid (104a): To a solution of 103a 
(277 mg, 1.0 mmol) in MeOH (3 mL) was added K2CO3 (3.0 mL, 1N) at 23 °C. The 
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mixture was stirred at 23 °C for 20 min and poured into 5% HCl (3.0 mL), and 
successively extracted with EtOAc (10 mL × 3). The combined organic phase was 
washed with brine and dried over anhydrous Na2SO4. After removal of the solvents in 
vacuo, the residue was purified by column chromatography (CH2Cl2/MeOH: 5/1) to give 
104a (237 mg, 95%) as colorless solid. M.p.: 134–135 °C. 1H NMR (300 MHz, DMSO-
d6) δ = 8.71 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.34 (s, 1H), 8.30–8.20 (m, 1H), 8.03 (dd, 
J = 8.0, 1.1 Hz, 1H), 7.92 (ddd, J = 8.1, 7.4, 1.8 Hz, 1H), 7.75–7.59 (m, 2H), 7.41 (ddd, 
J = 7.5, 4.8, 1.1 Hz, 1H), 3.18 (s, 1H). 13C NMR (101 MHz, DMSO-d6) δ = 165.4 (t, 
2JC-F = 33.3 Hz, Cq), 155.0 (Cq), 150.1 (CH), 139.6 (Cq), 138.0 (Cq), 134.1 (t, 2JC–F = 
25.6 Hz, Cq), 130.0 (CH), 129.4 (CH), 126.1 (t, 3JC–F = 6.0 Hz, CH), 123.7 (CH), 123.5 
(t, 3JC–F = 6.2 Hz, CH), 121.0 (CH), 114.1 (t, 1JC–F = 250.3 Hz, Cq). 
19F NMR (282 MHz, 
DMSO-d6) δ = -102.3 (s). IR (neat): 3000, 1710, 1358, 1419, 1219, 1092, 899, 528 cm-1. 
MS (ESI) m/z (relative intensity) 272 (20) [M+Na]+, 250 (100) [M+H]+. HR-MS (ESI) 
m/z calcd for C13H10F2NO2 [M+H]+: 250.0674, found: 250.0685.  
 
2,2-Difluoro-2-[2-fluoro-5-(1H-pyrazol-1-yl)phenyl]acetic acid (104b): To a 
solution of 103k (284 mg, 1.0 mmol) in MeOH (3.0 mL) was added K2CO3 (3.0 mL, 1N) 
at 23 °C. The mixture was stirred at 23 °C for 20 min and poured into 5% HCl (3.0 mL), 
and successively extracted with EtOAc (10 mL × 3). The combined organic phase was 
washed with brine and dried over anhydrous Na2SO4. After removal of the solvents in 
vacuo, the residue was purified by column chromatography (CH2Cl2/MeOH: 5/1) to give 
104b (275 mg, 97%) as colorless solid. M.p.: 119–120 °C. 1H NMR (300 MHz, DMSO-
d6) δ = 8.53 (dd, J = 2.6, 0.6 Hz, 1H), 7.98 (dd, J = 6.3, 2.8 Hz, 1H), 7.95–7.87 (m, 1H), 
7.76 (dd, J = 1.7, 0.6 Hz, 1H), 7.38 (dd, J = 10.1, 8.9 Hz, 1H), 6.55 (dd, J = 2.6, 1.7 Hz, 
1H). 13C NMR (101 MHz, DMSO-d6) δ = 164.0 (t, 2JC–F = 26.5 Hz, Cq), 157.6 (dt, 1,3JC-F = 
249.7, 3.8 Hz, Cq), 141.6 (CH), 136.1 (d, 4JC–F = 2.9 Hz, Cq), 128.5 (CH), 126.4 (dt, 
2,2JC–F = 26.5, 13.1 Hz, Cq), 121.3 (d, 3JC–F = 8.6 Hz, CH), 118.1 (td, 3,3JC–F = 7.6, 3.3 Hz, 
CH), 117.6 (d, 2JC–F = 23.0 Hz, CH), 114.2 (t, 1JC–F = 254.4 Hz, Cq), 108.5 (CH). 
19F NMR 
(282 MHz, DMSO-d6) δ = -98.4 (d, J = 11.2 Hz, 2F), -117.9 (t, J = 11.2 Hz, 1F). IR 
(neat): 3148, 1708, 1663, 1522, 1505, 1405, 1225, 1040, 753 cm-1. MS (ESI) m/z 
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(relative intensity) 279 (20) [M+Na]+, 257 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C11H6F3N2O2 [M-H]+: 255.0387, found: 255.0391.  
5.3.3 Ruthenium-Catalyzed meta-C–H Alkylation 
5.3.3.1 Characterization Data 
  
1-[3-(tert-Butyl)phenyl]-1H-pyrazole (103k) 
The general procedure C was followed using substrate 13i (72.0 mg, 0.50 mmol) and 
bromide 24B (206 mg, 1.5 mmol). Purification by column chromatography 
(nhexane/EtOAc: 10/1) yielded 103k (74.0 mg, 74%) as a colorless oil. 1H NMR 
(300 MHz, CDCl3) δ = 7.90 (dd, J = 2.5, 0.6 Hz, 1H), 7.75 (ddd, J = 2.2, 1.7, 0.6 Hz, 
1H), 7.72 (dd, J = 1.8, 0.6 Hz, 1H), 7.43 (ddd, J = 7.5, 2.2, 1.7 Hz, 1H), 7.36 (ddd, J = 
8.1, 7.5, 0.6 Hz, 1H), 7.31 (dd, J = 8.1, 1.7, 1.7 Hz, 1H), 6.44 (dd, J = 2.5, 1.8 Hz, 1H) 
13C NMR (126 MHz, CDCl3) δ = 152.8 (Cq), 140.7 (CH), 140.0 (Cq), 128.9 (CH), 126.8 
(CH), 123.5 (CH), 116.7 (CH), 116.4 (CH), 107.3 (CH), 35.0 (Cq), 31.3 (CH3). IR (ATR): 
2963, 2867, 1589, 1519, 1391, 1043, 947, 787, 745, 698 cm–1. MS (EI) m/z (relative 
intensity) 200 (40) [M]+, 185 (100), 157 (20). HR-MS (EI) m/z calcd for C13H16N2 [M]+: 
200.1308, found: 200.1312. 
 
1-[3-(tert-Butyl)-4-methoxyphenyl]-1H-pyrazole (103l) 
The general procedure C was followed using substrate 13j (87.0 mg, 0.50 mmol) and 
bromide 24B (206 mg, 1.5 mmol). Purification by column chromatography 
(nhexane/EtOAc: 10/1) yielded 103l (95.9 mg, 83%) as a colorless oil. 1H NMR 
(300 MHz, CDCl3) δ = 7.80 (dd, J = 2.4, 0.7 Hz, 1H), 7.68 (dd, J = 1.8, 0.7 Hz, 1H), 
7.59 (d, J = 2.7 Hz, 1H), 7.40 (dd, J = 8.7, 2.7 Hz, 1H), 6.90 (d, J = 8.7 Hz, 1H), 6.41 
(dd, J = 2.4, 1.8 Hz, 1H), 3.85 (s, 3H), 1.40 (s, 9H). 13C NMR (126 MHz, CDCl3) δ = 
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157.1 (Cq), 140.3 (CH), 139.4 (Cq), 133.4 (Cq), 126.9 (CH), 119.0 (CH), 118.1 (CH), 
111.8 (CH), 106.8 (CH), 55.3 (CH3), 35.1 (Cq), 29.6 (CH3). IR (ATR): 2954, 2867, 1516, 
1493, 1234, 1045, 1028, 809, 746, 640 cm–1. MS (ESI) m/z (relative intensity) 231 (100) 
[M+H]+, 253 (25) [M+Na]+. HR-MS (ESI) m/z calcd for C14H19N2O [M+H]+: 231.1492, 




The general procedure C was followed using substrate 13h (79.0 mg, 0.50 mmol) and 
bromide 24B (206 mg, 1.5 mmol). Purification by column chromatography 
(nhexane/EtOAc: 10/1) yielded 103m (66.7 mg, 62%) as a colorless oil. 1H NMR 
(300 MHz, CDCl3) δ = 7.88 (dd, J = 2.5, 0.7 Hz, 1H), 7.74 (d, J = 2.4 Hz, 1H), 7.72 (d, 
J = 1.6 Hz, 1H), 7.35 (dd, J = 8.2, 2.4 Hz, 1H), 7.18 (d, J = 8.2 Hz, 1H), 6.52–6.40 (m, 
1H), 2.57 (s, 3H), 1.46 (s, 9H). 13C NMR (101 MHz, CDCl3) δ = 149.4 (Cq), 140.6 (CH), 
138.1 (Cq), 134.7 (Cq), 133.4 (CH), 126.8 (CH), 117.7 (CH), 116.6 (CH), 107.1 (CH), 
36.0 (Cq), 30.6 (CH3), 22.7 (CH3). IR (ATR): 2957, 2871, 1610, 1517,1395, 1045, 950, 
747, 611 cm–1. MS (EI) m/z (relative intensity) 214 (60) [M]+, 199 (100). HR-MS (EI) 
m/z calcd for C14H18N2 [M]+: 214.1465, found: 214.1472. 
 
2-[3-(tert-butyl)phenyl]pyridine (103n) 
The general procedure C was followed using substrate 13a (77.5 mg, 0.50 mmol) and 
bromide 24B (206 mg, 1.5 mmol). Purification by column chromatography 
(nhexane/EtOAc: 10/1) yielded 103n (78.1mg, 74%) as a colorless oil. 1H NMR 
(300 MHz, CDCl3) δ = 8.78–8.70 (m, 1H), 8.07 (ddd, J = 1.6, 1.6, 0.6 Hz, 1H), 7.79 
(ddd, J = 7.3, 1.6, 1.6 Hz, 1H), 7.76 (dd, J = 3.3, 1.4 Hz, 1H), 7.75 (d, J = 1.4 Hz, 1H), 
7.53–7.47 (m, 1H), 7.45 (dd, J = 7.3, 0.6 Hz, 1H), 7.30–7.20 (m, 1H), 1.42 (s, 9H). 
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13C NMR (75 MHz, CDCl3) δ = 158.1 (Cq), 151.6 (Cq), 149.6 (CH), 139.2 (Cq), 136.6 
(CH), 128.4 (CH), 126.1 (CH), 124.2 (CH), 124.0 (CH), 121.9 (CH), 120.8 (CH), 34.9 
(Cq), 31.4 (CH3). IR (ATR): 2960, 2865, 1584, 1565, 1461, 1252, 774, 700, 614cm–1. 
MS (EI) m/z (relative intensity) 212 (5) [M+H]+, 211 (20) [M]+, 196 (100). HR-MS (EI) 
m/z calcd for C15H17N [M]+: 211.1356, found: 211.1367. The spectral data are in 
accordance with those reported in the literature.[62c] 
 
2-[3-(tert-Butyl)-4-methoxyphenyl]pyridine (103o) 
The general procedure C was followed using substrate 13b (92.5 mg, 0.50 mmol) and 
bromide 24B (206 mg, 1.5 mmol). Purification by column chromatography 
(nhexane/EtOAc: 10/1) yielded 103o (97.7 mg, 81 %) as a colorless oil. 1H NMR (400 
MHz, CDCl3) δ = 8.64 (ddd, J = 4.9, 1.6, 1.0 Hz, 1H), 7.95 (d, J = 2.4 Hz, 1H), 7.79 (dd, 
J = 8.5, 2.4 Hz, 1H), 7.71–7.61 (m, 2H), 7.14 (ddd, J = 7.0, 4.9, 1.6 Hz, 1H), 6.95 (d, 
J = 8.5 Hz, 1H), 3.88 (s, 3H), 1.43 (s, 9H). 13C NMR (101 MHz, CDCl3) δ = 159.4 (Cq), 
157.8 (Cq), 149.5 (CH), 138.4 (Cq), 136.5 (CH), 131.4 (Cq), 125.7 (CH), 125.4 (CH), 
121.1 (CH), 119.9 (CH), 111.6 (CH), 55.1 (CH3), 35.0 (Cq), 29.7 (CH3). IR (ATR): 2954, 
2864, 1586, 1463, 1235, 1092, 1027, 780, 742, 610 cm–1. MS (ESI) m/z (relative 
intensity) 242 (100) [M+H]+, 165 (15), 151 (10), 119 (15). HR-MS (ESI) m/z calcd for 
C16H20NO [M+H]+: 242.1539, found: 242.1536. The spectral data are in accordance 
with those reported in the literature.[62c] 
 
2-[3-(tert-Butyl)phenyl]pyrimidine (103p) 
The general procedure C was followed using substrate 13k (78.0 mg, 0.50 mmol) and 
bromide 24B (206 mg, 1.5 mmol). Purification by column chromatography 
(nhexane/EtOAc: 9/1) yielded 103p (89.1 mg, 84%) as a colorless solid. M.p.: 78–
79 °C. 1H NMR (300 MHz, CDCl3) δ = 8.80 (d, J = 4.8 Hz, 2H), 8.53 (dd, J = 1.7, 1.7 Hz, 
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1H), 8.28 (dd, J = 7.7, 3.0, 3.0 Hz, 1H), 7.55 (ddd, J = 7.7, 2.0, 1.3 Hz, 1H), 7.44 (dd, 
J = 7.7, 7.7 Hz, 1H), 7.15 (dd, J = 4.8, 4.8 Hz, 1H), 1.42 (s, 9H). 13C NMR (75 MHz, 
CDCl3) δ = 165.1 (Cq), 157.2 (CH), 151.5 (Cq), 137.3 (Cq), 128.4 (CH), 127.9 (CH), 
125.5 (CH), 125.1 (CH), 119.0 (CH), 34.9 (Cq), 31.5 (CH3). IR (ATR): 3070, 2953, 1567, 
1553, 1417, 1404, 1259, 781, 696, 623 cm–1. MS (ESI) m/z (relative intensity): 235 (3) 
[M+Na]+, 213 (100) [M+H]+. HR-MS (ESI): m/z calcd for C14H17N2 [M+H]+: 213.1386, 




The general procedure C was followed using substrate 13l (80.5 mg, 0.50 mmol) and 
bromide 24B (206 mg, 1.5 mmol). Purification by column chromatography 
(nhexane/EtOAc: 10/1) yielded 103q (69.0 mg, 63%) as a colorless oil. 1H NMR 
(400 MHz, CDCl3) δ = 7.97 (ddd, J = 2.2, 1.6, 0.6 Hz, 1H), 7.72 (ddd, J = 7.8, 1.6, 1.2 
Hz, 1H), 7.49 (ddd, J = 7.8, 2.2, 1.2 Hz, 1H), 7.32 (ddd, J = 7.8, 7.8, 0.6 Hz, 1H), 4.83 
(ddq, J = 9.4, 7.4, 6.2 Hz, 1H), 4.13 (dd, J = 14.4, 9.4 Hz, 1H), 3.59 (dd, J = 14.4, 
7.4 Hz, 1H), 1.41 (d, J = 6.2 Hz, 3H), 1.33 (s, 9H). 13C NMR (101 MHz, CDCl3) δ = 
164.3 (Cq), 151.3 (Cq), 128.3 (CH), 128.0 (CH), 127.7 (Cq), 125.3 (CH), 125.0 (CH), 
76.2 (CH), 61.6 (CH2), 34.8 (Cq), 31.2 (CH3), 21.1 (CH3). IR (ATR): 2963, 2866, 1646, 
1331, 1243, 1070, 903, 804, 699, 582 cm–1. MS (EI) m/z (relative intensity) 218 (5), 
217 (30) [M]+, 202 (100), 173 (50), 145 (40). HR-MS (EI) m/z calcd for C14H19NO [M]+: 
17.1461, found: 217.1468. 
 
2-[3-(tert-Butyl)phenyl]-5-phenyl-4,5-dihydrooxazole (103r) 
The general procedure C was followed using substrate 13m (111.5 mg, 0.50 mmol) 
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and bromide 24B (206 mg, 1.5 mmol). Purification by column chromatography 
(nhexane/EtOAc: 15/1) yielded 103r (78.2 mg, 56%) as a pale yellow solid. M.p.: 94–
96 °C. 1H NMR (400 MHz, CDCl3) δ = 8.07–8.06 (m, 1H), 7.81 (ddd, J = 7.8, 1.2, 1.2 Hz, 
1H), 7.53 (ddd, J = 7.8, 2.1, 1.2 Hz, 1H), 7.40–7.37 (m, 1H), 7.36–7.34 (m, 3H), 7.34–
7.29 (m, 2H), 5.65 (dd, J = 10.2, 8.0 Hz, 1H), 4.47 (dd, J = 14.7, 10.2 Hz, 1H), 3.98 
(dd, J = 14.7, 8.0 Hz, 1H), 1.34 (s, 9H). 13C NMR (101 MHz, CDCl3) δ = 164.6 (Cq), 
151.5 (Cq), 141.0 (Cq), 128.8 (CH), 128.7 (CH), 128.3 (CH), 128.2 (CH), 127.2 (Cq), 
125.8 (CH), 125.6 (CH), 125.3 (CH), 81.1 (CH), 63.0 (CH2), 34.8 (Cq), 31.3 (CH3). IR 
(ATR): 2962, 2869, 1649, 1334, 1242, 1067, 943, 805, 697, 541cm–1. MS (ESI) m/z 
(relative intensity) 280 (100) [M+H]+, 201 (15), 139 (20), 117 (15). HR-MS (ESI) m/z 
calcd for C19H22NO [M+H]+: 280.1696, found: 280.1696. 
 
2-[3-(tert-Butyl)phenyl]-5,6-dihydro-4H-1,3-oxazine (103s) 
The general procedure C was followed using substrate 13n (80.5 mg, 0.50 mmol) and 
bromide 24B (206 mg, 1.5 mmol). Purification by column chromatography 
(nhexane/EtOAc: 10/1) yielded 103s (73.9mg, 69%) as a colorless oil. 1H NMR 
(300 MHz, CDCl3) δ = 7.92 (ddd, J = 2.1, 1.7, 0.5 Hz, 1H), 7.68 (ddd, J = 7.8, 1.7, 
1.2 Hz, 1H), 7.43 (ddd, J = 7.8, 2.1, 1.2 Hz, 1H), 7.27 (ddd, J = 7.8, 7.8, 0.5 Hz, 1H), 
4.34 (tt, J = 5.5, 0.8 Hz, 2H), 3.60 (tt, J = 6.1, 0.8 Hz, 2H), 2.04–1.86 (m, 2H), 1.32 (s, 
9H). 13C NMR (126 MHz, CDCl3) δ = 155.8 (Cq), 150.7 (Cq), 133.7 (Cq), 127.6 (CH), 
127.3 (CH), 124.0 (CH), 123.6 (CH), 65.1 (CH2), 42.7 (CH2), 34.8 (Cq), 31.4 (CH3), 
22.0 (CH2). IR (ATR): 2958, 2861, 1714, 1653, 1346, 1247, 1133, 804, 718, 530 cm–1. 
MS (EI) m/z (relative intensity) 217 (60) [M]+, 202 (100), 161 (65), 145 (60). HR-MS 
(EI) m/z calcd for C14H20NO [M+H]+: 218.1539, found: 218.1548. 
 
 





The general procedure C was followed using substrate 13o (88.5 mg, 0.50 mmol) and 
bromide 24B (206 mg, 1.5 mmol). Purification by column chromatography 
(nhexane/EtOAc: 10/1) yielded 103t (93.2 mg, 80%) as a pale yellow solid. M.p.: 100–
102 °C. 1H NMR (300 MHz, CDCl3) δ = 7.87 (d, J = 2.2 Hz, 1H), 7.75 (dd, J = 8.5, 2.2 
Hz, 1H), 6.85 (d, J = 8.5 Hz, 1H), 4.46–4.29 (m, 2H), 4.01 (td, J = 9.4, 0.8 Hz, 2H), 
3.86 (s, 3H), 1.37 (s, 9H). 13C NMR (126 MHz, CDCl3) δ = 164.8 (Cq), 160.9 (Cq), 138.1 
(Cq), 127.5 (CH), 126.7 (CH), 119.5 (Cq), 110.9 (CH), 67.4 (CH2), 55.1 (CH3), 54.9 
(CH2), 35.0 (Cq), 29.6 (CH3). IR (ATR): 2917, 2839, 1645, 1359, 1239, 1082, 830, 709, 
634 cm–1. MS (ESI) m/z (relative intensity) 234 (5) [M+H] +, 233 (30) [M]+, 218 (100), 
190 (20). HR-MS (ESI) m/z calcd for C14H19NO2 [M]+: 233.1410, found: 233.1417. 
 
2-[3-(tert-Butyl)-4-fluorophenyl]-4,5-dihydrooxazole (103u) 
The general procedure C was followed using substrate 13p (82.5 mg, 0.50 mmol) and 
bromide 24B (206 mg, 1.5 mmol). Purification by column chromatography 
(nhexane/EtOAc: 10/1) yielded 103u (98.4 mg, 89%) as a pale yellow solid. M.p.: 65–
66 °C. 1H NMR (300 MHz, CDCl3) δ = 7.90 (dd, J = 8.4, 2.2 Hz, 1H), 7.73 (ddd, J = 8.4, 
4.6, 2.2 Hz, 1H), 6.99 (dd, J = 12.2, 8.4 Hz, 1H), 4.39 (td, J = 9.4, 0.8 Hz, 2H), 4.09–
3.93 (m, 2H), 1.37 (d, J = 1.1 Hz, 9H). 13C NMR (126 MHz, CDCl3) δ = 164.0 (Cq), 163.7 
(d, 1JC–F = 254.5 Hz, Cq), 137.2 (d, 2JC–F = 12.6 Hz, Cq), 137.1 (Cq), 127.7 (d, 3JC–F = 
10.1 Hz, CH), 127.5 (d, 3JC–F = 7.6 Hz, CH), 123.4 (d, 4JC–F = 3.8 Hz, Cq), 116.3 (d, 
2JC-F = 25.2 Hz, CH), 67.6 (CH2), 55.0 (CH2), 34.4 (d, 3JC–F = 2.5 Hz, Cq), 29.8 (d, 4JC-F = 
2.5 Hz, CH3). 
19F NMR (282 MHz, CDCl3) δ = -104.7 (s). IR (ATR): 2952, 2877, 1645, 
1476, 1363, 1077, 948, 852, 707, 633 cm–1. MS (EI) m/z (relative intensity) 222 (10) 
[M+H]+, 221 (35) [M]+, 206 (100), 178 (40), 163.1 (30). HR-MS (EI) m/z calcd for 
5. Experimental Section  
131 
 
C13H16FNO [M]+: 221.1210, found: 221.1213. 
5.3.4 Nickela-Electrocatalyzed C–H Amination 
5.3.4.1 Characterization Data 
 
2-Morpholino-N-(quinolin-8-yl)benzamide (58aa) 
The general procedure D was followed using benzamide 35a (62.0 mg, 0.25 mmol) 
and morpholine (56a) (43.5 mg, 0.50 mmol). Purification by column chromatography 
on silica gel (nhexane/EtOAc: 9/1→4/1) yielded 58aa (64.2 mg, 77%) as a white solid. 
M. p.: 148–149 °C. 1H NMR (400 MHz, CDCl3) δ = 12.64 (s, 1H), 9.11 (dd, J = 7.6, 
1.5 Hz, 1H), 8.85 (dd, J = 4.2, 1.7 Hz, 1H), 8.17 (dd, J = 8.3, 1.7 Hz, 2H), 7.60–7.56 
(m, 1H), 7.54–7.50 (m, 1H), 7.49–7.43 (m, 2H), 7.25–7.21 (m, 2H), 4.03–3.88 (m, 4H), 
3.27–2.95 (m, 4H). 13C NMR (101 MHz, CDCl3) δ = 165.7 (Cq), 151.0 (Cq), 148.0 (CH), 
138.7 (Cq), 136.4 (CH), 135.5 (Cq), 132.3 (CH), 132.1 (CH), 128.9 (Cq), 128.3 (Cq), 
127.6 (CH), 124.2 (CH), 121.7 (CH), 121.6 (CH), 119.2 (CH), 117.8 (CH), 66.1 (CH2), 
53.9 (CH2). IR (ATR): 2958, 2829, 1656, 1515, 1112, 730, 696 cm–1. MS (ESI) m/z 
(relative intensity): 356 (25) [M+Na]+, 334 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C20H20N3O2 [M+H]+: 334.1550, found: 334.1550. The analytical data correspond with 
those reported in the literature.[115] 
 
3-Morpholino-N-(quinolin-8-yl)-(1,1'-biphenyl)-4-carboxamide (58ba) 
The general procedure D was followed using benzamide 35b (81.0 mg, 0.25 mmol) 
and morpholine (56a) (43.5 mg, 0.50 mmol). Purification by column chromatography 
on silica gel (nhexane/EtOAc: 9/1→4/1) yielded 58ba (81.8 mg, 80%) as a white solid. 
M. p.: 184–186 °C. 1H NMR (300 MHz, CDCl3) δ = 12.70 (s, 1H), 9.15 (dd, J = 7.6, 
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1.6 Hz, 1H), 8.89 (dd, J = 4.2, 1.7 Hz, 1H), 8.27 (d, J = 8.0 Hz, 1H), 8.21 (dd, J = 8.3, 
1.7 Hz, 1H), 7.65 (dd, J = 7.0, 2.1 Hz, 2H), 7.61 (d, J = 7.6 Hz, 1H), 7.56 (dd, J = 8.3, 
1.6 Hz, 1H), 7.51 (d, J = 4.2 Hz, 1H), 7.50–7.45 (m, 4H), 7.44–7.38 (m, 1H), 4.02–3.99 
(m, 4H), 3.25–3.22 (m, 4H). 13C NMR (125 MHz, CDCl3) δ = 165.3 (Cq), 151.3 (Cq), 
147.9 (CH), 145.2 (Cq), 140.1 (Cq), 138.7 (Cq), 136.4 (CH), 135.5 (Cq), 132.6 (CH), 
128.8 (CH), 128.3 (Cq), 128.0 (CH), 127.5 (CH), 127.5 (Cq), 127.1 (CH), 122.9 (CH), 
121.7 (CH), 121.5 (CH), 118.0 (CH), 117.8 (CH), 66.2 (CH2), 54.0 (CH2). IR (ATR): 
2957, 2828, 1659, 1519, 1323, 1113, 760, 700 cm–1. MS (ESI) m/z (relative intensity): 
432 (25) [M+Na]+, 410 (100) [M+H]+. HR-MS (ESI) m/z calcd for C26H24N3O2 
[M+H]+: 410.1863, found: 410.1868. The analytical data correspond with those 
reported in the literature.[115] 
 
4-Methyl-2-morpholino-N-(quinolin-8-yl)benzamide (58ca) 
The general procedure D was followed using benzamide 35c (65.5 mg, 0.25 mmol) 
and morpholine (56a) (43.5 mg, 0.50 mmol). Purification by column chromatography 
on silica gel (nhexane/EtOAc: 9/1→4/1→2/1) yielded 58ca (52.1 mg, 60%) as a white 
solid. M. p.: 186–187 °C. 1H NMR (300 MHz, CDCl3) δ = 12.66 (s, 1H), 9.11 (dd, J = 
7.5, 1.6 Hz, 1H), 8.85 (dd, J = 4.2, 1.7 Hz, 1H), 8.16 (dd, J = 8.3, 1.7 Hz, 1H), 8.12–
8.01 (m, 1H), 7.62–7.54 (m, 1H), 7.51 (dd, J = 8.2, 1.6 Hz, 1H), 7.46 (dd, J = 8.3, 
4.2 Hz, 1H), 7.07–7.02 (m, 2H), 4.02–3.86 (m, 4H), 3.23–3.03 (m, 4H), 2.40 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ = 165.6 (Cq), 151.0 (Cq), 147.9 (CH), 142.8 (Cq), 138.7 
(Cq), 136.3 (CH), 135.6 (Cq), 132.1 (CH), 128.2 (Cq), 127.5 (CH), 126.0 (Cq), 125.0 
(CH), 121.54 (CH), 121.50 (CH), 119.9 (CH), 117.7 (CH), 66.2 (CH2), 54.0 (CH2), 21.7 
(CH3). IR (ATR): 2957, 2827, 1658, 1519, 1322, 1113, 826, 700 cm–1. MS (ESI) m/z 
(relative intensity): 370 (100) [M+Na]+, 348 (60) [M+H]+, 186 (10). HR-MS (ESI) m/z 
calcd for C21H22N3O2 [M+H]+: 348.1707, found: 348.1709. The analytical data 
correspond with those reported in the literature.[115] 





The general procedure D was followed using benzamide 35d (76.0 mg, 0.25 mmol) 
and morpholine (56a) (43.5 mg, 0.50 mmol). Purification by column chromatography 
on silica gel (nhexane/EtOAc: 9/1→4/1) yielded 58da (63.6 mg, 65%) as a white solid. 
M. p.: 147–149 °C. 1H NMR (400 MHz, CDCl3) δ = 12.67 (s, 1H), 9.11 (dd, J = 7.6, 
1.5 Hz, 1H), 8.85 (dd, J = 4.2, 1.7 Hz, 1H), 8.16 (dd, J = 8.3, 1.7 Hz, 1H), 8.12 (d, J = 
8.8 Hz, 1H), 7.59–7.55 (m, 1H), 7.51 (dd, J = 8.3, 1.5 Hz, 1H), 7.46 (dd, J = 8.3, 4.2 Hz, 
1H), 7.30–7.25 (m, 2H), 4.14–3.87 (m, 4H), 3.38–3.05 (m, 4H), 1.35 (s, 9H). 13C NMR 
(101 MHz, CDCl3) δ = 165.7 (Cq), 156.0 (Cq), 150.8 (Cq), 148.0 (CH), 138.8 (Cq), 136.4 
(CH), 135.7 (Cq), 131.9 (CH), 128.3 (Cq), 127.6 (CH), 126.0 (Cq), 121.6 (CH), 121.5 
(CH), 121.5 (CH), 117.8 (CH), 116.2 (CH), 66.2 (CH2), 54.0 (CH2), 35.2 (Cq), 31.2 (CH3). 
IR (ATR): 2959, 1661, 1519, 1323, 1114, 963, 826, 792, 606 cm–1. MS (ESI) m/z 
(relative intensity): 412 (75) [M+Na]+, 390 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C24H28N3O2 [M+H]+: 390.2176, found: 390.2179. The analytical data correspond with 
those reported in the literature.[115] 
 
2-Morpholino-N-(quinolin-8-yl)-4-(trifluoromethyl)benzamide (58ea) 
The general procedure D was followed using benzamide 35e (79.0 mg, 0.25 mmol) 
and morpholine (56a) (43.5 mg, 0.50 mmol). Purification by column chromatography 
on silica gel (nhexane/EtOAc: 9/1→4/1) yielded 58ea (73.3 mg, 73%) as a white solid. 
M. p.: 175–177 °C. 1H NMR (500 MHz, CDCl3) δ = 12.42 (s, 1H), 9.07 (dd, J = 7.4, 
1.6 Hz, 1H), 8.84 (dd, J = 4.2, 1.7 Hz, 1H), 8.22 (dd, J = 8.1, 1.0 Hz, 1H), 8.18 (dd, J = 
8.3, 1.7 Hz, 1H), 7.58 (dd, J = 8.2, 7.4 Hz, 1H), 7.55 (dd, J = 8.2, 1.6 Hz, 1H), 7.50–
7.45 (m, 2H), 7.43 (d, J = 1.7 Hz, 1H), 3.96–3.89 (m, 4H), 3.21–3.13 (m, 4H). 13C NMR 
5. Experimental Section  
134 
 
(125 MHz, CDCl3) δ = 164.4 (Cq), 151.2 (Cq), 148.2 (CH), 138.5 (Cq), 136.5 (CH), 134.9 
(Cq), 133.8 (q, 2JC–F = 32.5 Hz, Cq), 132.7 (CH), 131.9 (Cq), 128.3 (Cq), 127.5 (CH), 
123.6 (q, 1JC–F = 272.9 Hz, Cq), 122.2 (CH), 121.7 (CH), 120.6 (q, 3JC–F = 3.7 Hz, CH), 
117.8 (CH), 115.9 (q, 3JC–F = 3.6 Hz, CH), 65.9 (CH2), 53.6 (CH2). 
19F NMR (470 MHz, 
CDCl3) δ = –62.9 (s). IR (ATR): 2960, 2833, 1666, 1522, 1310, 1114, 955, 736 cm–1. 
MS (ESI) m/z (relative intensity): 424 (100) [M+Na]+, 402 (30) [M+H]+, 382 (10). HR-MS 
(ESI) m/z calcd for C21H19F3N3O2 [M+H]+: 402.1424, found: 402.1424. The analytical 
data correspond with those reported in the literature.[115] 
 
4-Methoxy-2-morpholino-N-(quinolin-8-yl)benzamide (58fa) 
The general procedure D was followed using benzamide 35f (69.5 mg, 0.25 mmol) and 
morpholine (56a) (43.5 mg, 0.50 mmol). Purification by column chromatography on 
silica gel (nhexane/EtOAc: 9/1→4/1) yielded 58fa (57.0 mg, 63%) as a white solid. 
M. p.: 176–177 °C. 1H NMR (400 MHz, CDCl3) δ = 12.58 (s, 1H), 9.09 (dd, J = 7.6, 
1.4 Hz, 1H), 8.85 (dd, J = 4.2, 1.7 Hz, 1H), 8.18 (d, J = 1.7 Hz, 1H), 8.16 (d, J = 1.6 Hz, 
1H), 7.59–7.55 (m, 1H), 7.51 (dd, J = 8.2, 1.4 Hz, 1H), 7.46 (dd, J = 8.2, 4.2 Hz, 1H), 
6.76–6.73 (m, 2H), 3.98–3.93 (m, 4H), 3.86 (s, 3H), 3.22–3.04 (m, 4H). 13C NMR 
(101 MHz, CDCl3) δ = 165.4 (Cq), 162.8 (Cq), 152.9 (Cq), 147.9 (CH), 138.7 (Cq), 136.5 
(CH), 135.7 (Cq), 134.0 (CH), 128.3 (Cq), 127.6 (CH), 121.5 (CH), 121.5 (CH), 121.4 
(Cq), 117.8 (CH), 108.3 (CH), 106.1 (CH), 66.0 (CH2), 55.4 (CH2), 53.9 (CH3). IR (ATR): 
2961, 2834, 1655, 1599, 1519, 1485, 1251, 1113, 825 cm–1. MS (ESI) m/z (relative 
intensity): 386 (100) [M+Na]+, 364 (80) [M+H]+, 220 (10). HR-MS (ESI) m/z calcd for 
C21H22N3O3 [M+H]+: 364.1656, found: 364.1658. The analytical data correspond with 
those reported in the literature.[115] 
 
 





The general procedure D was followed using benzamide 35g (66.5 mg, 0.25 mmol) 
and morpholine (56a) (43.5 mg, 0.50 mmol). Purification by column chromatography 
on silica gel (nhexane/EtOAc: 9/1→4/1) yielded 58ga (49.5 mg, 56%) as a white solid. 
M. p.: 182–183 °C. 1H NMR (400 MHz, CDCl3) δ = 12.43 (s, 1H), 9.07 (dd, J = 7.5, 
1.5 Hz, 1H), 8.85 (dd, J = 4.2, 1.7 Hz, 1H), 8.18 (dd, J = 8.3, 1.7 Hz, 1H), 8.17–8.12 
(m, 1H), 7.61–7.56 (m, 1H), 7.53 (dd, J = 8.3, 1.5 Hz, 1H), 7.47 (dd, J = 8.3, 4.2 Hz, 
1H), 6.97–6.87 (m, 2H), 4.00–3.80 (m, 4H), 3.19–2.96 (m, 4H). 13C NMR (101 MHz, 
CDCl3) δ = 165.1 (d, 1JC–F = 256.0 Hz, Cq), 164.8 (Cq), 153.2 (d, 3JC–F = 8.1 Hz, Cq), 
148.0 (CH), 138.6 (Cq), 136.6 (CH), 135.3 (Cq), 134.3 (d, 3JC–F = 10.1 Hz, CH), 128.3 
(Cq), 127.6 (CH), 125.0 (d, 4JC–F = 4.0 Hz, Cq), 121.9 (CH), 121.6 (CH), 117.9 (CH), 
110.9 (d, 2JC–F = 21.2 Hz, CH), 106.6 (d, 2JC–F = 23.2 Hz, CH), 66.0 (CH2), 53.7 (CH2). 
19F NMR (282 MHz, CDCl3) δ = -106.5 (ddd, J = 10.5, 10.3, 7.3 Hz). IR (ATR): 2960, 
2833, 1661, 1520, 1485, 1114, 987, 826, 607 cm–1. MS (ESI) m/z (relative intensity): 
374 (100) [M+Na]+, 352 (40) [M+H]+. HR-MS (ESI) m/z calcd for C20H19FN3O2 
[M+H]+: 352.1456, found: 352.1456. The analytical data correspond with those 
reported in the literature.[115] 
 
4-Cyano-2-morpholino-N-(quinolin-8-yl)benzamide (58ha) 
The general procedure D was followed using benzamide 35h (68.3 mg, 0.25 mmol) 
and morpholine (56a) (43.5 mg, 0.50 mmol). Purification by column chromatography 
on silica gel (nhexane/EtOAc: 4/1→2/1) yielded 58ha (54.7 mg, 61%) as a white solid. 
M. p.: 175–176 °C. 1H NMR (400 MHz, CDCl3) δ = 12.34 (s, 1H), 9.04 (dd, J = 6.6, 
2.4 Hz, 1H), 8.85 (dd, J = 4.2, 1.7 Hz, 1H), 8.23–8.15 (m, 2H), 7.63–7.55 (m, 2H), 
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7.52–7.47 (m, 2H), 7.45 (d, J = 1.7 Hz, 1H), 3.97–3.86 (m, 4H), 3.21–3.07 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ = 163.9 (Cq), 151.2 (Cq), 148.3 (CH), 138.5 (Cq), 136.6 
(CH), 134.7 (Cq), 133.0 (Cq), 132.9 (CH), 128.3 (Cq), 127.5 (CH), 127.3 (CH), 122.7 
(CH), 122.4 (CH), 121.8 (CH), 118.1 (Cq), 117.9 (CH), 115.5 (Cq), 65.8 (CH2), 53.5 
(CH2). IR (ATR): 2921, 2852, 2231, 1663, 1522, 1324, 1113, 827 cm-1.MS (ESI) m/z 
(relative intensity): 381 (95) [M+Na]+, 359 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C21H19N4O2 [M+H]+: 359.1503, found: 359.1501. The analytical data correspond with 
those reported in the literature.[184]  
 
4-(Methylthio)-2-morpholino-N-(quinolin-8-yl)benzamide (58ia) 
The general procedure D was followed using benzamide 35i (73.5 mg, 0.25 mmol) and 
morpholine (56a) (43.5 mg, 0.50 mmol). Purification by column chromatography on 
silica gel (nhexane/EtOAc: 9/1→4/1) yielded 58ia (67.8 mg, 72%) as a white solid. 
M. p.: 146–148 °C. 1H NMR (400 MHz, CDCl3) δ = 12.56 (s, 1H), 9.08 (dd, J = 7.6, 
1.5 Hz, 1H), 8.85 (dd, J = 4.2, 1.7 Hz, 1H), 8.17 (dd, J = 8.3, 1.7 Hz, 1H), 8.11 (d, J = 
8.1 Hz, 1H), 7.59–7.55 (m, 1H), 7.51 (dd, J = 8.2, 1.5 Hz, 1H), 7.46 (dd, J = 8.3, 4.2 Hz, 
1H), 7.10–7.03 (m, 2H), 4.01–3.87 (m, 4H), 3.19–3.05 (m, 4H), 2.52 (s, 3H). 13C NMR 
(125 MHz, CDCl3) δ = 165.1 (Cq), 151.1 (Cq), 147.9 (CH), 144.1 (Cq), 138.6 (Cq), 136.4 
(CH), 135.4 (Cq), 132.5 (CH), 128.2 (Cq), 127.5 (CH), 125.1 (Cq), 121.6 (CH), 121.5 
(CH), 120.7 (CH), 117.8 (CH), 116.6 (CH), 66.0 (CH2), 53.9 (CH2), 15.1 (CH3). IR (ATR): 
2957, 2829, 1657, 1520, 1322, 1113, 951, 825 cm–1. MS (ESI) m/z (relative intensity): 
402 (40) [M+Na]+, 380 (100) [M+H]+, 334 (5), 236 (5), 186 (5). HR-MS (ESI) m/z calcd 









The general procedure D was followed using benzamide 35k (65.5 mg, 0.25 mmol) 
and morpholine (56a) (43.5 mg, 0.50 mmol). Purification by column chromatography 
on silica gel (nhexane/EtOAc: 9/1→4/1) yielded 58ka (63.2 mg, 73%) as a white solid. 
M. p.: 153–155 °C. 1H NMR (500 MHz, CDCl3) δ = 12.77 (s, 1H), 9.11 (dd, J = 7.7, 
1.4 Hz, 1H), 8.85 (dd, J = 4.2, 1.7 Hz, 1H), 8.16 (dd, J = 8.3, 1.7 Hz, 1H), 8.01 (d, J = 
2.3 Hz, 1H), 7.59–7.56 (m, 1H), 7.51 (dd, J = 8.2, 1.4 Hz, 1H), 7.45 (dd, J = 8.3, 4.2 Hz, 
1H), 7.28 (ddd, J = 8.2, 2.3, 0.8 Hz, 1H), 7.14 (d, J = 8.1 Hz, 1H), 4.06–3.87 (m, 4H), 
3.15–2.97 (m, 4H), 2.36 (s, 3H). 13C NMR (125 MHz, CDCl3) δ = 165.7 (Cq), 148.7 (Cq), 
148.0 (CH), 138.8 (Cq), 136.4 (CH), 135.6 (Cq), 134.0 (Cq), 132.8 (CH), 132.5 (CH), 
128.4 (Cq), 128.3 (Cq), 127.5 (CH), 121.7 (CH), 121.5 (CH), 119.3 (CH), 117.8 (CH), 
66.1 (CH2), 54.0 (CH2), 20.6 (CH3). IR (ATR): 2956, 2921, 1660, 1518, 1323, 1113, 
824 cm–1. MS (ESI) m/z (relative intensity): 370 (100) [M+Na]+, 348 (80) [M+H]+. 
HR-MS (ESI) m/z calcd for C21H22N3O2 [M+H]+: 348.1707, found: 348.1706. The 
analytical data correspond with those reported in the literature.[115] 
 
5-Methoxy-2-morpholino-N-(quinolin-8-yl)benzamide (58la) 
The general procedure D was followed using benzamide 35l (69.5 mg, 0.25 mmol) and 
morpholine (56a) (43.5 mg, 0.50 mmol). Purification by column chromatography on 
silica gel (nhexane/EtOAc: 9/1→4/1) yielded 58la (54.8 mg, 60%) as a white solid. 
M. p.: 154–156 °C. 1H NMR (400 MHz, CDCl3) δ = 13.07 (s, 1H), 9.12 (dd, J = 7.5, 
1.6 Hz, 1H), 8.87 (dd, J = 4.2, 1.7 Hz, 1H), 8.17 (dd, J = 8.3, 1.7 Hz, 1H), 7.81 (d, J = 
3.2 Hz, 1H), 7.61–7.55 (m, 1H), 7.53 (dd, J = 8.3, 1.6 Hz, 1H), 7.46 (dd, J = 8.3, 4.2 Hz, 
1H), 7.24 (d, J = 8.8 Hz, 1H), 7.04 (dd, J = 8.8, 3.2 Hz, 1H), 4.07–3.92 (m, 4H), 3.85 
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(s, 3H), 3.12–3.00 (m, 4H). 13C NMR (125 MHz, CDCl3) δ = 165.0 (Cq), 156.4 (Cq), 
147.9 (CH), 144.4 (Cq), 138.9 (Cq), 136.3 (CH), 135.7 (Cq), 129.8 (Cq), 128.2 (Cq), 
127.4 (CH), 121.8 (CH), 121.5 (CH), 121.3 (CH), 118.9 (CH), 118.1 (CH), 115.6 (CH), 
66.2 (CH2), 55.7 (CH3), 54.3 (CH2). IR (ATR): 2956, 2834, 1659, 1520, 1488, 1282, 
1113, 825 cm–1. MS (ESI) m/z (relative intensity): 386 (100) [M+Na]+, 364 (95) [M+H]+, 
345 (5). HR-MS (ESI) m/z calcd for C21H22N3O3 [M+H]+: 364.1656, found: 364.1660. 
The analytical data correspond with those reported in the literature.[115] 
 
5-Cyano-2-morpholino-N-(quinolin-8-yl)benzamide (58ma) 
The general procedure D was followed using benzamide 35m (68.3 mg, 0.25 mmol) 
and morpholine (56a) (43.5 mg, 0.50 mmol). Purification by column chromatography 
on silica gel (nhexane/EtOAc: 9/1→4/1) yielded 58ma (49.8 mg, 56%) as a white solid. 
M. p.: 170–171 °C. 1H NMR (300 MHz, CDCl3) δ = 12.05 (s, 1H), 9.04 (dd, J = 6.6, 
2.5 Hz, 1H), 8.86 (dd, J = 4.2, 1.7 Hz, 1H), 8.35 (d, J = 2.2 Hz, 1H), 8.23 (dd, J = 8.3, 
1.7 Hz, 1H), 7.74 (dd, J = 8.5, 2.2 Hz, 1H), 7.67–7.56 (m, 2H), 7.52 (dd, J = 8.3, 4.2 Hz, 
1H), 7.25–7.23 (m, 1H), 3.92–3.89 (m, 4H), 3.30–3.07 (m, 4H). 13C NMR (125 MHz, 
CDCl3) δ = 163.8 (Cq), 154.0 (Cq), 148.1 (CH), 138.2 (Cq), 136.7 (CH), 136.1 (CH), 
135.5 (CH), 134.5 (Cq), 129.4 (Cq), 128.2 (Cq), 127.6 (CH), 122.3 (CH), 121.7 (CH), 
119.3 (CH), 118.3 (Cq), 117.8 (CH), 106.9 (Cq), 65.8 (CH2), 53.2 (CH2). IR (ATR): 2964, 
2227, 1664, 1523, 1486, 1113, 914, 827, 582 cm–1. MS (ESI) m/z (relative intensity): 
381 (50) [M+Na]+, 359 (100) [M+H]+. HR-MS (ESI) m/z calcd for C21H19N4O2 
[M+H]+: 359.1503, found: 359.1507. 
 
2-Morpholino-N-(quinolin-8-yl)-5-(trifluoromethyl)benzamide (58na) 
The general procedure D was followed using benzamide 35n (79.0 mg, 0.25 mmol) 
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and morpholine (56a) (43.5 mg, 0.50 mmol). Purification by column chromatography 
on silica gel (nhexane/EtOAc: 9/1→4/1) yielded 58na (75.4 mg, 75%) as a white solid. 
M. p.: 172–173 °C. 1H NMR (400 MHz, CDCl3) δ = 12.33 (s, 1H), 9.07 (dd, J = 7.3, 
1.7 Hz, 1H), 8.84 (dd, J = 4.2, 1.7 Hz, 1H), 8.39 (dd, J = 2.4, 0.8 Hz, 1H), 8.18 (dd, J = 
8.3, 1.7 Hz, 1H), 7.71 (ddd, J = 8.5, 2.4, 0.8 Hz, 1H), 7.59 (dd, J = 8.2, 7.3 Hz, 1H), 
7.55 (dd, J = 8.2, 1.7 Hz, 1H), 7.48 (dd, J = 8.3, 4.2 Hz, 1H), 7.28 (dd, J = 8.5, 0.8 Hz, 
1H), 3.99–3.82 (m, 4H), 3.27–3.10 (m, 4H). 13C NMR (101 MHz, CDCl3) δ = 164.4 (Cq), 
153.6 (Cq), 148.2 (CH), 138.6 (Cq), 136.5 (CH), 134.9 (Cq), 129.5 (q, 3JC–F = 3.8 Hz, 
CH), 129.1 (Cq), 128.9 (q, 3JC–F = 3.7 Hz, CH), 128.3 (Cq), 127.6 (CH), 126.0 (q, 2JC-F = 
33.2 Hz, Cq), 123.9 (q, 1JC–F = 271.7 Hz, Cq), 122.1 (CH), 121.7 (CH), 119.2 (CH), 117.7 
(CH), 65.9 (CH2), 53.5 (CH2). 
19F NMR (282 MHz, CDCl3) δ = –62.2 (s). IR (ATR): 2960, 
2922, 1664, 1524, 1326, 1257, 1114, 826, 792 cm–1. MS (ESI) m/z (relative intensity): 
424 (100) [M+Na]+, 402 (25) [M+H]+. HR-MS (ESI) m/z calcd for C21H19F3N3O2 
[M+H]+: 402.1424, found: 402.1420. The analytical data correspond with those 
reported in the literature.[183c]  
 
2-Morpholino-N-(quinolin-8-yl)thiophene-3-carboxamide (58pa) 
The general procedure D was followed using benzamide 35p (63.5 mg, 0.25 mmol) 
and morpholine (56a) (43.5 mg, 0.50 mmol). Purification by column chromatography 
on silica gel (nhexane/EtOAc: 9/1→2/1) yielded 58pa (68.0 mg, 80%) as a white solid. 
M. p.: 158–159 °C. 1H NMR (600 MHz, CDCl3) δ = 12.31 (s, 1H), 9.05 (dd, J = 7.7, 
1.4 Hz, 1H), 8.89 (dd, J = 4.2, 1.7 Hz, 1H), 8.18 (dd, J = 8.2, 1.7 Hz, 1H), 7.58–7.55 
(m, 1H), 7.57 (d, J = 5.8 Hz, 1H), 7.51 (dd, J = 8.2, 1.4 Hz, 1H), 7.48 (dd, J = 8.2, 
4.2 Hz, 1H), 6.99 (d, J = 5.8 Hz, 1H), 4.21–4.00 (m, 4H), 3.26–3.08 (m, 4H).13C NMR 
(125 MHz, CDCl3) δ = 161.0 (Cq), 160.0 (Cq), 147.8 (CH), 138.7 (Cq), 136.4 (CH), 135.6 
(Cq), 128.1 (Cq), 128.0 (CH), 127.5 (CH), 127.4 (Cq), 121.5 (CH), 121.4 (CH), 118.5 
(CH), 117.8 (CH), 66.3 (CH2), 56.4 (CH2). IR (ATR): 2921, 1659, 1522, 1488, 1324, 
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1262, 1113, 792, 700 cm–1. MS (ESI) m/z (relative intensity): 362 (100) [M+Na]+, 340 
(40) [M+H]+, 340 (5). HR-MS (ESI) m/z calcd for C18H18N3O2S [M+H]+: 340.1114, 
found: 340.1114. The analytical data correspond with those reported in the 
literature.[165c] 
 
tert-Butyl 4-[2-(quinolin-8-ylcarbamoyl)phenyl]piperazine-1-carboxylate (58ab) 
The general procedure D was followed using benzamide 35a (62.0 mg, 0.25 mmol) 
and tert-butyl piperazine-1-carboxylate (56b) (93.1 mg, 0.50 mmol). Purification by 
column chromatography on silica gel (nhexane/EtOAc: 9/1→4/1) yielded 58ab 
(81.0 mg, 75%) as a white solid. M. p.: 193–194 °C. 1H NMR (400 MHz, CDCl3) δ = 
12.67 (s, 1H), 9.10 (dd, J = 7.6, 1.5 Hz, 1H), 8.79 (dd, J = 4.2, 1.7 Hz, 1H), 8.20–8.17 
(m, 2H), 7.61–7.57 (m, 1H), 7.53 (dd, J = 8.3, 1.5 Hz, 1H), 7.50–7.46 (m, 1H), 7.46–
7.43 (m, 1H), 7.29–7.21 (m, 1H), 7.21 (dd, J = 8.3, 1.1 Hz, 1H), 3.70 (s, 4H), 3.09 (s, 
4H), 1.41 (s, 9H). 13C NMR (101 MHz, CDCl3) δ = 165.6 (Cq), 154.8 (Cq), 151.0 (Cq), 
147.8 (CH), 138.6 (Cq), 136.7 (CH), 135.4 (Cq), 132.3 (CH), 132.1 (CH), 128.9 (Cq), 
128.4 (Cq), 127.7 (CH), 124.5 (CH), 121.8 (CH), 121.6 (CH), 119.5 (CH), 118.1 (CH), 
79.8 (Cq), 53.9 (CH2), 53.3 (CH2), 43.5 (CH2), 42.7 (CH2), 28.4 (CH3). IR (ATR): 2974, 
2826, 1682, 1659, 1520, 1419, 1125, 792, 754 cm–1. MS (ESI) m/z (relative intensity): 
455 (100) [M+Na]+, 433 (30) [M+H]+, 356 (10), 309 (10), 293 (35). HR-MS (ESI) m/z 
calcd for C25H29N4O3 [M+H]+: 433.2234, found: 433.2223. The analytical data 
correspond with those reported in the literature.[115] 
 
2-(4-Phenylpiperidin-1-yl)-N-(quinolin-8-yl)-5-(trifluoromethyl)benzamide (58nd) 
The general procedure E was followed using benzamide 35n (79.0 mg, 0.25 mmol) 
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and 4-phenylpiperidine (56d) (201 mg, 1.25 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 16/1→9/1) yielded 58nd (73.0 mg, 61%) 
as a white solid. M. p.: 143–144 °C. 1H NMR (400 MHz, CDCl3) δ = 12.36 (s, 1H), 9.12 
(dd, J = 7.4, 1.6 Hz, 1H), 8.83 (dd, J = 4.2, 1.7 Hz, 1H), 8.38 (dd, J = 2.4, 0.8 Hz, 1H), 
8.22 (dd, J = 8.3, 1.7 Hz, 1H), 7.70 (ddd, J = 8.5, 2.4, 0.8 Hz, 1H), 7.64–7.59 (m, 1H), 
7.57 (dd, J = 8.3, 1.6 Hz, 1H), 7.47 (dd, J = 8.3, 4.2 Hz, 1H), 7.31 (d, J = 8.5 Hz, 1H), 
7.13–7.07 (m, 3H), 6.86–6.70 (m, 2H), 3.71–3.49 (m, 2H), 3.00–2.94 (m, 2H), 2.63–
2.55 (m, 1H), 2.16–2.05 (m, 2H), 1.86–1.75 (m, 2H). 13C NMR (101 MHz, CDCl3) δ = 
164.9 (Cq), 154.6 (Cq), 148.4 (CH), 145.4 (Cq), 138.7 (Cq), 136.6 (CH), 135.1 (Cq), 
129.2 (q, 3JC–F = 3.8 Hz, CH), 129.1 (Cq), 128.7 (q, 3JC–F = 3.5 Hz, CH), 128.3 (Cq), 
128.2 (CH), 127.7 (CH), 126.6 (CH), 126.2 (CH), 125.2 (q, 2JC–F = 33.2 Hz, Cq), 124.1 
(q, 1JC–F = 272.7 Hz, Cq), 122.0 (CH), 121.4 (CH), 119.2 (CH), 117.7 (CH), 54.6 (CH2), 
42.0 (CH), 32.6 (CH2). 
19F NMR (376 MHz, CDCl3) δ = –62.0 (s). IR (ATR): 2945, 2820, 
1664, 1524, 1326, 1268, 1119, 825, 699 cm–1. MS (ESI) m/z (relative intensity): 498 
(50) [M+Na]+, 476 (100) [M+H]+, 315 (20). HR-MS (ESI) m/z calcd for C28H25F3N3O 
[M+H]+: 476.1944, found: 476.1949.  
 
2-(4-Methylpiperidin-1-yl)-N-(quinolin-8-yl)-5-(trifluoromethyl)benzamide (58ne) 
The general procedure E was followed using benzamide 35n (79.0 mg, 0.25 mmol) 
and 4-methylpiperidine (56e) (124 mg, 1.25 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 16/1→9/1) yielded 58ne (46.0 mg, 45%) 
as a white solid. M. p.: 174–175 °C. 1H NMR (300 MHz, CDCl3) δ = 12.41 (s, 1H), 9.12 
(dd, J = 7.4, 1.7 Hz, 1H), 8.86 (dd, J = 4.2, 1.7 Hz, 1H), 8.39 (d, J = 2.3 Hz, 1H), 8.19 
(dd, J = 8.3, 1.7 Hz, 1H), 7.68 (dd, J = 8.5, 2.3 Hz, 1H), 7.64–7.59 (m, 1H), 7.56 (dd, 
J = 8.3, 1.7 Hz, 1H), 7.48 (dd, J = 8.3, 4.2 Hz, 1H), 7.34–7.24 (m, 1H), 3.54–3.36 (m, 
2H), 2.97–2.73 (m, 2H), 1.53-1.43 (m, 4H), 1.54–1.37 (m, 1H), 0.77 (d, J = 6.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ = 164.9 (Cq), 154.9 (Cq), 147.9 (CH), 138.7 (Cq), 136.4 
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(CH), 135.3 (Cq), 129.2 (q, 3JC–F = 3.8 Hz, CH), 128.9 (Cq), 128.7 (q, 3JC–F = 3.6 Hz, 
CH), 128.3 (Cq), 127.6 (CH), 125.1 (q, 2JC–F = 33.1 Hz, Cq), 124.1 (q, 1JC–F = 271.6 Hz, 
Cq) , 121.9 (CH), 121.5 (CH), 119.3 (CH), 117.8 (CH), 54.3 (CH2), 33.2 (CH2), 30.3 
(CH), 21.5 (CH3). 
19F NMR (376 MHz, CDCl3) δ = –62.1 (s). IR (ATR): 2951, 1663, 
1522, 1327, 1267, 1119, 825, 792 cm–1. MS (ESI) m/z (relative intensity): 436 (40) 
[M+Na]+, 414 (100) [M+H]+, 191 (10). HR-MS (ESI) m/z calcd for C23H23F3N3O 
[M+H]+: 414.1788, found: 414.1786.  
 
2-(4-Cyanopiperidin-1-yl)-N-(quinolin-8-yl)-5-(trifluoromethyl)benzamide (58nf) 
The general procedure E was followed using benzamide 35n (79.0 mg, 0.25 mmol) 
and piperidine-4-carbonitrile (56f) (138 mg, 1.25 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 9/1→4/1) yielded 58nf (67.6 mg, 64%) 
as a white solid. M. p.: 193–195 °C. 1H NMR (300 MHz, CDCl3) δ = 12.32 (s, 1H), 9.12 
(dd, J = 7.0, 2.1 Hz, 1H), 8.86 (dd, J = 4.2, 1.7 Hz, 1H), 8.44 (d, J = 2.3 Hz, 1H), 8.21 
(dd, J = 8.3, 1.7 Hz, 1H), 7.72 (dd, J = 8.5, 2.3 Hz, 1H), 7.65–7.55 (m, 2H), 7.51 (dd, 
J = 8.3, 4.2 Hz, 1H), 7.31 (d, J = 8.5 Hz, 1H), 3.54–3.30 (m, 2H), 3.12–3.04 (m, 2H), 
2.73 (td, J = 7.5, 3.9 Hz, 1H), 2.29–2.16 (m, 4H). 13C NMR (101 MHz, CDCl3) δ = 164.2 
(Cq), 153.7 (Cq), 147.9 (CH), 138.5 (Cq), 136.8 (CH), 134.9 (Cq), 129.6 (q, 3JC–F = 3.8 
Hz, CH), 129.2 (Cq), 129.0 (q, 3JC–F = 3.6 Hz, CH), 128.4 (Cq), 127.6 (CH), 126.3 (q, 
2JC–F = 33.1 Hz, Cq), 123.8 (q, 1JC–F = 272.0 Hz, Cq), 122.3 (CH), 121.8 (CH), 121.1 
(Cq), 119.7 (CH), 118.0 (CH), 52.0 (CH2), 27.9 (CH2), 25.7 (CH). 
19F NMR (376 MHz, 
CDCl3) δ = –62.2 (s). IR (ATR): 3215, 2828, 2245, 1662, 1519, 1325, 1266, 1118, 826, 
735 cm–1. MS (ESI) m/z (relative intensity): 447 (98) [M+Na]+, 425 (50) [M+H]+, 327 
(10), 210 (10), 186 (100). HR-MS (ESI) m/z calcd for C23H20F3N4O [M+H]+: 425.1584, 
found: 425.1590.  






The general procedure E was followed using benzamide 35n (79.0 mg, 0.25 mmol) 
and (2R,6S)-2,6-dimethylmorpholine (56g) (144 mg, 1.25 mmol). Purification by 
column chromatography on silica gel (nhexane/EtOAc: 9/1→4/1) yielded 58ng 
(83.5 mg, 78%) as a white solid. M. p.: 150–151 °C. 1H NMR (400 MHz, CDCl3) δ = 
12.33 (s, 1H), 9.06 (dd, J = 7.4, 1.6 Hz, 1H), 8.78 (dd, J = 4.2, 1.7 Hz, 1H), 8.40 (dd, 
J = 2.4, 0.8 Hz, 1H), 8.17 (dd, J = 8.3, 1.7 Hz, 1H), 7.69 (ddd, J = 8.5, 2.4, 0.8 Hz, 1H), 
7.59 (dd, J = 8.2, 7.4 Hz, 1H), 7.54 (dd, J = 8.2, 1.6 Hz, 1H), 7.47 (dd, J = 8.3, 4.2 Hz, 
1H), 7.27 (dd, J = 8.5, 0.8 Hz, 1H), 4.10 (dqd, J = 10.2, 6.3, 2.0 Hz, 2H), 3.25 (dt, J = 
10.6, 1.6 Hz, 2H), 2.61 (dd, J = 11.7, 10.2 Hz, 2H), 1.12 (d, J = 6.3 Hz, 6H). 13C NMR 
(125 MHz, CDCl3) δ = 164.3 (Cq), 153.3 (Cq), 148.0 (CH), 138.5 (Cq), 136.4 (CH), 134.9 
(Cq), 129.4 (q, 3JC–F = 3.9 Hz, CH), 129.1 (Cq), 128.8 (q, 3JC–F = 3.7 Hz, CH), 128.2 (Cq), 
127.5 (CH), 125.8 (q, 2JC–F = 33.1 Hz, Cq), 123.9 (q, 1JC–F = 272.0 Hz, Cq), 122.0 (CH), 
121.6 (CH), 119.4 (CH), 117.7 (CH), 70.6 (CH), 59.0 (CH2), 19.0 (CH3). 
19F NMR (376 
MHz, CDCl3) δ = –62.2 (s). IR (ATR): 2975, 1667, 1526, 1331, 1264, 1123, 827 cm–1. 
MS (ESI) m/z (relative intensity): 452 (40) [M+Na]+, 430 (100) [M+H]+. HR-MS (ESI) 
m/z calcd for C23H23F3N3O2 [M+H]+: 430.1737, found: 430.1743. 
 
N-(Quinolin-8-yl)-2-thiomorpholino-5-(trifluoromethyl)benzamide (58nh) 
The general procedure E was followed using benzamide 35n (79.0 mg, 0.25 mmol) 
and thiomorpholine (56h) (124 mg, 1.25 mmol). Purification by GPC using CHCl3 
yielded 58nh (66.7 mg, 64%) as a white solid. M. p.: 182–184 °C. 1H NMR (400 MHz, 
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CDCl3) δ = 12.49 (s, 1H), 9.10 (dd, J = 7.3, 1.7 Hz, 1H), 8.90 (dd, J = 4.2, 1.7 Hz, 1H), 
8.47 (dd, J = 2.4, 0.8 Hz, 1H), 8.19 (dd, J = 8.3, 1.7 Hz, 1H), 7.71 (ddt, J = 8.5, 2.4, 
0.8 Hz, 1H), 7.59 (dd, J = 8.2, 7.3 Hz, 1H), 7.55 (dd, J = 8.2, 1.7 Hz, 1H), 7.49 (dd, J = 
8.3, 4.2 Hz, 1H), 7.32 (dd, J = 8.5, 0.8 Hz, 1H), 3.52–3.32 (m, 4H), 3.00–2.94 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ = 164.1 (Cq), 155.0 (Cq), 147.9 (CH), 138.5 (Cq), 136.6 
(CH), 135.0 (Cq), 129.6 (q, 3JC–F = 3.7 Hz, CH), 129.4 (Cq), 129.0 (q, 3JC–F = 3.5 Hz, 
CH), 128.3 (Cq), 127.5 (CH), 126.3 (q, 2JC–F = 33.3 Hz, Cq), 123.8 (q, 1JC–F = 272.0 Hz, 
Cq), 122.2 (CH), 121.8 (CH), 120.7 (CH), 118.2 (CH), 56.0 (CH2), 26.9 (CH2). 
19F NMR 
(376 MHz, CDCl3) δ = –62.2 (s). IR (ATR): 3349, 2925, 2833, 1667, 1526, 1327, 1123, 
826, 791 cm–1. MS (ESI) m/z (relative intensity): 440 (25) [M+Na]+, 418 (100) [M+H]+, 
339 (20), 317 (80), 119 (20). HR-MS (ESI) m/z calcd for C23H19F3N3OS 
[M+H]+: 418.1195, found: 418.1199.  
5.3.4.2 Competition Experiment 
 
Figure 5.3.4. Competition experiment between electronically different arenes 35. 
The general procedure D was followed using benzamides 35k (32.5 mg, 125 µmol) 
and 35n (39.5 mg, 125 µmol) and morpholine (56a) (43.5 mg, 0.50 mmol). Electrolysis 
was carried out at 120 °C and a constant current of 8 mA was maintained for 10 h. 
After cooling to ambient temperature, purification by column chromatography 
(nhexane/EtOAc: 16/1→9/1→2/1) yielded the desired products 58na (33.8 mg, 68%) 
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5.3.4.3 Experiments with Isotopically Labelled Solvent 
 
Figure 5.3.5. Experiments with isotopically labelled solvent CD3OD. 
The general procedure D was followed using benzamide 35a (62.0 mg, 0.25 mmol) 
and morpholine (56a) (43.5 mg, 0.50 mmol) using a mixture of DMA and CD3OD (10/1, 
3.3 mL) as solvent. Electrolysis was carried out at 100 °C and a constant current of 
8 mA was maintained for 10 h. Column chromatography (nhexane/EtOAc: 4/1) yielded 
the desired product [Dn]–58aa (33.2 mg, 40%) as a white solid and the reisolated 
starting material [Dn]–35a (22.1 mg, 35%) as a white solid. No deuteration could be 
detected in either compound as determined by 1H NMR spectroscopy.  
 
Figure 5.3.6. 1H NMR spectroscopy of reisolated [Dn]–35a. 




Figure 5.3.7. 1H NMR spectroscopy of [Dn]–58aa. 
5.3.4.4 Reaction Profile 
 
Figure 5.3.8. Reaction profile by in situ Rect-IR. 
An undivided cell equipped with a GF anode (10 mm × 15 mm × 6 mm) and a nickel-
foam cathode (10 mm × 15 mm × 1.4 mm) was charged under an atmosphere of N2 
with benzamide 35a (124 mg, 0.50 mmol, 1.00 equiv), Ni(DME)Cl2 (21.9 mg, 
20 mol %), NaOPiv (62.0 mg, 0.50 mmol, 1.00 equiv) and nBu4NBF4 (329 mg, 
0.50 mmol, 2.0 equiv), NMP (10.0 mL) and amine 56a (84.0 μL, 1.00 mmol, 2.0 equiv) 
and fitted with a diamond probe connected to a Mettler Toledo React–IR 15. After 
heating for 30 min to achieve a stable reaction temperature, electrolysis was started at 
a constant current of 8 mA for 16 h. An IR spectrum was recorded every 2 minutes. 
Peaks at 711 cm−1 and 760 cm−1 were identified to belong to the starting material and 
the product, respectively. 




Figure 5.3.9. Reaction profile of 35a and 58aa by in situ Rect-IR. Performed by Dr. Nicolas Sauermann. 
5.3.4.5 KIE studies 
 
Figure 5.3.10. KIE studies of C–H amination. 
Two parallel reactions were carried out with 35a (248 mg, 1.0 mmol, 1.0 equiv) or [D5]–
35a (253 mg, 1.0 mmol, 1.0 equiv) following the general procedure D for the React–IR 
studies (vide supra) using Ni(DME)Cl2 (44 mg, 20 mol %), NaOPiv (124.0 mg, 
1.0 mmol, 1.0 equiv), nBu4NBF4 (658 mg, 2.0 mmol, 2.0 equiv) and 56a (166 μL, 
2.0 mmol, 2.0 equiv) in NMP (10 mL). An IR spectrum was recorded every two minutes, 
and the KIE was determined by the analysis of the initial rates of the increase of the 
peak at 1117 cm−1 as measured by the integration of the peak area between 1108 cm−1 
and 1124 cm−1 after subtraction of the solvent spectrum. 




Figure 5.3.11. Initial rates for 58aa and [D4]–58aa.  
5.3.4.6 H2–Detection 
 
Figure 5.3.12. H2–detection under the optimized condition. 
Following the general procedure D, a reaction was performed under N2 atmosphere in 
a tightly closed flask. After 10 h, the gas–phase over the reaction mixture was analyzed 
by headspace GC analysis using an Agilent 7890B Chromatograph equipped with an 
Agilent CP–Molsieve 5Å column (length: 25 m, diameter: 0.32 mm, temperature 
100 °C). Helium was used as the carrier gas (1.5 mL/min) and the sample was 
analyzed by a temperature conductivity detector at 110 °C. For comparison, also a 
blank sample of the carrier gas and a pure sample of hydrogen was obtained. 




Figure 5.3.13. Headspace analysis of the reaction mixture. Performed by Dr. Nicolas Sauermann. 
5.3.4.7 Cyclic Voltammetry 
The cyclic voltammetry studies were carried out with a Metrohm Autolab PGSTAT204 
workstation and following analysis was performed with Nova 2.0 software. A glassy 
carbon electrode (3 mm diameter, disc–electrode) was used as the working electrode, 
a Pt–Wire as auxiliary electrode and an Ag–Wire as pseudoreference. The 
measurements were then referenced using ferrocene. The measurements were 
carried out at a scan rate of 100 mV/s. 
 
Figure 5.3.14. Cyclic voltammogram of the individual components at 100 mV/s. Cyclic voltammograms at 
100 mV/s: nBu4NBF4 (0.05 M in DMA); concentration of substrates 5 mM. blank (black); 35a (red); 
Ni(DME)Cl2 (blue); NaOPiv (pink); 56a (green). Performed by Dr. Nicolas Sauermann. 




Figure 5.3.15. Cyclic voltammogram of Ni(DME)Cl2 and the reaction components at ambient temperature 
at 100 mV/s: nBu4NBF4 (0.05 M in DMA); concentration of substrates 5 mM. blank (black); Ni(DME)Cl2 
(blue); Ni(DME)Cl2 + 35a (yellow); Ni(DME)Cl2 + NaOPiv (grey); Ni(DME)Cl2 + 35a + NaOPiv (brown). 
Performed by Dr. Nicolas Sauermann. 
 
Figure 5.3.16. Cyclic voltammogram of Ni(DME)Cl2 and the reaction components after heating to 120 °C 
for 30 min, spectra recorded after cooling to ambient temperature at 100 mV/s: nBu4NBF4 (0.05 M in DMA); 
concentration of substrates 5 mM. blank (black); Ni(DME)Cl2 + 35a (yellow); Ni(DME)Cl2 + NaOPiv (grey); 
Ni(DME)Cl2 + 35a + NaOPiv (brown). Performed by Dr. Nicolas Sauermann. 
5. Experimental Section  
151 
 
5.3.5 Nickela-Electrocatalyzed C–H Alkoxylation 
5.3.5.1 Characterization Data 
 
N-(6-Methylquinolin-8-yl)-2-(1-phenylethoxy)benzamide (107a) 
The general procedure F was followed using benzamide 106a (0.25 mmol, 65.5 mg) 
and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 16/1→9/1) yielded 107a (70.7 mg, 74%) 
as a white solid. M.p.: 126–127 °C. 1H NMR (400 MHz, CDCl3) δ = 12.12 (s, 1H), 9.01 
(d, J = 1.8 Hz, 1H), 8.69 (dd, J = 4.2, 1.7 Hz, 1H), 8.29 (dd, J = 7.8, 1.9 Hz, 1H), 8.07 
(dd, J = 8.2, 1.7 Hz, 1H), 7.62–7.56 (m, 2H), 7.38 (dd, J = 8.2, 4.2 Hz, 1H), 7.35–7.29 
(m, 3H), 7.29–7.22 (m, 2H), 7.02 (ddd, J = 8.3, 7.3, 1.0 Hz, 1H), 6.91–6.88 (m, 1H), 
5.61 (q, J = 6.5 Hz, 1H), 2.58 (d, J = 1.0 Hz, 3H), 1.94 (d, J = 6.5 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ = 164.1 (Cq), 156.0 (Cq), 146.8 (CH), 142.5 (Cq), 137.9 (Cq), 137.7 
(Cq), 135.5 (CH), 135.4 (Cq), 132.7 (CH), 132.4 (CH), 128.8 (CH), 128.1 (Cq), 127.7 
(CH), 125.6 (CH), 123.1 (Cq), 121.5 (CH), 121.0 (CH), 120.5 (CH), 119.9 (CH), 114.0 
(CH), 77.9 (CH), 25.0 (CH3), 22.4 (CH3). IR (ATR): 3298, 2924, 1657, 1531, 1476, 1222, 
855, 754, 696 cm–1. MS (ESI) m/z (relative intensity): 405 (40) [M+Na]+, 383 (100) 
[M+H]+. HR-MS (ESI) m/z calcd for C25H23N2O2 [M+H]+: 383.1754, found: 383.1754. 
 
N-(6-Methoxyquinolin-8-yl)-2-(1-phenylethoxy)benzamide (107b) 
The general procedure F was followed using benzamide 106b (0.25 mmol, 69.5 mg) 
and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 12/1→6/1) yielded 107b (66.5 mg, 67%) 
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as a white solid and reisolated 106b (13.0 mg, 19%). M.p.: 150–151 °C. 1H NMR 
(400 MHz, CDCl3) δ = 12.18 (s, 1H), 8.93 (d, J = 2.8 Hz, 1H), 8.63 (dd, J = 4.2, 1.7 Hz, 
1H), 8.32 (dd, J = 7.9, 1.9 Hz, 1H), 8.08 (dd, J = 8.3, 1.7 Hz, 1H), 7.65–7.57 (m, 2H), 
7.41 (dd, J = 8.3, 4.2 Hz, 1H), 7.39–7.33 (m, 2H), 7.33–7.27 (m, 2H), 7.05 (ddd, J = 
8.1, 7.3, 1.0 Hz, 1H), 6.94 (dd, J = 8.5, 1.0 Hz, 1H), 6.88 (d, J = 2.8 Hz, 1H), 5.65 (q, 
J = 6.5 Hz, 1H), 4.00 (s, 3H), 1.99 (d, J = 6.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 
164.2 (Cq), 158.6 (Cq), 156.0 (Cq), 145.1 (CH), 142.4 (Cq), 136.8 (Cq), 135.8 (Cq), 134.9 
(CH), 132.8 (CH), 132.5 (CH), 129.0 (Cq), 128.8 (CH), 127.7 (CH), 125.6 (CH), 122.9 
(Cq), 121.9 (CH), 121.0 (CH), 114.0 (CH), 109.9 (CH), 100.0 (CH), 77.9 (CH), 55.6 
(CH3), 25.0 (CH3). IR (ATR): 3230, 1656, 1520, 1477, 1222, 1157, 1067, 752, 700 cm-1. 
MS (ESI) m/z (relative intensity): 421 (35) [M+Na]+, 399 (100) [M+H]+, 295 (50). HR-MS 
(ESI) m/z calcd for C25H23N2O3 [M+H]+: 399.1703, found: 399.1703.  
 
N-(5-Methylquinolin-8-yl)-2-(1-phenylethoxy)benzamide (107c) 
The general procedure F was followed using benzamide 106c (0.25 mmol, 65.5 mg) 
and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 16/1→9/1) yielded 107c (57.8 mg, 61%) 
as a white solid and reisolated 106c (13.9 mg, 21%). M.p.: 151–152 °C. 1H NMR (300 
MHz, CDCl3) δ = 12.19 (s, 1H), 9.06 (d, J = 7.9 Hz, 1H), 8.81 (dd, J = 4.2, 1.6 Hz, 1H), 
8.36 (ddd, J = 7.6, 5.9, 1.8 Hz, 2H), 7.67–7.60 (m, 2H), 7.53–7.45 (m, 2H), 7.43–7.25 
(m, 4H), 7.10–7.03 (m, 1H), 6.94 (d, J = 8.2 Hz, 1H), 5.66 (q, J = 6.4 Hz, 1H), 2.69 (d, 
J = 0.8 Hz, 3H), 1.99 (d, J = 6.4 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 164.0 (Cq), 
156.0 (Cq), 147.3 (CH), 142.5 (Cq), 139.5 (Cq), 134.3 (Cq), 132.9 (CH), 132.7 (CH), 
132.5 (CH), 128.9 (CH), 128.2 (Cq), 127.8 (CH), 127.7 (CH), 127.4 (Cq), 125.7 (CH), 
123.2 (Cq), 121.1 (CH), 121.0 (CH), 117.5 (CH), 114.0 (CH), 77.8 (CH), 25.1 (CH3), 
18.3 (CH3). IR (ATR): 3306, 1654, 1520, 1495, 1455, 1225, 753, 701 cm–1. MS (ESI) 
m/z (relative intensity): 405 (40) [M+Na]+, 383 (100) [M+H]+, 279 (85), 159 (50), 105 
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(40). HR-MS (ESI) m/z calcd for C25H23N2O2 [M+H]+: 383.1754, found: 383.1755. 
 
2-(1-Phenylethoxy)-N-(quinolin-8-yl)benzamide (107d) 
The general procedure F was followed using benzamide 35a (0.25 mmol, 62.0 mg) 
and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 16/1→9/1) yielded 107d (48.9 mg, 53%) 
as a white solid and reisolated 35a (23.0 mg, 37%). M.p.: 112–114 °C. 1H NMR 
(400 MHz, CDCl3) δ = 12.22 (s, 1H), 9.18 (dd, J = 7.7, 1.4 Hz, 1H), 8.81 (dd, J = 4.2, 
1.7 Hz, 1H), 8.35 (dd, J = 7.8, 1.9 Hz, 1H), 8.21 (dd, J = 8.2, 1.7 Hz, 1H), 7.68–7.61 
(m, 3H), 7.58 (dd, J = 8.3, 1.4 Hz, 1H), 7.47 (dd, J = 8.2, 4.2 Hz, 1H), 7.42–7.32 (m, 
2H), 7.34–7.27 (m, 2H), 7.06 (ddd, J = 8.0, 7.3, 1.0 Hz, 1H), 6.94 (dd, J = 8.5, 1.0 Hz, 
1H), 5.66 (q, J = 6.5 Hz, 1H), 1.99 (d, J = 6.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 
164.2 (Cq), 156.0 (Cq), 147.8 (CH), 142.5 (Cq), 139.3 (Cq), 136.3 (CH), 135.9 (Cq), 
132.8 (CH), 132.5 (CH), 128.9 (CH), 128.2 (Cq), 127.8 (CH), 127.6 (CH), 125.7 (CH), 
123.1 (Cq), 121.6 (CH), 121.5 (CH), 121.0 (CH), 117.8 (CH), 114.1 (CH), 77.9 (CH), 
25.1 (CH3). IR (ATR): 3304, 1655, 1519, 1324, 1221, 1066, 790, 750, 699 cm–1. MS 
(ESI) m/z (relative intensity): 391 (45) [M+Na]+, 369 (90) [M+H]+, 265 (100), 145 (70), 
105 (30). HR-MS (ESI) m/z calcd for C24H21N2O2 [M+H]+: 369.1598, found: 369.1597. 
 
N-(5-Methoxyquinolin-8-yl)-2-(1-phenylethoxy)benzamide (107e) 
The general procedure F was followed using benzamide 106e (0.25 mmol, 69.5 mg) 
and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 16/1→9/1) yielded 107e (27.4 mg, 28%) 
as a white solid and reisolated 106e (44.6 mg, 64%). M.p.: 147–148 °C. 1H NMR 
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(400 MHz, CDCl3) δ = 11.99 (s, 1H), 9.05 (d, J = 8.6 Hz, 1H), 8.77 (dd, J = 4.2, 1.7 Hz, 
1H), 8.59 (dd, J = 8.4, 1.7 Hz, 1H), 8.30 (dd, J = 7.8, 1.9 Hz, 1H), 7.61–7.55 (m, 2H), 
7.42 (dd, J = 8.4, 4.2 Hz, 1H), 7.35–7.29 (m, 2H), 7.31–7.20 (m, 2H), 7.01 (ddd, J = 
8.1, 7.2, 1.0 Hz, 1H), 6.94–6.87 (m, 2H), 5.61 (q, J = 6.5 Hz, 1H), 4.01 (s, 3H), 1.95 (d, 
J = 6.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 163.6 (Cq), 155.9 (Cq), 150.3 (Cq), 
148.2 (CH), 142.5 (Cq), 139.9 (Cq), 132.5 (CH), 132.4 (CH), 131.1 (CH), 129.3 (Cq), 
128.8 (CH), 127.7 (CH), 125.6 (CH), 123.1 (Cq), 121.0 (CH), 120.6 (CH), 120.5 (Cq), 
117.9 (CH), 114.0 (CH), 104.6 (CH), 77.8 (CH), 55.8 (CH3), 25.1 (CH3). IR (ATR): 3311, 
1644, 1526, 1269, 1222, 1089, 751, 701 cm–1. MS (ESI) m/z (relative intensity): 421 
(30) [M+Na]+, 399 (100) [M+H]+, 295 (80), 175 (40), 105 (10). HR-MS (ESI) m/z calcd 
for C25H23N2O3 [M+H]+: 399.1703, found: 399.1704. 
 
N-(6-Methylquinolin-8-yl)-2-[1-(p-tolyl)ethoxy]benzamide (107f) 
The general procedure F was followed using benzamide 106a (0.25 mmol, 65.5 mg) 
and 1-(p-tolyl)ethan-1-ol (66b) (341 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 16/1→9/1) yielded 107f (54.4 mg, 55%) 
as a white solid. M.p.: 128–130 °C. 1H NMR (300 MHz, CDCl3) δ = 12.18 (s, 1H), 9.06 
(d, J = 1.8 Hz, 1H), 8.79–8.74 (m, 1H), 8.34 (dd, J = 7.9, 1.9 Hz, 1H), 8.11 (dd, J = 8.2, 
1.7 Hz, 1H), 7.56–7.49 (m, 2H), 7.42 (dd, J = 8.2, 4.2 Hz, 1H), 7.39–7.29 (m, 2H), 7.17 
(d, J = 7.9 Hz, 2H), 7.09–7.03 (m, 1H), 7.00–6.94 (m, 1H), 5.63 (q, J = 6.4 Hz, 1H), 
2.63 (d, J = 0.9 Hz, 3H), 2.34 (s, 3H), 1.97 (d, J = 6.4 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ = 164.2 (Cq), 156.1 (Cq), 146.8 (CH), 139.5 (Cq), 138.0 (Cq), 137.7 (Cq), 137.5 
(Cq), 135.5 (Cq),135.5 (CH), 132.8 (CH), 132.5 (CH), 129.5 (CH), 128.2 (Cq), 125.7 
(CH), 123.1 (Cq), 121.5 (CH), 120.9 (CH), 120.5 (CH), 119.8 (CH), 114.1 (CH), 77.8 
(CH), 25.1 (CH3), 22.4 (CH3), 21.2 (CH3). IR (ATR): 3302, 1657, 1527, 1476, 1422, 
1291, 1221, 1067, 753 cm–1. MS (ESI) m/z (relative intensity): 419 (15) [M+Na]+, 397 
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(100) [M+H]+, 279 (90), 159 (50), 119 (100). HR-MS (ESI) m/z calcd for C26H25N2O2 




The general procedure F was followed using benzamide 106a (0.25 mmol, 65.5 mg) 
and 1-[4-(trifluoromethyl)phenyl]ethan-1-ol (66c) (475 mg, 2.5 mmol). Purification by 
column chromatography on silica gel (nhexane/EtOAc: 16/1→9/1) yielded 107g (73.6 
mg, 65%) as a white solid. M.p.: 138–139 °C. 1H NMR (400 MHz, CDCl3) δ = 12.03 (s, 
1H), 9.01 (d, J = 1.8 Hz, 1H), 8.63 (dd, J = 4.2, 1.7 Hz, 1H), 8.30 (dd, J = 7.8, 1.8 Hz, 
1H), 8.07 (dd, J = 8.2, 1.7 Hz, 1H), 7.75–7.66 (m, 2H), 7.64–7.53 (m, 2H), 7.38 (dd, 
J = 8.2, 4.2 Hz, 1H), 7.33–7.27 (m, 2H), 7.06 (ddd, J = 8.2, 7.3, 1.0 Hz, 1H), 6.83 (dd, 
J = 8.5, 1.0 Hz, 1H), 5.66 (q, J = 6.5 Hz, 1H), 2.58 (d, J = 0.9 Hz, 3H), 1.93 (d, J = 
6.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 163.9 (Cq), 155.5 (Cq), 146.7 (CH), 146.5 
(Cq), 137.8 (Cq), 137.7 (Cq), 135.6 (CH), 135.2 (Cq), 132.8 (CH), 132.6 (CH), 130.0 (q, 
2JC–F = 32.4 Hz, Cq), 128.1 (Cq), 126.0 (CH), 125.9 (q, 3JC–F = 3.8 Hz, CH), 123.9 (q, 
1JC–F = 272.3 Hz, Cq), 123.3 (Cq), 121.5 (CH), 121.4 (CH), 120.6 (CH), 119.8 (CH), 
113.7 (CH), 77.1 (CH), 24.7 (CH3), 22.4 (CH3). 
19F NMR (282 MHz, CDCl3) δ = -62.5 
(s). IR (ATR): 3312, 2926, 1658, 1531, 1478, 1325, 1125, 1069, 753 cm–1. MS (ESI) 
m/z (relative intensity): 473 (15) [M+Na]+, 451 (100) [M+H]+. HR-MS (ESI) m/z calcd 
for C26H22F3N2O2 [M+H]+: 451.1628, found: 451.1636.  
 
2-(1-Cyclohexylethoxy)-N-(6-methylquinolin-8-yl)benzamide (107h) 
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The general procedure F was followed using benzamide 106a (0.25 mmol, 65.5 mg) 
and 1-cyclohexylethan-1-ol (66d) (320 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/acetone: 16/1→9/1) yielded 107h (77.9 mg, 
80%) as a colourless oil. 1H NMR (400 MHz, CDCl3) δ = 11.95 (s, 1H), 8.98 (d, J = 
1.9 Hz, 1H), 8.76 (dd, J = 4.2, 1.7 Hz, 1H), 8.32 (dd, J = 7.9, 1.9 Hz, 1H), 8.05 (dd, J = 
8.2, 1.7 Hz, 1H), 7.45 (ddd, J = 8.4, 7.3, 1.9 Hz, 1H), 7.40 (dd, J = 8.2, 4.2 Hz, 1H), 
7.28 (dq, J = 1.9, 1.0 Hz, 1H), 7.12–7.03 (m, 2H), 4.46 (p, J = 6.2 Hz, 1H), 2.56 (d, J = 
1.0 Hz, 3H), 2.16–2.05 (m, 1H), 2.02 (ddt, J = 11.7, 3.7, 1.9 Hz, 1H), 1.92–1.84 (m, 
1H), 1.77–1.68 (m, 1H), 1.69–1.56 (m, 2H), 1.47 (d, J = 6.2 Hz, 3H), 1.21–1.00 (m, 
5H). 13C NMR (101 MHz, CDCl3) δ = 164.3 (Cq), 156.7 (Cq), 146.7 (CH), 138.0 (Cq), 
137.6 (Cq), 135.5 (Cq), 135.4 (CH), 132.9 (CH), 132.6 (CH), 128.1 (Cq), 123.5 (Cq), 
121.4 (CH), 120.8 (CH), 120.5 (CH), 119.8 (CH), 113.8 (CH), 80.6 (CH), 42.3 (CH), 
29.8 (CH2), 28.1 (CH2), 26.4 (CH2), 26.1 (CH2), 25.9 (CH2), 22.3 (CH3), 16.9 (CH3). IR 
(ATR): 3295, 2923, 2851, 1656, 1521, 1475, 1420, 1286, 854, 752 cm–1. MS (ESI) m/z 
(relative intensity): 411 (90) [M+Na]+, 389 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C25H29N2O2 [M+H]+: 389.2224, found: 389.2217 
 
2-[(Heptan-2-yl)oxy]-N-(6-methylquinolin-8-yl)benzamide (107i) 
The general procedure F was followed using benzamide 106a (0.25 mmol, 65.5 mg) 
and heptan-2-ol (66e) (290 mg, 2.5 mmol). Purification by column chromatography on 
silica gel (nhexane/EtOAc: 16/1→9/1) yielded 107i (75.0 mg, 80%) as a colourless oil. 
1H NMR (400 MHz, CDCl3) δ = 12.00 (s, 1H), 8.98 (d, J = 1.9 Hz, 1H), 8.74 (dd, J = 
4.2, 1.7 Hz, 1H), 8.34 (dd, J = 7.8, 1.9 Hz, 1H), 8.05 (dd, J = 8.2, 1.7 Hz, 1H), 7.45 
(ddd, J = 8.3, 7.2, 1.9 Hz, 1H), 7.39 (dd, J = 8.2, 4.2 Hz, 1H), 7.28 (dq, J = 1.9, 0.9 Hz, 
1H), 7.12–7.04 (m, 2H), 4.71 (h, J = 6.2 Hz, 1H), 2.55 (d, J = 0.9 Hz, 3H), 2.17 (dddd, 
J = 13.6, 10.1, 6.5, 5.6 Hz, 1H), 1.79 (ddt, J = 13.6, 9.8, 6.0 Hz, 1H), 1.53 (d, J = 6.2 Hz, 
3H), 1.51–1.44 (m, 1H), 1.44–1.35 (m, 1H), 1.31–1.15 (m, 4H), 0.78 (t, J = 7.0 Hz, 3H). 
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13C NMR (101 MHz, CDCl3) δ = 164.2 (Cq), 156.5 (Cq), 146.7 (CH), 138.0 (Cq), 137.6 
(Cq), 135.5 (Cq), 135.4 (CH), 132.9 (CH), 132.6 (CH), 128.1 (Cq), 123.4 (Cq), 121.4 
(CH), 120.9 (CH), 120.4 (CH), 119.8 (CH), 113.8 (CH), 76.2 (CH), 36.0 (CH2), 31.7 
(CH2), 25.4 (CH2), 22.5 (CH2), 22.3 (CH3), 19.8 (CH3), 13.9 (CH3). IR (ATR): 3295, 
2929, 1656, 1525, 1476, 1421, 1288, 752 cm–1. MS (ESI) m/z (relative intensity): 399 
(98) [M+Na]+, 377 (100) [M+H]+. HR-MS (ESI) m/z calcd for C24H29N2O2 
[M+H]+: 377.2224, found: 377.2225.  
 
N-(6-Methylquinolin-8-yl)-2-[(octan-2-yl)oxy]benzamide (107j) 
The general procedure F was followed using benzamide 106a (0.25 mmol, 65.5 mg) 
and octan-2-ol (66f) (325 mg, 2.5 mmol). Purification by column chromatography on 
silica gel (nhexane/acetone: 16/1→9/1) yielded 107j (89.6 mg, 92%) as a white solid. 
M.p.: 133–134 °C. 1H NMR (400 MHz, CDCl3) δ = 12.00 (s, 1H), 8.97 (d, J = 1.9 Hz, 
1H), 8.75 (dd, J = 4.2, 1.7 Hz, 1H), 8.33 (dd, J = 7.8, 1.9 Hz, 1H), 8.05 (dd, J = 8.2, 
1.7 Hz, 1H), 7.45 (ddd, J = 8.2, 7.2, 1.9 Hz, 1H), 7.40 (dd, J = 8.2, 4.2 Hz, 1H), 7.28 
(dq, J = 1.9, 1.0 Hz, 1H), 7.15–7.01 (m, 2H), 4.71 (h, J = 6.2 Hz, 1H), 2.56 (d, J = 
1.0 Hz, 3H), 2.17 (dddd, J = 13.6, 10.1, 6.6, 5.5 Hz, 1H), 1.79 (ddt, J = 13.6, 9.9, 5.9 Hz, 
1H), 1.53 (d, J = 6.2 Hz, 3H), 1.51–1.33 (m, 2H) 1.33–1.09 (m, 6H), 0.77 (t, J = 6.9 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ = 164.2 (Cq), 156.5 (Cq), 146.7 (CH), 138.0 (Cq), 
137.7 (Cq), 135.5 (Cq), 135.4 (CH), 132.9 (CH), 132.6 (CH), 128.1 (Cq), 123.5 (Cq), 
121.4 (CH), 120.9 (CH), 120.4 (CH), 119.8 (CH), 113.8 (CH), 76.3 (CH), 36.1 (CH2), 
31.7 (CH2), 29.2 (CH2), 25.7 (CH2), 22.5 (CH2), 22.4 (CH3), 19.9 (CH3), 14.0 (CH3). IR 
(ATR): 3299, 2927, 1659, 1530, 1477, 753 cm–1. MS (EI) m/z (relative intensity): 391 
(10) [M+H]+, 390 (30) [M]+, 158 (100), 121 (50). HR-MS (EI) m/z calcd for C25H30N2O2 
[M]+: 390.2302, found: 390.2311. 





The general procedure F was followed using benzamide 106a (0.25 mmol, 65.5 mg) 
and 1-phenylpropan-2-ol (66g) (340 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 16/1→9/1) yielded 107k (84.7 mg, 86%) 
as a colourless oil. 1H NMR (400 MHz, CDCl3) δ = 12.07 (s, 1H), 9.01 (d, J = 1.9 Hz, 
1H), 8.76 (dd, J = 4.2, 1.7 Hz, 1H), 8.35 (dd, J = 7.9, 1.9 Hz, 1H), 8.06 (dd, J = 8.2, 
1.7 Hz, 1H), 7.43 (ddd, J = 8.3, 7.2, 1.9 Hz, 1H), 7.40 (dd, J = 8.2, 4.2 Hz, 1H), 7.30 
(dq, J = 1.9, 1.0 Hz, 1H), 7.28–7.25 (m, 2H), 7.25–7.20 (m, 2H), 7.18–7.13 (m, 1H), 
7.09 (ddd, J = 8.1, 7.2, 1.0 Hz, 1H), 7.02 (dd, J = 8.3, 0.8 Hz, 1H), 4.99–4.85 (m, 1H), 
3.59 (dd, J = 13.6, 6.3 Hz, 1H), 3.08 (dd, J = 13.6, 6.7 Hz, 1H), 2.58 (d, J = 1.0 Hz, 
3H), 1.55 (d, J = 6.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 164.0 (Cq), 156.0 (Cq), 
146.8 (CH), 138.1 (Cq), 137.9 (Cq), 137.7 (Cq), 135.5 (CH), 135.4 (Cq), 132.9 (CH), 
132.6 (CH), 129.3 (CH), 128.4 (CH), 128.1 (Cq), 126.4 (CH), 123.6 (Cq), 121.4 (CH), 
121.2 (CH), 120.5 (CH), 119.8 (CH), 113.9 (CH), 77.3 (CH), 42.4 (CH2), 22.3 (CH3), 
19.5 (CH3). IR (ATR): 3230, 2925, 1655, 1524, 1476, 1422, 1288, 750, 698 cm–1. MS 
(EI) m/z (relative intensity): 397 (5) [M+H]+ , 396 (15) [M]+, 158 (100), 120 (50), 91 (50). 
HR-MS (EI) m/z calcd for C26H24N2O2 [M]+: 396.1832, found: 396.1848. 
 
2-[(1-Ethoxypropan-2-yl)oxy]-N-(6-methylquinolin-8-yl)benzamide (107l) 
The general procedure F was followed using benzamide 106a (0.25 mmol, 65.5 mg) 
and 1-ethoxypropan-2-ol (66h) (260 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 16/1→9/1) yielded 107l (48.5 mg, 54%) 
as a colourless oil. 1H NMR (400 MHz, CDCl3) δ = 11.95 (s, 1H), 8.96 (d, J = 1.9 Hz, 
1H), 8.77 (dd, J = 4.2, 1.7 Hz, 1H), 8.32 (dd, J = 7.9, 1.9 Hz, 1H), 8.06 (dd, J = 8.2, 
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1.7 Hz, 1H), 7.46 (ddd, J = 8.4, 7.2, 1.9 Hz, 1H), 7.41 (dd, J = 8.2, 4.2 Hz, 1H), 7.28 
(dq, J = 1.9, 1.0 Hz, 1H), 7.16 (ddd, J = 8.4, 1.0, 0.5 Hz, 1H), 7.11 (ddd, J = 7.9, 7.2, 
1.0 Hz, 1H), 4.89 (tdd, J = 6.1, 5.4, 0.7 Hz, 1H), 4.03 (dd, J = 10.1, 6.1 Hz, 1H), 3.71 
(dd, J = 10.1, 5.4 Hz, 1H), 3.49 (q, J = 7.0 Hz, 2H), 2.55 (d, J = 1.0 Hz, 3H), 1.56 (d, 
J = 6.3 Hz, 3H), 1.09 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 164.0 (Cq), 
156.3 (Cq), 146.7 (CH), 138.0 (Cq), 137.7 (Cq), 135.6 (CH), 135.4 (Cq), 132.9 (CH), 
132.5 (CH), 128.1 (Cq), 123.7 (Cq), 121.4 (CH), 121.4 (CH), 120.5 (CH), 119.8 (CH), 
114.4 (CH), 75.5 (CH), 73.6 (CH2), 66.9 (CH2), 22.3 (CH3), 17.4 (CH3), 15.1 (CH3). IR 
(ATR): 3300, 2976, 1655, 1523, 1475, 1219, 1109, 854, 751, 692 cm–1. MS (ESI) m/z 
(relative intensity): 387 (30) [M+Na]+, 365 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C22H25N2O3 [M+H]+: 365.1860, found: 365.1861.  
 
N-(6-Methylquinolin-8-yl)-2-[(1-phenylbutan-2-yl)oxy]benzamide (107m) 
The general procedure F was followed using benzamide 106a (0.25 mmol, 65.5 mg) 
and 1-phenylbutan-2-ol (66i) (375 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/acetone: 30/1→15/1) yielded 107m (58.5 mg, 
57%) as a colourless oil. 1H NMR (400 MHz, CDCl3) δ = 12.12 (s, 1H), 9.03 (d, J = 
1.9 Hz, 1H), 8.74 (dd, J = 4.2, 1.7 Hz, 1H), 8.36 (dd, J = 7.9, 1.9 Hz, 1H), 8.06 (dd, J = 
8.3, 1.7 Hz, 1H), 7.44–7.38 (m, 2H), 7.30 (dq, J = 1.9, 1.0 Hz, 1H), 7.28–7.23 (m, 2H), 
7.22–7.17 (m, 2H), 7.15–7.10 (m, 1H), 7.08 (ddd, J = 7.9, 7.2, 1.0 Hz, 1H), 6.99 (d, J = 
8.4, 1H), 4.85–4.72 (m, 1H), 3.50 (dd, J = 13.8, 6.8 Hz, 1H), 3.11 (dd, J = 13.8, 5.8 Hz, 
1H), 2.58 (d, J = 1.0 Hz, 3H), 2.10 (ddd, J = 14.2, 7.5, 6.8 Hz, 1H), 1.98–1.86 (m, 1H), 
1.04 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 164.0 (Cq), 156.7 (Cq), 146.6 
(CH), 138.1 (Cq), 138.0 (Cq), 137.6 (Cq), 135.5 (Cq), 135.5 (CH), 132.9 (CH), 132.7 
(CH), 129.3 (CH), 128.4 (CH), 128.1 (Cq), 126.3 (CH), 123.3 (Cq), 121.4 (CH), 121.0 
(CH), 120.5 (CH), 119.8 (CH), 113.7 (CH), 82.5 (CH), 40.0 (CH2), 26.4 (CH2), 22.3 
(CH3), 9.9 (CH3). IR (ATR): 3295, 2968, 1654, 1521, 1475, 1419, 1219, 854, 747, 
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692 cm–1. MS (ESI) m/z (relative intensity): 433 (50) [M+Na]+, 411 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C27H27N2O2 [M+H]+: 411.2067, found: 411.2067.  
  
2-[(Hexan-3-yl)oxy]-N-(6-methylquinolin-8-yl)benzamide (107n) 
The general procedure F was followed using benzamide 106a (0.25 mmol, 65.5 mg) 
and hexan-3-ol (66j) (255 mg, 2.5 mmol). Purification by column chromatography on 
silica gel (nhexane/EtOAc: 20/1→9/1) yielded 107n (45.5 mg, 50%) as a colourless oil. 
1H NMR (400 MHz, CDCl3) δ = 12.05 (s, 1H), 8.99 (d, J = 1.9 Hz, 1H), 8.74 (dd, J = 
4.2, 1.7 Hz, 1H), 8.47–8.26 (m, 1H), 8.05 (dd, J = 8.2, 1.7 Hz, 1H), 7.49–7.42 (m, 1H), 
7.40 (dd, J = 8.2, 4.2 Hz, 1H), 7.28 (dd, J = 1.9, 1.0 Hz, 1H), 7.12–7.05 (m, 2H), 4.65–
4.48 (m, 1H), 2.56 (d, J = 1.0 Hz, 3H), 2.19–2.00 (m, 2H), 1.96–1.73 (m, 2H), 1.63–
1.38 (m, 2H), 1.01 (t, J = 7.4 Hz, 3H), 0.87 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ = 164.2 (Cq), 157.1 (Cq), 146.6 (CH), 138.1 (Cq), 137.6 (Cq), 135.6 (Cq), 135.4 
(CH), 132.9 (CH), 132.7 (CH), 128.1 (Cq), 123.1 (Cq), 121.4 (CH), 120.7 (CH), 120.5 
(CH), 119.9 (CH), 113.6 (CH), 81.2 (CH), 35.6 (CH2), 26.7 (CH2), 22.4 (CH3), 18.8 
(CH2), 14.1 (CH3), 10.0 (CH3). IR (ATR): 3293, 2960, 1654, 1522, 1475, 1287, 949, 
854, 752, 692 cm–1. MS (ESI) m/z (relative intensity): 385 (30) [M+Na]+, 363 (100) 
[M+H]+. HR-MS (ESI) m/z calcd for C23H27N2O2 [M+H]+: 363.2067, found: 363.2068.  
 
2-[(2,3-Dihydro-1H-inden-2-yl)oxy)-N-(6-methylquinolin-8-yl)benzamide (107o) 
The general procedure F was followed using benzamide 106a (0.25 mmol, 65.5 mg) 
and 2,3-dihydro-1H-inden-2-ol (66k) (335 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/acetone: 16/1→9/1) yielded 107o (70.7 mg, 
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72%) as a white solid. M.p.: 157–158 °C. 1H NMR (300 MHz, CDCl3) δ = 11.77 (s, 1H), 
8.91 (d, J = 1.9 Hz, 1H), 8.41 (dd, J = 4.2, 1.7 Hz, 1H), 8.34 (dd, J = 8.0, 1.9 Hz, 1H), 
8.00 (dd, J = 8.2, 1.7 Hz, 1H), 7.54–7.46 (m, 1H), 7.31 (dd, J = 8.2, 4.2 Hz, 1H), 7.26–
7.23 (m, 1H), 7.18–7.09 (m, 6H), 5.59–5.39 (m, 1H), 3.73 (dd, J = 16.7, 4.6 Hz, 2H), 
3.54 (dd, J = 16.7, 7.2 Hz, 2H), 2.53 (d, J = 0.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) 
δ = 163.7 (Cq), 155.8 (Cq), 146.6 (CH), 140.1 (Cq), 137.7 (Cq), 137.4 (Cq), 135.3 (CH), 
135.1 (Cq), 132.8 (CH), 132.7 (CH), 127.9 (Cq), 126.6 (CH), 124.5 (CH), 123.4 (Cq), 
121.3 (CH), 121.2 (CH), 120.4 (CH), 119.6 (CH), 113.5 (CH), 79.4 (CH), 39.6 (CH2), 
22.4 (CH3). IR (ATR): 3300, 1651, 1531, 1475, 1290, 1028, 860, 744, 684, 591 cm–1. 
MS (ESI) m/z (relative intensity): 417 (30) [M+Na]+, 395 (100) [M+H]+. HR-MS (ESI) 
m/z calcd for C26H23N2O2 [M+H]+: 395.1754, found: 395.1755. 
 
2-Cyclobutoxy-N-(6-methylquinolin-8-yl)benzamide (107p) 
The general procedure F was followed using benzamide 106a (0.25 mmol, 65.5 mg) 
and cyclobutanol (66l) (188 mg, 2.5 mmol). Purification by column chromatography on 
silica gel (nhexane/acetone: 16/1→9/1) yielded 107p (61.8 mg, 74%) as a white solid. 
M.p.: 86–87 °C. 1H NMR (300 MHz, CDCl3) δ = 12.01 (s, 1H), 8.98 (d, J = 1.9 Hz, 1H), 
8.74 (dd, J = 4.2, 1.7 Hz, 1H), 8.35 (dd, J = 7.9, 1.8 Hz, 1H), 8.04 (dd, J = 8.3, 1.7 Hz, 
1H), 7.43 (ddd, J = 8.4, 7.2, 1.8 Hz, 1H), 7.38 (dd, J = 8.3, 4.2 Hz, 1H), 7.28 (dq, J = 
1.9, 1.0 Hz, 1H), 7.09 (ddd, J = 7.9, 7.2, 1.0 Hz, 1H), 6.88 (dd, J = 8.4, 1.0 Hz, 1H), 
4.94 (pd, J = 7.2, 1.0 Hz, 1H), 2.76–2.57 (m, 4H), 2.55 (d, J = 1.0 Hz, 3H), 2.11–1.91 
(m, 1H), 1.85–1.72 (m, 1H). 13C NMR (126 MHz, CDCl3) δ = 163.8 (Cq), 155.7 (Cq), 
146.7 (CH), 137.9 (Cq), 137.5 (Cq), 135.5 (Cq), 135.4 (CH), 132.9 (CH), 132.5 (CH), 
128.0 (Cq), 122.3 (Cq), 121.3 (CH), 120.9 (CH), 120.4 (CH), 119.8 (CH), 112.9 (CH), 
72.9 (CH), 30.7 (CH2), 22.4 (CH3), 13.6 (CH2). IR (ATR): 3298, 2937, 1654, 1524, 1476, 
1290, 1219, 854, 750, 689 cm–1. MS (ESI) m/z (relative intensity): 355 (80) [M+Na]+, 
333 (100) [M+H]+. HR-MS (ESI) m/z calcd for C21H21N2O2 [M+H]+: 333.1598, 
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found: 333.1601.  
 
2-(Cyclopentyloxy)-N-(6-methylquinolin-8-yl)benzamide (107q) 
The general procedure F was followed using benzamide 106a (0.25 mmol, 65.5 mg) 
and cyclopentanol (66m) (215 mg, 2.5 mmol). Purification by column chromatography 
on silica gel (nhexane/acetone: 16/1→9/1) yielded 107q (68.4 mg, 79%) as a white 
solid. M.p.: 96–98 °C. 1H NMR (300 MHz, CDCl3) δ = 11.80 (s, 1H), 9.03 (d, J = 1.9 Hz, 
1H), 8.77 (dd, J = 4.2, 1.7 Hz, 1H), 8.36 (dd, J = 7.8, 1.9 Hz, 1H), 8.09 (dd, J = 8.2, 
1.7 Hz, 1H), 7.49 (ddd, J = 8.2, 7.3, 1.9 Hz, 1H), 7.43 (dd, J = 8.2, 4.2 Hz, 1H), 7.33 
(dq, J = 1.9, 1.0 Hz, 1H), 7.16–7.06 (m, 2H), 5.13 (tt, J = 6.1, 2.9 Hz, 1H), 2.60 (d, J = 
1.0 Hz, 3H), 2.45–2.33 (m, 2H), 2.22–2.02 (m, 2H), 1.98–1.80 (m, 2H), 1.67 (tdd, J = 
10.9, 8.2, 5.2 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ = 164.3 (Cq), 156.3 (Cq), 146.6 
(CH), 138.0 (Cq), 137.6 (Cq), 135.5 (CH), 135.4 (Cq), 132.8 (CH), 132.7 (CH), 128.1 
(Cq), 123.1 (Cq), 121.4 (CH), 120.6 (CH), 120.5 (CH), 120.0 (CH), 113.6 (CH), 81.2 
(CH), 32.9 (CH2), 24.4 (CH2), 22.3 (CH3). IR (ATR): 3305, 2960, 1656, 1528, 1478, 
1421, 1289, 753 cm–1. MS (ESI) m/z (relative intensity): 369 (100) [M+Na]+, 347 (90) 
[M+H]+. HR-MS (ESI) m/z calcd for C22H23N2O2 [M+H]+: 347.1754, found: 347.1756.  
 
2-(Cyclohexyloxy)-N-(6-methylquinolin-8-yl)benzamide (107r) 
The general procedure F was followed using benzamide 106a (0.25 mmol, 65.5 mg) 
and cyclohexanol (66n) (251 mg, 2.5 mmol). Purification by column chromatography 
on silica gel (nhexane/acetone: 20/1) yielded 107r (68.4 mg, 76%) as a white solid. 
M.p.: 121–123 °C. 1H NMR (300 MHz, CDCl3) δ = 11.97 (s, 1H), 9.01 (d, J = 1.9 Hz, 
1H), 8.78 (dd, J = 4.2, 1.7 Hz, 1H), 8.34 (dd, J = 8.1, 1.9 Hz, 1H), 8.09 (dd, J = 8.2, 
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1.7 Hz, 1H), 7.48 (ddd, J = 8.4, 7.3, 1.9 Hz, 1H), 7.44 (dd, J = 8.2, 4.2 Hz, 1H), 7.32 
(dq, J = 1.9, 1.0 Hz, 1H), 7.16–7.06 (m, 2H), 4.59 (tt, J = 9.8, 4.0 Hz, 1H), 2.60 (d, J = 
1.0 Hz, 3H), 2.29–2.20 (m, 2H), 2.03–1.92 (m, 2H), 1.88 (dt, J = 7.3, 3.3 Hz, 2H), 1.74–
1.65 (m, 1H), 1.51–1.26 (m, 3H). 13C NMR (101 MHz, CDCl3) δ = 164.3 (Cq), 156.0 
(Cq), 146.7 (CH), 137.9 (Cq), 137.6 (Cq), 135.4 (CH), 135.4 (Cq), 132.7 (CH), 132.5 
(CH), 128.1 (Cq), 123.6 (Cq), 121.4 (CH), 120.9 (CH), 120.4 (CH), 119.8 (CH), 113.9 
(CH), 77.9 (CH), 31.9 (CH2), 25.6 (CH2), 24.4 (CH2), 22.3 (CH3). IR (ATR): 3293, 2936, 
2857, 1656, 1527, 1476, 1289, 1221, 753 cm–1. MS (ESI) m/z (relative intensity): 383 
(25) [M+Na]+, 361 (100) [M+H]+. HR-MS (ESI) m/z calcd for C23H25N2O2 
[M+H]+: 361.1911, found: 361.1913.  
 
N-(6-Methylquinolin-8-yl)-2-[(tetrahydrofuran-3-yl)oxy]benzamide (107s) 
The general procedure F was followed using benzamide 106a (0.25 mmol, 65.5 mg) 
and tetrahydrofuran-3-ol (66o) (220 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 16/1→9/1) yielded 107s (70.2 mg, 81%) 
as a white solid. M.p.: 113–114 °C. 1H NMR (400 MHz, CDCl3) δ = 11.76 (s, 1H), 8.96 
(d, J = 1.9 Hz, 1H), 8.79 (dd, J = 4.2, 1.7 Hz, 1H), 8.36 (dd, J = 7.9, 1.9 Hz, 1H), 8.04 
(dd, J = 8.2, 1.7 Hz, 1H), 7.47 (ddd, J = 8.4, 7.3, 1.9 Hz, 1H), 7.39 (dd, J = 8.2, 4.2 Hz, 
1H), 7.28 (dq, J = 1.9, 1.0 Hz, 1H), 7.13 (ddd, J = 7.9, 7.3, 1.0 Hz, 1H), 6.98 (dd, J = 
8.4, 1.0 Hz, 1H), 5.26–5.17 (m, 1H), 4.54 (dd, J = 10.3, 2.3 Hz, 1H), 4.21 (dd, J = 10.3, 
5.4 Hz, 1H), 4.09 (td, J = 8.8, 6.3 Hz, 1H), 3.96 (td, J = 8.2, 3.6 Hz, 1H), 2.55 (d, J = 
1.0 Hz, 3H), 2.59–3.53 (m, 1H), 2.32 (dddd, J = 13.4, 9.0, 8.0, 6.4 Hz, 1H). 13C NMR 
(101 MHz, CDCl3) δ = 163.7 (Cq), 155.5 (Cq), 146.9 (CH), 137.9 (Cq), 137.6 (Cq), 135.5 
(CH), 135.2 (Cq), 133.1 (CH), 132.9 (CH), 128.1 (Cq), 123.1 (Cq), 121.6 (CH), 121.4 
(CH), 120.6 (CH), 119.9 (CH), 112.9 (CH), 79.1 (CH), 72.9 (CH2), 67.3 (CH2), 33.2 
(CH2), 22.3 (CH3). IR (ATR): 3307, 1653, 1525, 1477, 1421, 1290, 1220, 855, 752, 
688 cm–1. MS (ESI) m/z (relative intensity): 371 (70) [M+Na]+, 349 (100) [M+H]+. HR-
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MS (ESI) m/z calcd for C21H21N2O3 [M+H]+: 349.1547, found: 349.1550. 
 
N-(6-Methylquinolin-8-yl)-2-[(tetrahydro-2H-pyran-4-yl)oxy]benzamide (107t) 
The general procedure F was followed using benzamide 106a (0.25 mmol, 65.5 mg) 
and tetrahydro-2H-pyran-4-ol (66p) (255 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 4/1→2/1) yielded 107t (73.4 mg, 81%) 
as a white solid. M.p.: 145–147 °C. 1H NMR (400 MHz, CDCl3) δ = 11.81 (s, 1H), 8.94 
(d, J = 1.7 Hz, 1H), 8.76 (dd, J = 4.3, 1.6 Hz, 1H), 8.28 (dd, J = 7.8, 1.9 Hz, 1H), 8.05 
(dd, J = 8.3, 1.6 Hz, 1H), 7.45 (ddd, J = 8.9, 7.5, 1.9 Hz, 1H), 7.40 (dd, J = 8.3, 4.3 Hz, 
1H), 7.30–7.27 (m, 1H), 7.14–7.05 (m, 2H), 4.79 (tt, J = 8.9, 4.3 Hz, 1H), 4.03 (dt, J = 
11.9, 4.3 Hz, 2H), 3.52 (ddd, J = 12.1, 9.9, 2.8 Hz, 2H), 2.55 (s, 3H), 2.27 (dtd, J = 13.5, 
9.3, 4.3 Hz, 2H), 2.18–2.09 (m, 2H). 13C NMR (101 MHz, CDCl3) δ = 164.0 (Cq), 155.2 
(Cq), 146.9 (CH), 137.8 (Cq), 137.7 (Cq), 135.5 (CH), 135.1 (Cq), 132.8 (CH), 132.7 
(CH), 128.1 (Cq), 124.0 (Cq), 121.6 (CH), 121.4 (CH), 120.6 (CH), 119.7 (CH), 113.8 
(CH), 74.0 (CH), 65.7 (CH2), 31.8 (CH2), 22.4 (CH3). IR (ATR): 3295, 2960, 1649, 1524, 
1477, 980, 857, 753, 590 cm–1. MS (EI) m/z (relative intensity): 363 (5) [M+H]+, 362 
(15) [M]+, 158 (100), 121 (50). HR-MS (EI) m/z calcd for C22H22N2O3 [M]+: 362.1625, 




The general procedure F was followed using benzamide 106aj (0.25 mmol, 82.5 mg) 
and (1S,2R,5S)-menthol (66q) (391 mg, 2.5 mmol). Purification by column 
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chromatography on silica gel (nhexane/acetone: 30/1) yielded 107u (64.0 mg, 53%) 
as a white solid. M.p.: 87–89 °C. 1H NMR (300 MHz, CDCl3) δ = 12.07 (s, 1H), 9.00 (d, 
J = 1.7 Hz, 1H), 8.81 (dd, J = 4.2, 1.6 Hz, 1H), 8.50 (d, J = 8.1 Hz, 1H), 8.12 (dd, J = 
8.3, 1.6 Hz, 1H), 7.47 (dd, J = 8.3, 4.2 Hz, 1H), 7.40–7.35 (m, 3H), 4.50 (td, J = 10.2, 
4.3 Hz, 1H), 2.61 (s, 3H), 2.36–2.11 (m, 3H), 1.86 (tt, J = 10.2, 3.0 Hz, 2H), 1.64 (dt, 
J = 9.0, 5.6 Hz, 2H), 1.34–1.05 (m, 2H), 1.01 (d, J = 5.8 Hz, 3H), 0.77 (dd, J = 8.6, 
6.9 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ = 162.8 (Cq), 156.6 (Cq), 146.9 (CH), 138.0 
(Cq), 137.7 (Cq), 135.6 (CH), 135.1 (Cq), 134.5 (q, 2JC–F = 32.4 Hz, Cq), 133.5 (CH), 
128.1 (Cq), 126.3 (Cq), 123.6 (q, 1JC–F = 272.9 Hz, Cq), 121.6 (CH), 120.9 (CH), 120.0 
(CH), 117.4 (q, 3JC–F = 3.8 Hz, CH), 110.1 (q, 3JC–F = 3.8 Hz, CH), 80.3 (CH), 47.0 (CH), 
40.1 (CH2), 34.6 (CH2), 31.5 (CH), 26.1 (CH), 23.6 (CH2), 22.3 (CH3), 22.1 (CH3), 20.6 
(CH3), 16.5 (CH3). 
19F NMR (376 MHz, CDCl3) δ = -62.9 (s). IR (ATR): 3300, 2956, 
2927, 1665, 1532, 1325, 1127, 984, 855, 696 cm–1. MS (ESI) m/z (relative intensity): 
507 (8) [M+Na]+, 485 (100) [M+H]+, 347 (10). HR-MS (ESI) m/z calcd for C28H32F3N2O2 





The general procedure F was followed using benzamide 106a (0.25 mmol, 65.5 mg) 
and cholesterol (66r) (966 mg, 2.5 mmol). Purification by column chromatography on 
silica gel (nhexane/EtOAc: 20/1→9/1) yielded 107v (98.6 mg, 61%) as a white solid. 
M.p.: 227–229 °C. 1H NMR (400 MHz, CDCl3) δ = 11.93 (s, 1H), 8.99 (d, J = 1.8 Hz, 
1H), 8.75 (dd, J = 4.2, 1.7 Hz, 1H), 8.33 (dd, J = 7.8, 1.9 Hz, 1H), 8.05 (dd, J = 8.2, 
1.7 Hz, 1H), 7.44 (ddd, J = 8.3, 7.3, 1.9 Hz, 1H), 7.39 (dd, J = 8.2, 4.2 Hz, 1H), 7.28 
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(dq, J = 1.8, 1.0 Hz, 1H), 7.11–7.04 (m, 2H), 5.43 (dt, J = 5.5, 1.9 Hz, 1H), 4.44 (tt, J = 
11.2, 4.6 Hz, 1H), 2.90 (tq, J = 11.4, 2.7 Hz, 1H), 2.70–2.64 (m, 1H), 2.55 (d, J = 1.0 Hz, 
3H), 2.19 (dt, J = 11.0, 3.6 Hz, 1H), 2.11 (ddd, J = 14.4, 11.0, 3.8 Hz, 1H), 2.06–1.91 
(m, 3H), 1.91–1.77 (m, 1H), 1.64–1.41 (m, 8H), 1.45–1.21 (m, 4H), 1.22–1.07 (m, 5H), 
1.06 (s, 3H), 1.07–0.91 (m, 3H), 0.91 (d, J = 6.5 Hz, 3H), 0.85 (dd, J = 6.6, 1.8 Hz, 6H), 
0.67 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 164.2 (Cq), 156.1 (Cq), 146.8 (CH), 140.2 
(Cq), 138.0 (Cq), 137.7 (Cq), 135.5 (Cq), 135.5 (CH), 132.9 (CH), 132.7 (CH), 128.2 (Cq), 
123.4 (Cq), 122.6 (CH), 121.4 (CH), 121.0 (CH), 120.5 (CH), 119.9 (CH), 114.0 (CH), 
79.3 (CH), 56.7 (CH), 56.1 (CH), 50.1 (CH), 42.3 (Cq), 39.7 (CH2), 39.5 (CH2), 38.7 
(CH2), 37.3 (CH2), 36.9 (Cq), 36.2 (CH2), 35.8 (CH), 32.0 (CH2), 31.9 (CH), 28.2 (CH2), 
28.1 (CH2), 28.0 (CH), 24.3 (CH2), 23.8 (CH2), 22.8 (CH3), 22.6 (CH3), 22.4 (CH3), 21.1 
(CH2), 19.6 (CH3), 18.7 (CH3), 11.8 (CH3). IR (ATR): 3331, 2946, 1655, 1535, 1477, 
1221, 1019, 858, 746, 675 cm–1. MS (ESI) m/z (relative intensity): 669 (15) [M+Na]+, 
647 (100) [M+H]+. HR-MS (ESI) m/z calcd for C44H59N2O2 [M+H]+: 647.4571, 





The general procedure F was followed using benzamide 106a (0.25 mmol, 65.5 mg) 
and β-estradiol 3-methyl ether (66s) (716 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 16/1→9/1) yielded 107w (88.2 mg, 
65%) as a white solid. M.p.: 193–195 °C. 1H NMR (300 MHz, CDCl3) δ = 11.52 (s, 1H), 
9.02 (d, J = 1.7 Hz, 1H), 8.75 (dd, J = 4.2, 1.7 Hz, 1H), 8.27 (dd, J = 7.8, 1.9 Hz, 1H), 
8.09 (dd, J = 8.3, 1.7 Hz, 1H), 7.52–7.46 (m, 1H), 7.43 (dd, J = 8.3, 4.2 Hz, 1H), 7.34 
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(dq, J = 1.9, 1.0 Hz, 1H), 7.21 (dd, J = 8.4, 6.9 Hz, 2H), 7.16–7.09 (m, 1H), 6.72 (dd, 
J = 8.6, 2.8 Hz, 1H), 6.64 (d, J = 2.8 Hz, 1H), 4.76 (t, J = 8.2 Hz, 1H), 3.79 (s, 3H), 
2.91–2.83 (m, 2H), 2.61 (s, 3H), 2.52–2.21 (m, 4H), 2.17 (dt, J = 11.7, 2.7 Hz, 1H), 
1.99–1.78 (m, 1H), 1.63–1.28 (m, 7H), 0.91 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 
164.6 (Cq), 157.4 (Cq), 157.0 (Cq), 146.7 (CH), 137.8 (Cq), 137.7 (Cq), 137.6 (Cq), 135.5 
(CH), 135.1 (Cq), 132.6 (CH), 132.4 (CH), 132.3 (Cq), 128.2 (Cq), 126.3 (CH), 123.7 
(Cq), 121.4 (CH), 120.9 (CH), 120.6 (CH), 120.1 (CH), 114.2 (CH), 113.8 (CH), 111.4 
(CH), 87.8 (CH), 55.2 (CH3), 50.3 (CH), 44.1 (Cq), 43.7 (CH), 38.6 (CH), 38.1 (CH2), 
29.7 (CH2), 27.9 (CH2), 27.2 (CH2), 26.3 (CH2), 23.4 (CH2), 22.3 (CH3), 12.3 (CH3). IR 
(ATR): 3273, 2921, 1651, 1530, 1475, 1423, 1252, 760, 696 cm–1. MS (EI) m/z (relative 
intensity): 547 (10) [M+H]+, 546 (30) [M]+, 262 (10), 158 (100). HR-MS (EI) m/z calcd 




The general procedure F was followed using benzamide 106aa (0.25 mmol, 82.5 mg) 
and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 16/1) yielded 107aa (81.5 mg, 72%) as 
a white solid. M.p.: 136–137 °C. 1H NMR (400 MHz, CDCl3) δ = 12.08 (s, 1H), 8.99 (d, 
J = 1.7 Hz, 1H), 8.70 (dd, J = 4.2, 1.7 Hz, 1H), 8.60 (dd, J = 2.5, 0.8 Hz, 1H), 8.08 (dd, 
J = 8.3, 1.7 Hz, 1H), 7.62–7.56 (m, 2H), 7.52 (ddd, J = 8.7, 2.5, 0.8 Hz, 1H), 7.40 (dd, 
J = 8.3, 4.2 Hz, 1H), 7.37–7.32 (m, 3H), 7.30–7.25 (m, 1H), 6.98 (d, J = 8.7 Hz, 1H), 
5.66 (q, J = 6.4 Hz, 1H), 2.59 (d, J = 0.9 Hz, 3H), 1.99 (d, J = 6.4 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ = 162.6 (Cq), 158.1 (Cq), 146.9 (CH), 141.6 (Cq), 137.8 (Cq), 137.7 
(Cq), 135.6 (CH), 135.0 (Cq), 130.1 (q, 3JC–F = 3.8 Hz, CH), 129.6 (q, 3JC–F = 3.5 Hz, 
CH), 129.0 (CH), 128.1 (CH), 128.1 (Cq), 125.5 (CH), 123.9 (q, 1JC–F = 271.7 Hz, Cq), 
123.4 (Cq), 123.3 (q, 2JC–F = 33.3 Hz, Cq), 121.6 (CH), 120.9 (CH), 120.0 (CH), 114.3 
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(CH), 78.6 (CH), 25.0 (CH3), 22.4 (CH3). 
19F NMR (282 MHz, CDCl3) δ = -61.9 (s). IR 
(ATR): 3307, 1660, 1529, 1329, 1270, 1114, 1066, 738, 700 cm–1. MS (ESI) m/z 
(relative intensity): 473 (10) [M+Na]+, 451 (100) [M+H]+, 347 (45), 105 (40). HR-MS 




The general procedure F was followed using benzamide 106ab (0.25 mmol, 84.5 mg) 
and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/acetone: 20/1) yielded 107ab (65.5 mg, 57%) 
as a white solid. M.p.: 120–122 °C. 1H NMR (400 MHz, CDCl3) δ = 12.22 (s, 1H), 9.09 
(d, J = 1.8 Hz, 1H), 8.75 (dd, J = 4.2, 1.7 Hz, 1H), 8.63 (d, J = 2.6 Hz, 1H), 8.12 (dd, 
J = 8.2, 1.7 Hz, 1H), 7.67–7.61 (m, 4H), 7.57 (dd, J = 8.6, 2.6 Hz, 1H), 7.47–7.43 (m, 
2H), 7.43–7.36 (m, 4H), 7.36–7.29 (m, 2H), 7.02 (d, J = 8.6 Hz, 1H), 5.70 (q, J = 6.5 Hz, 
1H), 2.64 (d, J = 0.9 Hz, 3H), 2.02 (d, J = 6.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 
164.1 (Cq), 155.5 (Cq), 146.9 (CH), 142.5 (Cq), 139.8 (Cq), 138.0 (Cq), 137.8 (Cq), 135.6 
(CH), 135.5 (Cq), 133.9 (Cq), 131.1 (CH), 131.0 (CH), 128.9 (CH), 128.8 (CH), 128.2 
(Cq), 127.9 (CH), 127.0 (CH), 126.7 (CH), 125.7 (CH), 123.2 (Cq), 121.6 (CH), 120.6 
(CH), 119.9 (CH), 114.5 (CH), 78.1 (CH), 25.1 (CH3), 22.4 (CH3). IR (ATR): 3303, 2924, 
1656, 1525, 1422, 1266, 1067, 760, 735, 698 cm–1. MS (ESI) m/z (relative intensity): 
481 (15) [M+Na]+, 459 (100) [M+H]+, 352 (30). HR-MS (ESI) m/z calcd for C31H27N2O2 
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The general procedure F was followed using benzamide 106ac (0.25 mmol, 82.5 mg) 
and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/acetone: 16/1) yielded 107ac (72.2 mg, 64%) 
as a white solid. M.p.: 126–128 °C. 1H NMR (400 MHz, CDCl3) δ = 10.11 (s, 1H), 8.88 
(d, J = 1.7 Hz, 1H), 8.72 (dd, J = 4.2, 1.6 Hz, 1H), 8.11 (dd, J = 8.3, 1.6 Hz, 1H), 7.46–
7.39 (m, 3H), 7.37 (td, J = 2.0, 1.0 Hz, 1H), 7.34 (dd, J = 8.1, 1.0 Hz, 1H), 7.31–7.26 
(m, 3H), 7.26–7.21 (m, 1H), 7.03 (d, J = 8.1 Hz, 1H), 5.40 (q, J = 6.5 Hz, 1H), 2.64 (d, 
J = 1.0 Hz, 3H), 1.53 (d, J = 6.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 163.6 (Cq), 
155.2 (Cq), 147.2 (CH), 142.1 (Cq), 137.8 (Cq), 137.2 (Cq), 135.6 (CH), 134.1 (Cq), 
130.4 (CH), 129.2 (q, 2JC–F = 31.8 Hz, Cq), 128.7 (CH), 128.1 (Cq), 127.7 (CH), 126.2 
(q, 3JC–F = 2.2 Hz, Cq), 125.5 (CH), 123.5 (q, 1JC–F = 274.2 Hz, Cq), 121.7 (CH), 120.9 
(CH), 119.0 (CH), 118.2 (q, 3JC–F = 5.0 Hz, CH), 117.6 (CH), 77.5 (CH), 24.5 (CH3), 
22.4 (CH3). 
19F NMR (376 MHz, CDCl3) δ = -59.2 (s). IR (ATR): 3343, 1684, 1527, 
1318, 1268, 1131, 701 cm–1. MS (ESI) m/z (relative intensity): 473 (90) [M+Na]+, 451 
(100) [M+H]+. HR-MS (ESI) m/z calcd for C26H22F3N2O2 [M+H]+: 451.1628, 
found: 451.1625.  
 
N-(6-Methylquinolin-8-yl)-2-(1-phenylethoxy)-1-naphthamide (107ad) 
The general procedure F was followed using benzamide 106ad (0.25 mmol, 78.0 mg) 
and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 16/1→9/1) yielded 107ad (92.3 mg, 
86%) as a white solid. M.p.: 155–157 °C. 1H NMR (400 MHz, CDCl3) δ = 10.47 (s, 1H), 
9.05 (d, J = 1.8 Hz, 1H), 8.65 (dd, J = 4.2, 1.7 Hz, 1H), 8.19 (dq, J = 8.6, 1.0 Hz, 1H), 
8.07 (dd, J = 8.3, 1.7 Hz, 1H), 7.77–7.72 (m, 2H), 7.51–7.44 (m, 3H), 7.40–7.31 (m, 
3H), 7.27–7.21 (m, 2H), 7.21–7.14 (m, 2H), 5.52 (q, J = 6.4 Hz, 1H), 2.64 (d, J = 1.0 Hz, 
3H), 1.57 (d, J = 6.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 165.9 (Cq), 152.4 (Cq), 
147.1 (CH), 142.8 (Cq), 137.7 (Cq), 137.3 (Cq), 135.5 (CH), 134.6 (Cq), 131.9 (Cq), 
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131.2 (CH), 128.9 (Cq), 128.6 (CH), 128.1 (Cq), 127.9 (CH), 127.5 (CH), 127.4 (CH), 
125.7 (CH), 124.7 (CH), 124.2 (CH), 121.7 (Cq), 121.6 (CH), 120.6 (CH), 118.7 (CH), 
115.6 (CH), 77.8 (CH), 24.5 (CH3), 22.4 (CH3). IR (ATR): 3351, 1669, 1525, 1424, 1246, 
1070, 701 cm–1. MS (ESI) m/z (relative intensity): 455 (10) [M+Na]+, 433 (100) [M+H]+, 
329 (45), 159 (50). HR-MS (ESI) m/z calcd for C29H25N2O2 [M+H]+: 433.1911, 
found: 433.1907.  
 
4-Methyl-N-(6-methylquinolin-8-yl)-2-(1-phenylethoxy)benzamide (107ae) 
The general procedure F was followed using benzamide 106ae (0.25 mmol, 69.0 mg) 
and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 16/1→9/1) yielded 107ae (54.4 mg, 
55%) as a white solid. M.p.: 160–162 °C. 1H NMR (400 MHz, CDCl3) δ = 12.12 (s, 1H), 
9.01 (d, J = 1.8 Hz, 1H), 8.67 (dd, J = 4.2, 1.7 Hz, 1H), 8.19 (d, J = 8.0 Hz, 1H), 8.05 
(dd, J = 8.2, 1.7 Hz, 1H), 7.62–7.57 (m, 2H), 7.37 (dd, J = 8.2, 4.2 Hz, 1H), 7.35–7.30 
(m, 2H), 7.30–7.29 (m, 1H), 7.28–7.20 (m, 1H), 6.84 (ddd, J = 8.0, 1.5, 0.8 Hz, 1H), 
6.77–6.68 (m, 1H), 5.62 (q, J = 6.5 Hz, 1H), 2.58 (d, J = 1.0 Hz, 3H), 2.25 (d, J = 0.8 Hz, 
3H), 1.94 (d, J = 6.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 164.2 (Cq), 156.0 (Cq), 
146.7 (CH), 143.5 (Cq), 142.5 (Cq), 138.0 (Cq), 137.7 (Cq), 135.6 (Cq), 135.4 (CH), 
132.4 (CH), 128.8 (CH), 128.1 (Cq), 127.7 (CH), 125.7 (CH), 122.0 (CH), 121.4 (CH), 
120.4 (Cq), 120.4 (CH), 119.7 (CH), 114.7 (CH), 77.7 (CH), 25.0 (CH3), 22.4 (CH3), 
21.7 (CH3). IR (ATR): 3305, 1655, 1528, 1423, 1286, 1258, 1067, 762, 701 cm–1. MS 
(ESI) m/z (relative intensity): 419 (10) [M+Na]+, 397 (100) [M+H]+, 293 (70), 159 (40). 
HR-MS (ESI) m/z calcd for C26H25N2O2 [M+H]+: 397.1911, found: 397.1909.  
 
4-Methoxy-N-(6-methylquinolin-8-yl)-2-(1-phenylethoxy)benzamide (107af) 
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The general procedure F was followed using benzamide 106af (0.25 mmol, 73.0 mg) 
and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 16/1→9/1) yielded 107af (74.4 mg, 
72%) as a white solid. M.p.: 130–131 °C. 1H NMR (300 MHz, CDCl3) δ = 12.10 (s, 1H), 
9.05 (d, J = 1.8 Hz, 1H), 8.72 (dd, J = 4.2, 1.7 Hz, 1H), 8.31 (d, J = 8.8 Hz, 1H), 8.09 
(dd, J = 8.3, 1.7 Hz, 1H), 7.68–7.59 (m, 2H), 7.41 (dd, J = 7.7, 3.7 Hz, 1H), 7.38 (d, J = 
5.7 Hz, 1H), 7.37–7.32 (m, 2H), 7.32–7.26 (m, 1H), 6.59 (dd, J = 8.8, 2.3 Hz, 1H), 6.47 
(d, J = 2.3 Hz, 1H), 5.62 (q, J = 6.4 Hz, 1H), 3.74 (s, 3H), 2.61 (d, J = 0.9 Hz, 3H), 2.01 
(d, J = 6.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 164.0 (Cq), 163.3 (Cq), 157.4 (Cq), 
146.7 (CH), 142.4 (Cq), 138.1 (Cq), 137.7 (Cq), 135.7 (Cq), 135.5 (CH), 134.1 (CH), 
128.9 (CH), 128.2 (Cq), 127.9 (CH), 125.7 (CH), 121.5 (CH), 120.3 (CH), 119.7 (CH), 
116.0 (Cq), 105.7 (CH), 100.9 (CH), 78.0 (CH), 55.3 (CH3), 25.1 (CH3), 22.4 (CH3). IR 
(ATR): 3308, 1651, 1523, 1476, 1261, 1247, 1168, 701 cm–1. MS (ESI) m/z (relative 
intensity): 435 (10) [M+Na]+, 413 (100) [M+H]+, 309 (30). HR-MS (ESI) m/z calcd for 




The general procedure F was followed using benzamide 106ag (0.25 mmol, 84.5 mg) 
and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/acetone: 16/1→9/1) yielded 107ag (75 mg, 
66%) as a white solid. M.p.: 161–162 °C. 1H NMR (400 MHz, CDCl3) δ = 12.21 (s, 1H), 
9.07 (d, J = 1.7 Hz, 1H), 8.75 (dd, J = 4.2, 1.7 Hz, 1H), 8.39 (d, J = 8.1 Hz, 1H), 8.12 
(dd, J = 8.3, 1.7 Hz, 1H), 7.73–7.61 (m, 2H), 7.47–7.42 (m, 5H), 7.40–7.35 (m, 4H), 
7.36–7.26 (m, 2H), 7.18 (d, J = 1.5 Hz, 1H), 5.75 (q, J = 6.4 Hz, 1H), 2.63 (d, J = 0.9 Hz, 
3H), 2.04 (d, J = 6.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 164.0 (Cq), 156.3 (Cq), 
146.8 (CH), 145.6 (Cq), 142.5 (Cq), 140.1 (Cq), 138.1 (Cq), 137.8 (Cq), 135.5 (CH), 
135.5 (Cq), 133.0 (CH), 128.9 (CH), 128.8 (CH), 128.2 (Cq), 128.0 (CH), 127.9 (CH), 
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127.1 (CH), 125.8 (CH), 121.8 (Cq), 121.5 (CH), 120.6 (CH), 119.9 (CH), 119.8 (CH), 
113.0 (CH), 78.1 (CH), 25.0 (CH3), 22.4 (CH3). IR (ATR): 3305, 1655, 1529, 1475, 1422, 
1199, 854, 756, 697 cm–1. MS (ESI) m/z (relative intensity): 481 (15) [M+Na]+, 459 (100) 
[M+H]+. HR-MS (ESI) m/z calcd for C31H27N2O2 [M+H]+: 459.2067, found: 459.2067.  
 
4-Fluoro-N-(6-methylquinolin-8-yl)-2-(1-phenylethoxy)benzamide (107ah) 
The general procedure F was followed using benzamide 106ah (0.25 mmol, 70.0 mg) 
and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 16/1→9/1) yielded 107ah (81.1 mg, 
81%) as a white solid. M.p.: 157–159 °C. 1H NMR (400 MHz, CDCl3) δ = 12.08 (s, 1H), 
9.02 (d, J = 1.8 Hz, 1H), 8.73 (dd, J = 4.2, 1.7 Hz, 1H), 8.35 (dd, J = 8.8, 7.1 Hz, 1H), 
8.11 (dd, J = 8.2, 1.7 Hz, 1H), 7.65–7.60 (m, 2H), 7.43 (dd, J = 8.2, 4.2 Hz, 1H), 7.41–
7.34 (m, 3H), 7.34–7.29 (m, 1H), 6.76 (ddd, J = 8.8, 7.6, 2.4 Hz, 1H), 6.66 (dd, J = 
10.9, 2.4 Hz, 1H), 5.59 (q, J = 6.4 Hz, 1H), 2.62 (d, J = 0.9 Hz, 3H), 2.01 (d, J = 6.4 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ =165.3 (d, 1JC–F = 252.0 Hz, Cq), 163.2 (Cq), 157.4 
(d, 3JC–F = 10.7 Hz, Cq), 146.9 (CH), 141.7 (Cq), 138.0 (Cq), 137.7 (Cq), 135.6 (CH), 
135.4 (Cq), 134.4 (d, 3JC–F = 10.7 Hz, CH), 129.0 (CH), 128.2 (Cq), 128.1 (CH), 125.7 
(CH), 121.6 (CH), 120.6 (CH), 119.9 (CH), 119.4 (d, 4JC–F = 3.0 Hz, Cq), 108.1 (d, 2JC-F = 
21.4 Hz, CH), 102.0 (d, 2JC–F = 26.4 Hz, CH), 78.6 (CH), 25.0 (CH3), 22.4 (CH3). 
19F NMR (376 MHz, CDCl3) δ = -105.3 (s). IR (ATR): 3309, 1657, 1528, 1477, 1428, 
1261, 997, 836, 701 cm–1. MS (ESI) m/z (relative intensity): 423 (15) [M+Na]+, 401 (100) 
[M+H]+, 297 (75), 159 (35), 105 (30). HR-MS (ESI) m/z calcd for C25H22FN2O2 
[M+H]+: 401.1660, found: 401.1660.  
 
4-Chloro-N-(6-methylquinolin-8-yl)-2-(1-phenylethoxy)benzamide (107ai) 
The general procedure F was followed using benzamide 106ai (0.25 mmol, 74.0 mg) 
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and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol) at 3 mA for 32 h. Purification by 
column chromatography on silica gel (nhexane/EtOAc: 16/1→9/1) yielded 107ai 
(67.3 mg, 65%) as a white solid. M.p.: 115–117 °C. 1H NMR (400 MHz, CDCl3) δ = 
12.08 (s, 1H), 9.01 (d, J = 1.8 Hz, 1H), 8.72 (dd, J = 4.2, 1.7 Hz, 1H), 8.27 (d, J = 
8.5 Hz, 1H), 8.11 (dd, J = 8.3, 1.7 Hz, 1H), 7.68–7.60 (m, 2H), 7.43 (dd, J = 8.3, 4.2 Hz, 
1H), 7.41–7.35 (m, 3H), 7.34–7.29 (m, 1H), 7.05 (dd, J = 8.5, 1.9 Hz, 1H), 6.95 (d, J = 
1.9 Hz, 1H), 5.63 (q, J = 6.4 Hz, 1H), 2.62 (d, J = 0.9 Hz, 3H), 2.00 (d, J = 6.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ = 163.2 (Cq), 156.4 (Cq), 146.9 (CH), 141.7 (Cq), 138.4 
(Cq), 138.0 (Cq), 137.7 (Cq), 135.6 (CH), 135.3 (Cq), 133.6 (CH), 129.0 (CH), 128.2 (Cq), 
128.1 (CH), 125.7 (CH), 121.7 (Cq), 121.6 (CH), 121.5 (CH), 120.8 (CH), 119.9 (CH), 
114.6 (CH), 78.5 (CH), 25.0 (CH3), 22.4 (CH3). IR (ATR): 3306, 1662, 1531, 1475, 1426, 
1229, 948, 855, 701 cm–1. MS (ESI) m/z (relative intensity): 439 (5) [M+Na]+, 417 (100) 
[M+H]+, 313 (30), 263 (30). HR-MS (ESI) m/z calcd for C25H22ClN2O2 [M+H]+: 417.1364, 




The general procedure F was followed using benzamide 106aj (0.25 mmol, 82.5 mg) 
and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/acetone: 16/1) yielded 107aj (93.5 mg, 83%) 
as a white solid. M.p.: 153–154 °C. 1H NMR (400 MHz, CDCl3) δ = 12.13 (s, 1H), 9.02 
(d, J = 1.7 Hz, 1H), 8.75 (dd, J = 4.2, 1.7 Hz, 1H), 8.43 (dd, J = 8.2, 1.0 Hz, 1H), 8.13 
(dd, J = 8.2, 1.7 Hz, 1H), 7.68–7.61 (m, 2H), 7.45 (dd, J = 8.2, 4.2 Hz, 1H), 7.41–7.35 
(m, 3H), 7.35–7.29 (m, 2H), 7.22 (d, J = 1.5 Hz, 1H), 5.70 (q, J = 6.4 Hz, 1H), 2.63 (d, 
J = 0.9 Hz, 3H), 2.02 (d, J = 6.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 162.8 (Cq), 
155.9 (Cq), 147.0 (CH), 141.4 (Cq), 137.9 (Cq), 137.7 (Cq), 135.6 (CH), 135.0 (Cq), 
134.0 (q, 2JC–F = 32.4 Hz, Cq), 133.2 (CH), 129.0 (CH), 128.2 (CH), 128.2 (Cq), 126.3 
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(Cq), 125.8 (CH), 123.4 (q, 1JC–F = 272.8 Hz, Cq), 121.7 (CH), 121.0 (CH), 120.0 (CH), 
117.7 (q, 3JC–F = 3.8 Hz, CH), 111.2 (q, 3JC–F = 3.9 Hz, CH), 78.7 (CH), 24.8 (CH3), 22.4 
(CH3). 
19F NMR (376 MHz, CDCl3) δ = -63.2 (s). IR (ATR): 3297, 1655, 1531, 1424, 
1320, 1163, 1116, 952, 852, 702 cm–1. MS (ESI) m/z (relative intensity): 473 (10) 
[M+Na]+, 451 (100) [M+H]+, 347 (50), 105 (20). HR-MS (ESI) m/z calcd for 
C26H22F3N2O2 [M+H]+: 451.1628, found: 451.1628. 
 
Methyl 4-[(6-methylquinolin-8-yl)carbamoyl]-3-(1-phenylethoxy)benzoate (107ak)  
The general procedure F was followed using benzamide 106ak (0.25 mmol, 80.0 mg) 
and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/acetone: 10/1) yielded 107ak (62.3 mg, 57%) 
as a white solid. M.p.: 178–180 °C. 1H NMR (400 MHz, CDCl3) δ = 12.18 (s, 1H), 9.03 
(d, J = 1.8 Hz, 1H), 8.74 (dd, J = 4.2, 1.7 Hz, 1H), 8.37 (d, J = 8.5 Hz, 1H), 8.12 (dd, 
J = 8.2, 1.7 Hz, 1H), 7.77–7.60 (m, 4H), 7.44 (dd, J = 8.2, 4.2 Hz, 1H), 7.38–7.32 (m, 
3H), 7.32–7.26 (m, 1H), 5.77 (q, J = 6.4 Hz, 1H), 3.91 (s, 3H), 2.63 (s, 3H), 2.01 (d, J = 
6.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 166.2 (Cq), 163.2 (Cq), 155.7 (Cq), 147.0 
(CH), 141.8 (Cq), 138.0 (Cq), 137.7 (Cq), 135.6 (CH), 135.2 (Cq), 133.8 (Cq), 132.6 (CH), 
128.9 (CH), 128.2 (Cq), 128.0 (CH), 127.0 (Cq), 125.9 (CH), 121.8 (CH), 121.6 (CH), 
120.9 (CH), 120.0 (CH), 115.3 (CH), 78.2 (CH), 52.4 (CH3), 24.8 (CH3), 22.4 (CH3). IR 
(ATR): 3292, 1721, 1656, 1529, 1434, 1283, 1216, 1009, 738, 704 cm–1. MS (ESI) m/z 
(relative intensity): 463 (10) [M+Na]+, 441 (100) [M+H]+, 337 (55), 159 (15), 105 (10). 
HR-MS (ESI) m/z calcd for C27H25N2O4 [M+H]+: 441.1809, found: 441.1810.  
 
N-(6-Methylquinolin-8-yl)-4-(methylthio)-2-(1-phenylethoxy)benzamide (107al) 
The general procedure F was followed using benzamide 106al (0.25 mmol, 77.0 mg) 
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and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/acetone: 10/1) yielded 107al (56.2 mg, 53%) 
as a white solid. M.p.: 120–122 °C. 1H NMR (400 MHz, CDCl3) δ = 12.10 (s, 1H), 9.03 
(d, J = 1.8 Hz, 1H), 8.73 (dd, J = 4.2, 1.7 Hz, 1H), 8.25 (d, J = 8.3 Hz, 1H), 8.10 (dd, 
J = 8.2, 1.7 Hz, 1H), 7.67–7.59 (m, 2H), 7.42 (dd, J = 8.2, 4.2 Hz, 1H), 7.38 (dd, J = 
8.3, 6.7 Hz, 2H), 7.34 (d, J = 1.4 Hz, 1H), 7.33–7.29 (m, 1H), 6.90 (dd, J = 8.3, 1.7 Hz, 
1H), 6.76 (d, J = 1.8 Hz, 1H), 5.63 (q, J = 6.5 Hz, 1H), 2.61 (d, J = 0.9 Hz, 3H), 2.37 (s, 
3H), 2.00 (d, J = 6.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 163.8 (Cq), 156.1 (Cq), 
146.8 (CH), 144.8 (Cq), 142.3 (Cq), 138.0 (Cq), 137.7 (Cq), 135.5 (CH), 135.5 (Cq), 
132.7 (CH), 129.0 (CH), 128.2 (Cq), 128.0 (CH), 125.7 (CH), 121.5 (CH), 120.5 (CH), 
119.8 (CH), 119.5 (Cq), 118.0 (CH), 111.0 (CH), 78.2 (CH), 25.0 (CH3), 22.4 (CH3), 14.9 
(CH3). IR (ATR): 3307, 1655, 1528, 1478, 1423, 1222, 950, 702 cm–1. MS (ESI) m/z 
(relative intensity): 451 (10) [M+Na]+, 429 (100) [M+H]+, 325 (20). HR-MS (ESI) m/z 
calcd for C26H25N2O2S [M+H]+: 429.1631, found: 429.1637.  
 
4-Cyano-N-(6-methylquinolin-8-yl)-2-(1-phenylethoxy)benzamide (107am) 
The general procedure F was followed using benzamide 106am (0.25 mmol, 71.8 mg) 
and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 16/1→9/1) yielded 107am (57.0 mg, 
56%) as a white solid. M.p.: 214–216 °C. 1H NMR (400 MHz, CDCl3) δ = 12.10 (s, 1H), 
8.99 (d, J = 1.7 Hz, 1H), 8.74 (dd, J = 4.2, 1.7 Hz, 1H), 8.40 (d, J = 8.0 Hz, 1H), 8.13 
(dd, J = 8.2, 1.7 Hz, 1H), 7.65–7.60 (m, 2H), 7.45 (dd, J = 8.2, 4.2 Hz, 1H), 7.43–7.37 
(m, 3H), 7.36–7.31 (m, 2H), 7.18 (d, J = 1.3 Hz, 1H), 5.64 (q, J = 6.4 Hz, 1H), 2.63 (d, 
J = 0.9 Hz, 3H), 2.01 (d, J = 6.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 162.2 (Cq), 
155.8 (Cq), 147.0 (CH), 141.1 (Cq), 137.9 (Cq), 137.7 (Cq), 135.7 (CH), 134.8 (Cq), 
133.4 (CH), 129.2 (CH), 128.4 (CH), 128.2 (Cq), 127.4 (Cq), 125.6 (CH), 124.6 (CH), 
121.7 (CH), 121.2 (CH), 120.1 (CH), 118.1 (Cq), 117.5 (CH), 115.7 (Cq), 79.0 (CH), 
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25.0 (CH3), 22.4 (CH3). IR (ATR): 3306, 2230, 1664, 1533, 1426, 1282, 854, 702 cm-1. 
MS (ESI) m/z (relative intensity): 430 (10) [M+Na]+, 408 (100) [M+H]+, 117 (50). HR-MS 
(ESI) m/z calcd for C26H22N3O2 [M+H]+: 408.1707, found: 408.1710.  
 
N-(6-Methylquinolin-8-yl)-3-(1-phenylethoxy)isonicotinamide (107an) 
The general procedure F was followed using benzamide 106an (0.25 mmol, 65.8 mg) 
and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 9/1→4/1) yielded 107an (52.5 mg, 55%) 
as a white solid. M.p.: 156–158 °C. 1H NMR (400 MHz, CDCl3) δ = 12.13 (s, 1H), 9.00 
(d, J = 1.9 Hz, 1H), 8.76 (dd, J = 4.2, 1.7 Hz, 1H), 8.43 (s, 1H), 8.36 (d, J = 4.9 Hz, 1H), 
8.18–8.09 (m, 2H), 7.62 (dd, J = 7.4, 1.9 Hz, 2H), 7.45 (dd, J = 8.2, 4.2 Hz, 1H), 7.42–
7.34 (m, 3H), 7.33–7.25 (m, 1H), 5.79 (q, J = 6.4 Hz, 1H), 2.62 (s, 3H), 2.04 (d, J = 
6.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 162.0 (Cq), 150.9 (Cq), 147.1 (CH), 143.0 
(CH), 141.4 (Cq), 137.9 (Cq), 137.7 (Cq), 137.6 (CH), 135.6 (CH), 134.8 (Cq), 129.3 (Cq), 
129.1 (CH), 128.3 (CH), 128.2 (Cq), 125.7 (CH), 124.7 (CH), 121.7 (CH), 121.3 (CH), 
120.1 (CH), 78.8 (CH), 25.1 (CH3), 22.4 (CH3). IR (ATR): 3298, 1663, 1528, 1424, 1224, 
1064, 844, 734, 696 cm–1. MS (ESI) m/z (relative intensity): 406 (40) [M+Na]+, 384 (100) 
[M+H]+. HR-MS (ESI) m/z calcd for C24H22N3O2 [M+H]+: 384.1707, found: 384.1706.  
 
N-(6-Methylquinolin-8-yl)-2-(1-phenylethoxy)-4-(pyridin-2-yl)benzamide (107ao) 
The general procedure F was followed using benzamide 106ao (0.25 mmol, 84.8 mg) 
and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). Purification by column 
chromatography on silica gel (nhexane/EtOAc: 9/1) yielded 107ao (61.0 mg, 53%) as 
a white solid. M.p.: 165–167 °C. 1H NMR (400 MHz, CDCl3) δ = 12.25 (s, 1H), 9.07 (d, 
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J = 1.8 Hz, 1H), 8.73 (dd, J = 4.2, 1.7 Hz, 1H), 8.71 (ddd, J = 4.8, 1.9, 0.9 Hz, 1H), 
8.43 (d, J = 8.2 Hz, 1H), 8.11 (dd, J = 8.3, 1.7 Hz, 1H), 7.77 (d, J = 1.5 Hz, 1H), 7.74 
(dd, J = 7.9, 6.1 Hz, 1H), 7.72 (d, J = 1.5 Hz, 1H), 7.70 (t, J = 1.2 Hz, 1H), 7.64 (dd, 
J = 8.2, 1.6 Hz, 1H), 7.61 (dt, J = 8.0, 1.1 Hz, 1H), 7.43 (dd, J = 8.2, 4.2 Hz, 1H), 7.38–
7.32 (m, 3H), 7.31–7.21 (m, 2H), 5.90 (q, J = 6.4 Hz, 1H), 2.63 (d, J = 0.9 Hz, 3H), 2.03 
(d, J = 6.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 163.9 (Cq), 156.4 (Cq), 156.1 (Cq), 
149.7 (CH), 146.9 (CH), 143.5 (Cq), 142.4 (Cq), 138.1 (Cq), 137.7 (Cq), 136.8 (CH), 
135.5 (CH), 135.5 (Cq), 133.0 (CH), 128.8 (CH), 128.2 (Cq), 127.8 (CH), 125.9 (CH), 
123.3 (Cq), 122.7 (CH), 121.5 (CH), 120.8 (CH), 120.6 (CH), 119.9 (CH), 119.3 (CH), 
112.8 (CH), 77.9 (CH), 24.8 (CH3), 22.4 (CH3). IR (ATR): 3230, 2909, 1655, 1525, 1438, 
1422, 1199, 763, 732, 700 cm–1. MS (ESI) m/z (relative intensity): 482 (35) [M+Na]+, 
460 (100) [M+H]+, 356 (45). HR-MS (ESI) m/z calcd for C30H26N3O2 [M+H]+: 460.2020, 
found: 460.2020.  
 
N-(6-Methylquinolin-8-yl)-2-morpholinobenzamide (107ap) 
107ap: White solid. M.p.: 168–170 °C. 1H NMR (400 MHz, CDCl3) δ = 12.64 (s, 1H), 
9.03 (d, J = 1.7 Hz, 1H), 8.82 (dd, J = 4.2, 1.7 Hz, 1H), 8.20 (dd, J = 8.0, 1.8 Hz, 1H), 
8.11 (dd, J = 8.2, 1.7 Hz, 1H), 7.56–7.50 (m, 1H), 7.46 (dd, J = 8.2, 4.2 Hz, 1H), 7.35–
7.34 (m, 1H), 7.32–7.23 (m, 2H), 4.03–3.92 (m, 4H), 3.26–3.12 (m, 4H), 2.61 (d, J = 
0.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 165.7 (Cq), 151.1 (Cq), 147.2 (CH), 137.7 
(Cq), 137.6 (Cq), 135.7 (CH), 135.1 (Cq), 132.3 (CH), 132.1 (CH), 128.9 (Cq), 128.4 (Cq), 
124.3 (CH), 121.7 (CH), 120.8 (CH), 119.8 (CH), 119.2 (CH), 66.2 (CH2), 53.9 (CH2), 
22.4 (CH3). IR (ATR): 2958, 2830, 1659, 1521, 1478, 1114, 919, 763, 704 cm–1. MS 
(ESI) m/z (relative intensity): 370 (45) [M+Na]+, 348 (100) [M+H]+. HR-MS (ESI) m/z 
calcd for C21H22N3O2 [M+H]+: 348.1707, found: 348.1711.  





107aq: White solid. M.p.: 104–106 °C. 1H NMR (400 MHz, CDCl3) δ = 12.22 (s, 1H), 
8.92 (d, J = 1.8 Hz, 1H), 8.40 (dd, J = 4.2, 1.7 Hz, 1H), 8.32 (dd, J = 7.8, 1.8 Hz, 1H), 
8.01 (dd, J = 8.2, 1.7 Hz, 1H), 7.57–7.52 (m, 2H), 7.40 (ddd, J = 8.3, 7.3, 1.9 Hz, 1H), 
7.33–7.24 (m, 5H), 7.13–7.07 (m, 1H), 7.05 (dd, J = 8.4, 1.0 Hz, 1H), 5.49 (s, 2H), 2.56 
(d, J = 1.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 163.8 (Cq), 156.6 (Cq), 147.0 (CH), 
137.7 (Cq), 137.6 (Cq), 136.3 (Cq), 135.4 (CH), 135.1 (Cq), 132.8 (CH), 132.3 (CH), 
128.6 (CH), 128.0 (CH), 128.0 (Cq), 127.5 (CH), 123.2 (Cq), 121.5 (CH), 121.3 (CH), 
120.4 (CH), 119.5 (CH), 113.4 (CH), 71.1 (CH2), 22.3 (CH3). IR (ATR): 3277, 1655, 
1526, 1475, 1424, 1209, 1001, 853, 732, 691 cm–1. MS (ESI) m/z (relative intensity): 
391 (10) [M+Na]+, 369 (10) [M+H]+. HR-MS (ESI) m/z calcd for C24H21N2O2 
[M+H]+: 369.1598, found: 369.1599.  
 
2-[2-(1-Phenylethoxy)benzamido]pyridine 1-oxide (107D) 
107D was prepared according to the known method[129e] using benzamide 106D (0.20 
mmol, 1.0 equiv, 42.8 mg) and 1-phenylethan-1-ol (66a) (1.5 mL, 12.4 mmol). 
Purification by column chromatography on silica gel (CH2Cl2/acetone: 10/1) yielded 
107D (6.7 mg, 10%) as a white solid. M.p.: 179–180 °C. 1H NMR (400 MHz, CDCl3) 
δ = 12.39 (s, 1H), 8.77 (d, J = 8.6 Hz, 1H), 8.30 (s, 1H), 8.23 (dd, J = 7.9, 1.9 Hz, 1H), 
7.53–7.41 (m, 2H), 7.43–7.26 (m, 4H), 7.23 (t, J = 7.3 Hz, 1H), 6.99 (t, J = 7.6 Hz, 2H), 
6.89 (d, J = 8.4 Hz, 1H), 5.58 (q, J = 6.5 Hz, 1H), 1.97 (d, J = 6.5 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ = 164.1 (Cq), 156.4 (Cq), 145.4 (Cq), 141.8 (Cq), 137.4 (CH), 134.0 
(CH), 132.6 (CH), 128.9 (CH), 127.9 (CH), 127.7 (CH), 125.7 (CH), 121.0 (CH), 120.9 
(Cq), 118.5 (CH), 115.9 (CH), 114.3 (CH), 78.2 (CH), 24.8 (CH3). IR (ATR): 3214, 1668, 
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1562, 1504, 1477, 1426, 1234, 752, 701 cm–1. MS (ESI) m/z (relative intensity): 357 
(75) [M+Na]+, 335 (100) [M+H]+, 231 (90). HR-MS (ESI) m/z calcd for C20H19N2O3 
[M+H]+: 335.1390, found: 335.1395. 
 
2-(1-Phenylethoxy)-N-(quinolin-8-yl)-5-(trifluoromethyl)benzamide (107G) 
107G was prepared according to the known method[124b] using benzamide 35n 
(0.5 mmol, 1.0 equiv, 158 mg) and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). 
Purification by column chromatography on silica gel (nhexane/acetone: 16/1→9/1) 
yielded 107G (42.0 mg, 19%) as a white solid. M.p.: 118–120 °C. 1H NMR (400 MHz, 
CDCl3) δ = 12.13 (s, 1H), 9.10 (dd, J = 7.5, 1.5 Hz, 1H), 8.78 (dd, J = 4.2, 1.7 Hz, 1H), 
8.60 (dd, J = 2.5, 0.8 Hz, 1H), 8.19 (dd, J = 8.3, 1.7 Hz, 1H), 7.66–7.55 (m, 4H), 7.52 
(ddd, J = 8.7, 2.5, 0.8 Hz, 1H), 7.45 (dd, J = 8.3, 4.2 Hz, 1H), 7.39–7.32 (m, 2H), 7.31–
7.25 (m, 1H), 6.98 (d, J = 8.7 Hz, 1H), 5.67 (q, J = 6.4 Hz, 1H), 2.00 (d, J = 6.4 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ = 162.6 (Cq), 158.1 (Cq), 147.8 (CH), 141.6 (Cq), 
139.2 (Cq), 136.4 (CH), 135.5 (Cq), 130.2 (q, 3JC–F = 3.8 Hz, CH), 129.6 (q, 3JC–F = 
3.6 Hz, CH), 129.1 (CH), 128.2 (CH), 128.1 (Cq), 127.6 (CH), 125.5 (CH), 123.9 (d, 
1JC–F = 271.7 Hz, Cq), 123.4 (Cq), 123.4 (q, 2JC–F = 33.5 Hz, Cq), 122.0 (CH), 121.6 (CH), 
117.9 (CH), 114.3 (CH), 78.6 (CH), 25.1 (CH3). 
19F NMR (282 MHz, CDCl3) δ = -61.9 
(s). IR (ATR): 3308, 1662, 1529, 1325, 1271, 1120, 824, 701 cm–1. MS (ESI) m/z 
(relative intensity): 459 (10) [M+Na]+, 437 (100) [M+H]+, 333 (35). HR-MS (ESI) m/z 
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5.3.5.2 Mechanistic Studies 
Competitive Experiment 
 
Figure 5.3.17. Competitive experiment between arenes 106. 
The general procedure F was followed using benzamides 106a (65.5 mg, 0.25 mmol) 
and 106aa (82.5 mg, 0.25 mmol) and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). 
Electrolysis was carried out at 130 °C and a constant current of 8.0 mA was maintained 
for 12 h. After cooling to ambient temperature, 1,3,5-trimethoxybenzene (0.25 mmol) 
was added as the internal standard to determine the 1H NMR yield.  
 
Figure 5.3.18. Crude 1H NMR spectroscopy of competition experiment between arene 106a and 106aa. 




Figure 5.3.19. Competition experiment between arene 106aj and 106ae. 
The general procedure F was followed using benzamides 106ae (69.5 mg, 0.25 mmol) 
and 106aj (82.5 mg, 0.25 mmol) and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol). 
Electrolysis was carried out at 130 °C and a constant current of 8.0 mA was maintained 
for 12 h. After cooling to ambient temperature, 1,3,5-trimethoxybenzene (0.25 mmol) 
was added as the internal standard to determine the 1H NMR yield. 
 
Figure 5.3.20. Crude 1H NMR spectroscopy of competition experiment between arene 106aj and 106ae. 
 
Figure 5.3.21. Competition experiment between alcohol 66p and amine 56a. 
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The general procedure F was followed using benzamide 106a (65.5 mg, 0.25 mmol), 
tetrahydro-2H-pyran-4-ol (66p) (128 mg, 1.25 mmol) and morpholine (56a) (109 mg, 
1.25 mmol). Electrolysis was carried out at 130 °C and a constant current of 8.0 mA 
was maintained for 12 h. After cooling to ambient temperature, 1,3,5-
trimethoxybenzene (0.25 mmol) was added as the internal standard to determine the  
1H NMR yield. 107ap and 107t were purified by column chromatography on silica gel 
(nhexane/EtOAc: 10/1→4/1) yielded 107t (15.6 mg, 17%) as a white solid and 107ap 
(52.9 mg, 61%) as a white solid.  
 
Figure 5.3.22. Crude 1H NMR spectroscopy of competition experiment between alcohol 66p and amine 
56a. 
 
Figure 5.3.23. Competition experiment between primary alcohol 66 and secondary alcohol 106. 
The general procedure F was followed using benzamides 106a (65.5 mg, 0.25 mmol), 
1-phenylethan-1-ol (66a) (153 mg, 1.25 mmol) and phenylmethanol (66t) (135 mg, 
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1.25 mmol). Electrolysis was carried out at 130 °C and a constant current of 8.0 mA 
was maintained for 12 h. After cooling to ambient temperature, CH2Br2 (0.25 mmol) 
was added as the internal standard to determine the 1H NMR yield.  
 
Figure 5.3.24. Crude 1H NMR spectroscopy of competition experiment between secondary alcohol 66a 
and primary alcohol 66t. 
Experiments with Isotopically Labelled Solvent 
 
Figure 5.3.25. Deuteration experiment with tBuOD. 
The general procedure F was followed using benzamide 106a (65.5 mg, 0.25 mmol) 
and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol) using a mixture of DMA and tBuOD 
(3.0/0.3 mL) as solvent with a balloon. Electrolysis was carried out at 130 °C and a 
constant current of 8.0 mA was maintained for 5.0 h. Column chromatography 
(nhexane/EtOAc: 16/1) yielded [Dn]–107a (36.8 mg, 39%) as a white solid and 
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reisolated starting material [Dn]–106a (34.5 mg, 53%) as a white solid. No deuteration 
was detected in either compound as determined by 1H NMR spectroscopy.  
 
 
Figure 5.3.26. Experiments with isotopically labelled solvent tBuOD. 




Figure 5.3.27. Deuteration experiment with [D5]-106a. 
The general procedure F was followed using benzamide [D5]-106a (66.8 mg, 
0.25 mmol) and 1-phenylethan-1-ol (66a) (305 mg, 2.5 mmol) in DMA (3.0 mL). 
Electrolysis was carried out at 130 °C and a constant current of 8.0 mA was maintained 
for 5.0 h. Column chromatography (nhexane/EtOAc: 4/1) yielded [Dn]–107a (18.5 mg, 
19%) as a white solid and reisolated starting material [Dn]–106a (45.2 mg, 68%) as a 
white solid. 
 
Figure 5.3.28. Deuteration experiment with reisolated substrate [D5]-106a. 




Figure 5.3.29. Deuteration experiment with [D5]-107a. 
KIE Studies 
 
Figure 5.3.30. KIE studies by two parallel reactions.  
Two parallel reactions were carried out with 106a (196 mg, 0.75 mmol, 1.0 equiv) or 
[D5]–106a (200 mg, 0.75 mmol, 1.0 equiv) following the general procedure F using 
Ni(DME)Cl2 (15.9 mg, 10 mol %), 1-AdCO2H (27.0 mg, 20 mol %), NaO2CAd (151 mg, 
0.75 mmol, 1.0 equiv), nBu4NClO4 (511 mg, 1.5 mmol, 2.0 equiv) and 66a (0.90 mL, 
7.5 mmol, 10 equiv) in DMA (6.0 mL). 1,3,5-trimethoxybenzene (0.25 mmol) was 
added as an internal standard. After 10 minutes to reach a stable constant current of 
8.0 mA, aliquots of 0.40 mL were removed from the cell every twenty minutes. The 
mixture was extracted with EtOAc (3.0 mL). After evaporation of the solvent, the crude 
mixture was analyzed by 1H NMR spectroscopy. The KIE was determined by the 
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analysis of the initial rates. 
 
Table 5.3.1. KIE studies 
Time [min] 10 30 50 70 90 110 130 
107a [%] 0 2 6 10 13 17 19 
[D4]-107a [%] 0 2 4 6 9 11 14 
 
Figure 5.3.31. KIE studies by 1H NMR spectroscopy.  
Headspace GC-Analysis 
 
Figure 5.3.32. Headspace GC-analysis.  
Following the general procedure F, after 12 h, the gas–phase over the reaction mixture 
was analyzed by headspace GC analysis using an Agilent 7890B chromatograph 
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equipped with an Agilent CP–Molsieve 5Å column (length: 25 m, diameter: 0.32 mm, 
temperature 10 °C). Helium was used as the carrier gas (1.5 mL/min) and the sample 
was analyzed by a temperature conductivity detector at 110 °C. For comparison, also 
a blank sample of the carrier gas and a pure sample of hydrogen were obtained.  
 
Figure 5.3.33. Headspace analysis of the reaction mixture. 
Radical Trapping Experiment 
 
Figure 5.3.34. Radical trapping experiment with typical radical scavengers.  
The electrolysis was carried out in an undivided cell, with a GF anode (10 mm × 15 mm 
× 6 mm) and a nickel-foam cathode (10 mm × 15 mm × 1.4 mm). Ni(DME)Cl2 (5.5 mg, 
0.025 mmol, 10 mol %), 1-AdCO2H (9.0 mg, 0.050 mmol), NaO2CAd (50.5 mg, 
0.25 mmol), nBu4NClO4 (0.50 mmol), benzamide 106a (0.25 mmol, 1.0 equiv) and 
2.0 equiv of radical scavenger (TEMPO, benzoquinone or 2,6-di-tert-butyl-4-
methylphenol) was dissolved in DMA (3.0 mL) and then the 1-phenylethan-1-ol (66a) 
(2.5 mmol) was added. At 130 °C, electrolysis was started with a constant current of 
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8.0 mA which was then maintained for 12 h. At ambient temperature, the mixture was 
transferred into a separating funnel and the electrodes were rinsed with EtOAc (10 mL). 
Then, H2O (10 mL) was added to the reaction mixture and the organic layer was 
separated. The aqueous layer was extracted with EtOAc (2 × 5.0 mL). After 
evaporation of the collected organic layer, the mixture was checked by TLC and GC-
MS, and no desired products were found.  
Switch On-Off Experiment 
 
Figure 5.3.35. Switch on-off experiment. 
“Switch off-on” reactions were carried out with 106a (196 mg, 0.75 mmol, 1.0 equiv) 
following the procedure H using Ni(DME)Cl2 (15.9 mg, 10 mol %), 1-AdCO2H (27.0 mg, 
20 mol %), NaO2CAd (152 mg, 0.75 mmol, 1.0 equiv), nBu4NClO4 (512 mg, 1.5 mmol, 
2.0 equiv) and 1-phenylethan-1-ol (66a) (0.90 mL, 7.5 mmol, 10 equiv) in DMA 
(6.0 mL). 1,3,5-trimethoxybenzene (0.25 mmol) was added as an internal standard. 
Aliquots of 0.40 mL were removed from the cell every 1.5 hours. The mixture was 
extracted with EtOAc (3.0 mL). After evaporation of solvent, the crude mixture was 
analyzed by 1H NMR spectroscopy. 
 
Time [h] 1.5 3.0 4.5 6.0 7.5 9.0 10. 5 
106a [%] 100 86 87 77 77 68 67 
107a [%] 0 5 5 18 18 28 28 




Figure 5.3.36. Switch off-on experiment. 
5.3.5.3 Isolation and Characterization of Nickel(III) Intermediate 
 
Figure 5.3.37. Synthesis and its X-ray analysis of NiIII-H1. 
According to a reported method,[177] an oven-dried 10 mL undivided electrochemical 
cell was charged with N-(quinolin-8-yl)benzamide (35a) (248 mg, 1.0 mmol), Na2OCAd 
(202 mg, 1.0 mmol), Ni(cod)2 (138 mg, 0.50 mmol) and dry DMA (3.0 mL) in a glovebox. 
The reaction vessel was capped and heated in an oil bath at 130 °C for 2.0 h. Upon 
cooling to room temperature, the cap of the undivided cell was exchanged by a GF 
anode and a nickel-foam cathode. Electrolysis was continued with a constant current 
of 8.0 mA which was then maintained for 4.0 h at ambient temperature under N2. Then 
the reaction mixture was diluted with EtOAc (10 mL) and washed with H2O (10 mL). 
The aqueous layer was extracted with EtOAc (2 x 10 mL). The combined organic 
phase was dried over Na2SO4, filtered and evaporated in vacuum. The residue was 
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purified by silica gel column chromatography at low temperature (eluent: 
nhexane/EtOAc = 4/1, then EtOAc) to afford NiIII-H1 (108 mg, 39%) as a dark red solid. 
The product was crystallized using CH2Cl2 and nhexane. 
 
Figure 5.3.38. Catalytic reaction of substrate 35a with NiIII-H1. 
The electrolysis was carried out in an undivided cell, with a GF anode (10 mm × 15 mm 
× 6 mm) and a nickel-foam cathode (10 mm × 15 mm × 1.4 mm). NiIII-H1 (27.6 mg, 
0.025 mmol, 10 mol %), 1-AdCO2H (9.0 mg, 0.050 mmol), NaO2CAd (50.5 mg, 
0.25 mmol), nBu4NClO4 (0.50 mmol) and benzamide 1s (62.0 mg, 0.25 mmol, 
1.0 equiv) were dissolved in DMA (3.0 mL), and then the 1-phenylethan-1-ol (66a) 
(2.5 mmol) was added. At 130 °C, electrolysis was started with a constant current of 
8.0 mA (or without current) which was then maintained for 12 h. At ambient temperature, 
the mixture was transferred into a separating funnel and the electrodes were rinsed 
with EtOAc (10 mL). Then, H2O (10 mL) was added to the reaction mixture and the 
organic layer was separated. The aqueous layer was extracted with EtOAc (2 × 5.0 
mL). Evaporation of the collected organic layer and subsequent column 
chromatography on silica gel (nhexane/EtOAc: 16/1) yielded the desired product 107d 
(with electricity: 41.6 mg, 0.113 mmol, 38%; without electricity: trace) and recovered 
35a (with electricity: 36.0 mg, 0.145 mmol, 48%; without electricity: 63.2 mg, 0.255 
mmol, 85%).  
 
Figure 5.3.39. Catalytic reaction of substrate 106a with NiIII-H1. 
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The electrolysis was carried out in an undivided cell, with a GF anode (10 mm × 15 mm 
× 6 mm) and a nickel-foam cathode (10 mm × 15 mm × 1.4 mm). NiIII-H1 (27.6 mg, 
0.025 mmol, 10 mol %), 1-AdCO2H (9.0 mg, 0.050 mmol), NaO2CAd (50.5 mg, 
0.25 mmol), nBu4NClO4 (0.50 mmol) and benzamide 106a (65.5 mg, 0.25 mmol, 
1.0 equiv) were dissolved in DMA (3.0 mL), and then the 1-phenylethan-1-ol (66a) 
(2.5 mmol) was added. At 130 °C, electrolysis was started with a constant current of 
8.0 mA which was then maintained for 12 h. After cooling to ambient temperature, 
1,3,5-trimethoxybenzene (0.25 mmol) was added as the internal standard to determine 
the 1H NMR yield.  
 
Figure 5.3.40. NiIII-H1 catalyzed reaction of substrate 106a.  
 
 
Figure 5.3.41. Stoichiometric reaction using nickel(III) complex.  
5. Experimental Section  
193 
 
The electrolysis was carried out in an undivided cell, with a GF anode (10 mm × 15 mm 
× 6 mm) and a nickel-foam cathode (10 mm × 15 mm × 1.4 mm). NiIII-H1 (55.2 mg, 
0.10 mmol), 1-AdCO2H (3.6 mg, 0.020 mmol), NaO2CAd (20.2 mg, 0.10 mmol) and 
nBu4NClO4 (0.20 mmol) were dissolved in DMA (1.5 mL), and then alcohol 66a 
(1.0 mmol) was added. Then the reaction was carried out without or with electricity at 
130 °C for 12 h. After cooling to ambient temperature, 1,3,5-trimethoxybenzene 
(0.10 mmol) was added as the internal standard to determine the 1H NMR yield.  
 
Figure 5.3.42. NiIII-H1 reacted with the alcohol 66a without electricity. 
The electrolysis was carried out in an undivided cell, with a GF anode (10 mm × 15 mm 
× 6 mm) and a nickel-foam cathode (10 mm × 15 mm × 1.4 mm). NiIII-H1 (110.4 mg, 
0.20 mmol), 1-AdCO2H (7.2 mg, 0.040 mmol), NaO2CAd (40.4 mg, 0.20 mmol) and 
nBu4NClO4 (0.50 mmol) were dissolved in DMA (3.0 mL), and then alcohol 66a 
(2.0 mmol) was added. At 130 °C, electrolysis was started with a constant current of 
8.0 mA which was then maintained for 12 h. After cooling to ambient temperature, 
1,3,5-trimethoxybenzene (0.20 mmol) was added as the internal standard to determine 
the 1H NMR yield. 




Figure 5.3.43. NiIII-H1 reacted with the alcohol 66a with electricity. 
5.3.5.4 Gram-Scale Experiment 
 
Figure 5.3.44. Gram-scale experiment with 106aa. 
The electrolysis was carried out in 100 mL Schlenk flask, with a GF anode (20 mm × 
30 mm × 6 mm) and a nickel-foam cathode (20 mm × 30 mm × 1.4 mm). Ni(DME)Cl2 
(87.6 mg, 0.40 mmol, 10 mol %), 1-AdCO2H (144 mg, 0.80 mmol), NaO2CAd (808 mg, 
4.0 mmol), nBu4NClO4 (7.0 mmol, 2.39 g) and benzamide 106aa (4.0 mmol, 1.32 g) 
were dissolved in DMA (40.0 mL), and then the 1-phenylethan-1-ol (66a) (40 mmol) 
was added. At 130 °C, electrolysis was started with a constant current of 32.0 mA 
which was then maintained for 42 h. At ambient temperature, the mixture was 
transferred into a separating funnel and the electrodes were rinsed with EtOAc (50 mL). 
Then, the mixture was washed with H2O (50 mL) and the organic layer was separated. 
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The aqueous layer was extracted with EtOAc (2 × 50 mL). Evaporation of the collected 
organic layer and subsequent column chromatography on silica gel 
(nhexane/acetone:16/1→9/1) yielded the desired product 107aa (1.28 g, 71%). 
5.3.5.5 Traceless Removal of the Directing Group 
As to the synthetic utility of this method, it is noteworthy that the 6-methylquinuoline 
was easily removed in a traceless fashion to provide efficient access to benzamide 
109a, benzoic acid 109b, or aromatic aldehyde 109c (Figure 3.4.17). 
 
Figure 5.3.45. Traceless removal of the directing group to obtain primary amide 109a. 
According to the literature,[185] a stream of O3 was passed through a solution of N-(6-
methylquinolin-8-yl)-2-(1-phenylethoxy)benzamide (107a) (76.4 mg, 0.20 mmol) in 
CH2Cl2 (15 mL) at -78 °C until the characteristic blue color appeared. A stream of 
oxygen was passed through until decolorization occurred and the mixture was 
quenched with dimethylsulfide (0.050 mL). After stirring at room temperature for 2.0 h, 
the mixture was concentrated under reduced pressure. The residue was redissolved 
in NH4OH (25%)/THF (6.0 mL, 1/1) and stirred for 48 h at ambient temperature. The 
mixture was diluted with CH2Cl2 (20.0 mL) and washed with aqueous HCl (1N, 2 x 
10 mL), and subsequently 1N NaOH (2 x 10 mL). The organic layer was dried with 
MgSO4 and concentrated to dryness to give the primary amide 109a (39.7 mg, 82%). 
M.p.: 134–135 ºC. 1H NMR (400 MHz, CDCl3) δ = 8.23 (dd, J = 7.9, 1.9 Hz, 1H), 8.06–
7.99 (m, 1H), 7.38 (d, J = 4.3 Hz, 4H), 7.35–7.28 (m, 2H), 7.02 (td, J = 7.5, 1.0 Hz, 1H), 
6.85 (dd, J = 8.4, 1.0 Hz, 1H), 6.31 (s, 1H), 5.52 (q, J = 6.4 Hz, 1H), 1.77 (d, J = 6.4 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ = 167.3 (Cq), 156.2 (Cq), 141.6 (Cq), 133.1 (CH), 
132.5 (CH), 129.0 (CH), 128.1 (CH), 125.4 (CH), 121.4 (Cq), 121.2 (CH), 114.3 (CH), 
77.6 (CH), 24.4 (CH3). IR (ATR): 3455, 1663, 1592, 1454, 1374, 1229, 1066, 755, 
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701 cm–1. MS (ESI) m/z (relative intensity): 264 (100) [M+Na]+, 242 (10) [M+H]+, 138 
(50), 117 (60). HR-MS (ESI) m/z calcd for C15H16NO2 [M+H]+: 242.1176, 
found: 242.1184.  
 
Figure 5.3.46. Traceless removal of the directing group to obtain benzoic acid 109b. 
An oven-dried 25 mL sealed tube equipped with a stir bar was charged with N-(6-
methylquinolin-8-yl)-2-(1-phenylethoxy)benzamide (107a) (95.5 mg, 0.25 mmol), 
NaOH (100 mg, 2.5 mmol) and EtOH (2.0 mL). The resulting mixture was stirred at 
120 °C for 24 h. After completion, the reaction mixture was cooled down to room 
temperature, diluted by 20.0 mL ethyl acetate and washed by HCl (3 × 10 mL of 0.5 N 
aqueous solution). The aqueous layers were combined and extracted with EtOAc (3 ×  
10 mL). Combined organic layers were dried over MgSO4. Evaporation to remove 
organic solvent gave the pure acid 109b (52.0 mg, 86%) as a colorless gummy. 
1H NMR (400 MHz, CDCl3) δ = 11.13 (s, 1H), 8.15 (dd, J = 7.8, 1.8 Hz, 1H), 7.42–7.27 
(m, 6H), 7.06–7.02 (m, 1H), 6.88 (dd, J = 8.4, 0.9 Hz, 1H), 5.57 (q, J = 6.4 Hz, 1H), 
1.79 (d, J = 6.4 Hz, 3H).13C NMR (101 MHz, CDCl3) δ = 165.5 (Cq), 156.5 (Cq), 140.4 
(Cq), 134.7 (CH), 133.7 (CH), 129.1 (CH), 128.5 (CH), 125.4 (CH), 122.2 (CH), 118.3 
(Cq), 114.4 (CH), 79.3 (CH), 24.0 (CH3). IR (ATR): 3252, 2979, 1732, 1692, 1600, 1455, 
1241, 1065, 753, 700 cm–1 MS (ESI) m/z (relative intensity): 265 (100) [M+Na]+. 
HR-MS (ESI) m/z calcd for C15H14O3Na+ [M+Na]+: 265.0835, found: 265.0834. The 
analytical data correspond with those reported in the literature.[186] 
 
Figure 5.3.47. Traceless removal of the directing group to gain aromatic aldehyde 109c. 
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According the literature,[97a] N-(6-methylquinolin-8-yl)-2-(1-phenylethoxy)benzamide 
(107a) (95.5 mg, 0.25 mmol), Cp2ZrHCl (0.50 mmol, 125 mg), and THF (2.0 mL) were 
charged to a 25 mL Schlenk tube under N2. The reaction mixture was stirred at room 
temperature for 6 hrs before carefully being quenched by saturated ammonium 
chloride at 0 °C. After being extracted with CH2Cl2 (3 × 25.0 mL), the combined organic 
extract was washed with brine, dried over Na2SO4, and concentrated in vacuum. The 
residue was purified by column chromatography on silica gel (eluent: nhexane/EtOAc: 
20/1) to afford aromatic aldehyde 109c as a colorless oil (40.7 mg, 72%). 1H NMR (400 
MHz, CDCl3) δ = 10.64 (d, J = 0.8 Hz, 1H), 7.80 (dd, J = 7.7, 1.8 Hz, 1H), 7.41–7.29 
(m, 5H), 7.30–7.24 (m, 1H), 7.00–6.87 (m, 1H), 6.82 (dd, J = 8.5, 0.8 Hz, 1H), 5.42 (q, 
J = 6.4 Hz, 1H), 1.69 (d, J = 6.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 189.9 (CH), 
160.4 (Cq), 142.1 (Cq), 135.6 (CH), 128.8 (CH), 128.2 (CH), 127.8 (CH), 125.4 (CH), 
125.4 (Cq), 120.7 (CH), 114.5 (CH), 77.0 (CH), 24.2 (CH3). IR (ATR): 2979, 1683, 1596, 
1478, 1455, 1235, 1067, 755, 699 cm–1. MS (ESI) m/z (relative intensity): 249 (100) 
[M+Na]+, 105 (25). HR-MS (ESI) m/z calcd for C15H14O2Na [M+Na]+: 249.0886, 
found: 249.08867. The analytical data correspond with those reported in the 
literature.[186] 
5.3.5.6 Cyclic Voltammetry 
A glassy-carbon electrode (3 mm diameter, disc-electrode) was used as the working 
electrode, a Pt–wire as auxiliary electrode and an Ag–wire as pseudoreference. The 
measurements were then referenced using ferrocene. The measurements were 
carried out at a scan rate of 100 mV/s. 




Figure 5.3.48. Cyclic voltammograms at 100 mV/s. nBu4NPF6 (0.1 M in DMA); concentration of substrates 
5 mM. blank (black); 106a (red); 66a (blue); [Ni(DME)Cl2] (purple); NaO2CAd (green). Performed by Julia 
Struwe. 
 
Figure 5.3.49. Cyclic voltammograms at 100 mV/s. nBu4NPF6 (0.1 M in DMA); concentration of substrates 
5 mM. blank (black); Ni(DME)Cl2 (red); Ni(DME)Cl2 + 106a (blue); Ni(DME)Cl2 + NaO2CAd (purple); 
Ni(DME)Cl2 + 1-AdCO2H (green). Performed by Julia Struwe. 
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5.3.5.7 Studies on the Potential Racemization of 107u 
A racemic sample of rac-107u was synthesized following the general procedure using 
L-Menthol/D-Menthol (1.25 mmol/1.25 mmol). Analysis by chiral HPLC showed that 
racemization did not take place. HPLC chromatograms were recorded on an Agilent 
1290 Infinity instrument using CHIRALPAK ® IA-1 column and nhexane/iPrOH (98/2, 
1.0 mL/min, detection at 273 nm, 99% ee)  
 
 
Figure 5.3.50. HPLC–Chromatogram of rac-107u. 
 
 
Figure 5.3.51. HPLC–Chromatogram of 107u. 
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5.3.6 Nickela-Electrocatalyzed C–H Phosphorylation 
5.3.6.1 Characterization Data 
 
Diisopropyl {2-[(6-methylquinolin-8-yl)carbamoyl]phenyl}phosphonate (110a) 
The general procedure G was followed using benzamide 106a (65.5 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1→1/1) 
yielded 110a (78.2 mg, 73%) as a white solid. M.p.: 127–129 °C. 1H NMR (300 MHz, 
CDCl3) δ = 10.12 (s, 1H), 8.83 (d, J = 1.8 Hz, 1H), 8.70 (dd, J = 4.2, 1.6 Hz, 1H), 8.17–
8.05 (m, 2H), 7.76–7.55 (m, 3H), 7.41 (ddd, J = 8.2, 4.2, 1.0 Hz, 1H), 7.36–7.31 (m, 
1H), 4.77 (dhept, J = 7.8, 6.2 Hz, 2H), 2.61 (s, 3H), 1.26 (d, J = 6.2 Hz, 6H), 1.18 (d, 
J = 6.2 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ = 167.4 (d, 3JC–P = 4.6 Hz, Cq), 147.2 
(CH), 140.9 (d, 2JC–P = 9.3 Hz, Cq), 137.5 (Cq), 137.4 (Cq), 135.5 (CH), 134.3 (Cq), 133.4 
(d, 3JC–P = 9.3 Hz ,CH), 132.3 (d, 4JC–P = 2.9 Hz ,CH), 129.4 (d, 2JC–P = 14.2 Hz ,CH), 
128.6 (d, 3JC–P = 13.0 Hz ,CH), 128.0 (Cq), 127.4 (d, 1JC–P = 188.0 Hz, Cq), 121.6 (CH), 
120.9 (CH), 119.2 (CH), 71.5 (d, 2JC–P = 6.0 Hz ,CH), 23.8 (d, 3JC–P = 4.2 Hz, CH3), 23.7 
(d, 3JC–P = 4.8 Hz, CH3), 22.3 (CH3). 
31P{1H} NMR (162 MHz, CDCl3) δ = 14.4 (dd, J = 
14.1, 7.2 Hz). IR (ATR): 3357, 2979, 1677, 1523, 1237, 979, 869, 670, 603 cm–1. MS 
(ESI) m/z (relative intensity): 449 (35) [M+Na]+, 427 (100) [M+H]+. HR-MS (ESI) m/z 
calcd for C23H28N2O4P [M+H]+: 427.1781, found: 427.1783. 
 
Diisopropyl [2-(quinolin-8-ylcarbamoyl)phenyl]phosphonate (110b) 
The general procedure G was followed using benzamide 35a (62.0 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol). 
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Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1→1/1) 
yielded 110b (61.2 mg, 59%) as a white solid. M.p.: 105–107 °C. 1H NMR (400 MHz, 
CDCl3) δ = 10.18 (s, 1H), 8.96 (dd, J = 7.5, 1.6 Hz, 1H), 8.79 (dd, J = 4.2, 1.7 Hz, 1H), 
8.19 (dd, J = 8.3, 1.7 Hz, 1H), 8.15–8.07 (m, 1H), 7.76–7.70 (m, 1H), 7.69–7.55 (m, 
4H), 7.46 (dd, J = 8.3, 4.2 Hz, 1H), 4.77 (dhept, J = 7.8, 6.2 Hz, 2H), 1.26 (d, J = 6.2 Hz, 
6H), 1.17 (d, J = 6.2 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ = 167.5 (d, 3JC–P = 4.5 Hz, 
Cq), 148.2 (CH), 140.8 (d, 2JC–P = 9.3 Hz, Cq), 138.7 (Cq), 136.3 (CH), 134.7 (Cq), 133.5 
(d, 3JC–P = 9.4 Hz, CH), 132.3 (d, 4JC–P = 3.0 Hz, CH), 129.5 (d, 2JC–P = 14.2 Hz, CH), 
128.6 (d, 3JC–P = 13.1 Hz, CH), 128.0 (Cq), 127.4 (CH), 127.4 (d, 1JC–P = 188.4 Hz, Cq), 
122.0 (CH), 121.6 (CH), 117.3 (CH), 71.5 (d, 3JC–P = 6.0 Hz, CH), 23.8 (d, 3JC–P = 4.2 Hz, 
CH3), 23.8 (d, 3JC–P = 4.8 Hz, CH3). 
31 P{1H} NMR (121 MHz, CDCl3) δ = 14.5–14.3 (m). 
IR (ATR): 3331, 2978, 1674, 1523, 1243, 969, 768, 567, 543 cm–1. MS (ESI) m/z 
(relative intensity): 435 (100) [M+Na]+, 413 (35) [M+H]+. HR-MS (ESI) m/z calcd for 
C22H26N2O4P [M+H]+: 413.1625, found: 413.1629.  
The analytical data correspond with those reported in the literature.[139] 
 
Diisopropyl {2-[(5-methylquinolin-8-yl)carbamoyl]phenyl}phosphonate (110c) 
The general procedure G was followed using benzamide 106c (65.5 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1→1/1) 
yielded 110c (77.9 mg, 73%) as a white solid. M.p.: 125–127 °C. 1H NMR (400 MHz, 
CDCl3) δ = 10.14 (s, 1H), 8.83 (d, J = 7.8 Hz, 1H), 8.77 (dd, J = 3.9, 1.8 Hz, 1H), 8.33 
(dq, J = 8.5, 1.5 Hz, 1H), 8.14–8.07 (m, 1H), 7.74–7.69 (m, 1H), 7.63 (td, J = 7.6, 
1.5 Hz, 1H), 7.56 (tdd, J = 7.5, 3.0, 1.4 Hz, 1H), 7.47 (ddt, J = 8.5, 4.2, 1.1 Hz, 1H), 
7.42 (d, J = 7.8 Hz, 1H), 4.76 (dhept, J = 7.8, 6.2 Hz, 2H), 2.74–2.60 (m, 3H), 1.25 (d, 
J = 6.2 Hz, 6H), 1.16 (d, J = 6.2 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ = 167.3 (d, 
3JC-P = 4.4 Hz, Cq), 147.6 (CH), 141.0 (d, 2JC–P = 9.3 Hz, Cq), 139.0 (Cq), 133.5 (d, 
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3JC-P = 9.4 Hz, CH), 133.1 (Cq), 132.9 (CH), 132.2 (d, 4JC–P = 3.0 Hz, CH), 129.4 (d, 
2JC–P = 14.3 Hz, CH), 128.7 (Cq), 128.6 (d, 3JC–P = 13.0 Hz, CH), 127.5 (CH), 127.3 (d, 
1JC–P = 188.3 Hz, Cq), 127.3 (Cq), 121.1 (CH), 117.0 (CH), 71.5 (d, 2JC–P = 6.1 Hz, CH), 
23.8 (d, 3JC–P = 4.3 Hz, CH3), 23.8 (d, 3JC–P = 4.9 Hz, CH3), 18.3 (CH3). 
31P{1H} NMR 
(121 MHz, CDCl3) δ = 14.4 (ddq, J = 11.9, 7.7, 4.0 Hz). IR (ATR): 3336, 2976, 1671, 
1522, 1243, 974, 769, 567, 544 cm–1. MS (ESI) m/z (relative intensity): 449 (100) 
[M+Na]+, 427 (50) [M+H]+, 369 (5). HR-MS (ESI) m/z calcd for C23H28N2O4P [M+H]+: 
427.1781, found: 427.1784. 
 
Diisopropyl {2-[(5-methoxyquinolin-8-yl)carbamoyl]phenyl}phosphonate (110d) 
The general procedure G was followed using benzamide 106e (69.5 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1→1/1) 
yielded 110d (79.0 mg, 71%) as a white solid. M.p.: 155–157 °C. 1H NMR (300 MHz, 
CDCl3) δ = 9.94 (s, 1H), 8.87 (d, J = 8.6 Hz, 1H), 8.79 (dd, J = 4.2, 1.7 Hz, 1H), 8.60 
(dd, J = 8.4, 1.7 Hz, 1H), 8.16–8.05 (m, 1H), 7.76–7.70 (m, 1H), 7.67–7.61 (m, 1H), 
7.57 (tdd, J = 7.4, 3.4, 1.5 Hz, 1H), 7.44 (dd, J = 8.4, 4.2 Hz, 1H), 6.92 (d, J = 8.6 Hz, 
1H), 4.76 (dhept, J = 7.6, 6.2 Hz, 2H), 4.03 (s, 3H), 1.26 (d, J = 6.2 Hz, 6H), 1.17 (d, 
J = 6.2 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ = 167.0 (d, 3JC–P = 4.6 Hz, Cq), 150.6 
(Cq), 148.6 (CH), 141.0 (d, 2JC–P = 9.4 Hz, Cq), 139.5 (Cq), 133.4 (d, 3JC–P = 9.4 Hz, CH), 
132.2 (d, 4JC–P = 2.9 Hz, CH), 131.2 (CH), 129.3 (d, 2JC–P = 14.3 Hz, CH), 128.7 (d, 
3JC-P = 13.0 Hz, CH), 128.2 (Cq), 127.3 (d, 1JC–P = 188.5 Hz, Cq), 120.7 (CH), 120.5 
(Cq), 117.5 (CH), 104.4 (CH), 71.5 (d, 2JC–P = 6.1 Hz, CH), 55.8 (CH3), 23.8 (d, 3JC–P = 
4.1 Hz, CH3), 23.8 (d, 3JC–P = 4.8 Hz, CH3). 
31P{1H} NMR (121 MHz, CDCl3) δ = 14.6 
(td, J = 8.2, 4.4 Hz). IR (ATR): 3344, 2978, 1665, 1532, 1272, 1247, 974, 786, 552, 
539 cm–1. MS (ESI) m/z (relative intensity): 465 (100) [M+Na]+, 443 (35) [M+H]+. 
HR-MS (ESI) m/z calcd for C23H28N2O5P [M+H]+: 443.1730, found: 443.1734. 




Diisopropyl {2-[(6-methoxyquinolin-8-yl)carbamoyl]phenyl}phosphonate (110e) 
The general procedure G was followed using benzamide 106b (69.5 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1→1/1) 
yielded 110e (60.0 mg, 54%) as a white solid. M.p.: 100–102 °C. 1H NMR (300 MHz, 
CDCl3) δ = 10.13 (s, 1H), 8.70 (d, J = 2.7 Hz, 1H), 8.61 (dd, J = 4.2, 1.6 Hz, 1H), 8.17–
8.02 (m, 2H), 7.76–7.53 (m, 3H), 7.39 (dd, J = 8.3, 4.2 Hz, 1H), 6.85 (d, J = 2.7 Hz, 
1H), 4.76 (dhept, J = 7.6, 6.2 Hz, 2H), 3.97 (s, 3H), 1.26 (d, J = 6.2 Hz, 6H), 1.17 (d, 
J = 6.2 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ = 167.5 (d, 3JC–P = 4.5 Hz, Cq), 158.5 
(Cq), 145.6 (CH), 140.7 (d, 2JC–P = 9.2 Hz, Cq), 135.6 (Cq), 135.3 (Cq), 134.9 (CH), 133.4 
(d, 3JC–P = 9.4 Hz, CH), 132.3 (d, 4JC–P = 2.9 Hz, CH), 129.5 (d, 2JC–P = 14.2 Hz, CH), 
129.0 (Cq), 128.6 (d, 3JC–P = 12.9 Hz, CH), 127.3 (d, 1JC–P = 188.3 Hz, Cq), 122.1 (CH), 
109.7 (CH), 100.1 (CH), 71.5 (d, 2JC–P = 6.0 Hz, CH), 55.6 (CH3), 23.8 (d, 3JC–P = 4.1 Hz, 
CH3), 23.8 (d, 3JC–P = 4.9 Hz, CH3). 
31P{1H} NMR (121 MHz, CDCl3) δ = 14.3 (td, J = 
9.0, 4.9 Hz). IR (ATR): 3341, 2978, 1688, 1524, 1452, 1234, 983, 832, 566, 544 cm-1. 
MS (ESI) m/z (relative intensity): 465 (100) [M+Na]+, 443 (40) [M+H]+, 369 (5). HR-MS 




The general procedure G was followed using benzamide 106i (79.0 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1→1/1) 
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yielded 110f (50.2 mg, 42%) as a white solid. M.p.: 104–106 °C. 1H NMR (300 MHz, 
CDCl3) δ = 10.23 (s, 1H), 9.20 (d, J = 1.9 Hz, 1H), 8.91 (dd, J = 4.2, 1.7 Hz, 1H), 8.29 
(dd, J = 8.3, 1.7 Hz, 1H), 8.20–8.05 (m, 1H), 7.90 (dd, J = 1.9, 1.0 Hz, 1H), 7.77–7.54 
(m, 4H), 4.78 (dhept, J = 7.7, 6.2 Hz, 2H), 1.26 (d, J = 6.2 Hz, 6H), 1.18 (d, J = 6.2 Hz, 
6H). 13C NMR (101 MHz, CDCl3) δ = 167.7 (d, 3JC–P = 4.5 Hz, Cq), 150.2 (CH), 140.3 
(d, 2JC–P = 9.2 Hz, Cq), 139.5 (Cq), 137.3 (CH), 135.8 (Cq), 133.4 (d, 3JC–P = 9.2 Hz, CH), 
132.3 (d, 4JC–P = 3.0 Hz, CH), 129.7 (d, 2JC–P = 14.3 Hz, CH), 129.3 (q, 2JC–F = 32.5 Hz, 
Cq), 128.6 (d, 3JC–P = 12.9 Hz, CH), 127.5 (d, 1JC–P = 188.4 Hz, Cq), 127.0 (Cq), 123.9 
(q, 1JC–F = 272.8 Hz, Cq), 122.8 (CH), 119.4 (q, 3JC–F = 4.6 Hz, CH), 112.8 (d, 3JC–F = 
3.3 Hz, CH), 71.6 (d, 2JC–P = 6.1 Hz, CH), 23.8 (d, 3JC–P = 4.2 Hz, CH3), 23.7 (d, 3JC–P = 
4.9 Hz, CH3). 
31P{1H} NMR (121 MHz, CDCl3) δ = 14.2 (d, J = 13.0 Hz). 
19F NMR 
(376 MHz, CDCl3) δ = -62.7. IR (ATR): 3363, 2987, 1682, 1523, 1244, 1115, 977, 661, 
567, 538 cm–1. MS (ESI) m/z (relative intensity): 503 (100) [M+Na]+, 481 (20) [M+H]+, 





The general procedure G was followed using benzamide 106ae (69.0 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1→1/1) 
yielded 110g (73.5 mg, 67%) as a white solid. M.p.: 119–121 °C. 1H NMR (400 MHz, 
CDCl3) δ = 10.09 (s, 1H), 8.81 (d, J = 1.9 Hz, 1H), 8.69 (dd, J = 4.3, 1.7 Hz, 1H), 8.08 
(dd, J = 8.3, 1.7 Hz, 1H), 7.93 (dd, J = 14.6, 1.8 Hz, 1H), 7.62 (dd, J = 7.8, 5.3 Hz, 1H), 
7.45 (d, J = 7.8 Hz, 1H), 7.40 (dd, J = 8.3, 4.3 Hz, 1H), 7.35–7.32 (m, 1H), 4.76 (dhept, 
J = 7.7, 6.2 Hz, 2H), 2.60 (s, 3H), 2.47 (s, 3H), 1.26 (d, J = 6.2 Hz, 6H), 1.17 (d, J = 
6.2 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ = 167.6 (d, 3JC–P = 4.4 Hz, Cq), 147.2 (CH), 
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139.7 (d, 2JC–P = 14.2 Hz, Cq), 138.2 (d, 3JC–P = 9.1 Hz, Cq), 137.6 (Cq), 137.5 (Cq), 
135.5 (CH), 134.4 (Cq), 134.0 (d, 3JC–P = 9.6 Hz, CH), 132.8 (d, 4JC–P = 3.1 Hz, CH), 
128.7 (d, 2JC–P = 13.7 Hz, CH), 128.0 (Cq), 127.1 (d, 1JC–P = 186.9 Hz, Cq), 121.6 (CH), 
120.8 (CH), 119.2 (CH), 71.4 (d, 2JC–P = 6.0 Hz, CH), 23.8 (d, 3JC–P = 4.4 Hz, CH3), 23.8 
(d, 3JC–P = 5.1 Hz, CH3), 22.4 (CH3), 21.3 (CH3). 
31P{1H} NMR (162 MHz, CDCl3) δ = 
14.9 (dd, J = 14.2, 6.9 Hz). IR (ATR): 3355, 2980, 1675, 1525, 1236, 975, 600, 571 cm-1. 
MS (ESI) m/z (relative intensity): 463 (10) [M+Na]+, 441 (100) [M+H]+. HR-MS (ESI) 




The general procedure G was followed using benzamide 106af (73.0 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1→1/1) 
yielded 110i (70.0 mg, 61%) as a white solid. M.p.: 151–153 °C. 1H NMR (300 MHz, 
CDCl3) δ = 10.11 (s, 1H), 8.79 (d, J = 1.8 Hz, 1H), 8.70 (dd, J = 4.2, 1.7 Hz, 1H), 8.07 
(dd, J = 8.3, 1.7 Hz, 1H), 7.74–7.57 (m, 2H), 7.39 (dd, J = 8.3, 4.2 Hz, 1H), 7.34–7.30 
(m, 1H), 7.13 (ddd, J = 8.5, 2.7, 0.8 Hz, 1H), 4.76 (dhept, J = 7.6, 6.2 Hz, 2H), 3.91 (s, 
3H), 2.61–2.56 (m, 3H), 1.27 (d, J = 6.2 Hz, 6H), 1.17 (d, J = 6.2 Hz, 6H). 13C NMR 
(101 MHz, CDCl3) δ = 167.3 (d, 3JC–P = 4.2 Hz, Cq), 160.1 (d, 2JC–P = 17.8 Hz, Cq), 
147.2 (CH), 137.5 (Cq), 137.5 (Cq), 135.5 (CH), 134.4 (Cq), 133.4 (d, 3JC–P = 8.7 Hz, 
Cq), 130.6 (d, 2JC–P = 15.3 Hz, CH), 129.1 (d, 1JC–P = 186.5 Hz, Cq), 128.1 (Cq), 121.6 
(CH), 120.8 (CH), 119.2 (CH), 118.4 (d, 3JC–P = 10.6 Hz, CH), 117.8 (d, 4JC–P = 3.0 Hz, 
CH), 71.6 (d, 2JC–P = 6.1 Hz, CH), 55.6 (CH3), 23.8 (d, 3JC–P = 4.2 Hz, CH3), 23.7 (d, 
3JC–P = 4.9 Hz, CH3), 22.3 (CH3). 
31P{1H} NMR (121 MHz, CDCl3) δ = 14.3 (dq, J = 14.7, 
7.3 Hz). IR (ATR): 3336, 2975, 1674, 1526, 1250, 970, 874, 682, 584, 559 cm–1. MS 
(ESI) m/z (relative intensity): 479 (100) [M+Na]+, 457 (35) [M+H]+. HR-MS (ESI) m/z 
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The general procedure G was followed using benzamide 106aj (82.5 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1→1/1) 
yielded 110k (36.0 mg, 29%) as a white solid. M.p.: 139–140 °C. 1H NMR (300 MHz, 
CDCl3) δ = 10.16 (s, 1H), 8.80 (d, J = 1.7 Hz, 1H), 8.71 (dd, J = 4.3, 1.7 Hz, 1H), 8.47–
8.30 (m, 1H), 8.11 (dd, J = 8.3, 1.7 Hz, 1H), 7.96–7.89 (m, 1H), 7.85 (dd, J = 8.1, 4.5 
Hz, 1H), 7.43 (dd, J = 8.3, 4.3 Hz, 1H), 7.39–7.36 (m, 1H), 4.80 (dhept, J = 7.7, 6.2 Hz, 
2H), 2.61 (d, J = 0.9 Hz, 3H), 1.27 (d, J = 6.2 Hz, 6H), 1.21 (d, J = 6.2 Hz, 6H). 13C NMR 
(126 MHz, CDCl3) δ = 166.1 (d, 3JC–P = 4.2 Hz, Cq), 147.3 (CH), 143.9 (d, 2JC–P = 9.0 Hz, 
Cq), 137.5 (Cq), 137.3 (Cq), 135.6 (CH), 133.9 (Cq), 131.6 (qd, 2JC–F, 3JC–P = 33.2, 
14.8 Hz, Cq), 130.4 (dq, 2JC–P, 3JC–F = 10.9, 3.6 Hz, CH), 129.2 (d, 3JC–P = 13.0 Hz, CH), 
129.0 (q, 3JC–F = 3.5 Hz, CH), 128.9 (d, 1JC–P = 189.6 Hz, Cq), 128.0 (Cq), 123.3 (qd, 
1JC–F, 4JC–P = 272.8, 2.1 Hz, Cq), 121.7 (CH), 121.3 (CH), 119.3 (CH), 72.2 (d, 2JC–P = 
6.1 Hz, CH), 23.8 (d, 3JC–P = 4.1 Hz, CH3), 23.7 (d, 3JC–P = 4.9 Hz, CH3), 22.3 (CH3). 
31P{1H} NMR (121 MHz, CDCl3) δ = 12.1 (dd, J = 14.1, 6.7 Hz). 
19F NMR (470 MHz, 
CDCl3) δ = -62.9. IR (ATR): 3343, 2981, 1681, 1538, 1329, 1127, 979, 853, 653, 
562 cm–1. MS (ESI) m/z (relative intensity): 517 (40) [M+Na]+, 495 (100) [M+H]+. HR-
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The general procedure G was followed using benzamide 106ah (70.0 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1→1/1) 
yielded 110l (60.0 mg, 54%) as a colourless oil. 1H NMR (300 MHz, CDCl3) δ = 10.12 
(s, 1H), 8.79 (d, J = 1.8 Hz, 1H), 8.71 (dd, J = 4.2, 1.7 Hz, 1H), 8.09 (dd, J = 8.3, 1.7 Hz, 
1H), 7.86–7.69 (m, 2H), 7.41 (dd, J = 8.3, 4.2 Hz, 1H), 7.37–7.29 (m, 2H), 4.78 (dhept, 
J = 7.7, 6.2 Hz, 2H), 2.60 (d, J = 0.9 Hz, 3H), 1.27 (d, J = 6.2 Hz, 6H), 1.19 (d, J = 
6.2 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ = 166.5 (d, 3JC–P = 4.2 Hz, Cq), 162.6 (dd, 
1JC–F, 3JC–P = 252.4, 20.2 Hz, Cq), 147.3 (CH), 137.5 (Cq), 137.4 (Cq), 137.1 (dd, 2JC–P, 
4JC–F = 8.6, 3.9 Hz, Cq), 135.5 (CH), 134.2 (Cq), 131.1 (dd, 3JC–F, 3JC–P = 15.3, 7.9 Hz, 
CH), 130.5 (dd, 1JC–P, 3JC–F = 187.9, 6.3 Hz, Cq), 128.1 (Cq), 121.7 (CH), 121.0 (CH), 
120.4 (dd, 2JC–F, 4JC–P = 23.2, 9.8 Hz, CH), 119.3 (CH), 119.2 (dd, 2JC–F, 2JC–P = 15.3, 
7.9 Hz, CH), 72.0 (d, 2JC–P = 6.1 Hz, CH), 23.8 (d, 3JC–P = 4.1 Hz, CH3), 23.7 (d, 3JC–P = 
4.9 Hz, CH3), 22.4 (CH3). 
31P{1H} NMR (121 MHz, CDCl3) δ = 12.3 (dp, J = 14.4, 
7.3 Hz). 19F NMR (376 MHz, CDCl3) δ = -109.4 (ddt, J = 13.9, 9.5, 4.4 Hz). IR (ATR): 
3346, 2980, 1677, 1528, 1426, 1249, 978, 855, 690, 567 cm–1. MS (ESI) m/z (relative 
intensity): 467 (100) [M+Na]+, 445 (20) [M+H]+, 381 (10). HR-MS (ESI) m/z calcd for 




The general procedure G was followed using benzamide 106k (80.0 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1→1/1) 
yielded 110m (61.8 mg, 51%) as a white solid. M.p.: 129–130 °C. 1H NMR (300 MHz, 
CDCl3) δ = 10.15 (s, 1H), 8.81 (d, J = 1.7 Hz, 1H), 8.79–8.67 (m, 2H), 8.31 (dt, J = 8.0, 
1.5 Hz, 1H), 8.09 (dd, J = 8.3, 1.7 Hz, 1H), 7.80 (dd, J = 8.0, 4.7 Hz, 1H), 7.42 (dd, J = 
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8.3, 4.2 Hz, 1H), 7.38–7.34 (m, 1H), 4.79 (dhept, J = 7.7, 6.2 Hz, 2H), 3.99 (s, 3H), 
2.62–2.59 (m, 3H), 1.26 (d, J = 6.2 Hz, 6H), 1.20 (d, J = 6.2 Hz, 6H). 13C NMR (101 MHz, 
CDCl3) δ = 166.6 (d, 3JC–P = 4.4 Hz, Cq), 165.7 (d, 4JC–P = 1.8 Hz, Cq), 147.3 (CH), 
144.5 (d, 3JC–P = 9.5 Hz, Cq), 137.6 (Cq), 137.4 (Cq), 135.6 (CH), 134.5 (d, 3JC–P = 
10.3 Hz, CH), 134.0 (Cq), 133.3 (d, 4JC–P = 2.9 Hz, CH), 131.1 (d, 2JC–P = 14.4 Hz, Cq), 
128.9 (d, 2JC–P = 13.1 Hz, CH), 128.2 (d, 1JC–P = 189.3 Hz, Cq), 128.1 (Cq), 121.7 (CH), 
121.2 (CH), 119.4 (CH), 71.9 (d, 2JC–P = 6.1 Hz, CH), 52.5 (CH3), 23.8 (d, 3JC–P = 4.2 Hz, 
CH3), 23.7 (d, 3JC–P = 4.9 Hz, CH3), 22.4 (CH3). 
31P{1H} NMR (121 MHz, CDCl3) δ = 
12.9 (dq, J = 13.1, 6.8 Hz). IR (ATR): 3353, 2983, 1720, 1683, 1530, 1244, 978, 755, 
654, 545 cm–1. MS (ESI) m/z (relative intensity): 507 (100) [M+Na]+, 485 (40) [M+H]+, 




The general procedure G was followed using benzamide 106l (76.3 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1→1/1) 
yielded 110n (63.0 mg, 54%) as a white solid. M.p.: 160–162 °C. 1H NMR (300 MHz, 
CDCl3) δ = 10.16 (s, 1H), 8.79 (d, J = 1.8 Hz, 1H), 8.71 (dd, J = 4.4, 1.6 Hz, 1H), 8.08 
(d, J = 8.2 Hz, 1H), 7.65 (dd, J = 8.6, 6.3 Hz, 1H), 7.46–7.36 (m, 2H), 7.34–7.30 (m, 
1H), 6.88 (dd, J = 8.7, 2.7 Hz, 1H), 4.86–4.65 (m, 2H), 3.09 (s, 6H), 2.59 (s, 3H), 1.28 
(d, J = 6.2 Hz, 6H), 1.18 (d, J = 6.2 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ = 168.0 (d, 
3JC–P = 4.2 Hz, Cq), 150.6 (d, 2JC–P = 16.4 Hz, Cq), 147.1 (CH), 137.6 (Cq), 137.6 (Cq), 
135.5 (CH), 134.7 (Cq), 130.5 (d, 2JC–P = 14.9 Hz, CH), 128.2 (d, 1JC–P = 185.0 Hz, Cq) 
128.1 (Cq), 127.9 (d, 3JC–P = 8.7 Hz, Cq), 121.5 (CH), 120.5 (CH), 119.3 (CH), 116.6 (d, 
3JC–P = 11.7 Hz, CH), 114.3 (d, 4JC–P = 2.9 Hz, CH), 71.3 (d, 2JC–P = 5.9 Hz, CH), 40.2 
(CH3), 23.9 (d, 3JC–P = 4.0 Hz, CH3), 23.8 (d, 3JC–P = 4.9 Hz, CH3), 22.4 (CH3). 
31P{1H} NMR (162 MHz, CDCl3) δ = 16.2 (dd, J = 16.5, 7.9 Hz). IR (ATR): 3345, 2984, 
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1664, 1527, 1233, 1003, 974, 672, 566 cm–1. MS (ESI) m/z (relative intensity): 492 
(100) [M+Na]+, 470 (40) [M+H]+, 381 (10), 273 (10). HR-MS (ESI) m/z calcd for 




The general procedure G was followed using benzamide 106ad (78.0 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1→1/1) 
yielded 110o (98.0 mg, 82%) as a white solid. M.p.: 139–141 °C. 1H NMR (400 MHz, 
CDCl3) δ = 10.17 (s, 1H), 9.04 (d, J = 2.0 Hz, 1H), 8.60 (dd, J = 4.2, 1.8 Hz, 1H), 8.18 
(d, J = 8.4 Hz, 1H), 8.11–7.99 (m, 3H), 7.93 (d, J = 8.1 Hz, 1H), 7.67–7.51 (m, 2H), 
7.39–7.36 (m, 2H), 5.00–4.52 (m, 2H), 2.65 (s, 3H), 1.33–1.07 (m, 12H). 13C NMR 
(101 MHz, CDCl3) δ = 166.5 (d, 3JC–P = 5.9 Hz, Cq), 147.1 (CH), 140.0 (d, 3JC–P = 
10.3 Hz, Cq), 137.7 (Cq), 137.3 (Cq), 135.5 (CH), 135.0 (d, 4JC–P = 2.5 Hz, Cq), 134.4 
(Cq), 130.1 (d, 2JC–P = 15.1 Hz, Cq), 129.1 (d, 2JC–P = 13.8 Hz, CH), 128.3 (CH), 128.1 
(Cq), 128.0 (CH), 127.7 (CH), 127.6 (d, 3JC–P = 9.1 Hz, CH), 126.6 (CH), 124.3 (d, 
1JC-P = 186.9 Hz, Cq), 121.6 (CH), 120.9 (CH), 119.1 (CH), 71.4 (d, 2JC–P = 30.4 Hz, 
CH), 23.9 (CH3), 23.8 (d, 3JC–P = 4.8 Hz, CH3), 22.4 (CH3). 
31P{1H} NMR (162 MHz, 
CDCl3) δ = 14.3 (dtd, J = 11.8, 7.4, 4.0 Hz). IR (ATR): 3335, 2975, 1668, 1524, 1245, 
976, 868, 682, 530 cm–1. MS (ESI) m/z (relative intensity): 499 (5) [M+Na]+, 477 (100) 
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The general procedure G was followed using benzamide 106m (69.0 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1→1/1) 
yielded 110p (75.0 mg, 68%) as a white solid. M.p.: 138–140 °C. 1H NMR (300 MHz, 
CDCl3) δ = 9.93 (s, 1H), 8.90 (d, J = 1.8 Hz, 1H), 8.67 (dd, J = 4.2, 1.7 Hz, 1H), 8.08 
(dd, J = 8.3, 1.7 Hz, 1H), 7.96–7.85 (m, 1H), 7.49–7.42 (m, 2H), 7.39 (dd, J = 8.3, 
4.2 Hz, 1H), 7.35–7.32 (m, 1H), 4.71 (dhept, J = 7.6, 6.2 Hz, 2H), 2.60 (d, J = 0.9 Hz, 
3H), 2.47 (s, 3H), 1.21 (d, J = 6.2 Hz, 6H), 1.13 (d, J = 6.2 Hz, 6H). 13C NMR (101 MHz, 
CDCl3) δ = 166.9 (d, 3JC–P = 4.9 Hz, Cq), 147.1 (CH), 140.1 (d, 3JC–P = 10.0 Hz, Cq), 
137.6 (Cq), 137.3 (Cq), 136.2 (d, 2JC–P = 13.2 Hz, Cq), 135.5 (CH), 134.3 (d, 4JC–P = 
3.0 Hz, CH), 134.3 (Cq), 130.7 (d, 3JC–P = 9.1 Hz, CH), 128.6 (d, 2JC–P = 15.2 Hz, CH), 
128.0 (Cq), 127.1 (d, 1JC–P = 187.3 Hz, Cq), 121.6 (CH), 120.8 (CH), 119.0 (CH), 71.2 
(d, 2JC–P = 6.1 Hz, CH), 23.8 (d, 3JC–P = 4.1 Hz, CH3), 23.7 (d, 3JC–P = 4.8 Hz, CH3), 19.6 
(d, 4JC–P = 1.5 Hz, CH3). 
31P{1H} NMR (121 MHz, CDCl3) δ = 15.0–14.7 (m). IR (ATR): 
3366, 2977, 1674, 1526, 1249, 967, 869, 659, 611 cm–1. MS (ESI) m/z (relative 
intensity): 463 (100) [M+Na]+, 441 (25) [M+H]+, 381 (20). HR-MS (ESI) m/z calcd for 




The general procedure G was followed using benzamide 106n (73.0 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1→1/1) 
yielded 110q (98.0 mg, 86%) as a white solid. M.p.: 151–153 °C. 1H NMR (300 MHz, 
CDCl3) δ = 10.11 (s, 1H), 8.80 (d, J = 1.9 Hz, 1H), 8.69 (dd, J = 4.2, 1.7 Hz, 1H), 8.11–
7.96 (m, 2H), 7.39 (dd, J = 8.3, 4.2 Hz, 1H), 7.36–7.30 (m, 1H), 7.21 (dd, J = 4.1, 
2.6 Hz, 1H), 7.05 (dt, J = 8.6, 2.6 Hz, 1H), 4.72 (dhept, J = 7.7, 6.2 Hz, 2H), 3.88 (s, 
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3H), 2.58 (d, J = 1.0 Hz, 3H), 1.24 (d, J = 6.2 Hz, 6H), 1.14 (d, J = 6.2 Hz, 6H). 13C NMR 
(101 MHz, CDCl3) δ = 167.1 (d, 3JC–P = 4.2 Hz, Cq), 162.4 (d, 4JC–P = 3.2 Hz, Cq), 147.3 
(CH), 142.8 (d, 2JC–P = 10.7 Hz, Cq), 137.5 (Cq), 137.5 (Cq), 135.6 (d, 3JC–P = 10.7 Hz, 
CH), 135.5 (CH), 134.2 (Cq), 128.0 (Cq), 121.6 (CH), 120.9 (CH), 119.3 (CH), 118.6 (d, 
1JC–P = 195.0 Hz, Cq), 115.0 (d, 2JC–P = 15.2 Hz, CH), 114.1 (d, 3JC–P = 14.1 Hz, CH), 
71.2 (d, 2JC–P = 5.9 Hz, CH), 55.5 (CH3), 23.8 (d, 3JC–P = 4.2 Hz, CH3), 23.7 (d, 3JC–P = 
4.8 Hz, CH3), 22.3 (CH3). 
31P{1H} NMR (121 MHz, CDCl3) δ = 15.2. IR (ATR): 3329, 
2975, 1669, 1528, 1260, 973, 867, 556, 530 cm–1. MS (ESI) m/z (relative intensity): 
479 (100) [M+Na]+, 457 (35) [M+H]+. HR-MS (ESI) m/z calcd for C24H30N2O5P [M+H]+: 




The general procedure G was followed using benzamide 106o (69.0 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1→1/1) 
yielded 110r (75.2 mg, 68%) as a white solid. M.p.: 116–118 °C. 1H NMR (400 MHz, 
CDCl3) δ = 10.08 (s, 1H), 8.82 (d, J = 1.8 Hz, 1H), 8.70 (dd, J = 4.1, 1.6 Hz, 1H), 8.08 
(dt, J = 8.3, 1.4 Hz, 1H), 8.02–7.94 (m, 1H), 7.52 (d, J = 4.7 Hz, 1H), 7.45–7.36 (m, 
2H), 7.35–7.31 (m, 1H), 4.78–4.70 (m, 2H), 2.60 (s, 3H), 2.46 (s, 3H), 1.24 (d, J = 
6.2 Hz, 6H), 1.16 (d, J = 6.2 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ = 167.6 (d, 3JC–P = 
4.5 Hz, Cq), 147.2 (CH), 143.0 (d, 4JC–P = 3.0 Hz, Cq), 140.9 (d, 2JC–P = 9.7 Hz, Cq), 
137.5 (Cq), 137.5 (Cq), 135.5 (CH), 134.3 (Cq), 133.6 (d, 3JC–P = 9.8 Hz, CH), 130.1 (d, 
2JC–P = 14.6 Hz, CH), 129.3 (d, 3JC–P = 13.4 Hz, CH), 128.0 (Cq), 124.1 (d, 1JC–P = 
190.4 Hz, Cq), 121.6 (CH), 120.8 (CH), 119.2 (CH), 71.3 (d, 2JC–P = 6.0 Hz), 23.8 (d, 
3JC–P = 4.1 Hz, CH3), 23.7 (d, 3JC–P = 4.9 Hz, CH3), 22.4 (CH3), 21.5 (d, 5JC–P = 1.4 Hz). 
31P{1H} NMR (162 MHz, CDCl3) δ = 15.0 (d, J = 12.9 Hz). IR (ATR): 3349, 2984, 1680, 
1527, 1232, 1000, 975, 859, 661, 539 cm–1. MS (ESI) m/z (relative intensity): 463 (100) 
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[M+Na]+, 441 (30) [M+H]+, 381 (5). HR-MS (ESI) m/z calcd for C24H30N2O4P [M+H]+: 




The general procedure G was followed using benzamide 106q (80.5 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1→1/1) 
yielded 110t (98.0 mg, 81%) as a white solid. M.p.: 153–155 °C. 1H NMR (300 MHz, 
CDCl3) δ = 10.14 (s, 1H), 8.77 (d, J = 1.8 Hz, 1H), 8.70 (dd, J = 4.2, 1.7 Hz, 1H), 8.07 
(dd, J = 8.3, 1.7 Hz, 1H), 7.55 (d, J = 14.7 Hz, 1H), 7.40 (dd, J = 8.3, 4.2 Hz, 1H), 7.36–
7.30 (m, 1H), 7.22 (d, J = 4.9 Hz, 1H), 4.85–4.63 (m, 2H), 4.00 (s, 3H), 3.94 (s, 3H), 
2.59 (s, 3H), 1.26 (d, J = 6.2 Hz, 6H), 1.12 (d, J = 6.2 Hz, 6H). 13C NMR (101 MHz, 
CDCl3) δ = 167.3 (d, 3JC–P = 4.2 Hz, Cq), 151.7 (d, 4JC–P = 2.9 Hz, Cq), 149.3 (d, 2JC–P = 
17.6 Hz, Cq), 147.3 (CH), 137.6 (Cq), 137.5 (Cq), 135.5 (CH), 134.7 (d, 3JC–P = 9.3 Hz, 
Cq), 134.3 (Cq), 128.1 (Cq), 121.6 (CH), 121.0 (CH), 119.3 (CH), 119.0 (d, 1JC–P = 
193.3 Hz, Cq), 115.5 (d, 3JC–P = 11.9 Hz, CH), 112.0 (d, 2JC–P = 16.2 Hz, CH), 71.4 (d, 
2JC–P = 5.7 Hz, CH), 56.3 (CH3), 56.1 (CH3), 23.8 (d, 3JC–P = 3.9 Hz, CH3), 22.4 (CH3). 
31P{1H} NMR (162 MHz, CDCl3) δ = 15.3 (dq, J = 14.0, 7.1 Hz). IR (ATR): 3345, 2977, 
1671, 1530, 1510, 1268, 1213, 977, 575, 537 cm–1. MS (ESI) m/z (relative intensity): 
509 (35) [M+Na]+, 487 (100) [M+H]+. HR-MS (ESI) m/z calcd for C25H32N2O6P [M+H]+: 
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The general procedure G was followed using benzamide 106r (76.5 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1→1/1) 
yielded 110u (67.8 mg, 58%) as a white solid. M.p.: 139–141 °C. 1H NMR (400 MHz, 
CDCl3) δ = 10.09 (s, 1H), 8.77 (d, J = 1.8 Hz, 1H), 8.71 (dd, J = 4.2, 1.7 Hz, 1H), 8.08 
(dd, J = 8.3, 1.7 Hz, 1H), 7.51 (d, J = 13.8 Hz, 1H), 7.41 (dd, J = 8.3, 4.2 Hz, 1H), 7.35–
7.32 (m, 1H), 7.16 (d, J = 4.4 Hz, 1H), 6.11 (s, 2H), 4.73 (dhept, J = 7.6, 6.2 Hz, 2H), 
2.59 (s, 3H), 1.26 (d, J = 6.2 Hz, 6H), 1.16 (d, J = 6.2 Hz, 6H). 13C NMR (101 MHz, 
CDCl3) δ = 166.7 (d, 3JC–P = 4.8 Hz, Cq), 150.6 (d, 4JC–P = 3.3 Hz, Cq), 148.4 (d, 2JC–P = 
21.4 Hz, Cq), 147.2 (CH), 137.5 (Cq), 137.5 (Cq), 136.7 (d, 3JC–P = 10.4 Hz, Cq), 135.5 
(CH), 134.2 (Cq), 128.1 (Cq), 121.6 (CH), 121.3 (d, 1JC–P = 192.3 Hz, Cq), 120.9 (CH), 
119.3 (CH), 112.9 (d, 3JC–P = 11.4 Hz, CH), 109.4 (d, 2JC–P = 16.5 Hz, CH), 102.2 (CH2), 
71.5 (d, 2JC–P = 6.0 Hz, CH), 23.8 (d, 3JC–P = 3.8 Hz, CH3), 23.7 (d, 3JC–P = 4.4 Hz, CH3), 
22.3 (CH3). 
31P{1H} NMR (162 MHz, CDCl3) δ = 14.4 (dp, J = 12.4, 4.6, 4.0 Hz). IR 
(ATR): 3258, 2978, 1661, 1526, 1485, 1242, 967,768, 581, 523 cm–1. MS (ESI) m/z 
(relative intensity): 493 (100) [M+Na]+, 471 (30) [M+H]+. HR-MS (ESI) m/z calcd for 




The general procedure G was followed using benzamide 106s (67.0 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol) under 
a constant current of 8.0 mA for 5.0 h. Purification by column chromatography on silica 
gel (nhexane/EtOAc: 4/1→1/1) yielded 110v (85.0 mg, 79%) as a white solid. M.p.: 
119–120 °C. 1H NMR (400 MHz, CDCl3) δ = 10.54 (s, 1H), 8.77 (dd, J = 4.2, 1.7 Hz, 
1H), 8.73 (d, J = 1.8 Hz, 1H), 8.08 (dd, J = 8.3, 1.7 Hz, 1H), 7.69–7.64 (m, 1H), 7.63–
7.59 (m, 1H), 7.42 (dd, J = 8.3, 4.2 Hz, 1H), 7.37–7.33 (m, 1H), 4.83 (dhept, J = 7.9, 
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6.2 Hz, 2H), 2.59 (s, 3H), 1.32 (d, J = 6.3 Hz, 6H), 1.30 (d, J = 6.3 Hz, 8H). 13C NMR 
(101 MHz, CDCl3) δ = 161.9 (d, 3JC–P = 2.8 Hz, Cq), 147.5 (CH), 144.0 (d, 2JC–P = 
10.9 Hz, Cq), 137.9 (Cq), 137.4 (Cq), 135.5 (CH), 134.1 (Cq), 131.9 (d, 3JC–P = 7.6 Hz, 
CH), 130.5 (d, 3JC–P = 16.4 Hz, CH), 130.2 (d, 1JC–P = 206.4 Hz, Cq), 128.1 (Cq), 121.7 
(CH), 121.3 (CH), 120.0 (CH), 72.4 (d, 2JC–P = 5.8 Hz, CH), 24.0 (d, 3JC–P = 4.1 Hz, 
CH3), 23.6 (d, 3JC–P = 5.0 Hz, CH3), 22.2 (CH3). 
31P{1H} NMR (162 MHz, CDCl3) δ = 
7.1 (tt, J = 8.5, 4.6 Hz). IR (ATR): 3077, 2980, 1662, 1533, 1250, 982, 854, 545, 
529 cm–1. MS (ESI) m/z (relative intensity): 455 (100) [M+Na]+, 433 (40) [M+H]+. 
HR-MS (ESI) m/z calcd for C21H26N2O4PS [M+H]+: 433.1345, found: 433.1349. 
 
Diisopropyl {3-[(6-methylquinolin-8-yl)carbamoyl]furan-2-yl}phosphonate (110w) 
The general procedure G was followed using benzamide 106t (63.0 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol) under 
a constant current of 8.0 mA for 5.0 h. Purification by column chromatography on silica 
gel (nhexane/EtOAc: 4/1→1/1) yielded 110w (42.0 mg, 40%) as a white solid. M.p.: 
94–96 °C. 1H NMR (400 MHz, CDCl3) δ = 11.21 (s, 1H), 8.74 (dd, J = 4.2, 1.7 Hz, 1H), 
8.64 (d, J = 1.8 Hz, 1H), 8.02 (dd, J = 8.3, 1.7 Hz, 1H), 7.64 (dd, J = 2.8, 1.7 Hz, 1H), 
7.36 (dd, J = 8.3, 4.2 Hz, 1H), 7.31 (dt, J = 1.8, 0.9 Hz, 1H), 7.02 (dd, J = 2.4, 1.7 Hz, 
1H), 4.86 (dhept, J = 8.0, 6.2 Hz, 2H), 2.53 (d, J = 0.9 Hz, 3H), 1.37 (d, J = 6.2 Hz, 6H), 
1.27 (d, J = 6.2 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ = 159.9 (Cq), 147.6 (CH), 146.3 
(CH), 146.2 (CH), 143.4 (d, 1JC–P = 233.5 Hz, Cq), 138.4 (Cq), 137.1 (Cq), 135.3 (CH), 
134.2 (Cq), 133.1 (d, 2JC–P = 23.8 Hz, Cq), 128.2 (Cq), 121.5 (d, 3JC–P = 5.3 Hz, CH), 
121.0 (CH), 113.0 (d, 3JC–P = 10.1 Hz, CH), 72.7 (d, 2JC–P = 5.4 Hz, CH, CH3), 24.0 (d, 
3JC–P = 4.1 Hz), 23.6 (d, 3JC–P = 5.0 Hz, CH3), 22.2 (CH3). 
31P{1H} NMR (162 MHz, 
CDCl3) δ = 0.8 (t, J = 8.2 Hz). IR (ATR): 3115, 2982, 1667, 1537, 1255, 1001, 855, 748, 
557, 530 cm–1. MS (ESI) m/z (relative intensity): 439 (100) [M+Na]+, 417 (50) [M+H]+. 
HR-MS (ESI) m/z calcd for C21H26N2O5P [M+H]+: 417.1574, found: 417.1576. 






The general procedure G was followed using benzamide 106ao (84.8 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1→1/1) 
yielded 110x (65.3 mg, 52%) as a white solid. M.p.: 166–168 °C. 1H NMR (300 MHz, 
CDCl3) δ = 10.18 (s, 1H), 8.84 (d, J = 1.8 Hz, 1H), 8.76 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 
8.72 (dd, J = 3.6, 1.8 Hz, 1H), 8.69 (dd, J = 7.1, 1.8 Hz, 1H), 8.43–8.32 (m, 1H), 8.09 
(dd, J = 8.3, 1.8 Hz, 1H), 7.91–7.78 (m, 3H), 7.41 (dd, J = 8.3, 4.2 Hz, 1H), 7.35 (s, 
1H), 7.32 (ddd, J = 7.3, 4.8, 1.4 Hz, 1H), 4.80 (dhept, J = 7.7, 6.2 Hz, 2H), 2.61 (d, J = 
1.0 Hz, 3H), 1.28 (d, J = 6.2 Hz, 6H), 1.20 (d, J = 6.2 Hz, 6H). 13C NMR (101 MHz, 
CDCl3) δ = 167.2 (d, 3JC–P = 4.3 Hz, Cq), 155.5 (d, 4JC–P = 1.4 Hz, Cq), 149.9 (CH), 
147.3 (CH), 141.0 (d, 3JC–P = 9.3 Hz, Cq), 140.4 (d, 2JC–P = 14.2 Hz, Cq), 137.5 (Cq), 
137.5 (Cq), 136.9 (CH), 135.5 (CH), 134.3 (Cq), 131.9 (d, 3JC–P = 10.4 Hz, CH), 130.6 
(d, 4JC–P = 3.0 Hz, CH), 129.3 (d, 2JC–P = 13.4 Hz, CH), 128.1 (Cq), 127.9 (d, 1JC–P = 
188.0 Hz, Cq), 122.9 (CH), 121.6 (CH), 120.9 (CH), 120.8 (CH), 119.2 (CH), 71.6 (d, 
2JC–P = 6.0 Hz, CH), 23.9 (d, 3JC–P = 4.0 Hz, CH3), 23.8 (d, 3JC–P = 4.9 Hz, CH3), 22.4 
(CH3). 
31P{1H} NMR (121 MHz, CDCl3) δ = 14.3 (dq, J = 13.9, 7.1 Hz). IR (ATR): 3342, 
2982, 1665, 1528, 1234, 978, 852, 762, 654, 560 cm–1. MS (ESI) m/z (relative intensity): 
526 (100) [M+Na]+, 504 (35) [M+H]+. HR-MS (ESI) m/z calcd for C28H31N3O4P [M+H]+: 
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The general procedure G was followed using benzamide 106u (97.8 mg, 1.0 equiv, 
0.25 mmol), diisopropyl phosphonate (74a) (124 mg, 3.0 equiv, 0.75 mmol), 
Ni(DME)Cl2 (11.0 mg, 20 mol %) and [3,5-(CF3)2C6H3]3P (67.0 mg, 40 mol %). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 2/1→1/1→1/2) 
yielded 110y (98.7 mg, 71%) as a white solid. M.p.: 70–72 °C. 1H NMR (400 MHz, 
CDCl3) δ = 10.08 (s, 1H), 8.74 (d, J = 1.8 Hz, 1H), 8.64 (dd, J = 4.2, 1.7 Hz, 1H), 8.44 
(dd, J = 14.4, 1.8 Hz, 1H), 8.13–8.09 (m, 1H), 8.04 (dd, J = 8.3, 1.7 Hz, 1H), 7.74 (dd, 
J = 8.0, 4.6 Hz, 1H), 7.36 (dd, J = 8.3, 4.2 Hz, 1H), 7.30 (dd, J = 1.8, 1.0 Hz, 1H), 7.01 
(d, J = 7.2 Hz, 1H), 4.80 (q, J = 7.2 Hz, 1H), 4.77–4.65 (m, 2H), 3.76 (s, 3H), 2.55 (d, 
J = 1.0 Hz, 3H), 1.53 (d, J = 7.2 Hz, 3H), 1.21 (dd, J = 6.2, 1.9 Hz, 6H), 1.13 (dd, J = 
6.2, 2.3 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ = 173.2 (Cq), 166.4 (d, 3JC–P = 4.2 Hz, 
Cq), 165.2 (Cq), 147.3 (CH), 143.5 (d, 3JC–P = 9.2 Hz, Cq), 137.5 (Cq), 137.3 (Cq), 135.5 
(CH), 134.8 (d, 2JC–P = 13.6 Hz, Cq), 134.0 (Cq), 131.6 (d, 3JC–P = 10.3 Hz, CH), 131.4 
(d, 4JC–P = 2.8 Hz, CH), 129.1 (d, 2JC–P = 13.0 Hz, CH), 128.0 (Cq), 128.0 (d, 1JC–P = 
188.7 Hz, Cq), 121.7 (CH), 121.1 (CH), 119.2 (CH), 71.9 (d, 2JC–P = 6.1 Hz, CH), 52.5 
(CH), 48.7 (CH3), 23.7 (d, 3JC–P = 3.7 Hz, CH3), 23.6 (d, 3JC–P = 2.4 Hz, CH3), 22.3 (CH3), 
18.3 (CH3). 
31P{1H} NMR (121 MHz, CDCl3) δ = 13.1 (dt, J = 13.1, 6.8 Hz). IR (ATR): 
3336, 2980, 1745, 1663, 1527, 1234, 982, 891, 856, 564 cm–1. MS (ESI) m/z (relative 
intensity): 578 (60) [M+Na]+, 556 (100) [M+H]+. HR-MS (ESI) m/z calcd for 




The general procedure G was followed using benzamide 106v (66.5 mg, 1.0 equiv, 
0.25 mmol) and diisopropyl phosphonate (74a) (83.0 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 4/1→1/1) 
yielded 110z (59.0 mg, 55%) as a white solid. M.p.: 113–115 °C. 1H NMR (400 MHz, 
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CDCl3) δ = 9.85 (s, 1H), 8.78–8.70 (m, 2H), 8.06 (d, J = 8.2 Hz, 1H), 7.40 (dd, J = 8.2, 
4.2 Hz, 1H), 7.29 (d, J = 3.2 Hz, 1H), 4.86–4.56 (m, 2H), 2.58 (dt, J = 7.2, 3.4 Hz, 2H), 
2.55 (s, 3H), 2.40 (tt, J = 5.6, 3.0 Hz, 2H), 1.81–1.72 (m, 4H), 1.27 (d, J = 6.2 Hz, 6H), 
1.18 (d, J = 6.2 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ = 169.1 (d, 3JC–P = 9.6 Hz, Cq), 
148.2 (d, 2JC–P = 8.4 Hz, Cq), 147.0 (CH), 137.6 (Cq), 137.3 (Cq), 135.5 (CH), 134.3 
(Cq), 128.1 (Cq), 126.4 (d, 1JC–P = 180.1 Hz, Cq), 121.5 (CH), 120.6 (CH), 119.0 (CH), 
70.6 (d, 2JC–P = 6.0 Hz, CH), 29.1 (d, 2JC–P = 15.9 Hz, CH2), 25.9 (d, 3JC–P = 8.5 Hz, 
CH2), 23.9 (d, 3JC–P = 4.0 Hz, CH3), 23.8 (d, 3JC–P = 4.9 Hz, CH3), 22.3 (CH3), 21.6 (d, 
3JC–P = 9.3 Hz, CH2), 21.4 (d, 4JC–P = 1.4 Hz, CH2). 
31P{1H} NMR (162 MHz, CDCl3) δ = 
14.0. IR (ATR): 3354, 2981, 1672, 1525, 1255, 974, 870, 665, 580 cm–1. MS (ESI) m/z 
(relative intensity): 453 (25) [M+Na]+, 431 (100) [M+H]+, 369 (10). HR-MS (ESI) m/z 




The general procedure G was followed using benzamide 106n (73.0 mg, 1.0 equiv, 
0.25 mmol) and diethyl phosphonate (74b) (69.0 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 2/1→1/1) 
yielded 110ab (62.0 mg, 58%) as a white solid. M.p.: 132–134 °C. 1H NMR (300 MHz, 
CDCl3) δ = 10.17 (s, 1H), 8.82 (d, J = 1.8 Hz, 1H), 8.70 (dd, J = 4.2, 1.7 Hz, 1H), 8.19–
7.94 (m, 2H), 7.41 (dd, J = 8.3, 4.2 Hz, 1H), 7.35 (dd, J = 1.8, 1.0 Hz, 1H), 7.24 (dd, 
J = 4.2, 2.6 Hz, 1H), 7.08 (dt, J = 8.6, 2.6 Hz, 1H), 4.16–3.99 (m, 4H), 3.91 (s, 3H), 
2.60 (d, J = 1.0 Hz, 3H), 1.24–1.17 (m, 6H). 13C NMR (101 MHz, CDCl3) δ = 167.0 (d, 
3JC–P = 4.4 Hz, Cq), 162.8 (d, 4JC–P = 3.2 Hz, Cq), 147.2 (CH), 142.9 (d, 2JC–P = 11.0 Hz, 
Cq), 137.6 (Cq), 137.4 (Cq), 136.1 (d, 3JC–P = 10.6 Hz, CH), 135.6 (CH), 134.2 (Cq), 
128.1 (Cq), 121.7 (CH), 121.0 (CH), 119.1 (CH), 116.9 (d, 1JC–P = 193.6 Hz, Cq), 115.1 
(d, 2JC–P = 15.2 Hz, CH), 114.1 (d, 3JC–P = 14.1 Hz, CH), 62.4 (d, 2JC–P = 5.6 Hz, CH2), 
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55.6 (CH3), 22.4 (CH3), 16.1 (d, 3JC–P = 6.4 Hz, CH3). 
31P{1H} NMR (121 MHz, CDCl3) 
δ = 17.4 (ddp, J = 12.1, 7.9, 3.7 Hz). IR (ATR): 3300, 2984, 1656, 1533, 1252, 1023, 
959, 819, 672, 554 cm–1. MS (ESI) m/z (relative intensity): 451 (80) [M+Na]+, 429 (100) 




The general procedure G was followed using benzamide 106n (73.0 mg, 1.0 equiv, 
0.25 mmol) and 1,3,2-dioxaphosphinane 2-oxide (74g) (61.0 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 2/1→1/1) 
yielded 110ag (54.7 mg, 53%) as a white solid. M.p.: 194–196 °C. 1H NMR (300 MHz, 
CDCl3) δ = 10.29 (s, 1H), 8.82 (d, J = 1.8 Hz, 1H), 8.72 (dd, J = 4.3, 1.6 Hz, 1H), 8.07 
(dd, J = 8.3, 1.6 Hz, 1H), 8.00 (dd, J = 13.6, 8.6 Hz, 1H), 7.40 (dd, J = 8.3, 4.2 Hz, 1H), 
7.36–7.33 (s, 1H), 7.25 (dd, J = 4.2, 2.5 Hz, 1H), 7.09 (dt, J = 8.6, 2.5 Hz, 1H), 4.58–
4.44 (m, 2H), 4.16 (tt, J = 11.3, 5.4 Hz, 2H), 3.90 (s, 3H), 2.59 (s, 3H), 1.92–1.82 (m, 
2H). 13C NMR (101 MHz, CDCl3) δ = 166.8 (d, 3JC–P = 4.2 Hz, Cq), 163.1 (d, 4JC–P = 
3.0 Hz, Cq), 147.6 (CH), 143.0 (d, 2JC–P = 11.2 Hz, Cq), 137.4 (Cq), 137.3 (Cq), 136.1 (d, 
3JC–P = 10.8 Hz, CH), 135.5 (CH), 134.1 (Cq), 128.1 (Cq), 121.8 (CH), 121.3 (CH), 119.0 
(CH), 115.4 (d, 1JC–P = 194.7 Hz, Cq), 115.2 (d, 2JC–P = 15.5 Hz, CH), 114.4 (d, 3JC–P = 
14.2 Hz, CH), 66.8 (d, 2JC–P = 6.2 Hz, CH2), 55.7 (CH3), 25.9 (d, 3JC–P = 7.9 Hz, CH2), 
22.4 (CH3). 
31P{1H} NMR (162 MHz, CDCl3) δ = 13.7. IR (ATR): 3330, 1673, 1524, 
1268, 1057, 1046, 931, 819, 776, 681, 586, 525 cm–1. MS (ESI) m/z (relative intensity): 
435 (50) [M+Na]+, 413 (100) [M+H]+. HR-MS (ESI) m/z calcd for C21H22N2O5P [M+H]+: 
413.1261, found: 413.1263. 






The general procedure G was followed using benzamide 106n (73.0 mg, 1.0 equiv, 
0.25 mmol) and 5,5-dimethyl-1,3,2-dioxaphosphinane 2-oxide (74h) (75.0 mg, 2.0 
equiv, 0.50 mmol). Purification by column chromatography on silica gel 
(nhexane/EtOAc: 2/1→1/1) yielded 110ah (63.8 mg, 58%) as a white solid. M.p.: 156–
158 °C. 1H NMR (400 MHz, CDCl3) δ = 10.37 (s, 1H), 8.76 (d, J = 1.8 Hz, 1H), 8.73 
(dd, J = 4.2, 1.6 Hz, 1H), 8.05 (dd, J = 8.3, 1.6 Hz, 1H), 7.83 (dd, J = 13.0, 8.6 Hz, 1H), 
7.38 (dd, J = 8.3, 4.2 Hz, 1H), 7.35–7.31 (m, 1H), 7.30 (dt, J = 4.4, 2.2 Hz, 1H), 7.11 
(dt, J = 8.6, 2.6 Hz, 1H), 4.09–4.01 (m, 2H), 3.91 (s, 3H), 3.94–3.84 (m, 2H), 2.57 (s, 
3H), 1.18 (s, 3H), 0.87 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 166.7 (d, 3JC–P = 4.4 Hz, 
Cq), 162.8 (d, 4JC–P = 3.2 Hz, Cq), 147.5 (CH), 143.2 (d, 2JC–P = 12.1 Hz, Cq), 137.4 (Cq), 
137.3 (Cq), 135.5 (CH), 134.6 (d, 3JC–P = 10.1 Hz, CH), 134.0 (Cq), 128.1 (Cq), 121.7 
(CH), 121.3 (CH), 119.4 (CH), 115.9 (d, 2JC–P = 14.9 Hz, CH), 115.2 (d, 1JC–P = 187.7 Hz, 
Cq), 114.2 (d, 3JC–P = 14.2 Hz, CH), 76.8 (d, 2JC–P = 6.4 Hz, CH2), 55.7 (CH3), 32.4 (d, 
3JC–P = 6.4 Hz, Cq), 22.3 (CH3), 21.9 (CH3), 21.0 (CH3). 
31P{1H} NMR (162 MHz, CDCl3) 
δ = 11.8. IR (ATR):3340, 2969, 1675, 1526, 1276, 1055, 1004, 788, 509, 471 cm–1. MS 
(ESI) m/z (relative intensity): 463 (35) [M+Na]+, 441 (100) [M+H]+. HR-MS (ESI) m/z 
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The general procedure G was followed using benzamide 106n (73.0 mg, 1.0 equiv, 
0.25 mmol) and 4,4,7,7-tetramethyl-1,3,2-dioxaphosphepane 2-oxide (74i) (96.0 mg, 
2.0 equiv, 0.50 mmol). Purification by column chromatography on silica gel 
(nhexane/EtOAc: 2/1→1/1) yielded 110ai (87.0 mg, 72%) as a white solid. M.p.: 189–
191 °C. 1H NMR (400 MHz, CDCl3) δ = 10.09 (s, 1H), 8.83 (d, J = 1.9 Hz, 1H), 8.70 
(dd, J = 4.2, 1.9 Hz, 1H), 8.08 (dt, J = 8.4, 2.0 Hz, 1H), 8.01–7.93 (m, 1H), 7.40 (ddd, 
J = 8.4, 4.2, 2.3 Hz, 1H), 7.34 (s, 1H), 7.16 (dt, J = 4.4, 2.5 Hz, 1H), 7.03 (dq, J = 8.3, 
2.6 Hz, 1H), 3.87 (s, 3H), 2.61 (d, J = 2.6 Hz, 3H), 2.18–2.07 (m, 2H), 1.87–1.76 (m, 
2H), 1.52 (t, J = 2.3 Hz, 6H), 1.18 (t, J = 1.9 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ = 
167.3 (d, 3JC–P = 4.3 Hz, Cq), 162.2 (d, 4JC–P = 3.3 Hz, Cq), 147.3 (CH), 142.4 (d, 2JC-P = 
10.6 Hz, Cq), 137.5 (Cq), 137.4 (Cq), 135.6 (CH), 135.1 (d, 3JC–P = 10.5 Hz, CH), 134.3 
(Cq), 128.1 (Cq), 121.7 (CH), 121.0 (CH), 119.5 (CH), 118.9 (d, 1JC–P = 206.9 Hz, Cq), 
114.9 (d, 2JC–P = 15.5 Hz, CH), 113.7 (d, 3JC–P = 14.4 Hz, CH), 83.3 (d, 2JC–P = 8.2 Hz, 
Cq), 55.5 (CH3), 36.5 (d, 3JC–P = 1.7 Hz, CH2), 29.7 (d, 3JC–P = 9.3 Hz, CH3), 28.4 (CH3), 
22.4 (CH3). 
31P{1H} NMR (162 MHz, CDCl3) δ = 12.6 (d, J = 13.5 Hz). IR (ATR): 3343, 
2978, 1680, 1528, 1234, 982, 954, 677, 651, 572 cm–1. MS (ESI) m/z (relative intensity): 
505 (45) [M+Na]+, 483 (100) [M+H]+. HR-MS (ESI) m/z calcd for C26H32N2O5P [M+H]+: 




The general procedure G was followed using benzamide 106n (73.0 mg, 1.0 equiv, 
0.25 mmol) and dicyclohexylphosphine oxide (74j) (107 mg, 2.0 equiv, 0.50 mmol). 
Purification by column chromatography on silica gel (nhexane/EtOAc: 2/1→1/1) 
yielded 110aj (78.5 mg, 62%) as a white solid. M.p.: 230–232 °C. 1H NMR (400 MHz, 
CDCl3) δ = 10.15 (s, 1H), 8.76–8.71 (m, 1H), 8.68 (d, J = 4.3 Hz, 1H), 8.13–8.03 (m, 
2H), 7.40 (dd, J = 8.3, 4.3 Hz, 1H), 7.36–8.30 (s, 1H), 7.27 (q, J = 3.4, 2.6 Hz, 1H), 
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7.12 (dd, J = 8.6, 2.6 Hz, 1H), 3.90 (s, 3H), 2.60 (s, 3H), 2.32–2.19 (m, 2H), 2.15–2.01 
(m, 2H), 1.86–1.73 (m, 2H), 1.68–0.97 (m, 16H). 13C NMR (101 MHz, CDCl3) δ = 167.5 
(Cq), 161.6 (d, 4JC–P = 2.1 Hz, Cq), 147.4 (CH), 141.2 (d, 2JC–P = 7.6 Hz, Cq), 137.5 (Cq), 
137.3 (Cq), 136.4 (d, 3JC–P = 6.6 Hz, CH), 135.6 (CH), 134.0 (Cq), 128.0 (Cq), 121.8 
(CH), 121.4 (d, 1JC–P = 81.8 Hz, Cq), 121.1 (CH), 118.7 (CH), 114.6 (d, 2JC–P = 10.2 Hz, 
CH), 113.9 (d, 3JC–P = 9.1 Hz, CH), 55.5 (CH3), 37.6 (d, 1JC–P = 67.3 Hz, CH), 26.5 (d, 
2JC–P = 7.2 Hz, CH2), 26.5 (d, 3JC–P = 3.0 Hz, CH2), 26.4 (d, 2JC–P = 6.4 Hz, CH2), 26.3 
(d, 3JC–P = 3.0 Hz, CH2), 25.8 (CH2), 22.4 (CH3). 
31P{1H} NMR (162 MHz, CDCl3) δ = 
49.1. IR (ATR): 3347, 2920, 2850, 1679, 1524, 1447, 1279, 1152, 848, 575, 491 cm–1. 
MS (ESI) m/z (relative intensity): 527 (100) [M+Na]+, 505 (95) [M+H]+, 401 (70), 379 




The general procedure G was followed using benzamide 106n (73.0 mg, 1.0 equiv, 
0.25 mmol) and tert-butyl(phenyl)phosphine oxide (74k) (91.0 mg, 2.0 equiv, 
0.50 mmol). Purification by column chromatography on silica gel (nhexane/EtOAc: 
2/1→1/1) yielded 110ak (63.0 mg, 53%) as a white solid. M.p.: 263–265 °C. 1H NMR 
(300 MHz, CDCl3) δ = 10.01 (s, 1H), 8.60 (dd, J = 4.2, 1.6 Hz, 1H), 8.22 (d, J = 1.8 Hz, 
1H), 8.07–7.94 (m, 2H), 7.73–7.54 (m, 2H), 7.34 (dd, J = 8.3, 4.2 Hz, 1H), 7.31–7.17 
(m, 5H), 7.09 (dt, J = 8.6, 2.2 Hz, 1H), 3.89 (s, 3H), 2.51 (s, 3H), 1.34 (d, J = 14.9 Hz, 
9H). 13C NMR (101 MHz, CDCl3) δ = 167.0 (Cq), 161.8 (d, 4JC–P = 2.4 Hz, Cq), 147.3 
(CH), 145.1 (d, 2JC–P = 7.7 Hz, Cq), 137.6 (Cq), 137.0 (Cq), 135.1 (CH), 133.7 (d, 3JC-P = 
10.5 Hz, CH), 133.7 (Cq), 132.0 (d, 3JC–P = 8.6 Hz, CH), 131.5 (d, 1JC–P = 91.4 Hz, Cq), 
130.8 (d, 4JC–P = 2.6 Hz, CH), 127.9 (Cq), 127.7 (d, 2JC–P = 11.1 Hz, CH), 121.3 (CH), 
120.8 (CH), 120.2 (d, 1JC–P = 90.4 Hz, Cq), 119.7 (CH), 115.1 (d, 3JC–P = 9.7 Hz, CH), 
114.9 (d, 2JC–P = 11.5 Hz, CH), 55.5 (CH3), 34.4 (d, 1JC–P = 71.2 Hz, Cq), 25.9 (CH3), 




31P{1H} NMR (121 MHz, CDCl3) δ = 41.2. IR (ATR): 3356, 2971, 1683, 
1523, 1090, 757, 671, 535 cm–1. MS (ESI) m/z (relative intensity): 495 (5) [M+Na]+, 
473 (45) [M+H]+, 401 (60), 379 (100). HR-MS (ESI) m/z calcd for C28H30N2O3P [M+H]+: 




The general procedure G was followed using benzamide 106n (73.0 mg, 1.0 equiv, 
0.25 mmol) and 1,3-diphenyl-1,3,2-diazaphospholidine 2-oxide (74l) (129 mg, 
2.0 equiv, 0.50 mmol). Purification by column chromatography on silica gel 
(nhexane/EtOAc: 2/1→1/1) yielded 110al (98.8 mg, 72%) as a white solid. M.p.: 236–
238 °C. 1H NMR (400 MHz, CDCl3) δ = 9.51 (s, 1H), 8.76 (d, J = 1.8 Hz, 1H), 8.56–
8.47 (m, 1H), 8.29 (dt, J = 5.1, 2.4 Hz, 1H), 8.03 (dd, J = 8.1, 1.7 Hz, 1H), 7.36–7.30 
(m, 2H), 7.11 (dt, J = 8.8, 2.6 Hz, 1H), 7.04–6.96 (m, 9H), 6.81–6.75 (m, 2H), 3.93 (dt, 
J = 8.2, 3.9 Hz, 2H), 3.85 (s, 3H), 3.78–3.68 (m, 2H), 2.63 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ = 167.2 (d, 3JC–P = 4.3 Hz, Cq), 162.6 (d, 4JC–P = 3.2 Hz, Cq), 147.1 (CH), 
141.9 (d, 2JC–P = 12.0 Hz, Cq), 141.2 (d, 2JC–P = 8.5 Hz, Cq), 140.2 (d, 3JC–P = 10.7 Hz, 
CH), 137.2 (Cq), 136.6 (Cq), 135.2 (CH), 134.0 (Cq), 128.9 (CH), 127.8 (Cq), 121.5 (CH), 
121.2 (CH), 121.0 (CH), 119.0 (d, 1JC–P = 162.9 Hz, Cq), 117.7 (CH), 116.2 (d, 3JC–P = 
5.0 Hz, CH), 114.6 (d, 2JC–P = 14.3 Hz, CH), 113.8 (d, 3JC–P = 13.4 Hz, CH), 55.5 (CH3), 
43.1 (d, 2JC–P = 9.7 Hz, CH2), 22.5 (CH3). 
31P{1H} NMR (162 MHz, CDCl3) δ = 14.9. IR 
(ATR): 3343, 1684, 1598, 1526, 1252, 1231, 1092, 958, 745, 678, 557, 526 cm–1. MS 
(ESI) m/z (relative intensity): 571 (20) [M+Na]+, 549 (100) [M+H]+. HR-MS (ESI) m/z 
calcd for C32H30N4O3P [M+H]+: 549.2050, found: 549.2050. 
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5.3.6.2 Mechanistic Studies 
Competitive Experiment Between Different Nucleophiles 
 
Figure 5.3.52. C–H Amination under optimized conditions. 
Before the competitive experiment between amine and phosphonating reagent, C–H 
amination experiments were carried out independently. The general procedure G was 
followed using benzamides 106a (65.5 mg, 0.25 mmol), amine 56a (43.5 mg, 
0.50 mmol, 2.0 equiv). Electrolysis was carried out at 110 °C and a constant current of 
8.0 mA was maintained for 12 h. At ambient temperature, the mixture was transferred 
into a separating funnel and the electrodes were rinsed with EtOAc (10 mL). 
Subsequently, H2O (10 mL) was added to the mixture and the organic layer was 
collected. The aqueous layer was extracted with EtOAc (2 × 5.0 mL). Evaporation of 
the combined organic layers and subsequent column chromatography on silica gel 
(eluent: nhexane/EtOAc: 10/1→4/1) yielded the desired product 107ap (81.6 mg, 94%).  
 
Figure 5.3.53. Competitive experiment between amine 56a and phosphite 74a. 
The general procedure G was followed using benzamides 106a (65.5 mg, 0.25 mmol), 
phosphonate 74a (83.0 mg, 0.50 mmol, 2.0 equiv) and amine 56a (43.5 mg, 0.50 mmol, 
2.0 equiv). Electrolysis was carried out at 110 °C and a constant current of 8.0 mA was 
maintained for 12 h. After cooling to ambient temperature, 1,3,5-(MeO)3C6H3 
(0.25 mmol) was added as the internal standard to determine the 1H NMR yield. 




Figure 5.3.54. Crude 1H NMR spectrum of competitive experiments between phosphonate 74a and amine 
56a. 
Experiments with Isotopically Labelled Solvent 
 
Figure 5.3.55. Deuteration experiment using tBuOD as the cosolvent. 
The general procedure G was followed using Ni(DME)Cl2 (5.5 mg, 0.025 mmol, 
10 mol %), [3,5-(CF3)2C6H3]3P (33.5 mg, 0.050 mmol, 20 mol %), TMG (38.4 mg, 
0.25 mmol, 1.0 equiv), nBu4NI (40.3 mg, 0.125 mmol, 50 mol %) and 74a (83.0 mg, 
0.50 mmol, 2.0 equiv) in a mixture solvent of DMA and tBuOD (3.0/0.30 mL). 
Electrolysis was carried out at 110 °C and a constant current of 8.0 mA was maintained 
for 3.0 h. Column chromatography (nhexane/EtOAc: 8/1→1/1) yielded [Dn]–110a 
(17.2 mg, 16%) as a white solid and reisolated starting material [Dn]–106a (49.3 mg, 
75%) as a white solid. No deuteration was detected in either compound as determined 
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by 1H NMR spectroscopy.  
 
Figure 5.3.56. 1H NMR spectrum of the reisolated starting materials [Dn]-106a. 
 
Figure 5.3.57. 1H NMR spectrum of the product [Dn]-110a. 
 





Figure 5.3.58. KIE studies show a large KIE value (kH/kD ≈ 3.2). 
Two parallel reactions were carried out with 106a (196 mg, 0.75 mmol, 1.0 equiv) or 
[D5]–106a (200 mg, 0.75 mmol, 1.0 equiv) following The general procedure G using 
Ni(DME)Cl2 (15.9 mg, 0.075 mmol, 10 mol %), [3,5-(CF3)2C6H3]3P (100 mg, 0.15 mmol, 
20 mol %), TMG (86.4 mg, 0.75 mmol, 1.0 equiv), nBu4NI (121 mg, 0.375 mmol, 
50 mol %) and 74a (249 mg, 1.5 mmol, 2.0 equiv) in DMA (7.0 mL). 1,3,5-
trimethoxybenzene (42.0 mg, 0.25 mmol) was added as an internal standard. Aliquots 
of 0.40 mL were removed from the cell every twenty minutes. The reaction mixture was 
extracted with EtOAc (3.0 mL). After evaporation of the solvent, the mixture was 
analyzed by 1H NMR spectroscopy. The KIE was determined by the analysis of the 
initial rates. 
Table 5.3.2. Data collecting by NMR spectroscopy. 
Time [min] 10 30 50 70 90 110 130 
110a [%] 0 6 8 10 13 16 20 
[D4]-110a [%] 0 2 2 3 4 5 6 





y = 0.04286x + 0.2381
R2 = 0.96










time (min)  
Figure 5.3.59. KIE studies show a large kH/kD value (KIE ≈ 3.2). 





 Figure 5.3.60. Headspace GC-analysis. 
Following The general procedure G, after 5.0 h, the gas–phase over the reaction 
mixture was analyzed by headspace GC analysis using an Agilent 7890B 
chromatograph equipped with an Agilent CP–Molsieve 5Å column (length: 25 m, 
diameter: 0.32 mm, temperature 10 °C). Helium was used as the carrier gas 
(1.5 mL/min) and the sample was analyzed by a temperature conductivity detector at 
110 °C. For comparison, also a blank sample of the carrier gas and a pure sample of 
hydrogen were obtained. 
 
Figure 5.3.61. Headspace analysis of the reaction mixture showed the formation of H2. 
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Switch Off-On Experiment 
“Switch off-on” reactions were carried out with benzamide 106a (196 mg, 0.75 mmol, 
1.0 equiv) following the general procedure G using Ni(DME)Cl2 (15.9 mg, 0.075 mmol, 
10 mol %), [3,5-(CF3)2C6H3]3P (100 mg, 0.15 mmol, 20 mol %), TMG (86.4 mg, 0.75 
mmol, 1.0 equiv), nBu4NI (121 mg, 0.375 mmol, 50 mol %) and 74a (249 mg, 1.5 mmol, 
10.0 equiv) in DMA (6.0 mL) with 1,3,5-trimethoxybenzene (0.25 mmol) as an internal 
standard. Aliquots of 0.40 mL were removed from the cell one and a half hours, 
quenched by addition of H2O (2.0 mL) and extracted with EtOAc (2 x 3.0 mL). 
Subsequently, the solvent was evaporated from each sample and the resulted crude 
mixtures were analyzed by 1H NMR spectroscopy. 
 
Table 5.3.3. Data collecting by 1H NMR spectroscopy 
Entry Time [h] 1.5 3.0 4.5 6.0 7.5 9.0 
1 110a [%]-L1 17 23 29 35 41 46 
2 110a [%]-L2 0 18 27 35 43 52 
3 110a [%]-L3 18 18 27 27 35 34 
 
Figure 5.3.62. On-Off experiments. a), L1 (in black) got through current all the time and L2 (in red) without 
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Monitoring the Catalytic Reaction  
 
Figure 5.3.63. Catalytic reaction was monitored by HR-HESI-MS. 
Experiments were carried out with 106a (196 mg, 0.75 mmol, 1.0 equiv) following the 
general procedure G using Ni(DME)Cl2 (15.9 mg, 0.075 mmol, 10 mol %), [3,5-
(CF3)2C6H3]3P (100 mg, 0.15 mmol, 20 mol %), TMG (86.4 mg, 0.75 mmol, 1.0 equiv), 
nBu4NI (121 mg, 0.375 mmol, 50 mol %), 1,3,5-trimethoxybenzene (0.25 mmol) and 
74a (249 mg, 1.5 mmol, 2.0 equiv) in DMA (7.5 mL). Aliquots of 0.10 mL were removed 
from the cell every twenty minutes, quenched by addition of H2O (2.0 mL) and 
extracted with EtOAc (2 x 2.0 mL). Subsequently, the solvent was evaporated from 
each sample and the resulted crude mixtures were analyzed by 1H NMR spectroscopy 
resulting in the profile presented in Figure 5.3.64.  
 
Figure 5.3.64. 1H NMR spectroscopic monitoring of the reaction between 106a (0.75 mmol) and 74a 
(1.50 mmol) with Ni(DME)Cl2 (10 mol %) as precatalyst at 110 °C in DMA (7.5 mL) under constant current 
electrolysis at 8.0 mA. 
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Monitoring the Catalytic Reaction by HR-HESI-MS Spectrometry 
 
Figure 5.3.65. Catalytic reaction was monitored by HR-HESI-MS. Performed by Dr. Antonis M. Messinis. 
Electrocatalysis was carried out in a nitrogen filled glove box with 106a (196 mg, 
0.75 mmol, 1.0 equiv) following the general procedure G using Ni(DME)Cl2 (15.9 mg, 
0.075 mmol, 10 mol %), [3,5-(CF3)2C6H3]3P (100 mg, 0.15 mmol, 20 mol %), TMG 
(86.4 mg, 0.75 mmol, 1.0 equiv), nBu4NI (121 mg, 0.375 mmol, 50 mol %), 74a 
(249 mg, 1.5 mmol, 2.0 equiv) in DMA (7.5 mL) with 1,3,5-trimethoxybenzene 
(0.25 mmol) as an internal standard. During the course of the reaction, aliquots were 
collected, diluted with acetonitrile and analyzed by high resolution HESI mass 
spectrometry (Figure 5.3.67). The solution was quenched with H2O after about 
seven hours and the yield was found to be 49% according to an 1H NMR spectroscopic 
analysis (Figure 5.3.66). 
 
Figure 5.3.66. Crude 1H NMR spectroscopy after the reaction was carried out for about seven hours. 




Figure 5.3.67. HESI high resolution mass spectrometric monitoring of the reaction. Performed by Dr. 
Antonis M. Messinis. 
 
 




Figure 5.3.68. Comparison between the isotopic pattern of the experimentally observed species during 
catalysis (top spectra, expansion from Figure 5.3.67) and the simulated isotopic pattern (bottom spectrum) 
of the structures. a) product 110a. b) product 110a + TMG. Performed by Dr. Antonis M. Messinis. 
 




Figure 5.3.69. Comparison between the isotopic pattern of the experimentally observed species during 
catalysis (top spectra, expansion from Figure 5.3.67) and the simulated isotopic pattern (bottom spectrum) 
of the structures. a) NiII-M3 or/and NiII-M4. b) NiIV-M5 or/and NiII-M6. Performed by Dr. Antonis M. 
Messinis. 
 




Figure 5.3.70. Comparison between the isotopic pattern of the experimentally observed species during 
catalysis (top spectra, expansion from Figure 5.3.67) and the simulated isotopic pattern (bottom spectrum) 
of the structures. a) benzamide 106a. b) NiII-M7. Performed by Dr. Antonis M. Messinis. 
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5.3.6.3 (Electro)synthesis of Nickel(II) and Nickel(III) Complex 
 
Figure 5.3.71. Electrosynthesis of NiIII-M1 with NaO2CAd. 
According to our previous work, an oven-dried 10 mL undivided electrochemical cell 
was charged with benzamide 106a (262 mg, 1.0 mmol), NaO2CAd (202 mg, 1.0 mmol), 
Ni(cod)2 (138 mg, 0.50 mmol) and dry DMA (3.0 mL) in a glovebox. The reaction vessel 
was capped and heated in an oil bath at 130 °C for 2.0 h. Upon cooling to room 
temperature, the cap of the undivided cell was exchanged by a GF anode and a Ni 
foam cathode. Electrolysis was continued with a constant current of 8.0 mA which was 
then maintained for 5.0 h at ambient temperature under N2. Then, the reaction mixture 
was diluted with EtOAc (10 mL) and washed with H2O (10 mL). The aqueous layer was 
extracted with EtOAc (2 x 10 mL). The combined organic phases were dried over 
Na2SO4, filtered and evaporated in vacuum. The residue was purified by silica gel 
column chromatography at low temperature (eluent: nhexane/EtOAc = 4/1→EtOAc) to 
afford NiIII-M1 (125 mg, 43%) as a dark red solid. (The eluent was stored in the fridge 
for 2.0 hours before use to decrease the decomposition of nickel complex). NiIII-M1 
was crystallized using CH2Cl2 and nhexane.  
 
Figure 5.3.72. Synthesis of NiII-H3 with TMG from the direct C–H phosphorylation. 
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The experiment was carried out using benzamide 35a (496 mg, 2.0 mmol, 1.0 equiv), 
NiCl2 (311 mg, 2.4 mg, 1.2 equiv), TMG (553 mg, 4.8 mmol, 2.4 equiv) in acetone 
(5.0 mL) under N2, at 110 °C for 12 h. After the complication of the reaction, the reaction 
mixture was cooled down to ambient temperature, followed by filtration and washed 
with acetone. The combined mixture was added with 1,3,5-trimethoxybenzene 
(0.67 mmol) as the internal standard to obtain the crude 1H NMR spectrum. After 
removal of the solvent, the residue was purified by silica gel column chromatography 
at low temperature (eluent: nhexane/EtOAc 4:1→EtOAc) to reisolate benzamide 35a 
(248mg, 50%) and afford NiII-H3 (320 mg, 38%) as a red solid. NiII-H3 was crystallized 
using CH2Cl2 and nhexane in the glovebox. 
1H NMR (300 MHz, CDCl3) δ = 8.82 (d, J = 
7.8 Hz, 1H), 7.86 (d, J = 8.2 Hz, 1H), 7.73 (d, J = 4.8 Hz, 1H), 7.42–7.31 (m, 2H), 7.11–
6.79 (m, 4H), 6.41 (d, J = 7.2 Hz, 1H), 4.05 (s, 1H), 3.27 (s, 6H), 2.76 (s, 6H). 13C NMR 
(101 MHz, CDCl3) δ = 177.5 (Cq), 168.1 (Cq), 148.3 (Cq), 147.7 (Cq), 147.1 (Cq), 145.4 
(Cq), 144.6 (CH), 136.7 (CH), 133.3 (CH), 129.2 (CH), 129.0 (Cq), 128.5 (CH), 125.0 
(CH), 123.8 (CH), 120.8 (CH), 118.1 (CH), 115.9 (CH), 40.6 (CH3), 39.2 (CH3).  
 
Figure 5.3.73. Crude 1H NMR spectrum of TMG-assisted direct C–H phosphorylation. 




Figure 5.3.74. Electrosynthesis of NiIII-H1 from NiII-H3. 
The electrolysis was carried out in an undivided cell, with a GF anode (10 mm × 15 mm 
× 6 mm) and a Ni foam cathode (10 mm × 15 mm × 1.4 mm). NiII-H3 (84.0 mg, 
0.20 mmol, 1.0 equiv) and nBu4NI (32.2 mg, 0.10 mmol) with or without benzamide 
35a (49.6 mg, 0.20 mmol, 1.0 equiv) were dissolved in DMA (2.5 mL). Electrolysis was 
started with a constant current of 8.0 mA at 110 °C, which was then maintained for 
8.0 h under N2. At ambient temperature, the mixture was transferred into a separating 
funnel and the electrodes were rinsed with EtOAc (10 mL). Subsequently, H2O (10 mL) 
was added to the mixture and the organic layer was collected. The aqueous layer was 
extracted with EtOAc (2 × 5.0 mL). Evaporation of the combined organic layers and 
subsequent column chromatography on silica gel at low temperature (eluent: EtOAc) 
to afford NiIII-H1 as a dark red solid (7.0 mg, 0.0127 mmol, 13%) or (25.0 mg, 
0.045 mmol, 45%) when adding 35a.  
 
Figure 5.3.75. The reaction of NiII-H3 with benzamide 106n. 
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The electrolysis was carried out in an undivided cell, with a GF anode (10 mm × 15 mm 
× 6 mm) and a Ni foam cathode (10 mm × 15 mm × 1.4 mm). NiII-H3 (84.0 mg, 
0.20 mmol, 1.0 equiv) and nBu4NI (32.2 mg, 0.10 mmol) with benzamide 106n 
(58.4 mg, 0.20 mmol, 1.0 equiv) were dissolved in DMA (2.5 mL). Electrolysis was 
started with a constant current of 8.0 mA at 110 °C, which was then maintained for 
8.0 h under N2. At ambient temperature, the mixture was transferred into a separating 
funnel and the electrodes were rinsed with EtOAc (10 mL). Subsequently, H2O (10 mL) 
was added to the mixture and the organic layer was collected. The aqueous layer was 
extracted with EtOAc (2 × 5.0 mL). Evaporation of the combined organic layers and 
subsequent column chromatography on silica gel at low temperature (eluent: EtOAc) 
to afford as a mixture of nickel (III) complex (30 mg) which gave the isolated yield range 
from 47%-54%. The mixture was tested by HR-MS as following. 
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5.3.6.4 Catalytic and Stoichiometric Reaction Performance of NiIII-M1 
 
Figure 5.3.77. Stoichiometric reaction performance of NiIII-M1 without or with electricity.  
The electrolysis was carried out in an undivided cell, with a GF anode (10 mm × 15 mm 
× 6 mm) and a Ni foam cathode (10 mm × 15 mm × 1.4 mm). NiIII-M1 (58.0 mg, 
0.10 mmol), [3,5-(CF3)2C6H3]3P (13.4 mg, 0.020 mmol, 20 mol %), TMG (11.5 mg, 
0.10 mmol, 1.0 equiv), nBu4NI (16.1 mg, 0.050 mmol, 50 mol %) and 74a (33.2 mg, 
0.20 mmol, 2.0 equiv) were dissolved in DMA (1.5 mL). Subsequently, the reaction was 
carried out without or with electricity at 110 °C for 12 h. After cooling to ambient 
temperature, triphenylphosphine oxide (0.10 mmol) was added as the internal 
standard to determine the 31P{1H} NMR yield. 
 
Figure 5.3.78. Crude 31P{1H} NMR spectrum of stoichiometric reaction of NiIII-M1 without electricity. 




Figure 5.3.79. Crude 31P{1H} NMR spectrum of stoichiometric reaction of NiIII-M1 with electricity. 
 
Figure 5.3.80. Catalytic reaction performance of NiIII-M1 without or with electricity.  
The electrolysis was carried out in an undivided cell, with a GF anode (10 mm × 15 mm 
× 6 mm) and a Ni foam cathode (10 mm × 15 mm × 1.4 mm). NiIII-M1 (14.5 mg, 
0.025 mmol), [3,5-(CF3)2C6H3]3P (33.5 mg, 0.050 mmol, 20 mol %), TMG (28.8 mg, 
0.25 mmol, 1.0 equiv), nBu4NI (40.3 mg, 0.125 mmol, 50 mol %) and 74a (83.0 mg, 
0.50 mmol, 2.0 equiv) were dissolved in DMA (3.0 mL). Subsequently, the reaction was 
carried out without or with electricity at 110 °C for 12 h. After cooling to ambient 
temperature, triphenylphosphine oxide (0.20 mmol) was added as the internal 
standard to determine the 31P{1H} NMR yield. 




Figure 5.3.81. Crude 31P{1H} NMR spectrum of catalytic reaction of NiIII-M1 without electricity. 
 
Figure 5.3.82. Crude 31P{1H} NMR spectrum of catalytic reaction of NiIII-M1 with electricity. 
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5.3.6.5 Gram-Scale Experiment 
 
Figure 5.3.83. Gram-scale experiment with 106ad. 
The electrolysis was carried out in 100 mL Schlenk flask, with a GF anode (20 mm × 
30 mm × 6 mm) and a Ni foam cathode (20 mm × 30 mm × 1.4 mm). Benzamide 106ad 
(1.09 g, 3.5 mmol), Ni(DME)Cl2 (76.7 mg, 0.35 mmol, 10 mol %), [3,5-(CF3)2C6H3]3P 
(469 mg, 0.70 mmol, 20 mol %), TMG (403 mg, 3.5 mmol, 1.0 equiv), nBu4NI (564 mg, 
1.75 mmol, 50 mol %) and 74a (1.16 g, 7.0 mmol, 2.0 equiv) were dissolved in DMA 
(40 mL). Electrolysis was started with a constant current of 32 mA which was then 
maintained for 38 h at 110 °C. At ambient temperature, the mixture was transferred 
into a separating funnel and the electrodes were rinsed with EtOAc (50 mL). 
Subsequently, the mixture was washed with H2O (50 mL) and the organic layer was 
collected. The aqueous layer was extracted with EtOAc (2 × 50 mL). Evaporation of 
the collected organic layer and subsequent column chromatography on silica gel 
(nhexane/EtOAc: 4/1→1/1) yielded the desired product 110o (1.31 g, 78%). 
5.3.6.6 Studies on the Potential Racemization of 110y 
A racemic sample of rac-110y was synthesized following the general procedure G. 
Analysis by chiral HPLC showed that racemization did not take place. HPLC 
chromatograms were recorded on an Agilent 1290 Infinity instrument using 
CHIRALPAK ® IF-3 column and nhexane/iPrOH (70/30, 1.0 mL/min, detection at 
273 nm, 96% ee)  





Figure 5.3.84. HPLC–Chromatogram of rac-110y. 
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5.3.6.7 Cyclic Voltammetry 
A glassy-carbon electrode (3.0 mm diameter, disc-electrode) was used as the working 
electrode, a Pt–wire as auxiliary electrode and an Ag–wire as pseudoreference. The 
measurements were then referenced using ferrocene. The measurements were 
carried out at a scan rate of 100 mV/s. 


























Figure 5.3.86. Cyclic voltammograms at 100 mV/s. nBu4NPF6 (0.1 M in DMA); concentration of substrates 
5 mM. Performed by Zhipeng Lin. 





















 Ni(DME)Cl2+ TMG + 106a
 Ni(DME)Cl2+ TMG + 106a, 110 
oC
 
Figure 5.3.87. Cyclic voltammograms at 100 mV/s. nBu4NPF6 (0.1 M in DMA); concentration of substrates 
5 mM. Blank (black); Ni(DME)Cl2 + TMG + 106a (green); Ni(DME)Cl2 + TMG + 106a at 110 °C (blue). 
Performed by Zhipeng Lin. 
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 Ni(DME)Cl2 + TMG + 106a
 NiII-H3
 NiII-H3 + TMG
 
Figure 5.3.88. Cyclic voltammograms at 100 mV/s. nBu4NPF6 (0.1 M in DMA); concentration of substrates 
5 mM; temperature (110 °C). Ni(DME)Cl2 + TMG + 106a (red); NiII-H3 complex (green); NiII-H3 + TMG 
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